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Abstract 
 
Mitogen-activated protein kinases (MAPKs) play an essential role in the transduction of 
extracellular signals to cytoplasmic and nuclear effectors. MAP kinase kinases 
(MEKs/MAPKKs) represent protein kinases upstream of MAPKs, critically controlling 
cellular proliferation and apoptosis.  Mitogen/extracellular signal regulated kinase 
kinase-5 (MEK5) specifically activates extracellular signal-rlated kinase-5 (ERK5), also 
known as Big MAP kinase 1 (BMK1). Studies conducted in Newcastle have shown that 
abnormal MEK5/ERK5 signalling is present in certain types of prostate cancer and 
correlates with shorter disease-specific survival. ERK5 is over-expressed in 20% of 
breast cancers and is also thought to promote cell growth in hepatocellular carcinoma 
(HCC) by regulating mitotic entry. In addition, ERK5 has been shown to interact with, 
and inactivate promyleocytic leukaemia (PML) protein. This prevents activation of its 
downstream effector, tumour suppressor p21. An ERK5 inhibitor based on a series of 
isoform selective polo kinase inhibitors was reported in the literature. XMD8-92 
displayed selectivity for ERK5 when tested against a panel of 402 kinases in an ATP-
site competition binding assay (ERK5; IC50 = 300 nM) and the compound showed 
reasonable activity in HeLa cells (GI50 = 1.5 µM). XMD8-92 was also shown to inhibit 
growth in two human tumour xenograft models (HeLa cells and Lewis lung cells), 
highlighting that inhibition of ERK5 is a valid target for anti-cancer therapy. 
Encouragingly, both in vitro and in vivo activities of XMD8-92 have been tested and 
confirmed in our assays. 
 
A high throughput screening (HTS) campaign was conducted using an immobilised 
metal affinity polarisation (IMAP
TM
) format assay at Cancer Research Technology-
Discovery Laboratories (CRT-DL), identifying three distinct chemical series for further 
investigation. A pyrrole carboxamide series (1) has undergone hit validation by re-
synthesis and re-testing of the original HTS hits along with synthesis of closely related 
series. 
 
Initial hit-to-lead studies focussed on modification of R
1
 in structure 1, and the best 
activity against ERK5 was observed when R
1 
is an aromatic ring disubstituted with a 
5 
 
halogen at the 2,3- or 2,6-positions (e.g. 2, ERK5; IC50 = 2.3 M), with the R
2 
substituent being a pyridyl moiety linked to the amide via a methylene group. Further 
structure-activity relationship studies (SARs) revealed that removal of the methylene 
group led to an increase in potency (3, ERK5; IC50 = 1.1 M) and more importantly, in 
more than 100-fold selectivity for ERK5 over the closely related MAPK, p38α.  
 
Introduction of a different halogen atom into the 2-position of the aromatic ring 
conferred good potency and retained selectivity for ERK5 over p38α (e.g. 4, ERK5; 
IC50 = 0.6 M and 5, ERK5; IC50 = 0.8 M). Inhibitor 5 was selected for in vitro and in 
vivo pharmacokinetic (PK) studies with promising results [in vitro PK; solubility >100 
µM, PPB = 94% and in vivo PK; oral bioavailability = 68% and t1/2 = 65 min (p.o. 
mice)]. More recently, introduction of a 2,3,6-tri-substituted aromatic ring led to an 
increase in potency against ERK5, identifying the first compound with an ERK5 IC50 
<100 nM, 6 (ERK5; IC50 =  0.07 µM).  
 
Modification of R
2
 has also been investigated in order to improve CYP450 inhibition 
profiles. Synthesis of a series of compounds with various substituted pyridyl, pyrimidyl 
or pyridazyl rings was conducted. The SARs revealed compounds with a pyrimidyl 
moiety to be potent inhibitors of ERK5 (IC50 <5 M) with excellent CYP450 inhibition 
profiles when tested against a panel of five CYP450 isoforms (IC50>25 µM). Further lead 
optimisation studies are currently being undertaken in order to find an inhibitor suitable 
for clinical evaluation.  
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Chapter 1. Overview of drug discovery and cancer  
1.1 Introduction to drug discovery 
 
The typical stages in drug discovery are summarised in Figure 1, with the process being 
broadly divided into two stages: preclinical proof of principle and clinical 
development.
1
  
 
Figure 1. Summary of the drug discovery process. 
 
The preclinical proof of principle phase commonly commences with a high-throughput 
screening (HTS) initiative whereby a library containing  thousands of compounds is 
screened for activity against the biological target of interest. An IC50 value will be 
determined for each compound using a specifically designed assay and only compounds 
with moderate to good inhibitory activity or ‘hit compounds’ will then be taken forward 
for hit validation via re-synthesis and testing. Once validated, hit compounds are 
progressed to the hit-to-lead stage of the process. By this point, structure-activity 
relationship studies (SARs) can be undertaken based on potency. Physicochemical 
property assessment and selectivity studies will also be undertaken during the hit-to-
lead phase. The Lipinksi ‘rule of five’ may also be considered at this stage if it is 
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essential for the drug to be orally active.
2-3
 The ‘rule of five’ outlines specific rules for 
physicochemical properties believed to be required for a drug to be orally bioavailable 
and are: 1. the molecular weight should be below 500 amu, 2. the logP should be below 
5, 3. the number of H-bond donors should be below 5, 4. the number of H-bond 
acceptors should be below 10. If one or more of the criteria are not met, compounds 
would be expected to have poor absorption and cell permeation and not be orally 
active.
2
 Compounds which comply with Lipinski’s rules and are both potent and 
selective would be tested in a range of in vitro ADME (absorption, distribution, 
metabolism, elimination) studies. Based on the results of these studies, dozens of 
compounds would be selected for lead optimisation, where the in vivo efficacy would be 
tested using DMPK (drug metabolism and pharmacokinetic) studies. In vivo clearance, 
volume of distribution, bioavailability and half-life determinations can be performed in 
animal models during the lead optimisation stage. One or two compounds could then be 
selected as pre-clinical candidates and subsequently assessed for in vivo toxicology 
during pre-clinical development before being progressed to the three phases of clinical 
trials.   
1.2 Introduction to cancer 
 
Cancer is a complex disease that arises due to genetic malfunction. Causes of this 
malfunction can be endogenous factors, including hormones or metabolism, or 
exogenous factors such as exposure to carcinogens. Such factors can bring about 
mutations in either tumour suppressor genes or oncogenes. Once a single mutation 
remains unchecked, accumulation of further genetic mutations is able to occur, and this 
cannot be controlled by the usual DNA repair mechanisms. Normal cells undergo a cell 
cycle process that is tightly regulated, and in which they have a controlled rate of 
growth, become organised, and are programmed to carry out a specific function. They 
also die in a predetermined way (apoptosis). In cancer cells, a number of these controls 
are lost, leading to aberrant cell growth without apoptosis. This results in the 
proliferation of mutant (malignant) cells that no longer have a specific physiological 
function, and build up into a tumour.
4
  
 
In 2000, Hanahan and Weinberg proposed six common features observed in the vast 
majority of cancer types; 1. self-sufficiency, 2. insensitivity to anti-growth signals, 3. 
evasion of apoptosis, 4. sustained angiogenesis, 5. tissue invasion and metastasis and 6. 
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sustained angiogenesis.  These were termed them ‘the Hallmarks of cancer.’4 In 2011 
these ‘hallmarks’ were updated to include newly emerging capabilities of cancer cells 
for tumour progression (Figure 2).
5
  
 
 
 
Figure 2. The updated ‘Hallmarks of Cancer’ Adapted from ref 5. 
 
Each of the characteristics is induced by different mechanisms, depending on the 
specific type of cancer. These traits are the reason anticancer therapy can be so difficult, 
due to the vast variation in which cancer can manifest.  
 
Despite the difficulties outlined, significant progress has been made in research into 
new cancer therapeutics. This is exemplified by recent statistics, which show that the 
number of people reaching five-year survival has increased. The graph in Figure 3 
highlights the five-year survival rates for the most common cancer types in men and 
women in England between 2005 and 2010. The largest observed increase in five-year 
survival for males is for prostate cancer, where the percentage of people surviving for 
five years post-diagnosis has increased by 50% since the early 1970s (from 31% to 
81%). For female breast cancer, the percentage of people reaching the five-year survival 
point has increased by 33% over the same time period (from 52% to 85%).
6
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Figure 3. Age-standardised 5-year cancer survival rates for male and female adults (15-
99 years) in England.
6
  
 
One reason for the increase in five-year survival rates is the improvement in cancer 
therapy. This is due in part to a new generation of more specific targeted therapies that 
have a greater affinity for cancer cells over healthy cells. 
1.3 Targeted cancer therapies 
 
Previous cancer therapies have involved the use of highly toxic chemotherapeutic 
agents. One example is the alkylating agents, which cause inter- and intra-strand DNA 
cross links. This results in prevention of DNA strand separation, miscoding of bases, 
and finally double strand breaks. Platinum complexes, such as cisplatin, also covalently 
bind to DNA, with similar results. The overall action of such drugs is cytotoxicity, with 
cellular necrosis and apoptosis being observed. The main problem with classes of drugs 
such as these is there is no selectivity between healthy cells and cancer cells. This, in 
turn, results in high levels of toxicity.
7
  
 
Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Gene Directed Enzyme 
Prodrug Therapy (GDEPT) were among some of the first strategies developed towards 
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more targeted, less toxic therapies, using either an antibody or a section of DNA along 
with a prodrug to direct treatment to the site of a tumour.
8
  
 
A major breakthrough was the relationship discovered between hormones and certain 
cancers, and how this could be exploited to produce drugs to target hormone receptors. 
This approach was exemplified with the approval of Tamoxifen (1) in 1977 for patients 
with advanced breast cancer, acting as an antagonist of the oestrogen receptor. 
Tamoxifen is now used as the first-line treatment for advanced breast cancers that are 
positive for the oestrogen receptor, highlighting the importance of targeted therapies for 
cancer treatment.
9
 
 
 
1.4 Protein kinases and cancer therapy 
 
Protein kinases play an integral role in the move towards more targeted therapies for 
cancer treatment. They are involved in many cell signalling processes, and are key 
regulators of processes such as proliferation and invasion. There have been 518 distinct 
kinases identified, and research has shown that the genes coding for these proteins are 
often mutated in cancer cells. Protein kinases are structurally related and categorised by 
their catalytic domains (approximately 250-300 amino acids in size). There are two 
main sub-divisions; tyrosine kinases and serine/threonine kinases.
10
 Protein kinases 
catalyse the transfer of a terminal γ-phosphate group from ATP to either serine, 
threonine or tyrosine depending on which sub-division they belong to (Figure 4).  These 
residues form part of a target protein substrate, which may be either activated or 
inactivated as a result of the phosphorylation. Structural conformation changes in the 
protein can also occur as a consequence of phosphorylation, and this can change the 
binding and recognition properties of the protein. These conformational changes can 
induce a variety of responses within the cell, and stimulate a signal cascade that ceases 
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on removal of the phosphate group. This dephosphorylation is conducted by a 
phosphatase enzyme, which returns the protein to its original state.
10
 
 
 
 
Figure 4. The phosphorylation of the hydroxyl groups in serine, threonine and tyrosine 
mediated by protein kinases, and their subsequent dephosphorylation by phosphatases. 
 
In order to facilitate the transfer of the terminal γ-phosphate group from ATP to another 
protein, ATP binds to a specific binding domain on the kinase, through hydrogen bond 
interactions with amino acid residues. Recent research has centred on the development 
of effective mimics of ATP to competitively inhibit the phosphorylation process 
through binding to the active site of the kinase. Competitive inhibitors aim to mimic the 
hydrogen bond interactions of ATP within the binding sites of the mutated kinases that 
drive proliferation of cells in cancer. Inhibition of phosphorylation should then prevent 
the subsequent signalling cascade and hence prevent uncontrolled activation of 
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proliferation. Each kinase has a unique ATP binding domain with a highly conserved 
amino acid sequence. The differences in binding domain may be utilised in order to 
develop an inhibitor that binds selectively to the kinase of interest.
10
  
 
1.4.1 Protein kinase inhibitors  
 
The development of ATP-competitive inhibitors of protein kinases has proven to be a 
valid approach. The Bcr-Abl oncogene encodes a constitutively active tyrosine kinase in 
chronic myelogenous leukaemia (CML). The Bcr-Abl oncogenic protein arises from 
reciprocal translocation of genetic material from chromosomes 9 and 22 and its 
formation results in unregulated cell proliferation.
10-11
 Imatinib is an ATP-competitive 
inhibitor of the Abl protein kinase and was approved in 2001 for the treatment of CML 
(marketed as Glivec in Europe). Figure 5 shows the crystal structure of imatinib (2) 
bound in the ATP binding site of the Abl protein kinase. Imatinib has also been shown 
to be an effective treatment for gastrointestinal stromal tumour (GIST) as it was found 
to be an inhibitor of protein kinase c-Kit, which is elevated in patients with GIST.
12
  
 
 
 
Figure 5. Imatinib bound in the ATP binding site of the Abl tyrosine kinase.
11
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Due to the success of imatinib, interest in developing inhibitors of protein kinases has 
increased and over the past 11 years a number of kinase inhibitors have been approved 
for clinical use (Table 1).  
 
Table 1. Kinase inhibitors in the clinic for the treatment of cancer.
13-15
 
 
Name 
Marketed 
name 
Year approved Kinase target Clinical use 
Imatinib 
Glivec 
(Novartis) 
2001 Bcr-Abl fusion CML, GIST 
Gefitinib 
Iressa 
(AZ and Teva) 
2003 EGFR-TK 
Non-small cell 
lung cancer 
(NSCLC) 
Sorafenib 
 
 
Nexavar 
(Bayer and Onyx) 
 
2005 
Raf1 
(Multi-kinase 
inhibitor) 
Renal cell 
carcinoma 
(RCC), hepato-
cellular 
carcinoma 
(HCC) 
Sunitinib 
Sutent  
(Pfizer) 
2006 
Multi-kinase 
inhibitor 
RCC, imatinib 
resistant GIST 
Erlotinib 
Tarceva 
(Roche) 
2010 EGFR-TK 
Metastatic 
NSCLC 
Dasatinib 
Sprycel 
(BMS) 
2010 
Bcr-Abl fusion 
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Chapter 2. Mitogen Activated Protein Kinases (MAPKs) and cancer 
2.1 MAPK pathways  
 
The mitogen activated protein kinases (MAPKs) are a specific family of protein kinases 
which have been identified as a useful target for cancer therapy as they control a 
number of fundamental cellular processes including cell survival, proliferation, motility, 
differentiation and inflammatory responses.
16-17
 MAPKs regulate cellular signal 
pathways, which relay, amplify and integrate signals from a variety of stimuli including 
growth factors and cellular/extracellular responses such as osmotic and oxidative 
stress.
17-18
 Growth factor signals are transmitted via transmembranal receptors, which, 
upon stimulation, can initiate several signalling pathways, leading to a variety of 
cellular responses. These signalling pathways are mediated via a series of dual 
phosphorylation reactions occurring on serine/threonine residues.
19
 
 
In mammalian cells 14 highly conserved MAP kinases have been identified and 
categorised into seven groups. Four groups are known as the conventional MAPKs; 
Extracellular signal-related kinase (ERK) 1/2, the p38 isoforms, c-Jun amino (N)-
terminal kinase (JNK) isoforms and ERK5. ERKs 3, 4, 7 and 8 and Nemo-like kinase 
(NLK) are classified as atypical MAPKs.
20
 The TXY amino acid sequence present in 
the activation loop of conventional MAPKs varies between the four sub-families (ERK, 
TEY; p38, TGY; JNK TPY).
20
  Of the conventional MAPKs, ERK5 differs most greatly 
from the other members. ERK5, or ‘Big MAP kinase 1’ (BMK-1) contains an N-
terminus extension, which contains transactivation domain (TAD) and nuclear 
localisation sequences (NLS).
20
 Figure 6 shows a representation of the structural 
domains of conventional and atypical MAPKs, which have highly conserved regions..  
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Figure 6. Representation of the structures of (A) conventional and (B) atypical MAPKs. 
TAD: transactivating domain, NLS: nuclear localisation sequence, C34: conserved 
region in ERKs 3 and 4, AHQr: Ala, His and Glu rich domain. Adapted from ref 20. 
 
For selective signalling of a specific pathway, three docking domains have been 
identified; the D (δ) domain, the CD (C-terminal common docking) domain and the 
DEF (Asp-Glu-Phe) domain.
20
 The CD domain is present in ERK, p38 and JNK 
subfamilies and is located outside the catalytic site. The CD domain forms electronic 
interactions with the D domain of a specific downstream target to ensure selectivity for 
the correct kinase in the signalling pathway. The DEF domain (identified by a 
conserved Phe/Tyr-Xaa-Phe-Pro sequence) is involved in efficient binding of 
downstream targets and is essential for phosphorylation of the correct downstream 
effector.
20
  
 
Each MAPK cascade involves no fewer than three enzymes, which are activated in 
series; a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP 
kinase (MAPK).
17
 The Ras/Raf/MEK/ERK signalling cascade is the most studied  
classical MAPK cascade.  Following stimulation of the transmembranal receptor, 
through binding of a growth factor, cytokine or hormone, levels of Ras-GTP (guanosine 
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triphosphate) increase. Increased levels of Ras-GTP promote activation of the EGF-
receptor tyrosine kinase, which leads to the recruitment of the adaptor protein, Grb2 
(growth factor receptor-bound protein) and the guanine nucleotide exchange factor, SoS 
(Son of Sevenless), which form a complex with the activated receptor.
17
 Ras-GTP acts 
as a ‘molecular switch’ and is able to hydrolyse GTP to GDP. SoS binds to inactive 
Ras-GDP, and forces the delocalisation of GDP so that Ras is able to bind GTP and 
become activated once again. Activated Ras-GTP then activates MAPKKK, Raf. There 
are three isoforms of the Raf kinase, A-Raf, B-Raf and C-Raf, which are activated when 
Ras-GTP binds and delocalises Raf to the plasma membrane where Raf is 
phosphorylated either by Ras-GTP, or by autophosphorylation. The sequence then 
continues with membrane bound Raf assembly of a signalling complex consisting of 
MAPKK, MEK and MAPK, ERK. Raf then phosphorylates MEK, which in turn 
phosphorylates ERK. Activated ERK then dissociates from the complex and 
translocates to the cell nucleus, where the kinase is able to activate a number of 
transcription factors. This leads to changes in gene expression, promotion of growth, 
differentiation, mitosis and angiogenesis. Activated ERKs may also transmit signals to a 
variety of cytoplasmic effectors, and therefore play a vital role in numerous cellular 
processes.
17, 19, 21
   
Figure 7. A) General MAPK signalling pathway B) Classical MAPK pathway. 
 
A B 
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Disruption of MAPK signalling pathways can result in cellular transformation or altered 
proliferation.
17
 The Ras/Raf/MEK/ERK pathway is a key oncogenic pathway implicated 
in a variety of human cancers. The main cause of over-activation of the pathway is a 
mutated or over-expressed protein in the signal cascade. For example, Ras over-
expression is commonly observed, with Ras being locked in a permanently ‘switched 
on’ or activated state, leading to a constitutively active signalling pathway. Over 
expression of Raf, particularly B-Raf, has also been identified as a common mutation in 
around 70% of human carcinoma. An upregulation of trans-membrane growth factor 
receptors has also been observed (e.g. HER2) as a mutation that can lead to disrupted 
cell signalling, and, hence, over proliferation of cells.
21-23
  
2.2 Targeting the Ras/Raf/MEK/ERK pathway with inhibitors  
 
Inhibition of the Ras/Raf/MEK/ERK pathway has been attempted by targeting the 
extracellular receptors. Examples are the EGFR-TK inhibitors gefitinib (3) (EGFR-TK; 
IC50 = 220 nM) and erlotinib (4) (EGFR-TK; IC50 = 2 nM).
24-25
   
 
 
 
One major problem with drugs that target the EGFR-TK is the development of drug 
resistance, due to redundancy of the inhibited pathway.  A single secondary mutation in 
the EGFR, with substitution of a methionine residue at position 790 for threonine 
(T790M) is the most common cause of resistance to EGFR-TK inhibitors.
26
 
Development of second generation inhibitors which target the T790M variant of the 
EGFR-TK is in progress for the treatment of patients who no longer respond to gefitinib 
or erlotinib treatment. Canertinib (5) is a highly potent irreversible inhibitor of wild type 
EGFR and EGFR
T790M
 (EGFR; IC50 = 0.3 nM; EGFR
T790M
;
 
IC50
 
= 26 nM) and is 
currently being evaluated in Phase II clinical trials.
27
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A novel mutation in BRaf (V600E) has been identified in human tumours including 
malignant melanoma. Vemurafenib (6) shows significant anti-tumour effects in cell 
lines possessing BRaf
V600E
, but is inactive against cells containing wild type BRaf.
28
 
Drug resistance via secondary mutations highlights the necessity for continued genomic 
investigation and drug discovery for the development of new therapeutic agents. 
 
 
 
Ras oncoproteins activate signalling pathways such as the MEK/ERK cascade and, as 
such, play a key role in development of various cancers, with mutations in Ras present 
in approximately 30% of all human cancers.
29
 Raf, MEK and ERK1/2 have also been 
shown to be over-expressed in many cancers and have, therefore, proven to be an 
attractive target for inhibition.  
 
MEKs are an attractive target for inhibition as they have restricted substrate specificity 
and only phosphorylate a small number of downstream MAPKs, so their inhibition is 
not likely to disrupt any normally functioning cellular processes.
29
  Pfizer developed the 
first MEK1 inhibitor to reach clinical trials, PD184352 (CI-1040, 7) (MEK1; Ki = 17 
nM). PD184352 has been shown to act as an allosteric inhibitor reducing the affinity of 
ATP at the ATP binding site, enabling specificity for MEK1 over structurally similar 
kinases such as p38α and JNK2. PD184352 was advanced to phase II for patients with 
metastatic breast cancer, non-small cell lung cancer and pancreatic cancer, but was 
35 
 
unsuccessful in producing a response following single agent dosing.  As a result, second 
generation MEK1 inhibitor PD0325901 (8) (MEK1; IC50 = 1 nM) was developed. 
PD0325901 displays significantly improved in vivo efficacy and drug-like properties to 
PD184352.
21, 29
  
 
 
                           
AZD6244 (9) (MEK1/2; IC50= 14 nM) was developed by AstraZeneca as a second 
generation MEK inhibitor and is particularly effective in cell lines which display BRAF 
or Ras mutations.
30
 Phase II clinical trials for AZD6244 have been completed for 
treatment of non-small cell lung cancer (NSCLC) and are ongoing for BRAF 
mutations.
30
 Another MEK1 inhibitor, RO4987655 (10) is currently in Phase II clinical 
trials for the treatment of advanced solid tumours.
31
  
 
 
 
Inhibition of ERK1/2 by small molecules is less well investigated. FR180204 (11) was 
reported in 2005 an ATP competitive dual inhibitor of both ERK1 and ERK2 (IC50; 
ERK1 = 0.51 µM; ERK2 = 0.33 µM). A cell-based assay of FR180204 revealed that 
dual inhibition of ERK1/2 results in inhibition of downstream effector, transcription 
factor AP-1. AP-1 transactivation is associated with the TGF-β pathway, which is 
involved in many cellular functions including cell growth and differentiation.
32
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Potent pyrazolylpyrrole-based inhibitors of ERK1/2 have been identified by Vertex 
pharmaceuticals (12, Ki; ERK2 = 0.086 μM; 13, Ki; ERK2 = 0.035 μM; Ki; 14; ERK2 = 
0.002 μM ) and are in pre-clinical development.33 
 
 
2.3 p38 and JNK signalling pathways 
 
p38 and JNK are MAPK subfamilies and are known as stress-activated protein kinases 
(SAPKs) as their signalling pathways are activated by cellular stress. The p38 subfamily 
consists of four isoforms, α, β, γ and δ, with p38α being the most widely investigated as 
it is most abundantly expressed through cells. p38α is present in the majority of 
mammalian cells and is involved in the regulation of the immune response.
34
 p38α 
mediates cellular responses to UV, heat, and osmotic shock. Neutrophils, monocytes, 
macrophages and other inflammatory cells synthesise the p38α isoform. Activation of 
the p38 MAPK pathway is associated with inflammatory diseases due to the production 
of pro-inflammatory cytokines (e.g. Interleukin-1 (IL-1).
35
 The p38 pathway has been 
identified as a regulator of apoptosis and treatment with chemotherapeutic agents can 
induce p38-dependant apoptosis in certain cell lines.
36
  
 
The JNK subfamily are activated by environmental stress primarily and Figure 8 shows 
that both p38 and JNK are activated by the same MAPKKKs following the stimulus 
(MEKK1-4, DLK, MLK2, Tpl-2, ASK1, TAK1 and TAO1/2).
37
 The p38 isoforms are 
then phosphorylated by MAPKKs MEK3 and MEK6, resulting in the activation of a 
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number of cytoplasmic and nuclear targets (including cPLA2, MNK1/2, Tau, MEF2 and 
p53) regulating inflammatory response and inducing apoptosis. The JNK family are 
phosphorylated by MEK4 and MEK7, which leads to JNK-mediated activation of 
transcription factors including c-Jun, p53, Stat3 and c-Myc. Activation of the JNK 
pathway has been associated with tumour formation via disruption of cellular growth.
37
 
 
 
Figure 8. p38 and JNK signalling pathways. 
 
 
2.3.1 Targetting the p38 and JNK pathways with  small-molecule inhibitors 
 
Inhibitors of p38α have been successful in entering clinical trials for diseases associated 
with inflammatory response, e.g. PH797804 (15) and GW856553 (16), which are 
currently in phase II clinical trials for treatment of rheumatoid arthritis and chronic 
obstructive pulmonary disease (COPD), respectively.
38-39
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To date, only one inhibitor of p38α has entered clinical trials for the treatment of cancer, 
Talmapimod (SCIO-469, 17). In 2009, Talmapimod entered clinical trials with single 
agent dosing in patients with multiple myeloma, but it was found to be ineffective. A 
second trial using Talmapimod in combination with proteasome inhibitor Velcade (18) 
produced a synergistic effect and cell proliferation was significantly affected.
40
 p38 
inhibition is thought to induce sensitisation to proteasome inhibitors through the 
reduction of MAPK-activated protein kinase-2 (MAPKAPK-2) and activation of the 
anti-apoptotic heat shock protein 27 (HSP27).
41
 p38α inhibitors may be used clinically 
to increase sensitivity of resistant or unresponsive patients to existing anti-cancer 
therapies.  
 
 
                     
Inhibitors of members of the JNK subfamily of MAPKs are also under investigation. As 
for p38, JNK is implicated in inflammatory diseases and cancer. JNK family members, 
may also play a role in the progression of neurodegenerative and metabolic disease. At 
present, there are no known JNK inhibitors under clinical evaluation.  
2.4 Extracellular signal-related kinase 5 (ERK5)  
 
Extracellular signal-related kinase 5 or ERK5 is almost twice the size of other MAPKs 
consisting of 816 amino acids and is also known as Big MAPK 1 (BMK-1).
42
  The large 
size of ERK5 can be attributed to a unique C-terminal domain, which possesses a 
transcriptional activation domain and a MEF2 interacting domain.  The ERK5 
signalling pathway is associated with cell survival, proliferation and differentiation. 
Over-expression of ERK5 may lead to uncontrolled cell growth and tumourigenesis.
43-44
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ERK5 is part of a non-classical MAPK signalling cascade, which is independent of Raf 
activation (Figure 9).
45
 The ERK5 signalling cascade is initiated by binding of growth 
factors, i.e. epidermal growth factor (EGF), nerve growth factor (NGF), vascular 
endothelium growth factor (VEGF) or fibroblast growth factor-2 (FGF-2) to receptors 
found on the cell surface, activating the EGFR-TK.
46-48
 Activation of the signalling 
pathway can also occur as a result of cellular stresses, or cytokines as with the p38 and 
JNK signalling pathways. The EGFR-TK recruits Grb2 and SoS to activate Ras as in the 
classical pathway and then MAPKKKs, MEKK2/3 are then activated independently of 
Raf. MEKK2/3 activate MEK5, which has been identified as the sole activator of 
ERK5.
45
 Following activation, ERK5 can translocate to the cell nucleus and activate 
transcription factors such as myocyte enhancer factors (MEF2A, 2C and 2D), which 
mediate cell survival, c-Myc, c-Jun, c-Fos, activating protein 1 (AP-1) and NFκB. Bcl-2 
associated death promoter (Bad) and serine/threonine kinase (SGK) are also 
downstream targets of ERK5, along with the p90 ribosomal s6 kinase (RSK) involved 
in signal transduction. RSKs are themselves known to activate several cytosolic and 
nuclear substrates, and are implicated in the regulation of a number of cellular processes 
associated with the onset and progression of cancer, including cell proliferation, 
survival, and motility.
43-44, 49
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Figure 9. MEK5/ERK signalling cascade. 
 
2.4.1 Adaptor and scaffold proteins in ERK5  
 
In addition to docking domains, adaptor and scaffold proteins assemble signal cascade 
proteins in multi-enzyme complexes and ensure signal transduction to MAPKs.
46
  
Scaffolding proteins are a novel class of proteins, which bring specific components of 
the MAPK cascade together in close proximity so that rapid and efficient 
phosphorylation of the downstream target can occur. Adaptor protein Lad (Lck-
associated adaptor) promotes ERK5 activation by increasing the binding affinity 
between upstream kinases in the cascade, MEKK2 and MEK5.
50
 MEKKs 2/3 contain a 
Phox/Bem1 (PB1) domain which may associate with other PB1 containing proteins via 
protein-protein interactions, and it is this interaction which mediates MEK5 activation. 
Interestingly, ERK5 is the only MAPK to have a PB1 domain and it has been 
demonstrated that MEK5 itself is able to act as a scaffold protein by tethering 
MEKK1/2 to ERK5 via its N- and C-terminal regions of the PB1 domain. The three-
kinase complex is unique to the MAPK family.
51
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2.4.2 Structure of ERK5 
 
ERK5 belongs to the conventional MAPK family and as such contains a TXY tripeptide 
motif in its activation loop (for ERK1, ERK2 and ERK5 X = E). Phosphorylation of the 
threonine and tyrosine residues of this tripeptide sequence activates ERK5 (and ERK1 
and ERK2). Despite the conserved tripeptide motif, ERK5 differs from ERKs 1 and 2 
due to a unique loop-12 structure and extended C-terminal domain containing around 
400 amino acids (hence the alternative name, big MAPK 1, BMK-1). The C-terminus 
contains nuclear localisation and export sequences (NLS and NES) and a transcriptional 
activation domain that interacts with MEF2D.
46
 The C-terminal domain is 
autophosphorylated at multiple sites by the kinase domain, leading to increased 
transcriptional activity. The C-terminal domain of ERK5 can also act in an 
autoinhibitory capacity by masking the catalytic domain and blocking substrates from 
binding.
52
 It is only following phosphorylation of ERK5 by MEK5 that a 
conformational change occurs and the C-terminal domain no longer impedes binding of 
substrates.
52
  
2.4.3 Role of ERK5 in cancer development  
 
 
2.4.3.1 ERK5 and PML 
 
2.4.3.1.1 ERK5-mediated reduction of p21 via interaction with PML 
 
Mass spectrometric analysis has revealed that ERK5 interacts with and phosphorylates 
promyelocytic leukemia (PML) protein.
53
 There are a number of isoforms of PML (I-
VI) and ERK5 has been shown to interact with all isoforms except PML V.
54
 PML acts 
as a tumour suppressor due to activation of downstream effector p21. It is known that 
upon activation of ERK5 by MEK5, ERK5 translocates to the cell nucleus from the 
cytoplasm and it is thought this is where the interaction between ERK5 and PML 
occurs. PML is able to activate p21 expression leading to tumour suppression. ERK5 
phosphorylates PML on two phosphorylation sites, inactivating it and preventing 
activation of p21 (Figure 10). Inactivation of PML by ERK5 is usually a tightly 
controlled process. However, when there is an over-expression of ERK5, as observed in 
many tumour types, the levels of p21 are reduced so low that tumour suppression cannot 
be effected.
53
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Figure 10. Regulation of p21 activation via phosphorylation of PML by ERK5. 
 
 
Suppression of ERK5 using siRNA knockdown of MAPK7 (the gene encoding ERK5) 
induces expression of p21 and increases tumour suppression. For this reason, using an 
inhibitor to reduce levels of ERK5 would also be effective in inducing tumour 
suppression. An ERK5 inhibitor, XMD8-92 was shown to exert tumour suppression 
through increased p21 expression and is discussed in more detail in section 2.4.6.1 of 
this chapter.
53
  
 
2.4.3.1.2 ERK5-mediated reduction of p53 via interaction with PML 
 
More recently it has been shown that ERK5 has the highest affinity for the PML IV 
isoform. PML IV is able to interact with MDM2 and hence regulate levels of tumour 
suppressor, p53.
54
 MDM2 is the major E3 ubiquitin ligase for p53, facilitating p53 
ubiquitination and consequent degradation. Up-regulation of p53 can be achieved by 
disruption of the MDM2/p53 interaction. Doxorubicin (19) is a topoisomerase inhibitor 
and is able to induce p53 via nuclear sequestration of MDM2, which is thought to occur 
due to promotion of PML IV association with MDM2. Interaction of ERK5 with PML 
IV disrupts the MDM2-PML interaction leading to reduced levels of p53. It has been 
shown that inhibition of ERK5 with XMD8-92 (20) (section 2.4.6) or siRNA/shRNA 
43 
 
knockdown of ERK5 increases levels of cellular p53.
54
 Mouse embryonic fibroblast 
(MEF) cells with PML
+/+
 and PML
-/-
 were used alongside A549 (lung cancer) and HeLa 
(cervical cancer) cells and were treated with doxorubicin, PD184352 (7) (a MEK1/2 
inhibitor) and/or XMD8-92. Long-term treatment of the cells with XMD8-92 (32-40 h) 
showed significant synergy with doxorubicin and led to upregulation of p53 and tumour 
cell apoptosis. The synergistic effect was not observed in PML
-/- 
MEF cells. Mouse 
HeLa and A549 xenograft models were condcted and in each case dosing with XMD8-
92 and doxorubicin in combination led to tumour regression (Figure 11).
54
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Figure 11. Mouse HeLa and A549 xenograft models treated with control, doxorubicin, 
XMD8-92 and doxorubicin + XMD8-92. Adapted from ref 53 
 
This study indicates that the use of an ERK5 inhibitor may significantly enhance the 
anticancer effect of doxorubicin. The chemo-potentiation of doxorubicin in combination 
with XMD8-92 has been investigated in Newcastle using an SRB cytotoxicity assay in 
A549 cells. The cells were treated with doxorbubicin alone, or in combination with 
either 1 μM or 4 μM of XMD8-92. There is a reduction in cell growth for the cells 
treated with the combination therapy, validating the theory that an ERK5 inhibitor may 
enhance the effectiveness of doxorubicin treatment (Figure 12).  
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Figure 12. Percentage growth of A549 cells treated with doxorubicin alone or in 
combination with 1 μM or 4 μM of XMD8-92. 
 
 
2.4.3.2 ERK5 and cell cycle progression 
 
It is postulated that ERK5 may play a role in controlling progression through the cell 
cycle.
55
 There is some dispute over which stage of the cycle ERK5 regulates as the 
hypothesis that it controls the G1/S transition may not be correct due to levels of 
activated ERK5 being negligible in HeLa cells arrested in the G1/S phase.
56
 However, 
activated ERK5 levels have been shown to increase during the G2/M phase of the cell 
cycle.  It has been shown that the phosphorylation of ERK5 during this phase is not 
conducted by MEK5 and does not occur on the TEY motif, but at several sites on the C-
terminus.
55, 57
 ERK5 was found to activate the transcription factor NFκB, mediated by 
RSK2 during the G2/M phase, which is essential for mitotic entry.
58
  
 
It has been postulated that during mitosis, ERK5 phosphorylates Bim (a pro-apoptotic 
protein). However, in 2012 it was proven that it is CDK1 that mediates Bim 
phosphorylation rather than ERK5 as previously suggested.
59
 Despite this discovery, it 
is clear that ERK5 does play a role in cell cycle progression, particularly in the entry to 
mitosis,  and that an over-expression of ERK5 could lead to an uncontrolled increase in 
cell proliferation leading to tumourigenesis.  
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2.4.3.3 ERK5 and angiogenesis 
 
ERK5 has been identified as a regulator of embryonic angiogenesis, since embryos 
without ERK5 cannot survive.
60
 Tumours depend on angiogenesis in order to progress 
and therefore, a link between ERK5-mediated angiogenesis and tumourigenesis has 
been established.  
 
Tumour growth and metastasis was shown to be reduced in studies using siRNA 
knockdown of MAPK7 (the gene encoding ERK5) in BI6F10 (melonoma) and LL/2 
(Lewis lung) mouse xenografts and tumour vasculature was significantly affected.
60
 
ERK5 has been shown to activate ribosomal protein S6 (rpS6) following activation of 
the ERK5 signalling pathway by VEGF or FGF. rpS6 is involved in the RSK-rpS6 
signalling pathway. This pathway regulates cell proliferation and survival, which are 
key processes in tumour angiogenesis.
61
  
 
Interestingly, a link between ERK5 and Id1(‘inhibitor of differentiation’) activation has 
been estabished. Id1 is a negative regulator of TSP1 (thrombospondin-1), which is a 
known inhibitor of angiogenesis, therefore over-activation of ERK5 can induce 
angiogenesis.
62
  
 
 
2.4.3.4 ERK5 and migration, invasion and metastasis  
 
ERK5 activation may occur via integrin-mediated focal adhesion kinase (FAK) 
signalling.
63
 FAK signalling plays an important role in regulation of cell adhesion and 
motility. The integrins comprise a large family of cell-surface receptors that bind to, and 
control, the extracellular matrix. The extracellular matrix acts as a scaffold and mediates 
cellular organisation. Increased levels of ERK5 can lead to increased levels of matrix 
metallo-proteinase-9 (MMP-9), which leads to delocalisation of cancer cells via 
degradation of the extracellular matrix, increasing migration, invasion and metastasis.
63
 
It has been shown that prostate cancer cells transfected with a dominant negative mutant 
of FAK showed no ERK5 activation and cell migration, adhesion and motility was 
reduced as a result. ERK5 also activates the transcription factor AP-1, which can also 
promote several MMPs (including MMP-1, 3, 7, 9, 11, 13 and 19) to degrade the 
extracellular matrix, further implicating ERK5 in the development of tumour 
metastases.
63
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ERK5 has been linked to the HGF/Met/Brk signalling pathway, which has been 
associated with increased growth and migration in breast cancer cell lines. The levels of 
breast cancer kinase (Brk) are over-expressed in many breast cancer cell lines.
63-64
  HGF 
(hepatocyte growth factor) activates the receptor tyrosine kinase Met, the upstream 
activator of Brk. Activated Brk is able to phosphorylate ERK5 via formation of a 
complex initiated by scaffolding proteins. Brk-mediated phosphorylation of ERK5 
promotes HGF-induced migration of breast cancer cells.
64
 These findings imply that an 
ERK5 inhibitor may be therapeutically useful for the prevention of metastatic breast 
cancer.  
 
Interestingly, ERK5 has been shown to suppress epithelial-mesenchymal transition 
(EMT).
65
 EMT plays a crucial role in the development of cancer metastasis and is 
generally promoted by MAPK signalling pathways (e.g. ERK, JNK and p38). ERK5 has 
been shown to upregulate levels of adherent junction proteins (e.g. E-cadherin and ZO-
1) in the cell membrane leading to the development of close cell-cell contacts. The 
development of these contacts is a key indicator of mesenchymal-epithelial transition 
(MET), which is the reverse of EMT.
65
 The expression of mesenchymal markers 
vimentin and N-cadherin was shown to be low in cells were ERK5 was upregulated and 
these cells showed slower serum-induced migration. Furthermore, knockdown of ERK5 
in a number of cancer cell lines showed loss of close cell-cell contacts and cell 
scattering, both of which correlate with EMT.
65
 It appears that ERK5 acts as a critical 
controller of EMT and metastasis. ERK5 down-regulation increases the accumulation of 
Snail, which was found to be modulated by Akt/GSK3β signalling via the modulation of 
mTOR by inhibitor DEPTOR.
65
 Increased metastasis in patients undergoing treatment 
with EGFR inhibitors erlotinib and gefitinib has been observed and could be linked to 
the inhibition of downstream target, ERK5. Combination of EGFR antagonists with 
agents that effect the EMT process may enhance the sensitivity of more mesenchymal 
tumours to treatment, improving treatment strategies for metastatic cancer.
65
 
Combination studies are being conducted at Newcastle to determine if an ERK5 
inhibitor has an effect on treatment with an EGFR inhibtor.  
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2.4.3.5 Cancer types where ERK5 signalling is deregulated  
 
Deregulation of the MEK5/ERK5 signalling pathway has been associated with the 
development of a number of cancer types, usually resulting in more aggressive 
phenotypes and poor disease specific survival. An overview of the cancer types in 
which ERK5 has been implicated is provided herein demostrating the emerging 
requirement for develoment of ERK5 inhibitors as potential chemotherapeutics.   
 
 
2.4.3.5.1 ERK5 and prostate cancer 
 
Prostate cancer is the most commonly diagnosed cancer in men in the UK (Figure 13) 
and the second most frequent cause of cancer-related male deaths behind lung cancer.
6
 
 
 
Figure 13. The 10 most commonly diagnosed cancers in males in the UK in 2010.
6
 
 
There are several risk factors associated with the development of prostate cancer, the 
most prevalent being age. There may also be a genetic link to the development of 
prostate cancer. Men carrying germline mutations in the BRCA2 gene (associated with 
the onset of breast and ovarian cancers in females) may have an increased risk of 
developing prostate cancer.
66
  
 
There is currently no national screening program for prostate cancer in the UK, but the 
prostate specific antigen (PSA) test is a useful diagnostic tool for the disease. PSA, also 
49 
 
known as P-30 antigen, is a glycoprotein produced by prostate cells. A high level of 
PSA in the blood is thought to be indicative of prostate cancer, and can be a good initial 
non-invasive test for the disease.
6
 However, the PSA test is not a diagnostic measure, as 
elevated PSA levels may also be detected in non-cancerous conditions such as 
prostatitis, or benign enlargement of the prostate. If a high level of PSA is detected, a 
biopsy can be taken. The cells from the biopsy will be examined in order to deem how 
similar they are in appearance to healthy cells of the prostate. If the cells appear to be 
abnormal, as indicated by poor differentiation, a Gleason sum score can be determined. 
The Gleason score is based on the Gleason grading system, which is a helpful tool used 
to classify the stage of prostate cancer. Grading is on a scale of 1-5, based on the pattern 
of cell differentiation. Cells with a differentiation pattern similar to healthy prostate 
cells (i.e. small and uniform) will be graded as 1 on the Gleason grading scale, with 
cells that are poorly differentiated (i.e. lacking order) being graded as 5 (Figure 14). 
Grades from the two most common patterns seen in the biopsy sample are added 
together to give the overall Gleason score between 2 and 10, with a higher score, 
indicating more advanced and aggressive disease.
67-68
 
 
 
 
 
Figure 14. Gleason grading for prostate cancer cells. Adapted from ref 65. 
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The progression of prostate cancer predominantly relies on the androgens and, in 
particular, testosterone, which is required by the tumour for growth. It is estimated that 
80-90% of diagnosed prostate cancers are dependent on androgens and the androgen 
receptor for their development, and expression of the androgen receptor is maintained 
during prostate cancer progression.
69
 
Prostate cancer can be divided into two types, hormone sensitive (or dependent) and 
hormone insensitive (or independent), which is particularly more aggressive. Inhibition 
of androgen activity is particularly effective as a treatment against hormone dependent 
prostate cancer either via inhibition of the interaction between the androgen and its 
receptor or by androgen deprivation. There are currently several drug classes which 
suppress the action of androgens either by reducing serum testosterone and 5α-
dihydrotestosterone (DHT) levels, or by directly inhibiting the androgen receptor. 
Nilutamide 21 and flutamide 22 are competitive inhibitors of the androgen receptor 
blocking the binding of testosterone/DHT and directly inhibiting the androgen 
signalling pathway.
70
  
 
 
 
                          
 
Another class of drugs used for the treatment of hormone dependent prostate cancer are 
Gonadotropin Releasing Hormone (GnRH) agonists, e.g. Leuprolide or Goserelin.  
These drugs work by reducing the release of luteinising hormone (LH). Luteinising 
hormone is responsible for androgen synthesis in the testes and use of GnRH agonists 
has been shown to reduce testosterone and DHT levels in serum and therefore slow the 
progression of prostate tumours.
69
  
 
Most cases of prostate cancer are responsive to hormone therapies, and will show a 
positive response to androgen deprivation. However, around 20% of cases will show no 
response to this type of treatment. Along with the initially unresponsive patients, there 
is also a high possibility that responsive patients will develop a hormonal resistance to 
their treatment. This is very common after around 18-24 months of treatment, and 
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results in the development of the more aggressive hormone independent form of the 
disease, which can be ultimately fatal.
71-72
  
Development of hormone independent cancer (also known as castrate-resistant) is 
linked to the anti-apoptotic gene, bcl-2, which can be over-expressed in prostate cancer 
cells, but not in healthy cells of the prostate. This is thought to prevent the cancerous 
cells from undergoing apoptosis independent of hormone deprivation and so resistance 
to hormonal therapies is initiated. Once this resistance has developed it is necessary to 
use secondary hormonal and chemotherapeutic agents in an attempt to treat the disease. 
Paclitaxel (Taxol, 23) and Docetaxel (Taxotere, 24) are from the taxane family of 
chemotherapeutic agents, and are currently used as the standard for initial treatment of 
hormone independent prostate cancer in combination with prednisone 25, a 
corticosteroid. They are mitotic inhibitors and work by interrupting microtubule 
formation, causing apoptosis via preventing cells from entering mitosis.
73
  
 
Steroid hormones dehydroepiandrostenedione (DHEA) and androstenedione can be 
converted into testosterone by enzymes found in the prostate and the androgen 
receptor’s sensitivity to testosterone and DHT is often elevated in patients with 
hormone independent prostate cancer prostate cancer. In 2011, Abiraterone (26) was 
approved for use as a life-prolonging agent for patients suffering from terminal prostate 
cancer. Abiraterone works as a17α-hydroxylase and C17-20 lyase inhibitor, which 
prevents androgen biosynthesis. The prevention of extra-testicular androgen synthesis 
by Abiraterone has provided a novel therapy for patients suffering advanced prostate 
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cancer which is no longer responsive to the traditional anti-androgen drugs.
74
 Orteronel 
(27) is also in phase III clinical trials as an inhibitor of C17-20 lyase.
75
  
 
 
                           
 
The development of second-generation anti-androgen treatments is in progress for the 
treatment of patients resistant to first-line hormonal therapy. One mechanism of 
resistance is the up-regulation of the androgen receptor. Enzalutamide (28) was 
developed as an inhibitor of the androgen receptor following a screen of non-steroidal 
compounds and is  up to 8-fold more potent than common 1
st
 line treatments.
76
  
Enzalutamide also impairs nuclear translocation, and recruitment of co-activators of the 
androgen receptor ligand-receptor complex, and has recently been approved for the 
treatment of patients with hormone independent prostate cancer.
76
  
 
 
 
The MEK5/ERK5 pathway has become a potential target for the treatment of homone 
independent prostate cancer since expression of ERK5 is up-regulated in prostate cancer 
cells. Studies conducted at Newcastle university show that ERK5 over-expression 
correlates with a high Gleason sum score as shown by the graph in Figure 15. The 
ERK5 staining intensity is semi-quantitative, scored as either absent (0), weak (1), 
moderate (2) or strong (3).
42
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Figure 15. The relationship between ERK5 expression and Gleason sum score. Adapted 
from ref 42. 
 
 
Deregulation of the MEK5/ERK5 signalling pathway is also related to increased 
metastatic potential of prostate cancer cells and poor disease specific (Figure 16).  
Elevated cytoplasmic and nuclear levels of ERK5 serve as an independent prognostic 
marker for advanced prostate cancer, with nuclear ERK5 expression present only in 
malignant cells.
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Figure 16. A:ERK5 expression in the presence and absence of bone metastases; black = 
No ERK5 expression detected; white = ERK5 expression detected. 
B: Elevated ERK5 expression correlates with poor disease specific survival. Adapted 
from ref  42.
 
 
 
A prostate cancer cell line (PC3) was used in a xenograft study using mice. Prior to 
implantation, PC3 cells were either transfected with MAPK7 (the gene encoding ERK5) 
or empty vector. Cell proliferation was significantly higher in those transfected with 
MAPK7 with an increase in mean tumour volume at 40 days post implantation 
measured compared to the control (Figure 17).
42
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Figure 17. PC3 cells transfected with ERK5 show a more aggressive phenotype. 
Adapted from ref  42.  
 
Inhibition of ERK5 using small-molecule PD184352 (7) was shown to reduce cell 
growth, migration and invasion in PC3 cells. PD184352 is a known allosteric inhibitor 
of MEK1/2, but when administered at high concentrations (3 μM in this study) 
inhibition of ERK5 is observed.
42
These results suggest that clinical inhibition of ERK5 
may have a therapeutic application as an anti-proliferative, anti-metastatic agent. 
 
 
 
2.4.3.5.2 ERK5 and breast cancer 
 
Breast cancer is the most commonly diagnosed cancer in women, with approximately 
49,000 new cases in the United Kingdom in 2010 (Figure 18). Male breast cancer 
accounted for around 1% of all UK cancer diagnoses in 2010.
6
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Figure 18. 10 most commonly diagnosed cancer in females in UK in 2010.
6
  
 
The risk of developing breast cancer is strongly associated with production of the 
female hormone oestrogen and hormonal influences, such as use of the contraceptive 
pill and reproductive history exert a significant effect on the risk. Genetic predisposition 
is the most common risk factor. Mutations in the tumour suppressor genes BRCA1 and 
BRCA2 have been associated with an elevated risk of developing breast, increasing the 
lifetime risk to ≥80%.66 
 
An increase in MEK5 activation was detected in a non-malignant telomerase 
immortalised breast cancer (TERT) cell line. The increase in levels of activated MEK5 
is thought to be related to the oncogene Stat3 (signal transducer and activator of 
transcription 3), a member of a family of transcription factors responsible for cell 
growth and survival. Several genes are reported to be up-regulated by Stat3, including 
the matrix metalloproteinases MMP-1 and MMP-10, vascular endothelial growth factor 
(VEGF), and connective tissue growth factor (CTGF). In MDA-MB-435 Stat3 
expressing breast carcinoma cells, MEK5 expression and activation was inhibited 
following the use of Stat3 small-interfering RNA (siRNA), suggesting that MEK5 may 
be directly regulated by Stat3 in some breast cancers.
77
  
 
The HER2 receptor tyrosine kinase oncogene is found over-expressed in 20-30% of 
breast cancers, and is associated with a more aggressive phenotype, and poor disease 
specific survival. Monoclonal antibody trastuzamab (Herceptin) and small-molecule 
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inhibitor lapatanib (29) both target the HER2 protein, and are used clinically in patients 
with advanced or metastatic HER2-positive breast cancers.
78
 The extracellular HER2 
receptors mediate signalling via several pathways, including those involving the 
MAPKs.
78
  
 
 
 
In certain breast cancer cell lines, ERK5 levels are elevated due to binding of neuregulin 
to the HER2 receptor. Inhibition of ERK5 in combination with Herceptin has shown 
chemo-potentiation, sensitising cells to Herceptin treatment. ERK5 may be used as an 
independent prognostic factor in breast cancers with high levels of ERK5 correlating 
poor disease specific survival (Figure 19).
79
 Therefore, the development of a potent 
ERK5 inhibitor may provide a more successful approach for the treatment of advanced 
HER2-positive breast cancer. 
 
 
Figure 19. Disease-free survival with respect to ERK5 levels in; (A) patients with early 
stage breast cancer and (B) in patients with HER2 positive early stage breast cancer. 
Adapted from ref 76. 
 
 
2.4.3.5.3 ERK5 and the development of human lung cancer  
 
Insulin-like growth factor II (IGF-II) is over-expressed in a number of human lung 
cancer cell lines and correlates with a poor prognosis. ERK5 initiates IGF-II activation 
A B 
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of transcription factor, cAMP response element binding protein (CREB). CREB 
controls a number of genes including bcl-2, c-fos and erg-1, which are involved in cell-
cycle progression. ERK5-mediated activation of IGF-II has been identified as essential 
in promoting growth of lung cancer cells. Therefore, an ERK5 inhibitor may prove a 
useful therapy for the treatment of lung cancer.
80-81
  
 
 
2.4.3.5.4 ERK5 and leukaemia cell survival  
 
ERK5 expression in leukaemia cells containing the Bcr/Abl oncogene promotes cell 
survival.
82
 The Bcr/Abl oncogene is able to stabilise and promote ERK5 expression and 
activation. Leukemic cell line, MEG-01 were found to more readily enter apoptosis 
when they expressed lower levels of ERK5 and were treated with imatinib.
82
 The level 
of ERK5 expressed in CML cells had a direct relationship with the effectiveness of 
treatment with imatinib, suggesting ERK5 may be a factor in development of 
chemoresistance.  
 
Leukemic T-cells promote cell survival via activation of the transcription factor NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), which is regulated by 
the MEK5/ERK5 pathway.
83
 NF-κB is an anti-apoptotic protein resulting in increased 
cell survival. ERK5 involvement in the activation of NF-κB has been linked to the 
activation of RSK1 (a downstream target of ERK5), which liberates NF-κB from the 
cytoplasm.
83
 An ERK5 inhibitor may have potential as a useful therapy for promoting 
apoptosis in leukemic T-cells or for treatment of phenotypes that have developed 
chemoresistance to imatinib.  
 
2.4.3.5.5 ERK5 and hepatocellular carcinoma (HCC) 
 
Hepatocellular carcinoma (HCC) is the most commonly diagnosed form of liver 
cancer.
84
  Liver cancer in adults often suffers from poor prognosis at the time of initial 
diagnosis. The main risk factors associated with the development of liver cancer are 
exposure to the Hepatitis B and C viruses, and excessive consumption of alcohol.
6
  
 
Investigation of  DNA number copy abberations in HCC cell lines (SNU449 amd JHH-
7) identified a novel gene amplification at the 17p11, which corresponds to an over-
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expression of MAPK7 (the gene encoding for ERK5) (Figure 20). Over-expression of 
MAPK7 was thought to promote growth of HCC cells via regulation of mitosis.
84
  
 
 
Figure 20. Amplicon map of the 17p11 chromosome in SNU449 and JHH-7 cells 
corresponding to an over-expression of MAPK7. Adapted from ref 81. 
 
Immunohistochemical studies of 43 primary HCCs revealed ERK5 levels to be raised in 
aound 25% of cases. RNA interference using siRNA to knockdown MAPK7 in SNU449 
cells resulted in suppression of cell growth, an effect attributed to the prevention of 
ERK5-mediated mitotic entry (Figure 21).
84
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Figure 21. Knockdown of MAPK7 using siRNA in SNU449 cells. Adapted from ref 
81. 
 
An ERK5 inhibitor may, therefore, prove a valid therapeutic agent for patients with 
HCC.  
 
 
2.4.3.5.6 ERK5 and multiple myeloma  
 
ERK5 has also been implicated in the development of multiple myeloma (MM), which 
is the accumulation of neoplastic plasma cells of β-lymphocyte origin, associated with 
the immune system. MM accounts for 10% of all haematological malignancies and 
leads to the overproduction of antibodies that are no longer able to function normally.
85
 
The usual treatment is intensive chemotherapy which has little selectivity over normal 
and neoplastic cells. As for breast cancer, the Stat3 oncongene has been implicated in 
the progression of MM and is known to stimulate ERK5 activation.
85
 
 
The myeloma growth factor, interleukin 6 (IL-6) has also been shown to activate ERK5 
in MM cell lines. Expression of a dominant negative form of ERK5 was shown to 
reduce IL-6 dependent cell proliferation in MM cell lines.
85
 Chemo-potentiation of 
current therapies is observed following ERK5 knockout in MM cell lines, meaning that 
development of an ERK5 inhibitor could improve the current treatment of MM by 
reducing the intensity of the treatment regime.
85
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2.4.3.5.7 ERK5 and malignamt mesotheliomas 
 
Malignant mesothelioma is a cancer of the pleura, pericardium and peritoneum 
associated with asbestos exposure.
86
 At present there is no successful monotherapy for 
the treatment of malignant mesothelioma and survival post diagnosis is less than 12 
months. Doxorubicin and cisplatin were originally used as a first-line monotherapy for 
the disease and are still used in combination with other chemotherapeutic agents. The 
current standard of care is treatment with cisplatin in combination with pemetrexed, a 
folate antimetabolite drug. This treatment improves patient survival from 9 to 12 
months so there is still a need for improved therapeutics.
86
  
 
ERK5 has recently been shown to be constitutively active in human mesothial cell lines 
(HMESO, H2373, H2595, H2461 and HP-1) and plays a key role in tumoorigenesis.
86
 
Three of the five cell lines tested showed significant activation of ERK5 after treatment 
with doxorubicin. Silencing of ERK5 using shRNA in HMESO and H2373 cells 
showed down-regulation of ERK5 and rendered cells more sensitive to doxorubicin 
treatment, suggesting the ERK5 may be involved in drug resistance in malignant 
mesothelioma patients.
86
  ERK5 silencing was shown to correlate with a number of 
genes related to decreased proliferation, invasion and migration. In vivo studies were 
conducted in SCID mice and reduced tumour growth was observed in ERK5-silenced 
malignant mesotheliomas treated with doxorubicin compared control experiments.
86
 
This suggests that an ERK5 inhibitor may be able to attenuate tumour growth by 
chemo-potentiation of doxorubicin/cisplatin in human malignant mesotheliama. Studies 
are currently being conducted at Newcastle to see if this is a valid approach.  
 
 
2.4.4 Inhibitors of the MEK5/ERK5 pathway 
 
There are currently three published inhibitors of the MEK5/ERK5 pathway. BIX02188 
(30) and BIX02189 (31) were developed by Boehringer Ingelheim Pharmaceuticals in 
2008 and are indoline-6-carboxamide-based inhibitors. Compounds 30 and 31 inhibit 
the catalytic function of MEK5, blocking the phosphorylation and subsequent activation 
of ERK5. This leads to the inhibition of the transcriptional activity of MEF2C, a 
downstream substrate of the ERK5 pathway, resulting in reduced cell proliferation.
87
 
The two inhibitors are potent for both MEK5 and ERK5 and show excellent selectivity 
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for MEK5 and ERK5 against a wide panel of kinases with >100 fold selectivity against 
85 of 87 kinases tested. Importantly there is no observed inhibition of the closely related 
kinases, ERK2 and MEK1/2.
87
  
 
 
 
In 2010, an inhibitor of ERK5 was discovered by the Scripps Institute based on a series 
of isoform selective polo-like kinase (PLK) inhibitors.
53
  Analogues of the potent, ATP-
competitive PLK inhibitor, BI-2536 (32) were made, and after expansion of the 
aliphatic ring of BI-2536, PLK activity was reduced. The new inhibitor, XMD8-92 (20) 
displayed high selectivity for ERK5 when tested against a panel of 402 kinases in an 
ATP-site competition binding assay.
53
  Notably, MEK5 was not inhibited by XMD8-92 
up to a concentration of 50 µM. The IC50 was measured in an in vitro assay as 300 nM, 
meaning that XMD8-92 is both a potent and selective ERK5 inhibitor. A cellular assay 
was conducted also using HeLa cells and the IC50 for this was measured as 1.5 µM.
53, 88
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The in vivo efficacy of XMD8-92 was tested in two mouse tumour xenograft models 
using HeLa cells and Lewis lung (LL/2) cells. Growth inhibition of the tumours was 
observed over time, and importantly, inhibition of ERK5 was observed as well as the 
induction of p21 expression via PML activation.
53
  
 
 
 
 
 
Figure 22. Western blot analysis showing inhibition of ERK5 and increased expression 
of p21 and (A) mouse xenograft model using HeLa cells and (B) LL/2 cells. Adapted 
from ref 52. 
 
The discovery of a novel, selective ERK5 inhibitor with proven efficacy has assisted in 
the validation of our biological assays and guided PK studies on this project. XMD8-92 
is now used as a benchmark for our ‘in house’ development of novel inhibitors of 
ERK5.  
 
 
2.4.4.1 X-Ray crystal structure of ERK5 in complex with an analogue of 
XMD8-92 
 
Until recently, the X-ray crystal structure of ERK5 had not been elucidated, but 
emerging interest in the MAPK led to the determination of the crystal structure in 
A B 
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complex with an inhibitor.
89
 The kinase domain of ERK5 is known to have high 
structural similarity to a number of MAPKS; ERK1, 51%; ERK2, 51%; p38β, 47%; 
p38α, 46%; p38δ, 43%; NLK, 43% and p38γ, 38%, but it remains one of only two 
MAPKs for which the crystal structure remained unsolved.
89
  The X-ray crystal 
structure of the ERK5 kinase domain was published in 2013 in complex with an 
analogue of XMD8-92 in order to aid the structure-guided design of novel inhibitors. 
The protein was expressed and purified from baculovirus-infected insect cells and 
protein crystals were obtained from construct 1-397 of human ERK5. The crystal 
structure was obtained to 2.8 Å resolution and the protein was in the inactive form.
89
 
 
Inhibitor 33 forms two hydrogen bonds to the hinge region of the ERK5 ATP binding 
site at Met140 (Figure 23, C) from the pyrimidine nitrogen and the NH. Key hydrogen 
bonds are also made via a water molecule to the DGF motif Asp200 and Glu102 from 
the carbonyl oxygen (Figure 23, A).
89
  The piperidine-piperazine rings point out of the 
ATP binding site towards solvent. Overall, the shape of inhibitor 33 fits extremely well 
into the ERK5 ATP binding site, explaining the inhibitory activity of the 
benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one analogues. Interestingly, the ERK5 ATP 
binding site was found to have two unique residues; Gly199 before the DFG loop and 
Leu189 at the bottom of the ATP binding site. Despite structural similarities of the 
MAPKs, ERK5 is the only member to have these residues in the two specific 
locations.
89
 This partly explains the specificity of inhibitors such as XMD8-92 and 33 
for ERK5 and is key information for the development of novel selective inhibitors of 
ERK5.  
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Figure 23. (A) Inhibitor 33 bound in the ERK5 ATP binding site; (B) as in (A) with the 
surface of the ATP binding site shown around 33; (C) An alternative angle to A 
showing the key hinge binding.
86
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Chapter 3. The development of novel inhibitors of ERK5 
3.1 HTS for novel inhibitors  
 
In order to identify inhibitors of ERK5, a high throughput screen (HTS) was conducted 
using an immobilised metal affinity polarisation (IMAP
TM
) assay at CRT-DL in 2007. 
The IMAP
TM
 assay assesses the potency of compounds by measuring fluorescence 
polarisation. As shown in Figure 24, the assay uses a fluorescent labelled peptide, which 
is specifically selected to bind to the kinase of interest. In this case, the labelled peptide 
was chosen to be a substrate for ERK5, which is activated in situ by the presence of 
activated MEK5. Out of 60 peptides screened, just one was identified for use in the 
assay. Once the labelled peptide is bound to the kinase, it is phosphorylated by ATP 
present in the assay (at 300 µM), enabling it to bind to metal (M(III))-containing 
nanoparticles via a high affinity interaction. This leads to a measurable increase in the 
fluoresence polarisation readout. In the presence of a potent inhibitor of the kinase, 
phosphorylation of the labelled substrate is impeded, meaning that fewer 
phosphorylated substrates are able to interact with the M(III) nanoparticles and the 
polarisation readout is reduced. The HTS for inhibitors of ERK5 was carried out using a 
kinase focussed collection of 9000 compounds and a full compound collection 
comprising 48,500 compounds and confirmed hit compounds as having ERK5 
inhibitory activity. 
 
 
 
Figure 24.  IMAP
TM
 assay format. 
 
Following the high-throughput screening campaign, three distinct chemical series were 
identified as having good inhibitory activity against ERK5 based on their performance 
in the assay, the benzothiazoles (A), pyrrole carboxamides (B) and the cyanopyridines 
(C).  
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Initially, all three of these chemical series were investigated, with the most potent 
compounds from each series being re-synthesised and tested in order to validate the 
series as true ‘hits’. In the benzothiazole series, the re-synthesised hits were not 
validated and so further work into the development of inhibitors based around this 
chemical series was discontinued. The cyanopyridine series has also been discontinued. 
In this case, although the original hits were validated, it became apparent that there was 
a very narrow SAR around this chemical series and as a result, modifications that were 
made to the core structure did not improve ERK5 inhibitory activity.  
 
The final of these three series, the pyrrole carboxamide series, was validated by re-
synthesis of the initial hit compounds, which had activity in the 0.66 – 33 µM range 
(Table 2). This chemical series has now progressed to the lead optimisation stage of 
drug discovery with key SARs having been identified.  
 
 
 
Table 2. Initial pyrrole carboxamide hits identified and corresponding IC50 values.  
 
Compound R
1
 R
2
 
ERK5; IC50 
(µM) 
34 
  
3.7 
35 
 
 
1.9 
36 
 
 
3.5 
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37 
 
 
4.3 
38 
  
5.5 
39 
 
 
6.0 
40 
        
 
6.3 
41 
  
11 
42 
 
 
12 
43 
 
 
14 
44 
 
 
14 
45 
 
 
15 
46 
 
 
16 
47 
 
 
17 
48 
  
17 
49 
  
23 
50 
 
 
33 
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3.2 Preliminary structure-activity relationship studies (SARs) around the pyrrole 
carboxamide scaffold 
 
 
Initial SARs were conducted by Dr Sandrine Vidot and Dr Ruth Bawn.
90
  A 3-fold 
improvement in potency was considered significant after n = 2. Modifications to the 
aroyl ring found that substitution in the para-position was not tolerated. Dihalogenation 
in a 2,3- or 2,6-substitution pattern conferred the best potency exemplified by inhibitors 
with 2,3-dichloro and 2,6-difluorobenzoyl rings. N-Methylation of the pyrrole nitrogen 
abolished activity (ERK5; IC50>120 µM), indicating that the pyrrole NH is important 
and possibly acts as a hydrogen bond donor in the hinge region of the ATP binding site 
of ERK5. N-Methylation of the carboxamide motif was tolerated, but activity was 5-
fold lower than the non-methylated counterpart. Complete removal of the ketone of the 
benzoyl motif or reduction to the corresponding secondary alcohol also resulted in loss 
of activity (ERK5; IC50>120 µM), suggesting the possible need for a hydrogen bond 
acceptor in this position. Finally, 3- and 4-pyridyl substituents were found to be 
equipotent with the 4-fluorophenyl moiety present in the carboxamide side-chain. The 
most potent compounds identified in preliminary SARs are shown in Table 3. 
 
 
Table 3. Preliminary SAR data around the pyrrole-carboxamide core 
Compound R
1
 R
2
 ERK5; IC50 (µM) 
34 
  
3.7 ± 0.8 (n = 2) 
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2.0 ± 2.0 (n = 10) 
52 
  
3.8 ± 3.7 (n = 6) 
53 
  
2.3 ± 0.1 (n = 2) 
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54 
  
1.8 ± 0.6 (n = 10) 
55 
  
9.0 ± 0.2 (n = 2) 
 
3.3 Selectivity of hit compounds  
 
The MAPK, p38α is a close homologue of ERK5, with 48% sequence identity in the 
kinase domain and 56% in the active site. ERK2 is the closest homologue with 51% 
sequence identity in the kinase domain and 78% in the active site. Despite ERK2 having 
more structural identity with ERK5, it has a larger gatekeeper residue (glutamine) than 
ERK5 (leucine) meaning that gaining selectivity for ERK5 over ERK2 is easily 
achieved. The gatekeeper residue in p38α is a threonine residue and, as such, is more 
similar in size to the leucine gatekeeper residue of ERK5. This means achieving 
selectivity for ERK5 over p38α is more challenging. It is therefore essential to screen 
compounds with inhibitory activity for ERK5 against p38α. Compounds are tested for 
p38α activity using a LANCE assay. The LANCE assay uses time resolved fluorescence 
energy transfer (TR-FRET) in order to determine IC50 values. The assay uses ULight, 
which is an acceptor dye with a red-shifted fluorescent emission, and a europium 
chelate donor dye. The kinase of interest is labelled with the ULight dye and is 
phosphorylated. A europium labelled antibody is able to bind to the phosphorylated 
kinase, bringing the donor and acceptor in close proximity. Upon irradiation at 320 nm, 
FRET occurs between the europium donor and the ULight acceptor and light is emitted 
at 665 nm. The intensity of the light emitted is measured and in turn converted into the 
IC50 value for an inhibitor. If the phosphorylation of the ULight labelled kinase has been 
inhibited, the light emitted after FRET will be less intense (Figure 25).  
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Figure 25. LANCE Assay format. 
 
 
 
Pyrrole-carboxamide-based inhibitors of p38α have recently been described in the 
literature, with compound 56 showing good inhibitory activity (pIC50 = 6.6).
91
  
Compound 56 and the other analogues described are structurally similar to the 
Newcastle ERK5 pyrrole carboxamide inhibitor series, further highlighting the need for 
p38α counter-screening on all synthesised compounds. Subtle structural modification of 
the ERK5 pyrrole-carboxamide series is essential to obtain both potency against ERK5 
and selectivity over p38α taking advantage of the key differences in the active sites of 
the two MAPKs.  
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3.4 Development criteria for pyrrole carboxamide ERK5 inhibitors 
 
 
Following the HTS, the initial pyrrole carboxamide hit compounds were validated as 
ERK5 inhibitors via resynthesis and testing. Once clear SARs have been established, 
hit-to-lead studies can be conducted. If an inhibitor meets the criteria in vitro, in vivo 
efficacy and DMPK profile will be assessed. The desired criteria identified for a lead 
compound in the ERK5 project are outlined in Table 4.  
 
 
Table 4. Desired criteria for a lead compound in the ERK5 pyrrole carboxamide series. 
 
Category Parameter 
 
Lead criteria 
 
Physicochemical 
properties  
Molecular weight (MW) 
 
<500 
sLogP 
 
<5 
TPSA (Å
2
) 
 
75-100 
H bond donors 
 
H bond acceptors 
<5 
 
<10 
In Vitro pharmacology 
ERK5; IC50 (µM) 
 
< 1 
LE* 
 
>0.3 
Selectivity  
 
>10-fold 
Cellular ERK5; IC50 (µM) 
 
<10 
hERG; IC50 (µM) >25 
In Vitro ADME 
Solubility L/U (µM)** 
 
>50/50 
PPB (%)*** 
 
<99 
Mouse liver microsomal 
(MLM) clearance (µL/min/mg) 
 
<48 
Human liver microsomal 
(HLM) clearance (µL/min/mg) 
 
<48 
Caco-2 A2B Papp (x10
-6
 cm/s) 
 
>10 
Efflux Ratio 
 
<2 
CYP1A, CYP2C19, CYP2C9, 
CYP2D6, CYP3A4; IC50 (µM) 
All >10 
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In Vivo DMPK and 
Efficacy 
Clearance (mL/mg/kg) <30 
 
Vdss (L/kg) 
>1 
 
Bioavailability (F) (%) 
 
>30 
t1/2 Mouse (h) 
 
>1 
t1/2 Human (h) 
 
>1 
* LE = ∆G/HAC (where ∆G = -1.4 logIC50) 
**L/U = Lower bound/Upper bound solubility range 
*** PPB in human 
 
These criteria were utilised throughout the hit-to-lead phase of this drug discovery 
project. The physicochemical property criteria desired for a lead compound were based 
upon Lipinski’s rule of five (molecular weight, logP and number of H-bond donors and 
acceptors) since an orally bioavailable compound was desired. TPSA was also evaluated 
during this stage to give an indication of how cell permeable a compound may be. The 
desired range of 75-100 Å
2
 was chosen to give the best chance of having compounds 
that would be cell membrane permeable but would not cross the blood-brain barrier 
(compounds with a TPSA <75 may be lipophilic enough to do this) . Solubility data are 
generated by Cyprotex using a turbidimetric assay and are reported as an estimated 
precipitation range, L/U (Lower bound/Upper bound). The assay measures solubility of 
compounds by diluting in DMSO in aqueous buffer. Turbidimetry is used as the 
endpoint by measuring absorbance at 620 nm. It can be assumed that the compound will 
precipitate at some point during this range. A solubility value of less than 1µM would 
represent a highly insoluble compound, between 1 and 100µM partially soluble and 
>100µM a soluble compound.In vitro pharmacology was evaluated based on potency 
for ERK5 in the cell-free IMAP assay (IC50 < 1 μM) and in a cellular assay (IC50 < 1 
μM), selectivity over other kinases and the compound’s ligand efficiency (LE). LE is a 
measure of overall binding energy per heavy atom, with a value greater than 0.3 for LE 
indicating efficient binding. Routine counter-screening of inhibitors against p38α was 
conducted as discussed previously and for interesting compounds a counter-screen for 
selectivity against a panel of 131 diverse protein kinases was performed at the 
International Centre for Kinase Profiling in Dundee. Inhibition of hERG may also be 
measured at this stage.   
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Assessment of in vitro ADME determines if compounds meet the desired criteria for 
aqueous solubility, plasma protein binding (PPB) and microsomal clearance (tested in 
both mouse and human liver microsomes). Meeting the outlined criteria for in vitro 
ADME provides the best chance of good oral bioavailability and half-life in vivo.  
 
3.5 Structure-guided design 
 
 
3.5.1 First generation ERK2-derived homology model   
 
In the absence of a crystal structure of ERK5, homology modelling by sequence 
alignment and superimposition was conducted by Dr Susan Boyd on behalf of CRT-DL. 
ERK2 was identified as the closest homologue of ERK5 in a basic alignment search tool 
(BLAST) search, with 51% and 78% sequence homology in the kinase and ATP 
binding site domains, respectively and so the first generation homology model was 
based on ERK2. In the development of the homology model, three key differences were 
identified in the conserved residues of the two kinases; Ile103 (ERK2)/Val134 (ERK5), 
Gln105 (ERK2)/Leu136 (ERK5) and Cys164 (ERK2)/Gly198 (ERK5). Figure 26 shows 
the ERK2 template overlayed with the ERK5 homology model.  
 
 
Figure 26. Overlay of ERK5 homology model with ERK2 template.  
 
 
 
 
Red – ERK2 Template 
Green – ERK5 Template 
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3.5.2 Second generation p38α-derived homology model  
 
p38α is a the second closest homologue of ERK5, with 48% sequence identity in the 
kinase domain and 56% in the active site. A second generation homology model of 
ERK5 based on p38α was recently developed at Newcastle University. The p38α crystal 
structure was obtained from the protein data bank (PDB) and computationally mutated 
using MODELLER software to express the amino acid residues present in ERK5 and 
generate the homology model. The five key differences were identified as Glu110 
(p38α)/Ala107 (ERK5), Leu103 (p38α)/Thr106 (ERK5), Ala111 (p38α)/Ser108 (ERK5) 
Ala157 (p38α)/Leu155 (ERK5) and Leu167 (p38α)/Gly165 (ERK5) (Figure 27). 
Pyrrole-carboxamide inhibitors can be built into the ERK5 model using GROMACS 
(GROningen MAchine for Chemical Simulations) software enabling the structure-based 
design of new inhibitors exploiting previously unexplored areas of the ERK5 binding 
site. The docking of pyrrole carboxamide inhibitor 57 will be discussed in more detail in 
section 5.3.5.2 of chapter 5. 
 
 
 
 
 
Figure 27. (A) ERK5 model (magenta) compared to p38α crystal structure (cyan), both 
shown in complex with pyrrole carboxamide inhibitor 57; (B) 57 docked in the p38α-
derived homology model. 
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3.6 Synthesis of pyrroles 
 
Since we were interested in the synthesis of pyrrole carboxamide inhibitors of ERK5, 
the synthesis of the core pyrrole scaffold was investigated. There are three classical 
methods for the synthesis of pyrroles; the Knorr synthesis, Paal-Knorr synthesis, and the 
Hantzsch synthesis.  
 
3.6.1 The Knorr pyrrole synthesis  
 
The Knorr pyrrole synthesis was first published in 1884 and describes the reaction 
between an α-aminoketone with a β-ketoester in the presence of zinc and acetic acid to 
form pyrrole-3-carboxylates.
92
 Oximes are used in place of α-aminoketones and are 
reduced in situ by zinc to prevent self-condensation prior to condensation with the β-
ketoester (Scheme 1). After condensation with the β-ketoester, an aldol-type 
intramolecular condensation takes place to afford the substituted pyrrole. In the original 
reaction the R and R
1
 groups were both methyl and this compound is known as Knorr’s 
pyrrole.
92-93
 
 
 
Scheme 1. Knorr pyrrole synthesis  
 
 
3.6.2 The Paal-Knorr pyrrole synthesis  
 
An updated version of the Knorr pyrrole synthesis was developed by Knorr and Paal 
independently originally for the synthesis of substituted furans. This was later adapted 
by the two for the synthesis of substituted pyrroles and thiophenes.
94
 For pyrrole 
synthesis a 1,4-dicarbonyl compound is reacted with an excess of ammonia or a primary 
amine (Scheme 2). The mechanism for the Paal-Knorr synthesis was not understood 
until it was investigated in the 1990s by Amarnath et al, who discovered that the amine 
attacks a protonated carbonyl to form a hemiaminal intermediate.
95
 The amine is then 
able to attack the other carbonyl group to form a 2,5-dihydroxytetrahydropyrrole, which 
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undergoes dehydration to produce the substituted pyrrole. The reaction can be 
performed in neutral or weakly acidic conditions.
93
  
 
 
 
Scheme 2. Paal-Knorr pyrrole synthesis. 
 
 
3.6.3 The Hantzsch pyrrole synthesis  
 
The Hantzsch pyrrole synthesis was described in 1890 and is a multicomponent 
reaction.
96
 The first step involves the reaction of a β-ketoester with a primary amine to 
form an enamine (Scheme 3). The enamine then reacts with an α-haloketone and 
subsequent cyclisation occurs to afford the pyrrole product.
96
 The Hantzsch pyrrole 
synthesis suffers from poor reaction yields due to formation of furan by-products and so 
a solid-phase version of the reaction has been developed in more recent years to 
improve reaction yields and reduce by-product formation.
93, 97
 
 
 
 Scheme 3. Hantzsch pyrrole synthesis 
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Chapter 4. Structure activity relationship studies (SARs) around the 
amide side-chain 
4.1 Synthesis of ERK5 inhibitors based on potent CRT hits 58 and 59 
 
4.1.1 Rationale 
 
A high throughput screening (HTS) campaign was conducted at CRT-DL in 2007 
comprising a diverse library of around 48500, and a kinase-focussed library of around 
9000 compounds. Following this HTS, two hit triazole compounds (58 and 59) were 
identified as potent ERK5 inhibitors (IC50 = 0.31 and 0.20 µM, respectively). To expand 
the SARs, the synthesis of four compounds derived from primary hits 58 and 59 (Figure 
28) was proposed. The new targets contain a core pyrrole ring, a benzoyl substituent, 
and for compounds 60 and 61, an amide moiety.Compounds 62 and 63 were more 
similar to  the CRT hits 58 and 59 and have an amine directly attached to the core 
pyrrole ring at the 2-position.  
 
 
Figure 28.  CRT hit compounds and the 4 related compounds proposed for synthesis 
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4.1.2 Synthesis of 4-(4-isopropoxybenzoyl)-N-(4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl)-1H-pyrrole-2-carboxamide (60) based on CRT hit 58 
 
For compounds 60 and 61, a general synthetic scheme previously optimised within the 
NICR medicinal chemistry group was utilised (Scheme 4).
90
 This 3-step route involved 
an amide coupling as the final step to make pyrrole carboxamide compounds of general 
structure D. For compound 60, the amine side chain had to be synthesised, as it was not 
commercially available. Initially an O-alkylation of  4-aminophenol (64) using 1-(2-
chloroethyl)pyrrolidine hydrochloride (65) as shown in Scheme 5 was performed.
98
 The 
reaction was performed under conventional heating (75 
o
C, 2h), to give compound 66 in 
46% yield. Performing the reaction under microwave irradiation for various times did 
not improve the yield. The low yield could be attributed to the possible N-alkylation of 
the anilineand the fact that the electron donating amino substituent makes the phenol 
less acidic.  
 
Scheme 4. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C 
to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 
appropriate amine, 50 
o
C, to RT, 18 h. 
  
 
Scheme 5. Reagents and conditions: (i) DMF, NaOH, 2 h, 75 
o
C; (ii) DMF, NaOH, 30 
min, MW, 150 
o
C. 
 
Due to the low yield of compound 66, a modified 2-step approach starting with the O-
alkylation of 4-nitrophenol (67) followed by reduction of the nitro group was 
undertaken (Scheme 6). The electron withdrawing nitro group should increase the 
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lability of the phenol proton making the alkylation easier, and using the nitro compound 
rather than the aniline avoided the possibility of amine alkylation. Alkylation of 4-
nitrophenol (67) with 65 in the presence of potassium carbonate was successful with a 
good yield of 65%. The subsequent reduction of the nitro group was performed 
successfully in 92% yield.  
 
 
 
Scheme 6.  Reagents and conditions: (i) K2CO3, DMF, 80 
o
C, 2 h; (ii) Zn, AcOH, RT, 
18 h. 
 
Once the amine side chain was synthesised, the general synthetic route shown in 
Scheme 4 was applied. The first step was a Friedel-Crafts acylation of the commercially 
available methyl pyrrole 2-carboxylate (69) using 4-isopropoxybenzoyl chloride 71 and 
aluminium chloride to give methyl ester 72 in 65% yield (Scheme 7). The acylation 
occurred regioselectively in the 4-position of the pyrrole ring directed by the electron 
withdrawing substituent in the 2-position  
 
Subsequent ester hydrolysis using lithium hydroxide provided carboxylic acid 73 in 
97% yield. In order to couple aniline 66 to carboxylic acid 73, the optimised conditions 
using CDI as the coupling agent were employed, but were unsuccessful.  
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Scheme 7. Reagents and conditions: (i) SOCl2, DMF, THF, RT 3 h; (ii) methyl pyrrole 
2-carboxylate (69), AlCl3, DCM, 0 
o
C to RT, 18 h; (iii) LiOH (aq), THF, 60 
o
C, 18 h; 
(iv) (a) CDI, THF, 70 
o
C, 3 h; (b) 66, 50 
o
C to RT, 18 h. 
 
 
To activate carboxylic acid 73, N-hydroxysuccinimide and DCC were used to form 
succinimide ester 74 (Scheme 8). Aniline 66 was then added to 74, but unfortunately the 
coupling was unsuccessful. The reaction between succiminimide ester 74 and aniline 66 
was attempted at RT and under microwave irradiations at various temperatures but with 
no success (Table 5). A possible explanation for the lack of reaction is the basic nature 
of the side chain. 
 
 
Scheme 8. Reagents and conditions: (i) N-hydroxysuccinimide, DCC, EtOAc, 0 
o
C,  
2 h to RT, 18 h; (ii) See Table 5 for conditions. 
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Table 5. Attempted reaction conditions for step (ii) Scheme 8. 
Entry Solvent Temp. (
o
C) Heating Method Time (h) Result 
1 THF RT - 18 No reaction 
2 THF 100  MW 0.5 No reaction 
3 Dioxane 150  MW 0.5 No reaction 
 
 
A new approach was modelled coupling 4-aminophenol (64) to 2,6-difluoro analogue 
75 followed by alkylation of phenol 76 (Scheme 9). The first coupling reaction was 
performed successfully in 54% yield to afford compound 76. This phenol intermediate 
was also deemed to be an interesting target for biological testing, but, unfortunately, it 
was not stable and therefore could not be sent for biological evaluation. The alkylation 
step to form 77 was attempted under several conditions using potassium carbonate and 
DMF (Table 6). Entry 4 shows the best conditions (MW, 100 
o
C, 45 min) giving 77 in a 
moderate yield of 35%. In this reaction an extra 0.5 equivalent of potassium carbonate 
and 1-(2-chloroethyl)pyrrolidine.HCl were used, which did not significantly improve 
the yield compared to the conditions shown in entry 3.  
 
 
Scheme 9. Reagents and conditions: (i) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-aminophenol, 
50 
o
C to RT, 18 h; (ii) 1-(2-chloroethyl)pyrrolidine.HCl, DMF, NaOH, 80 
o
C, 2 h. 
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Table 6. Conditions attempted for the alkylation reaction in step (ii) Scheme 9.  
*Conversion by LCMS, **Reaction was performed with an extra 0.5 equivalent of 1-(2-
chloroethyl)pyrrolidine.HCl and potassium carbonate. 
 
Despite the low yield, compound 77 was successfully synthesised and sent for 
biological evaluation (section 4.1.3). During the synthesis of compound 77, a model 
reaction was conducted whereby carboxylic acid 75 was coupled with p-anisidine using 
CDI, leading to the synthesis of compound 78, which was also tested for ERK5 
inhibitory activity (section 4.1.3). 
 
 
4.1.3 Biological evaluation of compounds 77 and 78 
 
The ERK5 inhibitory activity for 77 and 78 is shown in Table 7, along with the 
inhibitory activity of hit pyrrole carboxamide 53 for comparison.  
 
Table 7. Biological evaluation of 77 and 78. 
 
 
Compound 77 showed complete lack of ERK5 inhibition, which led to the decision not 
to synthesise the original isopropoxy target compound 60. The ERK5 inhibitory activity 
Entry Temp. (
o
C) Heating Method Time (h) % yield 
1 80 Conventional 2 5%* 
2 80 Conventional 18 17%* 
3 100 MW 0.25 31%* 
4 100 MW 0.75 35%** 
Compound R ERK5; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 
77 
 
>120 
78 
 
10 ± 2.1 (n = 2) 
84 
 
of compound 78 was moderate compared to hit compound 53 (ERK5; IC50 = 10 μM). 
The improvement in inhibitory activity for 78 suggests that a shortened, more rigid 
amide side chain is more favourable for ERK5 binding.  
 
 
4.1.4 Synthesis of 4-(2,6-difluorobenzoyl)-N-(4-sulfamoylphenyl)-1H-
pyrrole-2-carboxamide (61) based on CRT hit 59 
 
For compound 61 the general synthetic scheme was applied again. The Friedel-Crafts 
acylation of methyl pyrrole 2-carboxylate (69) with 2,6-difluorobenzoyl chloride  
proceeded in 66% yield to give 79, and the hydrolysis step in 98% yield providing 
carboxylic acid 75 (Scheme 10). The final CDI coupling with sulphanilamide was 
unsuccessful, probably due to the reduced nucleophilicity of sulphanilamide.   
  
 
 
Scheme 10. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM,  
0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 
sulphanilamide, 50 
o
C to RT, 18 h.  
 
Alongside the attempted CDI coupling of sulphanilamide to carboxylic acid 75, 
coupling directly to methyl ester 79 using microwave irradiation was attempted. 
Unfortunately, this approach was also unsuccessful. A model coupling reaction between 
75 and aniline was conducted (Scheme 11). The reaction was successful with a yield of 
50%, and the biological evaluation of compound 80 is shown in section 4.1.5. The 
success of this reaction suggested that amide coupling between an aniline and 75 was 
possible and that it was most likely the added electron-withdrawing effect of the 
sulphonamide group of sulphanilamide causing reduced reactivity in the coupling 
reaction.  
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Scheme 11. Reagents and conditions: (i) (a) CDI, THF, 70 
o
C, 3 h; (b) aniline, 50 
o
C to 
RT, 18 h. 
 
In order to promote coupling between 75 and sulphanilamide, a number of different 
methods to activate the carboxylic acid were employed (Table 8).  
 
Table 8. Various conditions used to activate 75 prior to reaction with sulphanilamide. 
Entry Activating Agent Temp. (
o
C) Heating Method Time (h) Result 
1 
HBTU, Hunig’s 
base 
RT - 18 No reaction 
2 NHS, DCC RT - 18 No reaction 
3 NHS, DCC 100 Microwave 1 No reaction 
4 SOCl2, cat. DMF RT - 18 No reaction 
5 SOCl2, cat. DMF 70 Conventional 3 No reaction 
 
 
HBTU was used as an alternative coupling agent to CDI (entry 1, Table 8) but no 
reaction occurred when sulphanilamide was added. The carboxylic acid was converted 
to an acid chloride using SOCl2 and catalytic DMF, and N-hydroxysuccinimide was 
employed in order to synthesise the succinimide ester. In each case, subsequent reaction 
with sulphanilamide failed to yield 61. Upon formation of the succinimide ester, the 
reaction with sulphanilamide was attempted at both RT and also under microwave 
irradiation but was unsuccessful in both cases. 
 
A new approach was attempted starting with the conversion of 4-nitrobenzene-1-
sulfonyl chloride (81) to 2,2,2-trifluoroethyl 4-nitrobenzenesulfonate (82) in 87% yield 
(Scheme 12).  The subsequent reduction of the nitro- substituent gave 83 in 82% yield. 
The amino- substituent of 83 should be less electron-poor, and potentially reactive 
enough to couple with carboxylic acid 75. Once coupled, the 2,2,2-
trifluoroethoxysulfonate of compound 84 could be converted to a sulphonamide using a 
literature procedure via reaction with p-methoxybenzylamine under microwave 
irradiation followed by TFA removal of the p-methoxybenzyl group.
99
 However, the 
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coupling reaction of 83 with carboxylic acid 75 was unsuccessful using the CDI 
coupling method. No further coupling conditions were attempted at that stage.  
 
Scheme 12. Reagents and conditions: (i) NEt3, DMAP, TFE, RT, 3 h; (ii) Na2SO4, 
MeOH:H2O (4:1), MW, 100 
o
C, 15 min; (iii) (a) 75, CDI, THF, 70 
o
C, 3 h; (b) 
sulphanilamide, 50 
o
C to RT, 18 h; (iv) p-methoxybenzylamine, DBU, THF, MW,      
160 
o
C, 15 min; (v) TFA, RT, 1 h.  
 
Another potential route to synthesise 61 utilised compound 86, which was prepared via 
the general synthetic route (Scheme 13). It was proposed that the p-methoxybenzyl 
group could be cleaved using TFA, to form primary amide 87. This reaction worked in 
almost quantitative yield of 97% and following the literature, compound 87 was 
subjected to a copper-mediated coupling reaction with 4-(bromophenyl)sulfonamide.
100-
101
 The coupling reaction was conducted in the microwave at 150 
o
C for 15 min, and 
unfortunately did not afford the desired product 61. A complex mixture of products was 
obtained, and the reaction was not attempted again.  
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Scheme 13. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-
methoxybenzylamine, 50 
o
C to RT, 18 h; (iv) TFA, RT, 3 h; (v) 4-
(bromophenyl)sulfonamide, CuI, K2CO3, NMP, MW, 150 
o
C, 15 min. 
 
Activation of carboxylic acid 75 by conversion to an acid fluoride using cyanuric 
trifluoride followed by the reaction with sulphanilamide was conducted.  Although 
previously reported attempts to activate the carboxylic acid were unsuccessful, 
conversion to the acid fluoride could be sufficiently activating to enable electron-poor 
sulphanilamide to react (Scheme 14). 
  
 
Scheme 14. Reagents and conditions: (i) cyanuric trifluoride, pyridine, MeCN, RT, 45 
min; (ii) sulphanilamide, RT, 18 h. 
 
Initially, isolation of the acid fluoride 88 was attempted. However, hydrolysis back to 
the carboxylic acid was observed and therefore, a one-pot procedure was used with 
formation of the acid fluoride, followed by addition of sulphanilamide providing 61 in 
38% yield. 
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4.1.5 ERK5 inhibitory activity of 61 and 80 
 
Compound 61 was sent for biological evaluation in the cell-free assay at CRT-DL, 
along with the phenyl analogue 80 and the results are shown in Table 9. Again, the 
inhibitory activity of hit pyrrole carboxamide compound 53 is shown for comparison. 
 
 
Table 9. Biological evaluation of 61 and 80 
 
 
 
 
Phenyl analogue 80 displayed moderate activity against ERK5, but did not show an 
improvement compared to 61. Compound 61 displayed a 2-fold improvement in 
potency (ERK5; IC50 = 1.2 μM) compared to original hit 53, although it was not as 
potent as the CRT hit 59 (ERK5; IC50 = 0.20 μM). The most potent hit pyrrole 
carboxamide compounds identified from the HTS conducted at CRT-DL incorporated a 
methylene group in the amide side-chain as in compound 53 and it was thought this was 
necessary for ERK5 inhibitory activity. Very importantly, compound 61 suggests that 
the methylene group is not essential and activity can be maintained, or even improved, 
when it is removed.  
 
 
 
 
Compound  R ERK5; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 
80 
 
9.3 ± 1.4 (n = 2) 
61 
 
1.2 ± 0.36 (n = 6) 
89 
 
4.1.6 Synthesis of inhibitors with 2-aminopyrrole core structures based on 
CRT hits 58 and 59  
 
For the synthesis of the 2-aminopyrrole compounds 62 and 63, a Curtius rearrangement 
was utilised using diphenyl phosphoryl azide (DPPA) (Scheme 15). According to the 
literature using DPPA with 
t
BuOH as the solvent, carboxylic acids can undergo a 
Curtius rearrangement, and the product isocyanate can be trapped as the tert-butyl 
carbamate.
102-103
 This route was initially conducted with the isopropoxy carboxylic acid 
analogue 73 and the rearrangement completed in 71% crude yield. The isolated product 
was identified as a mixture of the desired compound 89 and some DPPA side products. 
The crude mixture was taken forward to the TFA deprotection step without purification. 
The supposedly formed compound 90 was obtained in 28% yield.  
 
 
Scheme 15.  Reagents and conditions: (i) DPPA, NEt3, 
t
BuOH, 30 
o
C, 18 h; (ii) TFA, 1  
h, RT; (iii) 1-(2-(4-bromophenoxy)ethyl)pyrrolidine, Pd
0
 (cat), NaO
t
Bu. 
 
In order to be sure that the correct 2-amino compound 90 had been synthesised, a 
sample was sent for LRMS at the EPSRC National Mass Spectrometry service in 
Swansea. We observed m/z 289 [M+H]
+
, suggesting the formation of carbamic acid 91 
via hydrolysis of the 
t
Bu ester (Figure 29). Carboxamic acids are often thought to be 
unstable, since they can easily decarboxylate. In this case, the carboxamic acid can be 
stabilised by formation of a 6-membered pseudocycle via a hydrogen-bond interaction 
of the carboxylate with the pyrrole NH (Figure 29). In order to obtain the desired amine 
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compound 90, carbamic acid 91 was boiled in ethanol for 30 min and the desired 
compound obtained in 90% yield.  
 
 
Figure 29.  Carbamic acid 91 obtained after TFA deprotection of 89 and postulated 6-
membered pseudocycle between the carboxamide and the pyrrole NH.  
 
 
Compound 90 was obtained in very low overall yield, and therefore the subsequent 
Buchwald coupling could not be attempted. Repetition of the first steps of the scheme in 
order to gain more material for the final step proved unsuccessful and the method was 
non-reproducible. At this stage, the same scheme had also been applied to the synthesis 
of the 2,6-difluoro analogue 63, and this proved equally unsuccessful, meaning this 
approach was unreliable. An alternative strategy had to be investigated.  
 
The first approach we attempted was to continue with the same scheme utilising the 
Curtius rearrangement, but using an N-protected pyrrole (Scheme 16). The protecting 
group of choice was a phenylsulfonyl group, described in the literature for similar 
reactions on a pyrrole-2-carboxylic acid.
104
 This route was attempted using both the 
isopropoxy and 2,6-difluoro analogues 62 and 63, with the protecting group being 
installed using phenylsulfonyl chloride and triethylamine to give protected ester 92 and 
93 in 65% yield each. The subsequent hydrolysis of methyl esters 92 and 93 was 
attempted using lithium chloride in DMF under microwave irradiation at 100 
o
C. 
Unfortunately, the reaction was unsuccessful with removal of the phenylsulfonyl 
protecting group observed after 10 min.  
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Scheme 16.  Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) NEt3, SO2PhCl, DCM, RT, 3 h; (iii) LiCl, DMF, MW, 100 
o
C, 10 
min; (iv) DPPA, NEt3, 
t
BuOH, 30 
o
C, 18 h (v) TFA, 1  h, RT. 
 
 
According to the literature, 2-aminopyrroles can be unstable and difficult to prepare.
93, 
105-106
 An alternative synthesis of the corresponding 2-bromopyrrole was attempted to 
allow the final Buchwald coupling to be performed with opposite coupling partners. 
This was achieved following a literature procedure (Scheme 17) starting with SEM 
protection of the pyrrole to give 101 in 60% yield. 
107
 Compound 101 was brominated 
in the 2-position using N-bromosuccinimide to give 2-bromopyrrole 102 in 99% yield. 
The bromination has the benefit of being very fast, taking only 15 min at 0 
o
C. 
However, a problem was encountered upon attempted scale up of the bromination, with 
a mixture of mono-, di-, tri- and tetra- brominated pyrrole being observed. The problem 
was overcome by slow addition of the N-bromosuccinimide in small portions. The 
Friedel-Crafts acylation of 102 was attempted prior to the Buchwald coupling, but was 
unsuccessful, probably due to the electron donating nature of the SEM protecting group. 
In order to install a benzoyl group into the 4-position of the pyrrole ring, it is usually 
required to have an electron withdrawing group in the 2-position. 
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Scheme 17.  Reagents and conditions: (i) NaH, SEMCl, DMF, 0 
o
C to RT, 1 h; (ii) 
NBS, THF, 0 
o
C, 15 min; (iii) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 
18 h; (iv) RNH2, Pd2(dba)3, P(
t
Bu)3, 
t
BuONa, toluene, 80 
o
C, 18 h. 
 
 
As an alternative, the final Buchwald coupling step was attempted prior to the Friedel-
Crafts acylation, using sulphanilamide to install the required group at the 2-position. 
The chosen reaction conditions were Pd2(bda)3, BINAP, 
t
BuOK with toluene as the 
solvent. The reaction was heated to 100 
o
C and left to stir for 18 h, which was consistent 
with methods used for similar Buchwald couplings in the literature.
108-110
 The reaction 
was unsuccessful, possibly due to the electron poor sulphanilamide not being reactive 
enough to undergo coupling (Scheme 18). 
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Scheme 18.  Reagents and conditions: (i) NaH, SEMCl, DMF, 0 
o
C to RT, 1 h; (ii) 
NBS, THF, 0 
o
C, 15 min; (iii) sulphanilamide, Pd2(dba)3, P(
t
Bu)3, 
t
BuONa, toluene, 80 
o
C, 18 h; (iv) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h.  
 
 
To determine if the nature of the aniline being coupled was causing the reaction to be 
unsuccessful, the same Buchwald conditions were attempted using p-anisidine and p-
methoxybenzylamine (Scheme 19). A similar reaction had been carried out in the 
literature on 1-(5-bromo-1-methyl-1H-pyrrol-2-yl)ethanone using p-
methoxybenzylamine.
109
 In both cases, the reaction was unsuccessful and we therefore 
postulated that the pyrrole ring of 102 may be too electron-rich to undergo coupling. 
The SEM protecting group is electron donating, and the anilines being used were 
relatively unreactive meaning that the reaction could possibly be disfavoured. In the 
literature example the bromo-pyrrole used also incorporated a methyl ketone, which 
would lower the electron density of the ring making the reaction more favourable.
109
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Scheme 19.  Reagents and conditions: (i) NaH, SEMCl, DMF, 0 
o
C to RT, 1 h; (ii) 
NBS, THF, 0 
o
C, 15 min; (iii) p-anisidine or p-methoxybenzylamine, Pd2(dba)3, P(
t
Bu)3, 
t
BuONa, toluene, 80 
o
C, 18 h; (iv) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to 
RT, 18 h.  
 
 
Due to the problems encountered with the Buchwald coupling of 2-bromopyrrole 102 
with different anilines, investigation into alternative ways to obtain the 2-aminopyrrole 
was undertaken. After the failed attempts to install a 2-amino substituent via the Curtius 
rearrangement as discussed previously, a literature procedure using N-
chlorophthalimide to install a phthalimide group in the 2-position of the pyrrole ring 
was attempted. This reaction was discovered by De Rosa et al, when trying to chlorinate 
the 2-position of pyrrole using NCP or NCS. Rather than obtaining the expected 
chlorinated product, they observed the formation of pyrroles substituted in the 2-
position with phthalimide or succinimide moieties.
106, 111-113
 The reaction is thought to 
go through the mechanism shown in Scheme 20, whereby the pyrrole ring first acts as a 
nucleophile and removes the electrophilic chlorine atom from NCP to give ion pair C. 
The phthalimide anion then attacks the pyrrole ring to give D.  The final step of the 
proposed mechanism is the loss of HCl to re-aromatise and give product E.
106, 111-113
 
Reaction of the pyrrole with N-bromosuccinimide or N-iodosuccinimide yields only the 
halogenated products, and this is thought to be due to the fact that the chloro- 
substituent affects the aromaticity of the pyrrole ring more than either bromo- or iodo- 
substituents do, due to its greater electron donating ability.
112
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Scheme 20. Postulated mechanism for the reaction of 1-substituted pyrroles with 
NCP.
106, 111-113
 
 
In the literature, the reaction was carried out in DCM using NaHCO3. When the reaction 
was conducted without base or in acidic conditions, the 2-chloropyrrole was obtained. 
The presence of base prevents the phthalimide anion from being protonated and 
therefore enables the addition to the pyrrole ring and subsequent loss of HCl to give the 
2-phthalimide product. It was postulated that the reaction could be used to install the 
phthalimide group and this could then be cleaved to leave the required 2-aminopyrrole 
for use in Buchwald coupling.  
 
The reaction was first attempted using phenylsulfonyl protected pyrrole. We initially 
thought that having an electron withdrawing protecting group would help to stabilise the 
2-aminopyrrole that would be obtained after phthalimide cleavage.
93
 The reaction of 
NCP and phenylsulfonylpyrrole (110) gave the phthalimide product 111, but in a poor 
yield of 7% (Scheme 21). After greater understanding of the mechanism of the reaction, 
it was not surprising that the reaction had not worked in greater yield, since the first step 
relies on the pyrrole ring to be nucleophilic, and therefore an electron donating 
protecting group would be more beneficial to aid the reaction. There was not enough 
material obtained from this initial reaction to progress with the synthesis.   
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Scheme 21. Reagents and conditions: (i) NCP, NaHCO3, DCM, RT, 18 h; (ii) 2,6-
difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (iii) hydrazine hydrate, 
MeCN, RT, 4 h.  
 
 
We also tried performing Friedel-Crafts acylation first, followed by phthalimide 
addition. Unsurpisingly, once the electron withdrawing benzoyl group had been 
installed in the 4-position, the pyrrole ring was too electron-poor to react as shown in 
the proposed mechanism shown in Scheme 21.  
 
The phenylsulfonyl protecting group was replaced with a SEM protecting group in 
order to test whether reaction with NCP would work better with an electron donating 
protecting group. Using this strategy, the phthalimide product 114 was obtained in 49% 
yield. However, attempts to perform the Friedel-Crafts acylation on 114, were not 
successful. Initially, it was reasoned that Friedel-Crafts reaction would not occur on the 
benzene ring of the phthalimide as it would be disfavoured due to the electron poor 
nature of this aromatic ring compared to the pyrrole ring. However, after the reaction it 
became apparent that the acylation had possibly occurred in several positions, with a 
complex reaction mixture being obtained. For this reason, the cleavage of the 
phthalimide prior to Friedel-Crafts reaction (Scheme 22) was conducted using a 40% 
aqueous solution of methylamine. The use of methylamine had been shown in the 
literature to be a milder method for cleaving phthalimides compared to the conventional 
methods using hydrazine hydrate.
114
 The reaction worked in an hour, and the correct 
mass for amine 115 was observed by LC-MS. However, after attempted work up, the 
product had degraded. As stated previously, the instability of 2-aminopyrroles is well 
documented, and the original literature which reports this route to their synthesis 
records that most of the compounds prepared decomposed on attempted isolation.
113
 
One way to overcome this is to make the salt of the 2-aminopyrrole, which should be 
stable enough to store.
115
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Scheme 22. Reagents and conditions: (i) NCP, NaHCO3, DCM, RT, 18 h; (i) MeNH2 
(40% in H2O), EtOH, RT, 1 h; (iii) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to 
RT, 18 h; (iv) 4-bromobenzenesulfonamide, Pd2(dba)3, P(
t
Bu)3, 
t
BuONa, toluene, 80 
o
C, 
18 h. 
 
Rather than making the salt of the product, we carried out the in situ protection of the 2-
amino group without isolating the free amine. Using an electron withdrawing protecting 
group was expected to stabilise the product by pulling electrons from the pyrrole ring 
and for this reason, we chose a trifluoroacetyl group (Scheme 23). After cleavage with 
methylamine, the reaction mixture was washed with water to remove any excess 
methylamine and the N
1
,N
2
-dimethylphthalamide side product, before trifluoroacetic 
anhydride was added. It was important to try and remove these as they could both 
potentially react with trifluoroacetic anhydride. When the protection strategy was 
conducted, the protected amine 118 was not isolated and the amine starting material had 
degraded.   
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Scheme 23. Reagents and conditions: (i) NCP, NaHCO3, DCM, RT, 18 h; (i) MeNH2 
(40% in H2O), EtOH, RT, 1 h; (iii) TFAA, pyridine, MeCN, RT, 18 h; (iv) 2,6-
difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (iv) 4-
bromobenzenesulfonamide, Pd2(dba)3, P(
t
Bu)3, 
t
BuONa, toluene, 80 
o
C, 18 h. 
 
A different synthetic scheme was developed using a literature procedure (Scheme 25). 
Starting from commercially available succinonitrile (120), the formyl potassium salt 
121 was produced in 84% yield by reaction with ethyl formate and potassium tert-
butoxide. Reaction of 121 with p-methoxybenzylamine in the presence of acetic acid, 
followed by addition of potassium hydroxide afforded compound 122 in 70% yield via 
the general route shown in Scheme 24.
116
  
 
 
Scheme 24. General route for  formation of 2-amino-4-cyanopyrroles.
116
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Previous attempts to synthesise 2-aminopyrroles have been unsuccessful due to their 
instability. Incorporation of a 4-cyano- substituent onto the pyrrole ring not only 
provides a synthetic handle for subsequent reactions, but also reduces the electron 
density of the 2-aminopyrrole, hence improving stability.  
 
In order to test whether the route would be viable for the desired targets, a model 
Buchwald amination of 122 was performed using bromobenzene, Pd2(dba)3, Xantphos 
and Cs2CO3 in dioxane. The reaction was successful, producing 123 in 75% yield. 
Another model reaction was conducted, using a Grignard reagent to react with the nitrile 
group of 123. Phenylmagnesium bromide was synthesised and used in situ to form 
imine 124. The initial idea was that the imine would hydrolyse upon acidic work-up to 
give the ketone 125. However, this was not the case and the imine 124 was isolated in 
90% yield. Refluxing 124 in 1.0 M H2SO4 for two hours afforded ketone 125 in 85% 
yield.
117
 Attempted deprotection of 125 by stirring in TFA at both RT and 80 
o
C failed 
to yield compound 126.  
 
 
Scheme 25. Reagents and conditions: (i) ethyl formate, 
t
BuOK, toluene, 
t
BuOH, RT, 4 
h; (ii) (a) PMBamine, EtOH, AcOH, reflux, 45 min; (b) KOH, EtOH, reflux, 2.5 h; (iii) 
bromobenzene, Pd2(dba)3, Xantphos, Cs2CO3, Dioxane, 110 
o
C, 18 h; (iv) 
bromobenzene, Mg turnings, THF, 80 
o
C, 5 h; (v) 1M H2SO4, reflux, 2 h; (vi) TFA, RT 
or 80 
o
C, 1 h. 
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No further conditions to deprotect compound 125 were attempted due to the likelihood 
that compounds without an amide group would be inactive. Homology modelling 
suggests that the carbonyl of the amide group makes a H-bond with the hinge region of 
ERK5 and is therefore important for achieving ERK5 inhibition. Therefore, the 
synthesis of 2-aminopyrrole inhibitors was ceased.   
 
4.2 Effect of removing a methylene group from the amide side chain on ERK5 
inhibitory activity  
 
4.2.1 Rationale 
 
During investigation towards the synthesis of targets based on CRT hit compounds 58 
and 59, three compounds were synthesised without a methylene group in the amide 
side-chain (61, 78 and 80) (Figure 30). The synthesis of these compounds is discussed 
in section 4.1 of this chapter.  
 
 
Figure 30. Improvement in ERK5 inhibitory activity for compound 61 compared to hit 
compound 53.  
 
In light of the 10-fold improved inhibitory activity observed for compound 61 compared 
to 78 and 80, and the 2-fold improvement compared to hit compound 53, further 
analogues without a methylene group in the amide side chain were proposed for 
synthesis. The target compounds contained a range of substituted aromatic and non-
aromatic amide side-chains whilst the 2,6-difluorobenzoyl group was maintained.  
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4.2.2 Synthesis of inhibitors with shorter amide side chains  
 
The compounds were synthesised via the 3-step route previously optimised within the 
group (Scheme 26).  The first step was the Friedel-Crafts acylation of the commercially 
available methyl pyrrole 2-carboxylate 69 using 2,6-difluorobenzoyl chloride, which 
gave 79 in 66% yield. Lithium hydroxide-mediated hydrolysis of 79 occurred in 99% 
yield to afford carboxylic acid 75. Finally, the amide side-chain was introduced using 
CDI as the coupling agent and occurred in moderate to good yield (35-75%) depending 
on the amine used.  
 
 
Scheme 26. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 
appropriate amine, 50 
o
C to RT, 18 h. 
 
Along with the synthesis of these 10 compounds, Boc-protected analogue 132 was 
deprotected and the resulting compound sent for biological evaluation. The deprotection 
was performed using neat TFA to give compound 137 in 87% yield. In addition, the N-
oxides of pyridyl compounds 127 and 128 were synthesised using m-
chloroperoxybenzoic acid providing compounds 138 and 139 in 65% and 77% yield, 
respectively.  
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4.2.3 ERK5 inhibitory activity of 127-139 
 
Compounds 127-139 were sent for biological evaluation and the results are shown in 
Table 10, alongside hit compound 53.  
 
Table 10. ERK5 inhibitory activity of analogues 125-137  
 
Compound R ERK5; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 
127 
 
0.90 ± 0.15(n = 8) 
128 
 
1.1 ± 0.27 (n = 6) 
129 
 
7.0 (n = 1) 
130 
 
1.2 ± 0.60 (n = 10) 
131 
 
1.7 ± 0.60 (n = 4) 
132 
 
2.9 ± 0.66 (n = 4) 
133 
 
2.7 ± 0.80 (n = 4) 
134 
 
13 ± 2.5 (n = 4) 
135 
 
2.2 ± 0.35 (n = 8) 
136 
 
31 ± 2.0 (n = 4) 
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The N-oxides 158 and 159 were expected to be major metabolites of pyridyl compounds 
127 and 128 via CYP450 oxidation. If these expected metabolites retained activity 
against ERK5, it would mean that metabolism would not inactivate the compound. 
However, an almost 13-fold loss in potency was observed. 
 
The 4-pyridyl analogue 127 was also tested for ERK5 inhibitory activity in the LANCE 
assay (IC50 = 0.43 ± 0.20 M). Compound 127 was the first sub-micromolar inhibitor of 
ERK5, and showed a 3-fold improvement in potency compared to the methylene-
containing counterpart 53 (Figure 31). This increase in inhibitory activity provides 
further evidence that the methylene in the amide side chain is not necessary to achieve 
good inhibition of ERK5.  
 
 
Figure 31. Increase in potency observed for 127 compared to 53. 
 
Interestingly, piperidine analogue 137 was essentially equipotent with the pyridine 
analogue 127, suggesting that a non-aromatic group is tolerated in the amide side-chain. 
N-oxide compounds 138 and 139 displayed reduced inhibitory activity, suggesting that 
the pyridyl nitrogen is required for inhibition of ERK5.  
 
 
 
137 
 
1.3 ± 0.36 (n = 6) 
138 
 
12 ± 0.86 (n = 4) 
139 
 
14 (n = 1)  
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4.2.4 Synthesis of tertiary amide analogues  
 
In order to determine whether the amide side-chain could be shortened further and 
potency retained, a small library of tertiary amide analogues (140-143) were 
synthesised. The general scheme was used and the amide coupling steps were 
performed in moderate to good yield (47-90%) (Scheme 27).  
 
 
Scheme 27. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 
appropriate amine, 50 
o
C to RT, 18 h. 
 
 
4.2.4 Biological evaluation of tertiary amide analogues  
 
The inhibitory activity of compounds 140-143 is shown in Table 11 alongside hit 
compound 53 and pyridyl analogue 127.  
 
 
 
 
 
 
 
 
 
 
X
X 
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Table 11. Biological evaluation of tertiary amide analogues.  
 
 
 
In each case, the potency was reduced, suggesting that shortening the amide side-chain 
further is not conducive to potent ERK5 inhibition. It was established in preliminary 
SARs that the amide NH is not essential for activity (chapter 3), therefore compounds 
140-143 were expected to retain potency for ERK5. Figure 32 shows the energy 
minimised structures for analogues 137 and 142. It is evident that replacing the 
secondary amide of potent compound 137 (ERK5; IC50 = 1.3 ± 0.36 µM) with a tertiary 
amide in 142 (ERK5; IC50 = 17 ± 2.5 µM) effects the conformation of both the amide 
side-chain and the benzoyl group, potentially affecting binding in the ERK5 ATP 
binding site. This change in conformation could explain the 13-fold loss in potency 
observed for 142 compared to 137. As a result of the lack of ERK5 inhibitory activity, 
the library of tertiary amide analogues was not expanded further.  
 
 
Compound  R ERK5; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 
127 
 
0.90 ± 0.15 (n = 8) 
140 
 
16 ± 2.5 (n = 8) 
141 
 
6.1 ± 1.3 (n = 2) 
142 
 
17 ± 2.5(n = 4) 
143 
 
5.7 ± 0.65 (n = 4) 
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Figure 32. Energy minimised conformations of (A) tertiary amide analogue 142 and (B) 
secondary amide analogue 137. Energy minimised using Chem3D.  
 
 
4.2.5 Development of an alternative amide coupling strategy for coupling 
of electron-poor anilines  
 
Following the success of removing the methylene group in the amide side-chain, further 
analogues were synthesised (144-148) using the general scheme. In these cases, the final 
CDI coupling was found to be unsuccessful possibly due to the reduced nucleophilicity 
of electron poor anilines to be coupled.  
 
An alternative strategy was to convert carboxylic acid 75 to the more activated acid 
fluoride 88 using cyanuric fluoride (Scheme 28). Conversion to the desired products 
was observed, but each reaction mixture was complex meaning the target compounds 
144 to 148 were difficult to purify.    
  
A 
B 
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Scheme 28. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) cyanuric trifluoride, pyridine, 
MeCN, RT, 45 min; (iv) appropriate amine, RT, 18 h. 
 
 
A review of the literature revealed phosphorus trichloride as a useful amide coupling 
agent for coupling of electron-poor anilines to carboxylic acids.
118
  Phosphorus 
trichloride-mediated coupling reactions are well reported, but the method has not been 
favoured due to the requirement of high reaction temperatures and long reaction 
times.
119-120
 Recently it has been shown that phosphorus trichloride-mediated coupling 
reaction rates can be enhanced by microwave irradiation at high temperature, 
exemplified by the coupling of a number of electron-poor anilines to benzoic acid.
118
 
The optimised reaction conditions were one equivalent of phosphorus trichloride and 
one equivalent of aniline in acetonitrile with heating under microwave irradiation at 150 
o
C for 5 min. Applying these coupling conditions to the synthesis of 3-fluoro analogue 
144 was successful in 30% yield. To improve the yield, the number of equivalents of 
aniline was increased to 2.5, leading to 144 in 65% yield. Compounds 145-148 were 
also synthesised using the improved coupling method in good yield (145, 83%, 146, 
64%, 147, 57% and 148, 75%).  The phosphorus trichloride coupling procedure was 
attractive for the reduced reaction time in comparison with both, the CDI and acid 
fluoride methods. The reaction mixtures were also generally much less complex 
meaning the products were easier to purify. The coupling procedure was also 
successfully applied to the synthesis of N-methyl piperidyl analogue 149 (72% yield), 
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showing that the reaction can be equally applied to coupling of aromatic and non-
aromatic amines.  
 
 
Scheme 29. Reagents and conditions: (i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) PCl3, appropriate amine, MeCN, 
MW, 150 
o
C, 5 min. 
 
The N-methyl piperidyl analogue 149 was synthesised in order to investigate what 
effect changing the basicity of the piperidine nitrogen would have on ERK5 inhibitory 
activity.  
 
 
4.2.6 ERK5 inhibitory activity compounds 144-149  
 
The biological results for compounds 144-149 are shown in Table 12 and are compared 
to hit compound 53.  
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Table 12. Biological evaluation of 144-149 
 
 
 
Interestingly, N-methylpiperidyl analogue 149 was shown to be equipotent with 
piperidyl analogue 137 (ERK5; IC50 = 1.3 μM), suggesting that modifying the basicity 
of the piperidyl nitrogen is tolerated. Incorporation of a trifluoromethyl substituent into 
the 3- or 4-position of the aryl ring was not tolerated. 2,6-Difluoro and 3-sulphonamide 
analogues 145 and 148 displayed moderate ERK5 inhibitory activity and were 
essentially equipotent with hit compound 53.  
 
 
 
 
 
 
Compound R ERK5; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 
144 
 
47 ± 27 (n = 4) 
145 
 
3.1 ± 0.64 (n = 4) 
146 
 
>120 
147 
 
>120 
148 
 
2.0 ± 0.05 (n = 4) 
149 
 
1.1 ± 0.1 (n = 8) 
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4.2.7 Physicochemical properties and in vitro ADME profiling for selected 
analogues containing shortened amide side-chains 
 
 
A number of the more potent shorter amide side-chain analogues were sent to ADME 
and toxicology profiling company Cyprotex for assessment of in vitro drug metabolism 
and pharmacokinetic (PK) properties. Prior to this, the physicochemical properties of 
the four compounds were reviewed (Table 13) to determine if they met the criteria for a 
lead compound (as outlined in chapter 3). The physicochemical properties were 
calculated using Optibrium StarDrop software.   
 
Table 13. Physicochemical properties of compounds 127, 128, 148 and 149.  
 
 
 
All of the compounds meet the lead criteria for MW (<500), H-bond donors/acceptors 
(<5/<10) and sLogP (<5). Compounds 127 and 128 also have TPSA within the 
acceptable range (75-100), whereas the TPSA of compounds 148 and 149 fall outside 
the optimum range. Despite this, the physicochemical properties of each compound 
were deemed acceptable enough to proceed to in vitro PK studies.  
Compound R MW 
H-
bond 
donors 
H-bond 
acceptors 
sLogP TPSA 
Lead 
criteria 
- <500 <5 <10 <5 75-100 
127 
 
327 2 5 2.4 75 
128 
 
327 2 5 2.4 75 
148 
 
405 3 7 1.9 122 
149 
 
347 2 5 2.0 65 
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Aqueous solubility, plasma protein binding (PPB) and stability in mouse and human 
liver microsomes were investigated for each compound and the results are shown in 
Table 14 and compared with the desired properties for a lead candidate. The ligand 
efficiency (LE) is also shown in Table 14 for each compound (calculated using the 
formula LE = ∆G/HAC (where ∆G = -1.4 logIC50)). 
 
Table 14. In vitro ADME profiling for compounds 127, 128, 148 and 149. 
 
ND – Not determined 
 
All compounds except 148 have a ligand efficiency above the desired value for a lead 
candidate. Pyridyl analogues 127 and 128 both displayed lower aqueous solubility 
compared to the optimal value, which could be an indicator of poor cell permeability in 
vivo. Human microsomal clearance was good for 127 (16.1 µM/min/mg), but mouse 
microsomal clearance was high (61.2 µM/min/mg). Microsomal stability was improved 
for 128 (0 and 15.5 µM/min/mg, in human and mouse, respectively). Compound 128 
was tested for plasma protein binding and displayed an optimum value of <99%.  
Solubility for 148 and 149 was improved (148; S (L/U) = 30/100 µM and 149;               
Compound R LE 
Solubility 
L/U (µM) 
PPB 
(%) 
Mouse 
CLint 
(µL/min/mg) 
Human CLint 
(µL/min/mg) 
Lead 
criteria 
- >0.30 >50/50 <99 <48 <48 
127 
 
0.35 10/65 ND 61.2 16.1 
128 
 
0.34 10/30 84 15.5 0 
148 
 
0.28 30/100 ND ND ND 
149 
 
0.33 100/100 ND 0 10.1 
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S (L/U) = 100/100 μM). Clearance from both human and mouse microsomes was also 
good for 149, meaning this compound had a good balance of in vitro ADME properties.  
 
 
4.2.8 Effect of shortening the amide side chain on selectivity for ERK5 
over p38α 

The MAPK, p38α is a close homologue of ERK5, with 48% sequence identity in the 
kinase domain and 56% in the active site. ERK2 is the closest homologue with 51% 
sequence identity in the kinase domain and 78% in the active site. Despite ERK2 having 
more structural identity with ERK5, it has a larger and electronically different 
gatekeeper residue (glutamine) compared to ERK5 (leucine) meaning that gaining 
selectivity for ERK5 over ERK2 is easily achieved. The gatekeeper residue in p38α is a 
threonine residue and, as such, is more similar in size to the leucine gatekeeper residue 
of ERK5. This means achieving selectivity for ERK5 over p38α is more challenging. It 
is therefore essential to screen compounds with inhibitory activity for ERK5 against 
p38α to ensure selectivity is achieved. Compounds are tested for p38α activity using a 
LANCE assay. The LANCE assay uses time resolved fluorescence energy transfer (TR-
FRET) in order to determine IC50 values.  
 
The ERK5 inhibitory activity was improved for all inhibitors lacking the methylene 
group in the amide side-chain. In order to determine the effect this would have on 
selectivity over p38, a selection of the most potent of the shortened amide side 
analogues (ERK5; IC50 <10 μM) were counter-screened and the results are shown in 
Table 15.  All of the compounds with aromatic side chains retained selectivity for ERK5 
over p38α, particularly 61 and 148, which showed no inhibition of p38α. The 
compounds with non-aromatic side chains were generally less selective for ERK5 over 
p38α. Compound 141 was included to determine if a tertiary amide side chain would 
have any effect on selectivity for ERK5 over p38 and it was shown to have reversed 
selectivity. These results highlight the fact that selectivity for ERK5 over p38α can be 
achieved by removing the methylene in the amide side chain without modification of 
the phenyl ring of the benzoyl group. Two of the best amide side-chains identified were 
the 3- and 4-pyridyl rings as they were both potent and selective for ERK5 in 
comparison to methylene-containing hit compound 53.  
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Table 15. p38α counter-screening data for most potent shortened amide side-chain 
analogues.  
 
Compound R ERK5; IC50 (µM) p38α; IC50 (µM) 
53 
 
2.4 ± 0.09 (n = 2) 0.58 ± 0.27 (n = 2) 
127 
 
0.90 ± 0.15 (n = 8) 100 ± 35(n = 2) 
128 
 
1.1 ± 0.27 (n = 6) 35 ± 0.90(n = 2) 
80 
 
9.4 ± 1.4 (n = 2) 60 (n = 1) 
129 
 
7.0 (n = 1) 60 (n = 1) 
130 
 
1.2 ± 0.60 (n = 10) 20 ± 1.3 (n = 2) 
148 
 
2.0 ± 0.05 (n = 4) >120 
61 
 
1.3 ± 0.40 (n = 2) >120 
145 
 
3.1 ± 0.64 (n = 4) 43 (n = 1) 
135 
 
2.3 ± 0.35 (n = 8) 4.8 ± 2.2 (n = 2) 
133 
 
2.7 ± 0.80 (n = 4) 23 ± 26 (n = 2) 
132 
 
2.9 ± 0.66 (n = 4) 24 ± 21 (n = 2) 
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4.3 Modification of the amide side-chain to reduce CYP450 inhibition  
 
4.3.1 Rationale  
 
One of the anticipated problems with some of the more potent inhibitors in the 
shortened amide side-chain series was that they may also be potent inhibitors of 
CYP450 enzymes. CYP450 enzymes are involved in the metabolism of chemicals in 
vivo. Their main function is to increase the ability of compounds to be excreted via 
conjugation of polar functionality, which is usually achieved via an oxidation reaction. 
Oxidation of potential drugs can lead to poor bioavailability and potentially toxic 
metabolites, meaning it is important to investigate whether any potential drug 
candidates will bind to, and be metabolised by, CYP450 enzymes.
121
 It is also important 
to ascertain whether compounds will inhibit CYP450 enzymes and prevent the 
metabolism of other substances in the body. All compounds with pyridyl side chains 
were expected to bind to CYP450 enzymes and be substrates for N-oxidation. Until 
recently, it was thought that the main enzyme involved in metabolism via N-oxidation 
was flavin-containing monooxygenases (FMO). However, mechanisms for N-oxidation 
by CYP450 enzymes have now been proposed. The active site of CYP450 enzymes 
contains a haem centre, which is tethered to the P450 enzyme via a thiolate ligand from 
a cysteine residue. The catalytic cycle of CYP450 enzymes begins with the binding of a 
substrate at a site near the haem centre. There are two postulated mechanisms for N-
oxidation by CYP450 enzymes. The first proposes an electron transfer from the nitrogen 
to the iron centre of FeO
3+
. The nitrogen radical can then attack the oxygen before Fe
3+
 
is regenerated and the N-oxide is formed (mechanism A, Scheme 30). The alternative 
mechanism involves a second electron transfer from the nitrogen to the iron centre 
before the N-oxide is formed (mechanism B, Scheme 30).
121
 
137 
 
1.3 ± 0.36 (n = 6) 9.8 ± 0.52 (n = 2) 
149 
 
1.1 ± 0.14 (n = 8) 6.8 ± 0.10 (n = 2) 
141 
 
6.1 ± 1.3 (n = 2) 2.1 ± 0.11 (n = 2) 
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Scheme 30. Two proposed mechanisms for N-oxidation by CYP450 enzymes. Modified 
from reference 26.  
 
With this in mind, two of the most potent compounds containing a pyridyl side chain 
were tested against a panel of CYP450 enzymes, and these results are shown in Table 
16. Compounds 150 and 151 have either a 2-chloro-6-fluorobenzoyl group or a 2-
chloro-6-fluorobenzoyl group as these groups were identified by another member of the 
groups as optimal for good selectivity for ERK5 over p38The 4-pyridyl compound 
150 was a potent inhibitor of all of the enzymes in the panel, particularly CYP2C19 and 
CYP2C9. The 3-pyridyl compound 151 showed reduced inhibition against the same 
panel of CYP450 enzymes, but was still shown to inhibit the enzymes with an IC50 <10 
µM, which could still mean a more rapid rate of metabolism than is desirable. The 
reason for the reduced CYP inhibition of the 3-pyridyl compounds could be due to the 
fact that the nitrogen atom in the ring is no longer in the optimal position to interact 
with the haem centre of the enzyme. 
 
Table 16. CYP450 Inhibition profile of 150 and 151 
 
Compound 150 151 
R 
  
R’ 
  
CYP1A; IC50 (µM) -* 6.0 ± 0.60 
CYP2C9; IC50 (µM) 0.35 ± 0.01 14 ± 1.7 
CYP3A4; IC50 (µM) 1.2 ± 0.18 8.4 ± 1.6 
CYP2C19; IC50 (µM) 0.07 ± 0.02 8.5 ± 2.5 
CYP2D6; IC50 (µM) 1.1 ± 0.16 9.2 ± 1.3 
*unable to calculate an IC50 value over concentration range tested. 32.8% inhibition observed at 5 µM 
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In order to try and reduce the CYP450 inhibition of these inhibitors, alternative side 
chains were investigated. A review of the literature found that replacement of a pyridyl 
group for substituted pyridyl moieties, various non-substituted and substituted 
pyrimidine groups or a pyridazine ring had been successful in reducing CYP450 
inhibition.
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4.3.2 Synthesis of inhibitors to reduce CYP450 inhibition 
 
A new series of inhibitors were synthesised and tested against ERK5 and p38α to ensure 
potency and selectivity were retained when the amide side-chain was modified (Scheme 
31). For the first set of inhibitors with a 4-aminopyrimidine side chain, compounds were 
synthesised with 2,6-difluorobenzoyl, 2,3-dichlorobenzoyl, 2-chloro-6-fluorobenzoyl 
and 2-bromo-6-fluorobenzoyl groups in the 4-position of the pyrrole ring. All 
subsequent compounds were synthesised with the 2-chloro-6-fluorobenzoyl and 2-
bromo-6-fluorobenzoyl solely as these groups had been found to be optimal in this 
position. Methyl pyrrole-2-carboxylate (69) was acylated regioselectively in the 4-
position using the Friedel-Crafts procedure with the appropriate benzoyl chloride in 
good yield (63-80%) (Scheme 31). Each methyl ester was then treated with aqueous 
LiOH to give the corresponding carboxylic acids 75 and 155-157 in excellent yield 
(99%). The appropriate aniline was then coupled using PCl3 under microwave 
irradiation to give the 20 desired compounds 158-177 with yields ranging from 45-76%. 
Table 17 shows the relevant yields for each compound.  
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Scheme 31. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM,   0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) PCl3, appropriate aniline, MeCN, 
MW, 150 
o
C, 5 min. 
 
 
Table 17. Yields achieved for Steps (i), (ii) and (iii) in Scheme 31. 
 Yield (%) 
Compound Step (i) Step (ii) Step (iii) 
158 66 99 76 
159 71 99 72 
160 63 99 60 
161 80 99 62 
162 63 99 50 
163 80 99 62 
118 
 
164 63 99 60 
165 80 99 69 
166 63 99 60 
167 80 99 52 
168 63 99 52 
169 80 99 63 
170 63 99 50 
171 80 99 45 
172 63 99 65 
173 80 99 61 
174 63 99 55 
175 80 99 58 
176 63 99 48 
177 80 99 55 
 
 
Three of the amine side chains to be incorporated were not commercially available and 
had to be synthesised prior to the amide coupling. The syntheses of 5-aminopyrimidine 
and 5-amino-2-methylpyrimidine are shown in Scheme 32. A literature procedure was 
followed for the dehalogenation reaction between commercially available 5-amino-4,6-
dichloropyrimidine (178) and 5-amino-4,6-dichloro-2-methylpyrimidine (179) with 
ammonium formate and palladium on carbon.
125
 The reaction proceeded smoothly at 
reflux for 1 h, providing 5-aminopyrimidine 180 and 5-amino-2-methylpyrimidine 181 
in 80% yield respectively. Amide coupling of 180 and 181 with carboxylic acid 
intermediates 156 and 157 provided 185-185 in 40-79% yield. Using the PCl3-mediated 
coupling method, the reactions required further heating time (30 min) due to the 
electron-poor pyrimidine coupling partners.  
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Scheme 32. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) NH4HCOO, Pd/C, MeOH, reflux, 
1 h; (iv) PCl3, appropriate amine, MeCN, MW, 150 
o
C, 30 min. 
 
 
4-Amino-2-methoxypyrimidine was synthesised following Scheme 33. Substitution of 
the chloro- substituent of 4-amino-2-chloropyrimidine (186) using sodium methoxide 
produced 4-amino-2-methoxypyrimidine (187) in 90% yield. Reaction of 4-amino-2-
methoxypyrimidine (187) with carboxylic acid intermediates 156 and 157 using the 
PCl3 coupling method produced pyrimidones 188 and 189, with in situ demethylation of 
the methoxy substituent, in 30% and 45%, respectively. The low yields in this case 
could be attributed to the fact that there was a mixture obtained of the pyrimidone 
compounds as the major product and also the methoxypyrimidine compounds. There 
was too little of the methoxypyrimidine compounds to purify.  
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Scheme 33. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) Na, MeOH, 50 
o
C, 4 h; (iv) PCl3, 
4-amino-2-methoxypyrimidine, MeCN, MW, 150 
o
C, 5 min. 
 
Compounds incorporating an indazole amide side-chain were also synthesised 
according to Scheme 34. 6-Nitroindazole (190) was protected with a Boc group using 
Boc2O to produce 191 in 92% yield.  Reduction of the nitro group of 191 via continuous 
flow hydrogenation gave 192 in 90% yield. Amide coupling of 192 to carboxylic acid 
intermediates 156 and 157 using CDI followed by in situ deprotection using TFA gave 
compounds 195 and 196 in 16 and 20% yield, respectively.  
 
 
121 
 
 
Scheme 34. Reagents and conditions: (i) Boc2O, NEt3, DCM, RT, 18 h; (ii) THF, H-
cube, full H2 mode, 1 mL/min, 2.5 h; (iii) (a) 156 or 157, CDI, THF, 70 
o
C, 3 h; (b) 
appropriate amine, 50 
o
C to RT, 18 h; (iv) TFA, RT, 1.5 h.  
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4.3.3 Biological evaluation of compounds 158-196 
 
The ERK5 inhibitory activity and p38α counterscreening data for compounds 158-196 
are shown in Table 18 with each compound compared to 3-pyridyl compound 151. 
 
Table 18. Biological results for compounds 158-196.  
 
Compound R R’ 
ERK5; IC50 
(µM) 
P38α; IC50 
(µM) 
151 
  
0.82 ± 0.07 
(n = 4) 
>120 
158 
  
2.1 ± 0.11 
(n = 4) 
>120 
159 
  
2.7 ± 1.6 
(n = 6) 
>120 
160 
  
1.2 ± 0.84 
(n = 6) 
>120 
161 
  
1.8 ± 1.1 
(n = 6) 
>120 
162 
  
0.34 ± 0.14 
(n = 6) 
>120 
163 
  
0.52 ± 0.25 
(n = 6) 
>120 
164 
  
0.35 ± 0.17 
(n = 6) 
>120 
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165 
  
1.1 ± 0.48 
(n = 6) 
>120 
172 
  
0.44 ± 0.26 
(n = 6) 
>120 
173 
  
0.68 ± 0.37 
(n = 6) 
>120 
174 
  
4.4 ± 0.92 
(n = 2) 
>120 
175 
  
7.8 ± 2.3 
(n = 2) 
>120 
176 
  
4.1 ± 0.55 
(n = 2) 
>120 
177 
  
5.0 ± 0.64 
(n = 2) 
>120 
182 
  
0.36 ± 0.10 
(n = 4) 
>120 
183 
  
0.79 ± 0.16 
(n = 4) 
>120 
188 
  
2.9 ± 0.24 
(n = 2) 
>120 
189 
  
34 ± 3.2 
(n = 2) 
>120 
166 
  
0.96 ± 0.16 
(n = 2) 
84 ± 5.0 
167 
  
2.4 ± 0.60 
(n = 2) 
>120 
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All of the inhibitors in Table 18 are selective for ERK5 over p38α. Introduction of one 
or two methyl groups flanking the pyridyl nitrogen greatly improved ERK5 inhibitory 
activity compared to compound 151 (i.e. 162, ERK5; IC50 = 0.34 μM and 164, ERK5; 
IC50 = 0.35 μM). Replacement of the pyridyl ring in 151 with a pyridazine or a 
pyrimidine moiety also provided more potent ERK5 inhibitors (i.e. 172, ERK5; IC50 = 
0.44 μM and 182, ERK5; IC50 = 0.36 μM).  
 
Introduction of a chloro substituent on the pyrimidine ring was detrimental to ERK5 
inhibitory activity (175, ERK5; IC50 = 7.8 μM) as was the introduction of an indazole 
ring (196, ERK5; IC50 = 7.2 μM), suggesting that increasing the size of the amide side-
chain was not tolerated in the ERK5 ATP binding site.  
 
 
168 
  
1.0 ± 0.07 
(n = 2) 
56 ± 4.4 
169 
  
1.5 ± 0.40 
(n = 4) 
93 ± 5.9 
170 
  
1.5 ± 0.80 
(n = 2) 
>120 
171 
  
1.7 ± 0.02 
(n = 2) 
>120 
183 
  
1.2 ± 0.60 
(n = 6) 
>120 
185 
  
1.2 ± 0.20 
(n = 2) 
>120 
195 
  
1.5 ± 0.40 
(n = 2) 
>120 
196 
  
7.2 ± 0.60 
(n = 2) 
>120 
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4.3.4 Physicochemical properties and in vitro ADME profiling of selected 
potent compounds  
 
The most potent compounds determined by the initial cell-free ERK5 inhibition assay 
were taken forward for in vitro ADME profiling and initial drug metabolism studies at 
Cyprotex. The physicochemical properties (calculated by StarDrop) of the seven 
compounds were reviewed initially in order to ensure they met the lead criteria (Table 
19). 
 
Table 19. Physicochemical properties of compounds 160-182. 
 
Compound R R’ MW 
H-bond 
donors 
H-bond 
acceptors 
sLogP TPSA 
Lead 
criteria 
- - <500 <5 <10 <5 75-100 
160 
  
345 2 6 3.3 88 
162 
  
372 2 5 3.8 75 
163 
  
416 2 5 3.9 75 
164 
  
358 2 5 3.4 75 
172 
  
345 2 6 3.3 88 
173 
  
389 2 6 3.3 88 
182 
  
345 2 6 3.3 88 
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All of the seven compounds fulfilled the lead candidate criteria in terms of 
physicochemical properties and were selected for in vitro ADME profiling and drug 
metabolism studies at Cyprotex (Table 20). 
 
 
Table 20. In vitro PK and drug metabolism properties of compounds 160-182. 
 
 
Compound R R’ LE 
Solubility 
L/U 
(µM) 
PPB 
(%) 
Human 
CLint 
(µL/min/
mg) 
Mouse 
CLint 
(µL/min/
mg) 
Lead 
criteria 
- - >0.30  >50/50 <99 <48 <48 
160 
  
0.37 100/100 94 7.7 49 
162 
 
 
0.34 10/30 91 24 13 
163 
 
 
0.33 3/20 93 33 26 
164 
  
0.35 10/30 94 27 25 
172 
  
0.36 100/100 87 7.9 39 
173 
  
0.35 100/100 85 6.4 64 
182 
  
0.37 100/100 88 4.6 5.0 
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The most potent compounds from this series were also sent for testing against a panel of 
CYP450 enzymes in order to see if replacement of the pyridyl side chain does reduce 
CYP450 inhibition. These results are shown in Table 21 and are compared to those for 
compound 151. The optimal IC50 value against each CYP450 isoform would be          
>10 μM. 
 
Table 21. CYP450 Inhibition profile of most potent compounds in Table 18. 
*n = 1 
 
Compound 160 was the most potent of the four compounds containing a 4-
aminopyrimidine side chain (IC50 = 1.2 µM) and also has excellent aqueous solubility 
(100 µM), plasma protein binding (94%) and human microsomal clearance (CLint = 
7.68 µL/min/mg). Clearance in mice is higher (CLint = 48.7 µL/min/mg), but the overall 
profile is good. However, 160 inhibits the CYP450 isoforms tested, with particularly 
potent inhibition observed in both CYP2C9 (IC50 = 0.58 µM) and CYP2C19 (IC50 = 
0.29 µM), meaning the replacement of the 4-pyridyl ring of 151 with a 4-pyrimidyl 
group does not reduce CYP450 inhibition. Both 162 and 163 showed potent ERK5 
activity (IC50 = 0.34 µM and IC50 = 0.52 µM, respectively). Although plasma protein 
binding and clearance were good for both inhibitors, aqueous solubility was reduced (S 
(L/U  = 10/30 µM and 3/20 µM). This is due to the introduction of lipophilicity through 
the introduction of the two methyl groups flanking the pyridyl nitrogen.  For both of 
these inhibitors the CYP450 inhibition profile was greatly improved with IC50 >25 µM 
against all CYP450 isoforms tested. This validates the theory that blocking the pyridyl 
nitrogen from possible oxidation by CYP450 enzymes reduces CYP450 inhibition. 
Introduction of just one flanking methyl group onto the pyridyl moiety was also 
interesting. Compound 164 was shown to be a potent inhibitor of ERK5 (IC50 = 0.35 
µM) and also had reduced activity against all of the CYP450 enzymes in the panel. 
Compound  
CYP1A; 
 IC50 
(µM) 
CYP2C9; 
IC50 
 (µM) 
CYP3A4; 
IC50  
(µM) 
CYP2C19; 
IC50  
(µM) 
CYP2D6; 
IC50  
(µM) 
151 6.0 ± 0.6 14 ± 1.7 8.4 ± 1.6 8.5 ± 2.5 9.2 ± 1.3 
160 23 ± 3.6 0.58 ± 0.06 4.5 ± 1.1 0.29 ± 0.05 6.0 ± 1.8 
162 >25 >25 >25 >25 >25 
163 >25 >25 >25 >25 >25 
164 >25 >25 >25 9.8* >25 
172 >25 1.3*  13* 0.50* 10* 
173 >25 1.1* 16* 0.90* 6.8* 
182 22 ± 3.2 24 ± 3.3 12 ± 2.8 22 ± 3.7 >25 
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Again the aqueous solubility was less than optimal (S (L/U) = 10/30 µM), but plasma 
protein binding and clearance were good (PPB = 94%; human CLint = 27 µL/min/mg 
and mouse CLint = 25 µL/min/mg). The two compounds containing pyridazine side 
chains, 172 and 173 were both potent inhibitors of ERK5 (IC50 = 0.44 and 0.68 µM 
respectively). They both had excellent aqueous solubility (S (L/U) = 100/100 µM), 
plasma protein binding (87% and 84%) and no clearance, with the exception of 173 in 
mouse microsomes (172; human Clint = 7.9 µL/min/mg, mouse CLint = 39 µL/min/mg; 
173; human CLint = 6.4 µL/min/mg, mouse CLint = 64 µL/min/mg). However, in both 
cases the CYP450 inhibition is not reduced, with both compounds showing potent 
inhibition of CYP2C19 (172; IC50 = 0.50 µM; 173; IC50 = 0.90 µM). Finally, 182 has 
excellent ERK5 inhibitory activity (IC50 = 0.36 µM), aqueous solubility (S (L/U) = 
100/100 µM), plasma protein binding (88%) and clearance (human CLint = 4.6 
µL/min/mg; mouse CLint = 5.0 µL/min/mg). Compound 182 has also been shown to 
have an excellent CYP450 inhibition profile with an IC50 value of >20 µM for four out 
of the five CYP450 isoforms tested and >10 µM for the final isoform. Overall 
compound 182 has an excellent drug-like profile with the right balance of in vitro 
ADME properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
Chapter 5. Structure-activity relationship studies (SARs) around the 
aroyl ring 
5.1 Effect of para-substitution of the aroyl ring on ERK5 inhibitory activity 
 
5.1.1 Rationale  
 
In the absence of a crystal structure of ERK5, homology modelling by sequence 
alignment and superimposition was conducted by Dr Susan Boyd on behalf of CRT-DL. 
As stated in chapter 3, ERK2 was identified as the closest homologue of ERK5 with 
51% and 78% sequence homology in the kinase and ATP binding site domains, 
respectively. The first generation homology model was based on ERK2 and was 
generated using MOE software from Chemical Computing Group, using the Amber99 
force field with Born solvation. 
 
Using the homology model, two pyrrole carboxamide inhibitors were docked into the 
ERK5 binding site, and two potential binding modes were proposed. Modelling of 197  
led to the development of binding mode A (Figure 33). This binding mode suggests that 
the halogenated aryl ring points out towards solvent whilst the pyridyl nitrogen interacts 
with a salt bridge lysine.  
   
 
     
Figure 33. Proposed binding mode A for the pyrrole carboxamide series, modelled 
using 197. 
 
Binding mode B was obtained using a compound with a penta-substituted aroyl ring 
(198) (Figure 34). In this binding mode, the pyrrole ring was thought to bind in the 
opposite orientation, with the pyridylmethylamine ring pointing out towards solvent. 
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The aroyl ring is directed into a hydrophobic pocket in the binding site, and is therefore 
constrained. The chloro substituents are shown in space-filling mode to illustrate the 
limited size of the binding pocket. This is consistent with previous SARs, which suggest 
the aroyl ring may be sensitive to substitution pattern.  
 
        
 
Figure 34.  Alternative binding mode B for the pyrrole carboxamide series. 
 
 
The rationale behind the synthesis of compounds with a para-substituent on the aroyl 
ring was to determine which of two proposed binding modes was preferred. If the para-
substituted compounds were potent inhibitors of ERK5, it would suggest that binding 
mode A was adopted as the benzoyl ring would not be constrained in this binding mode. 
Conversely, if inactivity was observed, it would appear binding mode B is preferred 
since this proposed mode suggests the benzoyl ring is tightly bound within a 
hydrophobic pocket.  
 
The inhibitors to be synthesised are shown in Figure 35. The amine substituent is fixed 
as the 4-pyridylmethylamine group based on the original hit compounds (i.e. 53, Figure 
35). The shortened amide side-chains had not been discovered at the time of synthesis. 
Varying the size and electronic properties of the groups to be incorporated at the para-
position, helps to further probe which groups will be tolerated in this position and gives 
information on the surrounding ATP binding site of ERK5. 
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Figure 35.  Proposed targets to probe tolerance of para-substitution. 
 
 
 
5.1.2 Synthesis of inhibitors 199-201 with a para-substituted aroyl ring 
 
 
The target compounds 199, 200 and 201 were synthesised following the previously 
optimised 3-step route (Scheme 34). The first step Friedel-Crafts acylation gave esters 
72, 203 and 204 in good yield (67%, 77% and 79%, respectively).  Hydrolysis of the 
methyl ester using lithium hydroxide gave the corresponding carboxylic acids, 73, 205 
and 206 in 94%, 84% and 84%, respectively. CDI-mediated coupling of picolylamine 
with the previously prepared carboxylic acids, provided 199, 200 and 201 in excellent 
yields (90%, 85% and 85%, respectively).  
 
 
Scheme 34. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM,   0 
o
C to RT, 18 h; (ii) LiOH(aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-
picolylamine, 50 
o
C to RT, 18 h. 
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5.1.3 ERK5 inhibitory activity of 199-201 
 
Compounds 199, 200 and 201 were tested for ERK5 inhibitory activity and the results 
are shown in Table 20 with compounds being compared to hit compound 53. All three 
compounds proved totally inactive against ERK5, with all IC50 values >120 µM.   
 
Table 20. Biological results for 199, 200 and 201. 
 
Compound R ERK5; IC50 (µM) 
53 2,6-diF 2.4 ± 0.09 (n = 2) 
199 4-O
i
Pr >120 
200 4-OMe >120 
201 4-OCF3 >120 
 
The observed lack of activity provides further evidence that para-sustitution is not 
tolerated on the aroyl ring, as suggested by previous SARs. It also shows that these 
compounds are more likely to bind within the ERK5 active site according to proposed 
binding mode B illustrated in Figure 34. This binding mode suggests that the aroyl ring 
is directed into a small hydrophobic pocket imposing limited tolerance around this ring.  
 
 
5.1.4 Synthesis of para-difluoromethoxybenzoyl analogue 202 
 
The general synthetic scheme outlined previously for the synthesis of the other para-
substituted analogues could not be employed for the synthesis of 200. Problems were 
encountered with the Friedel-Crafts acylation with none of the desired product isolated 
despite several attempts.  Conversion of the commercially available 4-OCHF2 benzoic 
acid to the corresponding benzoyl chloride was conducted using thionyl chloride and 
the product used immediately in order to rule out potential instability as a reason for the 
lack of reaction. A review of the literature suggested that the -OCHF2 group could react 
with the AlCl3 Lewis acid catalyst used in this step. It has been observed that C-F bonds 
can be activated by aluminium reagents. The C-F bond can be cleaved upon 
coordination with a strong activating agent such as aluminium or boron, both of which 
have been shown to bind strongly to fluorine (159 and 181 kcal/mol respectively), 
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meaning Friedel-Crafts type arylations can possibly occur on the CHF2 group with the 
loss of fluorine gas (Figure 36).
126
 
  
 
 
RCHF2        +     Ar-H     RCHAr2 
R = alkyl 
 
Figure 36. Possible Friedel-Crafts arylation of the CHF2 group in the presence of an 
aluminium reagent. 
 
 
According to the literature, this reaction has been investigated using a variety of 
hydrofluorocarbons (HFCs), and the expected arylated products according to the above 
proposed reaction were isolated when the reaction was completed at 0 
o
C.
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 It was also 
observed that there were differences in reactivity between CH2F, CHF2, and CF3 groups, 
with the following identified as the reactivity pattern, CH2F>CHF2>CF3, with CHF2 
fluorine atoms being substituted selectively in the presence of CF3 groups in the same 
molecule. This could explain why there were no problems encountered during the 
Friedel-Crafts acylation reaction involving the 4-OCF3 substituted benzoyl chloride, due 
to the fact that additional fluorine atoms in a molecule can strengthen neighbouring C-F 
bonds.
126
 According to these observations, the potential product from the originally 
attempted Friedel-Crafts reaction could be as shown in Scheme 35. Our hypothesis was 
also strengthened by 
19
F NMR of the crude isolated material where a lack of fluorine 
was observed.  
 
Scheme 35.  Reagents and Conditions: (i) AlCl3, DCM, 0 
o
C to RT, 18 h. 
 
Aluminium reagent 
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An alternative synthetic approach was attempted (Scheme 36), using a Friedel-Crafts 
reaction to insert a trichloroacetyl substituent into the 4-position of the pyrrole ring. We 
used the optimised reaction conditions with trichloroacetyl chloride, and the desired 
product 209 was obtained in 89% yield.  (4-(Difluoromethoxy)phenyl)magnesium 
bromide could then be used in order to displace the trichloromethyl anion  and give 210. 
 
 
Scheme 36. Reagents and conditions: (i) trichloroacetyl chloride, AlCl3, 0 
o
C to RT, 18 
h; (ii) (4-(difluoromethoxy)phenyl)magnesium bromide, Et2O, RT, 18 h. 
 
 The Grignard reaction was tested in a model reaction using phenylmagnesium bromide 
(Scheme 37). This reaction was unsuccessful when attempted either with commercial 
Grignard reagent, or when the reagent was formed in situ. The lack of success could be 
explained by a possible halogen metal exchange between the Grignard reagent and the 
trichoroacetyl group. As described in the literature, the trichloroacetyl group can act as a 
Cl
+
 donor.
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 It was also suggested that the Grignard reagent may be sufficiently basic 
to deprotonate the pyrrole NH, and chelation could occur between the pyrrole nitrogen 
and the carbonyl group, therefore preventing reaction in the desired position.  
 
 
Scheme 37. Reagents and conditions: (i) trichloroacetyl chloride, AlCl3, 0 
o
C to RT, 18 
h; (ii) phenylmagnesium bromide, Et2O, RT, 18 h. 
 
Conversion of the trichloroacetyl group to a Weinreb amide to give 212 was attempted 
using N,O-dimethylhydroxylamine (Scheme 38) followed by reaction with the Grignard 
reagent.
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 The trichloroacetyl group should react readily with an amine as this had been 
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performed successfully by other members of the group. However, using N,O-
dimethylhydroxylamine this reaction was unsuccessful, and so the subsequent Grignard 
reaction could not be attempted. Conversion to the Weinreb amide 212 was attempted 
using a variety of conditions in which the number of equivalents of the amine and base 
were modified, along with the temperature (Table 21). Since none of these 
modifications were successful, an alternative strategy towards the target compound was 
sought. 
 
 
Scheme 38. Reagents and conditions: (i) trichloroacetyl chloride, AlCl3, 0 
o
C to RT, 18 
h; (ii) phenylmagnesium bromide, Et2O, RT, 18 h; (iii) N,O-dimethylhydroxylamine 
hydrochloride, NEt3, DMF, see Table 21 for attempted conditions. 
 
 
Table 21. Conditions attempted for conversion of 207 to 210. 
Entry 
Temp. 
(
o
C) 
Time 
(h) 
Equiv. N,O-
dimethylhydroxylamine . HCl 
Equiv. 
NEt3 
Result 
1 RT 18 1.2 1.0 No reaction 
2 RT 18 3.2 3.0 Degradation 
3 50 18 1.2 1.0 Degradation 
4 RT 18 1.0 3.6 No reaction 
 
 
The next approach we explored consisted of using an alternative leaving group to the 
trichloro- group, the trifluoro- group. The Friedel-Crafts reaction was utilised to 
introduce a trifluoroacetyl substituent onto the 4-position of the pyrrole ring, using 
trifluoroacetic anhydride. Compound 213 was obtained in a good yield of 75%. The 
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subsequent model Grignard reaction was performed using phenylmagnesium bromide, 
and the desired product 211 was isolated in 40% yield (Scheme 39).  
 
 
Scheme 39. Reagents and conditions: (i) TFAA, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) 
phenylmagnesium bromide, THF, RT, 18 h. 
 
 
We applied this methodology to the synthesis of the 210 (Scheme 40). The Grignard 
reagent for this transformation was generated in situ using 1-(bromo-4-
difluoromethoxy)benzene and magnesium turnings before being reacted with 213 in a 
1:1 ratio of equivalents. After overnight reaction, a 6% conversion to the desired 
product 210 could be observed by LC-MS, and no further reaction occurred after further 
stirring overnight. Attempts to isolate 210 were unsuccessful due to the small scale of 
the reaction. 
 
 
 
 
Scheme 40. Reagents and conditions: (i) TFAA, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) (4-
(difluoromethoxy)phenyl)magnesium bromide, THF, RT, 18 h; (iii) LiOH(aq), THF,  
60 
o
C, 18 h; (iv) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-picolylamine, 50 
o
C to RT, 18 h. 
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In order to determine whether the in situ Grignard reagent had formed successfully, a 
model reaction was performed with acetophenone using the same conditions. This 
reaction was successful in 5 h, and the correct product 216 was obtained in 80% yield 
(Scheme 41). This suggested that (4-(difluoromethoxy)phenyl)magnesium bromide was 
being formed and could react successfully. The Grignard reagent may be sufficiently 
basic to deprotonate the pyrrole nitrogen and this could prevent the desired reaction 
occurring.  In order to try and overcome this, the reaction was attempted using 2 
equivalents of the Grignard reagent. However, this only improved the conversion to 
15% (detected by LC-MS). An alternative approach could be to protect the pyrrole 
nitrogen prior to reaction with the Grignard reagent; however, this was never attempted 
due to an alternative approach to the desired compound being identified in the literature.  
 
 
Scheme 41. Reagents and conditions: (i) Mg turnings, 1-(bromo-
difluoromethoxy)benzene, Et2O, RT, 5 h. 
 
 
Alkylation of a 4-phenol on the aryl ring of the aroyl substituent using diethyl 
bromodifluoromethylphosphonate was attempted.  Use of diethyl 
bromodifluoromethylphosphonate as an efficient difluorocarbene precursor has been 
shown in the literature to be useful for the difluoromethylation of phenols. The reaction 
is performed in the presence of potassium hydroxide, and is thought to proceed via the 
hydroxide-mediated cleavage of the P-C bond to give the bromodifluoromethyl anion C 
and diethyl phosphate B. The bromodifluoromethyl anion is unstable and, as such, 
eliminates bromide in order to generate the difluorocarbene D, which can react with the 
phenol to generate difluoromethoxy compound G (Scheme 42).
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Scheme 42. Proposed mechanism of phenol alkylation using                                
diethylbromodifluoromethylphosphonate
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Demethylation of previously prepared methoxy compound 200 was conducted using 
boron tribromide with the aim of performing the discussed alkylation to give 
difluoromethoxy compound 202 (Scheme 43).  
 
 
Scheme 43. Reagents and conditions: (i) 4-methoxybenzoyl chloride, AlCl3, DCM, 0 
o
C 
to RT, 18 h; (ii) LiOH(aq), THF, 60 
o
C, 18 h; (iii) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-
picolylamine, 50 
o
C to RT, 18 h; (iv) BBr3 (1.0 M in DCM), 0 
o
C to RT, 18 h ;(v) 
diethyl bromodifluoromethylphosphonate, KOH, MeCN-H2O, -78 
o
C to RT, 2 h. 
X
X 
X
X 
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The synthesis of 200 was discussed previously. The boron tribromide demethylation of 
200 was successful affording phenol 217 in 80% yield indicated by LC-MS. Isolation of 
phenol 217 was difficult due to remaining starting material 200, so removal of the 
methyl group earlier in the synthesis was attempted by reacting 205 with boron 
tribromide (Scheme 44).  
 
 
Scheme 44. Reagents and conditions: (i) 4-methoxybenzoyl chloride, AlCl3, DCM, 0 
o
C 
to RT, 18 h; (ii) LiOH(aq), THF, 60 
o
C, 18 h; (iii) BBr3 (1.0 M in DCM), 0 
o
C to RT, 18 
h (iv) (a) CDI, THF, 70 
o
C, 3 h; (b) 4-picolylamine, 50 
o
C to RT, 18 h;  (v) diethyl 
bromodifluoromethylphosphonate, KOH, MeCN-H2O, -78 
o
C to RT, 2 h. 
 
In this case the purification of 218 was achieved using MPLC producing the pure 
product in 79% yield. Subsequent amide coupling using CDI was performed to give 
phenol compound 217 in 32% yield. The low yield was possibly due to the side reaction 
of the phenol moiety with CDI. After successful isolation of 217, the alkylation of the 
phenol using diethyl bromodifluoromethylphosphonate was attempted, but without any 
success.  
 
Since the synthesis of compound 202 had proven difficult, and in light of the poor 
ERK5 inhibitory activity of the other p-substituted aroyl compounds (199, 200 and 
201), we decided to cease the synthesis of difluoromethoxy compound 202. The 
intermediate phenol 217 was sent for biological evaluation, and showed poor activity 
against ERK5 with an IC50 of 44 µM.  
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5.2 meta-Substitution of the aroyl ring  
 
5.2.1 Rationale 
 
In addition, two meta-substituted aroyl analogues were synthesised and tested for ERK5 
inhibitory activity. The 3-OMe substituted compound 219 was synthesised previously 
by another member of the group, and showed moderate activity against ERK5 (Figure 
37).
90
 The large increase in potency for this compound compared with the 4-OMe 
counterpart (198, IC50 > 120 µM) was encouraging, and showed that the synthesis of 3-
substitued analogues may provide interesting SARs. 
 
 
Figure 37. Improved potency for 3-substituted methoxy compound 219 compared to 4-
methoxy compound 200. 
 
 
5.2.2 Synthesis of inhibitors with a meta-substituted aroyl ring  
 
The 3-OCF3 analogue was synthesised following the general scheme outlined 
previously, with the Friedel-Crafts acylation being performed in 79% yield (220) and 
the subsequent hydrolysis in 89% yield (221). The amide coupling step proved to be 
very low yielding, with only 6% of the final compound obtained. In order to remedy this 
problem the synthesis was performed in a different order, with the hydrolysis and 
subsequent amide coupling being performed first followed by the Friedel-Crafts 
acylation (Scheme 45). Performing the reactions in this order improved the yields for 
each step (hydrolysis, compound 222; 98%, amide coupling, compound 223; 89% and 
acylation, compound 224; 84%). 
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Scheme 45. Reagents and conditions: (i) LiOH (aq), THF, 60 
o
C, 18 h; (ii) (a) CDI, 
THF, 70 
o
C, 3 h; (b) 4-picolylamine, 50 
o
C to RT, 18 h; (iii) (3-trifluoromethoxy) 
benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h. 
 
 
5.2.3 Biological evaluation of meta-substituted inhibitors 
 
The biological evaluation of compound 224 is shown in Table 22. Unsurprisingly, the 3-
OCF3 substituted compound showed improved inhibitory activity compared to the 4-
OCF3 substituted analogue (201, ERK5; IC50 > 120 μM).  
 
Table 22. ERK5 inhibitory activity of 219 and 224. 
 
 
Compound number R ERK; IC50 (µM) 
200 4-OMe >120 
201 4-OCF3 >120 
219 3-OMe 27 ± 1.2 (n = 2) 
224 3-OCF3 12 ± 1.2 (n = 2) 
 
Despite the improved ERK5 inhibitory activity observed for compounds 219 and 224, 
compared to 4-substituted analogues 200 and 201, the ERK5 inhibition remained quite 
poor compared to hit compound 53 (ERK5; IC50 = 2.4 μM) and no further analogues 
were synthesised. 
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5.3 Modification of the aroyl substituent to gain selectivity over p38α 
 
5.3.1 Rationale 
 
As stated previously, the MAPK p38α is a close homologue of ERK5, and as such, it is 
essential to screen compounds with inhibitory activity for ERK5 against p38α to ensure 
selectivity is achieved. It had been observed that original hit compound, 53 showed 
greater inhibitory activity against p38α compared to ERK5. Modification of the 
substituents on the aroyl ring was shown to improve selectivity for ERK5 over p38α 
(i.e. 225, 226 and 227) (Figure 38).  
 
 
Figure 38.  Improvement in selectivity for ERK5 over p38α by modification of the 
benzoyl group. 
 
In light of this and the success of the shorter amide side chain analogues (as discussed 
in Chapter 4), a small library of 15 compounds was proposed for synthesis, 
incorporating the three benzoyl groups that had shown improved selectivity over p38α 
and the five amide side chains that had conferred  best potency against ERK5 (Figure 
39). 
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Figure 39. Target molecules proposed to improve potency for ERK5 and selectivity 
over p38α. 
 
 
5.3.2 Synthesis of inhibitors with reduced p38α activity  
 
Compounds with aromatic amine side chains were synthesised according to the general 
procedure shown in Scheme 46. Methyl pyrrole-2-carboxylate (69) was acylated with 
either 2-(trifluoromethyl)benzoyl chloride, 2-(fluoro-6-trifluoromethyl)benzoyl chloride 
or 2,3-dichlorobenzoyl chloride in good yield (224; 84%, 225; 60% and 150; 71%, 
respectively). Each methyl ester was then treated with aqueous LiOH to afford the 
corresponding carboxylic acids, 226, 227 and 153 in excellent yield (all 99%). The 
appropriate aniline was then coupled using PCl3 under microwave irradiation to give the 
10 desired compounds (228-237) with yields ranging from 38-75%. The 3- and 4-
pyridyl analogues in the 2-fluoro-6-trifluoromethyl series were synthesised by another 
group member.
130
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Scheme 46. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) PCl3, appropriate aniline, MeCN, 
MW, 150 
o
C, 5 min.  
 
The three compounds with piperidinyl side chains were synthesised according to 
Scheme 47. Carboxylic acid intermediates 153, 226 and 227 were coupled with 1-
amino-1-boc-piperidine using CDI as the coupling agent to afford the Boc-protected 
compounds 238, 239 and 240 in 82%, 75% and 80%, respectively. Coupling of 1-
amino-1-boc-piperidine using the PCl3 coupling method was attempted with each of the 
carboxylic acid intermediates, but was not as successful as using the CDI approach. The 
by-products of the PCl3 coupling reaction, hydrochloric acid and phosphorus acid, were 
causing deprotection of the Boc-protected amino-piperidine. This meant that although 
some conversion to the correct product was observed, the reaction mixture was 
complex. Using the CDI method, compounds 242, 243 and 244 were isolated in good 
yield. Deprotection of 242, 243 and 244 was achieved using TFA in the presence of 
triethylsilane. Triethylsilane is used as a carbocation scavenger to remove the t-butyl 
carbocation generated in the reaction and prevent any side reactions that may occur with 
this reactive species.
131
 The three deprotected compounds, 245, 246 and 247 were 
obtained in good yield (97%, 65% and 80%, respectively).  
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Scheme 47. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) CDI, 4-amino-1-boc-piperidine, 
THF, 70 
o
C to RT, 18 h; (iv) TFA, Et3SiH, DCM, RT, 1 h. 
 
 
5.3.3 ERK5 inhibitory activity and p38α counter -screening data for 
compounds 232-247 
 
The 15 compounds synthesised in this series were evaluated for ERK5 inhibitory 
activity and counter-screened against p38α in order to determine whether selectivity had 
been achieved. The cellular activity of four analogues was also assessed. These results 
are shown in Table 23 and all compounds are compared to original hit compound 53 
and shortened amide side-chain analogue 127.  
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Table 23. Biological results for compounds 232-247. 
 
Compound R R’ 
ERK5; 
IC50 (µM) 
p38α; IC50 
(µM) 
Cellular 
activity 
(HEK293, µM) 
53 
 
 
2.4 ± 0.15 
(n = 4) 
0.58 ± 0.27 
(n = 2) 
- 
127 
  
0.90 ± 0.15 
(n = 4) 
100 ± 35 
(n = 2) 
- 
235 
  
5.5 ± 4.5 
(n = 8) 
>120 ND 
233 
  
1.5 ± 1.0 
(n = 6) 
22 ± 1.1 
(n = 2) 
24 ± 8.5 
(n = 2) 
238 
  
1.6 ± 0.30 
(n = 4) 
>120 ND 
241 
  
0.87 ± 0.57 
(n = 6) 
 
>120 ND 
247 
  
1.7 ± 0.6 
(n = 4) 
94 ± 23 
(n = 2) 
30 (n = 1) 
237 
  
2.6 ± 0.32 
(n = 4) 
>120 ND 
240 
  
0.94 ± 0.14 
(n = 4) 
>120 ND 
246 
  
2.4 ± 1.1 
(n = 4) 
>120 17 (n = 1) 
237 
  
3.6 ± 0.96 
(n = 2) 
>120 ND 
232 
  
2.3 ± 0.8 
(n = 4) 
>120 ND 
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ND – Not Determined 
 
In all cases, improved selectivity for ERK5 over p38α was observed compared to hit 
compound 53, with most compounds having IC50 values >120 µM against p38α. The 
only exceptions were 233 and 247, which had slightly improved activity against p38α, 
but were still 55-fold and 30-fold selective for ERK5, respectively. The most potent 
compounds were the two sulphonamides, 240 and 241 and all compounds had an IC50 
value for inhibition of ERK5 below 10 µM. Four of the compounds were tested for 
cellular activity at the Babraham Institute in Cambridge using a MEF2D reporter gene 
assay in HEK293 cells. ERK5 IC50 values are determined via the measurement of 
phosphorylation of MEF2D, which is a transcription factor and downstream target of 
ERK5. The level of phosphorylation is measured by extent of luminescence detected. 
The values obtained for the four compounds are shown in Table 23. Interestingly, the 
cellular activities obtained were lower than the inhibitory activities measured in the cell-
free assay in each case, and in order to explain this, the physicochemical properties and 
in vitro PK for selected compounds were reviewed.  
 
5.3.4 Physicochemical properties and in vitro ADME profiling for 
compounds 233 and 235 
 
The physicochemical properties of compounds 233 and 234 were analysed as a 
representative sample of the series (Table 24).   
 
Table 24. Physicochemical properties of 233 and 235. 
 
236 
  
9.4 ± 0.37 
(n = 2) 
>120 ND 
239 
  
8.8 ± 8.5 
(n = 4) 
>120 ND 
245 
  
3.3 ± 1.7 
(n = 4) 
>120 30 (n = 1) 
Compound 
 
MW 
H-bond 
donors 
H-bond 
acceptors 
sLogP TPSA 
Lead 
criteria 
<500 <5 <10 <5 75-100 
233 360 2 5 3.7 75 
235 360 2 5 3.7 75 
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Since 233 and 235 had fulfilled the physicochemcial properties of a lead candidate, the 
pharmacokinetic properties and drug metabolism profiles were evaluated at Cyprotex 
(Table 25). 
 
Table 25. In vitro ADME profiling properties for 233 and 235.  
 
 
Compound 235 had excellent solubilty (S (L/U) = 100/100 µM) compared to 233, 
which had reduced solubility of 15/50 µM. The poor solubility for compound 233 could 
be the reason for the lower activity observed in HEK293 cells, as it may suggest that the 
compound had poor cell permeability. In both cases the human and mouse microsomal 
clearance was good and plasma protein binding for both inhibitors was 99% or less, and 
therefore optimal.  
 
 
5.3.5 Inhibitors with a 2-fluoro-6-chloro or 2-fluoro-6-bromoaroyl ring 
with improved potency and selectivity for ERK5 over p38α  
 
Two alternative series of compounds to those described herein were synthesised by 
another member of the group.
132
 These series incorporated aroyl rings with novel 
substitution patterns. Biological testing of these inhibitors identified compounds with 
improved ERK5 inhibitory activity and good selectivity over p38α. The results for these 
compounds are shown for reference in Table 26. 
 
 
 
 
 
 
 
 
 
Compound 
 
LE 
Solubility 
L/U (µM) 
PPB (%) 
Mouse CLint 
(µL/min/mg) 
Human CLint 
(µL/min/mg) 
Lead 
criteria 
>0.30 >50/50 <99 <48 <48 
233 0.30 15/50 97 24 15 
235 0.30 100/100 99 23 0 
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Table 26. Compounds with improved ERK5 potency and selectivity over p38α 
 
 
 
5.3.5.1 In vitro and in vivo pharmacokinetic studies with 151 
 
Compound 151 was selected for in vitro and in vivo pharmacokinetic studies. The 
physicochemical properties of 151 are shown in Table 27. 
 
 
Compound R R’ 
ERK5; IC50 
(µM) 
p38α; IC50 
(µM) 
127 
  
0.90 ± 0.15 
(n = 4) 
100 ± 35 
(n = 2) 
150 
  
0.60 ± 0.27 
(n = 4) 
>120 
248 
  
0.58 ± 0.24 
(n = 4) 
93 ± 13 
(n = 2) 
249 
  
0.49 ± 0.04 
(n = 4) 
11 ± 1.0 
(n = 2) 
250 
  
0.20 ± 0.07 
(n = 4) 
8.5 (n = 1) 
251 
  
0.68 ± 0.15 
(n = 4) 
>120 
151 
  
0.82 ± 0.07 
(n = 4) 
>120 
252 
  
0.39 ± 0.12 
(n = 4) 
19 ± 0.33 
(n = 2) 
253 
  
0.28 ± 0.16 
(n = 8) 
11 ± 0.01 
(n = 2) 
150 
 
Table 27. Physicochemical properties of 151. 
 
 
In vitro pharmacokinetic studies were conducted at Cyprotex and the results are shown 
in Table 28. The solubility of 151 was measured as 100/100 µM (L/U), which is the 
optimum value for a lead compound. Both the human and mouse microsomal clearance 
were excellent. Caco-2 permeability was also evaluated and 151 was shown to be above 
the threshold (>10 x 10
-6
 cm/s) and the efflux ratio was low (0.82). In order to 
determine whether 151 would inhibit CYP450 enzymes, the compound was tested 
against a panel of CYP450 isoforms (2C19, 2C9, 2D6, 3A4). Encouragingly, inhibition 
of the CYP450 isoforms tested was measured as >5 µM in each case. In addition, 
compound 151 was tested in the MEF2D reporter gene assay and the IC50 was measured 
as 4.4 ± 2.1 µM. The GI50 for this compound was tested in Newcastle in PC3 cells as 44 
± 2.8 µM, which was not consistent with both the in vitro and cellular activity 
(HEK293). In addition, the selectivity of compound 151 was tested in a DiscovRx 
screen, which includes 456 kinases. Overall, the selectivity for ERK5 was good and 
MEK5 activity was observed. We obtained and IC50 against MEK5 by outsourcing 
compound 151 to Carna Bioscience (MEK5; IC50 = 3.4 μM). There was also evidence 
of 151 having activity against the JAK family of kinases. Overall 151 showed good 
drug-like properties and was entered into in vivo drug metabolism pharmacokinetics 
(DMPK) studies in mice.   
 
Table 28. In vitro ADME profiling data for 151. 
 
 
Two in vivo DMPK studies were conducted at Newcastle by Huw Thomas using CD1 
mice. A 10 mg/kg dose of 151 was administered orally (PO) to mice bearing a HCT116 
human colorectal tumour xenograft. The plasma of these mice was collected at five time 
Compound MW 
H-bond 
donors 
H-bond 
acceptors 
sLogP TPSA 
Lead 
criteria 
<500 <5 <10 <5 75-100 
151 388 2 5 3.1 75 
Compound 
Solubility 
(µM) 
PPB (%) 
Mouse CLint 
(µL/min/mg) 
Human CLint 
(µL/min/mg) 
Lead 
criteria 
>50/50 <99 <48 <48 
151 100/100 94 20 0 
151 
 
points following administration. A 100 mg/kg dose was also given to another set of 
mice bearing the same tumour xenograft and this time tumour tissue was removed at 
five time points following oral administration. The same experiments were also 
performed following intravenous (IV) and intraperitoneal (IP) administration in order to 
determine the pharmacokinetic properties associated with each dosing regimen. The 
results of these studies are summarised in Table 29. The oral bioavailability of 151 was 
measured as 68%, which above the desired oral bioavailability for a lead compound 
(>30%). The half life following oral dosing was determined to be 65 min. These values 
were not repeated following IV or IP administration, but the clearance in these cases 
was shown to be more desirable than in oral dosing when it was shown to be high (oral; 
39 mL/min/kg, IV; 27 mL/min/kg and IP; 25 mL/min/kg).  
 
Table 29. In vivo DMPK for 151. 
Administration PO IV IP 
Dose (mg/kg) 10 10 10 
AUC inf 
(µg/mL.min) 
254 372 398 
Cmax (µM) 6 25 12 
Vd (L/kg) ND 1.2 ND 
Tmax (min) 15 5.0 15 
Half-Life (min) 65 38 43 
Clearance 
(mL/min/kg) 
39 27 25 
Bioavailability, F 
(%) 
68 ND 108 
 
 
 
The in vivo efficacy of 151 was also tested at Newcastle by Huw Thomas using a 
matrigel plug assay and a human tumour xenograft model (using CD1 mice and A2780 
human ovarian carcinoma cells). In both studies, the efficacy of 151 was compared to 
that of competitor compound, XMD8-92. The matrigel plug assay is a measure of 
angiogenesis and was performed using CD1 mice, which were subcutaneously treated 
with matrigel containing fibroblast growth factor (bFGF). This induces formation of a 
matrigel plug, which can be permeated by host cells and leads to formation of new 
blood vessels. In the presence of an anti-angiogenic agent the extent of new blood 
vessels formed would be reduced. 24 hours after the mice were treated with bFGF, they 
were randomised to receive either; vehicle, XMD8-82 (50 mg/kg, IP) or 151 (50 mg/kg, 
PO) bi-daily for 7 days. On day 7 the mice were sacrificed and the matrigel plugs 
152 
 
removed and snap frozen in liquid nitrogen. The concentration of haemoglobin present 
could then be determined as a measure for the extent of blood vessel formation. The 
results are shown in Figure 40, which shows that the administration of an ERK5 
inhibitor has an anti-angiogenic effect.  
 
 
Figure 40. Haemoglobin levels determined in matrigel plug assay in CD1 mice treated 
with XMD8-92 or 151. 
 
 
In the human tumour xenograft model, CD1 mice were treated with A2780 human 
ovarian carcinoma cells and tumours were left to grow for 7 days. The mice were then 
randomised to receive either; vehicle, XMD8-82 (50 mg/kg, IP) or 151 (100 mg/kg, PO) 
bi-daily for 11 days. Tumour volumes were measured and the mice that had been treated 
with either XMD8-92 or 151 had tumours of a much reduced size compared with those 
in the control group (Figure 41). Nadir weight was used as an indicator of drug toxicity 
and in each case it remained at 98% for the mice treated with 151. These initial in vivo 
DMPK studies are encouraging and show that an ERK5 inhibitor could have potential 
as an anti-angiogenic and anti-proliferative agent. 
151 
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Figure 41. Treatment of CD1 mice bearing A2780 xenograft with XMD8-92 or 151. 
 
 
In order to determine the effect of 151 on cell migration, a scratch wound assay was 
performed at Newcastle by Lan Zhen Wang using a breast cancer cell line (MDA-MB-
231). Cells were grown and a ‘wound’ was introduced by scratching a pipette tip 
through the centre of the cell culture. The cells at the ‘wound’ edge were then allowed 
to migrate into the space created by the scratch after having been treated with either 
XMD8-92 or 151 (at 10 µM and 30 µM). After 17 hours the level of migration can then 
be determined simply by viewing the extent with which the cells appear to have 
migrated into the space. The results of this assay are shown in Figure 42 and show that 
there is some effect evident with both ERK5 inhibitors compared to the control 
experiment, but considering the high concentrations of inhibitor used, the effect is not 
significant. It is not clear from this assay whether an ERK5 inhibitor would have an 
effect on tumour cell migration.  
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Figure 42. Scratch wound assay; control experiment and those performed with 10 and 
30 μM of XMD8-92 and 151, respectively. 
 
 
5.3.5.2 Docking studies with 251 in second-generation p38α-derived 
homology model  
 
As outlined in chapter 3, a second generation homology model of ERK5 based on p38α 
(43% sequence identity in active site domain) was developed at Newcastle University 
by Prof. Martin Noble. Compound 251 was used as a representative potent pyrrole-
carboxamide inhibitor and was built into the ERK5 model using GROMACS 
(GROningen MAchine for Chemical Simulations). Figure 42 (A) shows compound 251 
bound in the ERK5 model (magenta) and also bound in p38α crystal structure (cyan) for 
comparison. Key differences in the protein sequences of p38α (cyan) and ERK5 
(magenta) have been highlighted to indicate where compound selectivity is most likely 
achieved. Figure 42 (B) shows the excellent fit of compound 251 into the new 
homology model.  
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Figure 42. (A) ERK5 model (magenta) compared to p38α crystal structure (cyan), both 
shown in complex with compound 251; (B) Compound 251 docked in the p38α-derived 
homology model. 
 
This homology model was utilised for the structure-based design of new inhibitors 
exploiting previously unexplored areas of the ERK5 ATP binding site.  
 
5.4  Synthesis and biological evaluation of inhibitors with trisubstituted aroyl rings 
 
5.4.1 Rationale  
 
Docking of compound 251 led to the design of a new set of proposed ERK5 inhibitors 
incorporating a third substituent in the 3-position of the aroyl ring, to probe a putative 
lipophilic pocket highlighted in Figure 43, and ultimately improve binding interactions.  
 
      
 
A B 
 
156 
 
 
 
 
Figure 43. p38α-derived homology model with 251 with potential lipophilic pocket to 
be exploited highlighted in blue.  
 
The initial synthetic targets introduced a variety of 3-substituents onto the 2,6-
difluoroaroyl motif.  Following the success of the introduction of 2-chloro-6-fluoro-
aroyl groups in improving selectivity for ERK5 over p38α, we decided to also 
synthesise 3-substituted analogues bearing the 2-chloro-6-fluoro substitution pattern. 
For each modification of the aroyl group, we introduced a 3-pyridyl, a N-
methylpiperidyl or a pyrimidyl amide side-chain. At the time of synthesis, these side-
chains combined optimal properties in terms of potency, aqueous solubility and reduced 
CYP450 inhibitory activity (Figure 44).   
 
 
Figure 44. Trisubstituted aroyl target molecules to exploit a potential lipophilic pocket 
in the ERK5 ATP binding site.  
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The hypothesis was tested by another member of the group, who synthesised 14 
compounds with substituents in the 3-position of the aroyl ring to determine if it would 
improve ERK5 inhibition.
132
 These compounds and corresponding biological evaluation 
are shown in Table 30 for reference. It was evident from these preliminary results that 
addition of a third substituent onto the aroyl ring was tolerated and in some cases 
improved potency (e.g. 267, ERK5; IC50 = 0.11 µM; 10-fold improvement compared to 
128). This suggests that further SARs into the incorporation of a 3-substituent onto the 
aroyl ring could improve potency further.  
 
 
Table 30. Inhibitory activity of previously synthesised compounds incorporating a 3-
substituent on the aroyl ring. 
 
Compound R R’ ERK5; IC50 (µM) p38α; IC50 (µM) 
128 
  
1.1 ± 0.27 
(n = 4) 
35 ± 0.90 
(n = 2) 
254 
  
0.40 ± 0.10 
(n = 4) 
>120 
255 
  
0.94 ± 0.14 
(n = 4) 
>120 
256 
  
0.57 ± 0.10 
(n = 4) 
29 ± 0.50 
(n = 2) 
257 
  
0.20 ± 0.05 
(n = 4) 
>120 
258 
  
0.24 ± 0.02 
(n = 4) 
>120 
259 
  
0.14 ± 0.02 
(n = 4) 
29 ± 5.2 
(n = 2) 
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5.4.2 Synthesis of tri-substituted aroyl-containing ERK5 inhibitors  
 
5.4.2.1 Synthesis of analogues with a 3-alkyl substituent  
 
In order to further validate the hypothesis that tri-substitution of the aroyl ring should 
improve potency against ERK5, further analogues were synthesised and tested for 
ERK5 inhibitory activity. The first set of compounds retained the 2,6-difluoro- 
substitution pattern and contained an alkyl group at the 3-position. Compounds with a 
methyl group in this position had already been tested (Table 30), and subsequent 
synthesis of compounds with larger alkyl groups was investigated. The synthesis of 
compounds with an ethyl group in the 3-position is shown in Scheme 48. The first step 
is the Friedel-Crafts acylation of 69 using 3-chloro-2,6-difluorobenzoyl chloride, which 
gave 268 in 94% yield. Protection of the pyrrole nitrogen with a SEM protecting group 
260 
  
0.42 ± 0.10 
(n = 4) 
>120 
261 
  
0.76 ± 0.09 
(n = 4) 
>120 
262 
  
0.39 ± 0.02 
(n = 4) 
40 ± 3.3 
(n = 2) 
263 
  
1.0 ± 0.28 
(n = 4) 
>120 
264 
  
0.80 
(n = 1) 
20 ± 0.7 
(n = 2) 
265 
 
 
0.96 ± 0.15 
(n = 4) 
>120 
266 
 
 
0.71 ± 0.02 
(n = 4) 
>120 
267 
 
 
0.11 
(n = 1) 
50 ± 6.4 
(n = 2) 
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was performed in 95% yield. Protection of the pyrrole nitrogen was essential at this 
stage to prevent side reactions in the subsequent Suzuki-Miyaura reaction. The SEM 
group was chosen as it had proven stable when used previously by other members of the 
group under palladium-mediated cross-coupling reaction conditions.
132
 The Suzuki-
Miyaura reaction utilised ethylboronic acid and Pd(dtbpf)Cl2 to produce 270 in 60% 
when the reaction was heated under microwave irradiation. The same yield could not be 
achieved under conventional heating. The optimal palladium catalyst for the 
transformation was Pd(dtbpf)Cl2 (no reaction occurred with palladium tetrakis and de-
chlorination was observed with Pd(dppf)Cl2). Once the ethyl group was installed, the 
SEM group was removed using TBAF at 65 
o
C, producing 271 in 65% yield. 
Hydrolysis of the methyl ester gave carboxylic acid 272 in 98% yield. The coupling 
reactions were performed using the conditions shown in Scheme 48 and were relatively 
low yielding (273; 45%, 274; 28% and 275; 19%). The low yields were due to difficult 
purification of the final products, which all had to be purified by semi-preparative 
HPLC after several failed attempts to purify by MPLC.  
 
 
Scheme 48. Reagents and conditions: (i) 3-chloro-2,6-difluorobenzoyl chloride, AlCl3, 
DCM, 0 
o
C to RT, 18 h; (ii) SEMCl, KO
t
Bu, THF, RT, 18 h; (iii) ethylboronic acid, 
Pd(dtbpf)Cl2, Cs2CO3, MW, 150 
o
C, 1.5 h; (iv) TBAF, THF, 65 
o
C, 18 h; (v) LiOH (aq), 
THF, 60 
oC, 18 h; (vi) where R’ = pyridyl or pyrimidyl; (a) cyanuric fluoride, pyridine, 
MeCN, RT, 45 min (b) appropriate amine, 18 h, RT; where R’ = N-methylpiperidine;  
(a) CDI, THF, 70 
o
C, 3 h; (b) N-methyl-4-aminopiperidine, RT, 18 h.  
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The same Suzuki-Miyaura cross-coupling reaction conditions were attempted using 
isopropylboronic acid, but without any success. The main product from the reaction was 
the de-chlorinated starting material. It was thought that the isopropylboronic acid may 
not be stable and therefore installation of an isopropenyl moiety, which could then be 
reduced to the isopropyl, was deemed a more viable approach. The best Suzuki-Miyaura 
conditions for the introduction of an isopropenyl group were tested using vinylboronic 
acid pinacol ester and are shown in Table 31. The same Suzuki-Miyaura conditions that 
had been applied to the ethyl analogues did not provide the vinyl analogues and de-
chlorination of the starting material was again observed. Using Pd(dppf)Cl2 as the 
catalyst produced the same result. After reviewing the literature, it was discovered that 
use of potassium vinyltrifluoroborate in place of a traditional boronic acid or pinacol 
ester was often successful for installation of a vinyl group.
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 Using the literature 
conditions (entry 3, Table 31) the product was obtained in 80% yield (compound 276). 
The reaction was repeated using potassium isopropenyltrifluoroborate and the correct 
product was synthesised in 42% yield (compound 277).  
 
Table 31. Suzuki-Miyaura conditions trialled for installation of vinyl and isopropenyl 
groups. 
Entry 1 2 3 4 
Boron 
coupling 
partner 
 
  
 
 
Catalyst 
 
Pd(dtbpf)Cl2 Pd(dtbpf)Cl2 PdCl2 PdCl2 
Ligand - - XPhos XPhos 
Solvent Dioxane Dioxane 
THF/H2O 
(9:1) 
THF/H2O 
(9:1) 
Base 
 
Cs2CO3 Cs2CO3 Cs2CO3 Cs2CO3 
Time (min) 
 
90 90 60 60 
Temp. (
o
C) 
 
150 150 85 85 
Heating 
method 
 
MW MW Conventional Conventional 
Result De-chlorination De-chlorination 80% yield 42% yield 
 
The subsequent steps were the same as those shown in Scheme 48 for the ethyl 
analogues, (deprotection, vinyl, 278; deprotection, isopropenyl, 279; hydrolysis, vinyl, 
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280; hydrolysis, isopropenyl, 281). The final coupling steps for the vinyl analogues 
gave final compounds 282, 283 and 284 in low yield (16%, 19% and 20%, 
respectively). Again, all compounds were purified by semi-preparative HPLC and were 
sent for evaluation of ERK5 inhibitory activity. For the isopropenyl analogues, only the 
pyridyl analogue (285) was synthesised in 40% yield, using CDI as the coupling agent, 
and sent for biological evaluation.  
 
 
5.4.2.2 Biological evaluation of inhibitors with a 3 -alkyl substituent 
 
The inhibitory activity against ERK5 and p38α for each compound is shown in Table 
32, and is compared to disubstituted compounds 128, 182 and 149.  
 
Table 32. Biological evaluation of compounds incorporating a 3-alkyl substituent on 
the aroyl ring. 
 
Compound R R’ ERK5; IC50 (µM) p38α; IC50(µM) 
128 
  
1.1 ± 0.27 
(n = 4) 
35 ± 0.90 
(n = 2) 
182 
  
0.36 ± 0.10 
(n = 4) 
>120 
149 
  
1.0 ± 0.10 
(n = 4) 
6.8 ± 0.10 
(n = 2) 
273 
  
1.3 ± 0.15 
(n = 4) 
>120 
274 
  
3.4 ± 0.14 
(n = 4) 
>120 
275 
  
0.61 ± 0.12 
(n = 4) 
>120 
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In each case, there was no improvement in inhibitory activity against ERK5 compared 
to compounds 128, 182 and 149, although selectivity for ERK5 over p38α was retained. 
These observations suggest that larger alkyl groups are tolerated, but are not necessary 
for ERK5 inhibition and that the size of the optimal substituent to fill the lipophilic 
pocket identified may be more limited than suggested by the homology model.  
 
 
5.4.2.3 Re-introduction of the 2-chloro-substituent into tri-substituted aroyl 
analogues  
 
The introduction of 2-chloro-6-fluoroaroyl groups onto the pyrrole carboxamide 
scaffold improved potency and selectivity for ERK5 over p38α (i.e. 148, ERK5; IC50 = 
0.60 μM, p38α; IC50 >120 μM). Synthesis of trisubstituted derivatives with a 2-chloro-
6-fluoro substitution pattern and a substituent in the 3-position was therefore deemed 
desirable. Analogues with a 3-fluoro-substituent were synthesised by a previous group 
member and the results for these are shown in Table 30.
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 In order to test whether a 
larger substituent would be tolerated at the 3-position, 3-chloro- and 3-methyl- 
analogues were synthesised according to the procedures outlined in Scheme 49. The 
synthetic route began with the optimised Friedel-Crafts acylation of 69 to give methyl 
esters 286-289 in good yield (60-99%). Hydrolysis to the corresponding carboxylic 
acids 290-293 was performed in almost quantitative yield (98-99%). All of the amide 
couplings were performed using PCl3 as the coupling agent and were performed in 
moderate to good yield (47-80%) to give compounds 294-305.    
 
282 
  
1.6 ± 0.35 
(n = 4) 
>120 
283 
  
1.4 (n = 1) 
46 ± 4.2 
(n = 2) 
284 
  
0.64 ± 0.14 
(n = 4) 
>120 
285 
  
2.4 ± 0.40 
(n = 4) 
>120 
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Scheme 49. Reagents and conditions: (i) appropriate benzoyl chloride, AlCl3, DCM,       
0 
o
C to RT, 18 h; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) PCl3, appropriate aniline, 
MeCN, MW, 150 
o
C, 5-30 min. 
 
 
5.4.2.4 ERK5 inhibitory activity and p38α counter -screening data for 294-
305 
 
The ERK5 and p38α inhibitory activity for compounds 294-305 is shown in Table 33. 
In each case, the results can be compared to 2-chloro-6-fluoro compounds 248, 182 and 
250. 
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Table 33. Biological Evaluation of 294-305 
 
 
Compound R R’ ERK5; IC50 (µM) p38α; IC50(µM) 
248 
  
0.58 ± 0.24 
(n = 4) 
93 ± 13 
(n = 2) 
182 
  
0.36 ± 0.10 
(n = 4) 
>120 
250 
  
0.20 ± 0.07 
(n = 4) 
8.5 (n = 1) 
294 
  
0.27 ± 0.10 
(n = 4) 
>120 
298 
  
0.35 ± 0.14 
(n = 4) 
>120 
302 
  
0.28 ± 0.10 
(n = 4) 
53 ± 7.8 
(n = 2) 
295 
 
 
0.07 ± 0.03 
(n = 7) 
>120 
299 
 
 
0.32 ± 0.37 
(n = 4) 
>120 
303 
 
 
0.11 (n = 1) 110 (n = 1) 
296 
  
0.65 ± 0.37 
(n = 4) 
>120 
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The results show that both chloro- and methyl- substituents are well tolerated in the 3-
position. Compound 295 showed an almost 9-fold improvement in ERK5 inhibitory 
activity compared with 248 (ERK5; IC50 = 0.58 μM), and was the first inhibitor tested 
to have an IC50 value below 100 nM in the pyrrole carboxamide series. Importantly, 
inhibitor 295 and all of the other compounds in this series, also retain selectivity for 
ERK5 over p38α. It is evident that introduction of a methyl group, although tolerated, 
does not provide the same increase in potency as that observed for the introduction of a 
chloro group as in compound 295.  
 
 
5.4.2.5 Physicochemical and in vitro ADME profiling for compounds  295, 
299 and 303 
 
Review of the physicochemical properties of compounds 295, 299 and 303 showed that 
they met the criteria for a lead candidate, although the TPSA for compound 303 was 
slightly low (Table 34).  
 
 
 
 
300 
  
1.8 ± 0.03 
(n = 4) 
>120 
304 
  
0.47 ± 0.08 
(n = 4) 
>120 
297 
 
 
0.51 ± 0.28 
(n = 4) 
>120 
301 
 
 
0.26 ± 0.13 
(n = 4) 
>120 
305 
 
 
0.49 ± 0.06 
(n = 4) 
>120 
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Table 34. Physicochemical properties of compounds 295, 299 and 303. 
 
The solubility and in vitro pharmacokinetic properties of inhibitors 295, 299 and 303 
were measured at Cyprotex and are shown in Table 35. Compounds 295 and 303 have 
poor aqueous solubility compared to 299. Clearance in both human and mouse liver 
microsomes is high for 295, but not above the desired threshold for a lead candidate. 
Plasma protein binding was good for all three compounds. Caco-2 permeability was 
also tested for 295 and was shown to be above the threshold (Papp A2B = 25 x 10
-6
 
cm/s) and the efflux ratio was low (0.66) suggesting the compound is not a substrate for 
efflux via P-glycoprotein (Pgp). In addition, 295 was counter-screened against MEK5 in 
an assay ran by Carna Bioscience. MEK5 inhibitory activity was measured as 0.79 µM 
indicating that 295 is ~10 fold selective for ERK5 over closely related MEK5. 
Investigations are underway to identify inhibitors that are equipotent with 295 with 
improved aqueous solubility. 
 
Table 35. In vitro ADME profiling for 295, 299 and 303. 
 
In order to explain the increase in ERK5 inhibitory activity of 295, docking studies have 
been conducted at Newcastle by Prof. Martin Noble using the recently published 
structure of monomeric ERK5 (Figure 45). An initial bound pose was deduced by 
superimposing the carboxamide-bound structure of p38α onto the ERK5 template, and 
modifying the drug molecule to match the structural formula of 295 using tools from the 
RDKIT toolkit. Bond restraints and partial charges for the ligand were calculated using 
PRODRG, and the complex was energy minimised using GROMACS. The model 
Compound 
 
MW 
H-bond 
donors 
H-bond 
acceptors 
sLogP TPSA 
Lead 
criteria 
<500 <5 <10 <5 75-100 
295 378 2 5 3.8 75 
299 379 2 6 4.0 88 
303 398 2 5 3.4 65 
Compound 
 
LE 
Solubility 
L/U (µM) 
Plasma 
Protein 
Binding (%) 
Mouse CLint 
(µL/min/mg) 
Human CLint 
(µL/min/mg) 
Lead 
criteria 
>0.3 >50/50 <99 <48 <48 
295 0.39 10/65 98 48 32 
299 0.36 100/100 95 0 0 
303 0.37 3/20 77 0 0 
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shows how well the tri-halogenated ring fits into pockets in the ERK5 ATP binding site 
and this could account for the increased inhibitory activity of 295.  
 
 
 
 
Figure 45. Docking of 295 using published ERK5 X-ray crystal structure. 
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5.4.2.6 Cellular activity of 295 in an Epidermal Growth Factor (EGF)-
stimulated HeLa cell assay 
 
In order to assess the cellular activity of compound 295, an EGF-stimulated HeLa cell 
assay was conducted at Newcastle by Lan-Zhen Wang. HeLa cells were treated with 
increasing concentrations of inhibitor 295 followed by EGF stimulation for 10 min 
before being harvested. Samples were run on 6% Tris–glycine gel and transferred to 
nitrocellulose, before Western blot analysis was conducted with ERK5 antibody (Figure 
46). The IC50 value was determined from densitometry of top bands, and was calculated 
as 0.09 ± 0.01 μM. The IC50 value obtained is consistent with that obtained in the cell-
free IMAP assay (ERK5; IC50 = 0.07 μM), suggesting that despite the low aqueous 
solubility of 295, the compound is cell permeable. Further in vivo PK/PD studies with 
compound 295 are underway.  
 
 
Figure 46. Western blot analysis showing inhibition of p-ERK5 by 295 at ≤100 nM. 
Figure shows the resolution of a phospho-ERK5 band (top) from non-phosphorylated 
ERK5 (lower band). 
 
5.4.2.7 Introduction of a bromo- substituent into the 3-position of the aroyl 
ring 
 
Following the success of 295, synthesis of analogues with a bromo- substituent in the 3-
position was undertaken. These analogues were synthesised for evaluation of their 
ERK5 inhibitory activity, but also as potential intermediates for the synthesis of further 
analogues since the bromo- substituent could potentially be used in a variety of 
295 (μM) 
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subsequent reactions (Scheme 50). Synthesis began with a literature procedure to afford 
3-bromo-6-chloro-2-fluorobenzoic acid (307) from 1-bromo-4-chloro-2-fluorobenzene 
(306) via deprotonation of the proton between the fluoro- and chloro- substituents using 
LDA and introduction of the carboxylic acid using solid CO2.
134
 This reaction worked 
well in 90% yield. Carboxylic acid 307 was converted to the acid chloride using thionyl 
chloride, which was subsequently used in situ in the Friedel-Crafts acylation of methyl 
pyrrole 2-carboxylate, giving 308 in 87% yield. Hydrolysis of 308 using LiOH gave 
carboxylic acid 309 in 99% yield. Coupling of 3-aminopyridine and 5-aminopyrimidine 
was performed using PCl3 affording 310 and 311 in 58% and 30% yield, respectively.  
 
 
Scheme 50. Reagents and conditions: (i) (a) LDA, THF, -70 
o
C, 2 h; (b) CO2, Et2O,  
-70 
o
C to RT, 4 h; (ii) (a) SOCl2, THF, RT, 3 h; (b) methyl pyrrole 2-carboxylate, AlCl3, 
DCM, RT, 18 h; (iii) LiOH (aq), THF, 60 
o
C, 18 h; (iv) PCl3, appropriate aniline, 
MeCN, MW, 150 
o
C, 5-30 min.  
 
Synthesis of the N-methylpiperidyl analogue was hampered by purification problems 
and a pure sample of this compound has, as yet, not been synthesised.  
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5.4.2.8 Biological evaluation of compounds 310 and 311. 
 
The ERK5 and p38α inhibitory activities of compounds 310 and 311 are shown in Table 
36 and can be compared to compounds 295 and 299. 
 
 
Table 36. Biological activity of 310 and 311. 
 
 
 
Increasing the size of the 3-chloro- substituent of 295 and 299 to a 3-bromo- substituent 
was well tolerated, although we did not observe an improvement in ERK5 inhibitory 
activity. As stated previously, intermediate 308 will be utilised as an intermediate for 
the synthesis of inhibitors with further variation at the 3-position of the aroyl ring. For 
example, upon protection of the pyrrole nitrogen, the bromo- substituent could be used 
as a coupling partner for a variety of palladium-mediated coupling reactions enabling 
further elaboration at this stage of the synthesis. This would help to further expand 
SARs around the introduction of tri-substituted aroyl rings into pyrrole carboxamide 
inhibitors of ERK5. 
Compound R R’ ERK5; IC50 (µM) p38α; IC50(µM) 
295 
 
 
0.07 ± 0.03 
(n = 7) 
>120 
299 
 
 
0.32 ± 0.37 
(n = 4) 
>120 
310 
 
 
0.067 ± 0.03 
(n = 4) 
>120 
311 
 
 
0.61 ± 0.23 
(n = 4) 
>120 
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Chapter 6. Structure-activity relationship studies (SARs) around the 
pyrrole core 
6.1 Introduction of substituents at the pyrrole 3-position  
 
6.1.1 Rationale  
 
Homology modelling based on p38α and conducted at Newcastle University identified a 
lipophilic pocket, which could potentially be exploited via substitution at the 3-position 
of the pyrrole ring (Figure 46).  
 
 
  
 
Figure 46. p38α-derived homology model with potential lipophilic pocket highlighted 
in blue. 
 
 
The initial set of compounds to be synthesised had small alkyl groups at the 3-position 
of the pyrrole in order to see if substitution would be tolerated and ERK5 inhibitory 
activity retained or improved. The aroyl group in each case was either the 2-chloro-6-
fluorobenzoyl or the 2-bromo-6-fluorobenzoyl as these groups had been identified as 
providing good selectivity over p38α. The potency of the trisubstituted aroyl rings had 
not been discovered at the time we started the synthesis of these analogues. For each 
modification of the pyrrole core and aroyl ring, three amide side-chains were to be 
incorporated; 3-pyridyl, N-methylpiperidyl and pyrimidyl (Figure 47). These amide 
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side-chains were chosen for their optimal properties (potency, aqueous solubility and 
improved CYP450 inhibition profile, respectively).  
 
Figure 47. Compounds to be synthesised with substituents at the 3-position of the 
pyrrole ring.  
 
 
6.1.2 Synthesis of 3-substituted pyrrole analogues  
 
 
In order to introduce a substituent at the 3-position of the pyrrole ring, a literature 
procedure was followed, initially introducing a bromo-substituent at this position 
(Scheme 51).
135
 The aim was to use this intermediate to perform Suzuki-Miyaura 
reactions and introduce the desired alkyl groups. Reaction of N-phenylsulfonylpyrrole 
(312) with bromine in acetic acid under reflux for 1 h produced 3-bromopyrrole 
derivative 313 in 69% yield. Deprotonation of the 2-position of pyrrole 313 using LDA 
followed by addition of methyl chloroformate afforded compound 314 in 75% yield. 
The subsequent Suzuki-Miyaura reaction was attempted using trimethylboroxine, 
palladium tetrakis and sodium carbonate under conventional heating overnight. 
Unfortunately, the reaction was unsuccessful and starting material was recovered. The 
reaction was also attempted using ethylboronic acid, but was equally unsuccessful. Both 
reactions were trialled under microwave heating, but to no avail. The coupling 
conditions used were based on literature procedures, whereby an aryl group had been 
introduced into the 3-position of intermediate 314.
135-136
 At the time, there were no 
published syntheses that had installed an alkyl group into the 3-position via a Suzuki-
Miyaura cross-coupling reaction.  
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Scheme 51. Reagents and conditions: (i) Br2, AcOH, reflux, 1 h; (ii) (a) 
diisopropylamine, n-BuLi, -78 
o
C, 1 h; (b) 313, -78 
o
C, 1 h then methyl chloroformate, 
THF, -78 
o
C to RT, 2 h; (iii) trimethylboroxine or appropriate boronic acid, Pd(PPh3)4, 
Na2CO3, dioxane:water (9:1), 110 
o
C, 18 h; (iv) appropriate benzoyl chloride, AlCl3, 
DCM, 0 
o
C to RT, 18 h; (v) LiOH (aq), THF, 60 
o
C, 18 h; (vi) appropriate amine, PCl3, 
MeCN, MW, 150 
o
C, 5-30 min.  
 
 
An alternative synthetic strategy required the convergent synthesis of two starting 
materials and was based on a literature procedure for the synthesis of the core pyrrole 
ring substituted in the 2-, 3- and 4-positions with the required groups (Scheme 52).
137-138
 
The synthetic route was trialled for the synthesis of inhibitors with 3-methyl and 3-ethyl 
substituents and a 2-chloro-6-fluorobenzoyl group in the 4-position of the pyrrole ring.  
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Scheme 52. Reagents and conditions: (i) N,N-dimethylformamide dimethyl acetal, 
toluene, reflux, 18 h; (ii) NaNO2 (aq), AcOH, H2O, 0 
o
C, 4 h; (iii) NaOAc, AcOH, Zn 
dust, 140 
o
C, 6 h; (iv) LiOH (aq), THF, 100 
o
C, 18 h; (v) appropriate amine, PCl3, 
MeCN, MW, 150 
o
C, 5 min.  
 
 
The first starting material was synthesised on reaction of commercially available 2’-
chloro-6’-fluoroacetophenone (319) with N,N-dimethylformamide dimethyl acetal 
providing enamine 320 in 80% yield.
137
 Reaction of ethyl acetoacetate (315) or ethyl 
propionylacetate (316) with sodium nitrite in acetic acid and water provided the second 
building block, oximes 317 or 318 in 85% yield (Scheme 52). Reaction of 320 with 317 
or 308 in a reductive cyclisation reaction in the presence of zinc provided 321 and 322 
both in 30% yield.
138
 Initial attempts at the cyclisation were much lower yielding and it 
was found that portion-wise addition of eight equivalents of zinc dust over 6 hours gave 
the best results, although the yield was still modest. The benefit of this route is that the 
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reductive cyclisation step provides a key intermediate with a 3-alkyl substituent (321; 
methyl or 322; ethyl), a 4-benzoyl substituent and a 2-carboxylate in place. One 
disadvantage is if any of the ethyl acetoacetate (315) or ethyl propionylacetate (316) 
remain after formation of oximes 317 and 318, the two can react together in the 
presence of zinc to form Knorr’s pyrrole (330) or the ethyl equivalent (331) as side 
products (Figure 48).  
 
 
 
 
Figure 48. Potential side-products formed in step (iii) (Scheme 52) in the presence of 
any remaining ethyl acetoacetate (315) or ethyl propionylacetate (316).  
 
 
The ethyl ester of 321 and 322 was hydrolysed using lithium hydroxide to give 
carboxylic acids 323 and 324 in 78% and 75% respectively. The final amide couplings 
were all performed using PCl3 and gave compounds 325-329 in moderate yields (20-
30%). Unfortunately the pyrimidyl analogue with a 3-ethyl substituent was not 
successfully isolated due to problems with purification.  
 
 
 
6.1.3 Biological Evaluation of 3-substituted pyrroles 325-329 
 
Compounds 325-329 were sent for biological evaluation and the results are shown in 
Table 37. The ERK5 inhibitory activity and p38α counter-screening data for compounds 
325-329 are compared to unsubstituted pyrrole derivatives 248, 182 and 250. 
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Table 37. ERK5 and p38α inhibitory activity for compounds 325-329. 
 
Compound R R’ ERK5; IC50 (µM) p38α; IC50 (µM) 
248 H 
 
0.58 ± 0.24 
(n = 4) 
93 ± 13 
(n = 2) 
182 H 
 
0.36 ± 0.10 
(n = 4) 
>120 
250 H 
 
0.20 ± 0.07 
(n = 4) 
8.5 (n = 1) 
325 Me 
 
40 ± 0.9 
(n = 4) 
43 ± 1.7 
(n = 2) 
326 Me 
 
69 ± 1.1 
(n = 4) 
>120 
327 Me 
 
45 ± 4.1 
(n = 4) 
36 ± 7.3 
(n = 2) 
328 Et 
 
38 ± 0.78 
(n = 4) 
50 ± 1.0 
(n = 2) 
329 Et 
 
59 ± 3.4 
(n = 4) 
24 ± 2.7 
(n = 2) 
 
In each case the ERK5 inhibitory activity was reduced compared to inhibitors 248, 182 
and 250. As with all inhibitors synthesised in this project, these compounds were 
counter-screened for p38α activity. For most compounds, the selectivity for ERK5 over 
p38α was also abolished with compounds being equipotent for both kinases. With this 
in mind, synthesis of any further analogues with larger alkyl groups in the 3-position or 
different aroyl groups in the 4-position was ceased.  
 
These results indicate that the introduction of a substituent at the 3-position of the 
pyrrole ring is not tolerated. The lack of activity is most likely due to the change in 
conformation a substituent in the 3-position could impose on both, the benzoyl ring and 
the amide side chain.  A change in conformation could mean that essential interactions 
between the inhibitor and ERK5 binding site are no longer being fulfilled (i.e. changing 
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the conformation of the amide group could disrupt hinge binding). Figure 49 shows the 
energy minimised structures of inhibitors with and without substituents at the 3-position 
of the pyrrole ring. It is evident that the introduction of a methyl or ethyl group at the 3-
position has an effect on both the aroyl ring and amide group conformations, with the 3-
ethyl group imposing the greatest change. This does not explain how the compounds 
would bind in the ERK5 binding site and obtaining a co-crystal of each compound 
bound to ERK5 would be the only way to definitively demonstrate the effect a 
substituent at the pyrrole 3-position would have on binding.  
 
 
 
Figure 49. Energy minimised conformations of pyrrole carboxamide inhibitors; (A) 
with no 3-substituent, (B) with a 3-methyl substituent and (C) with a 3-ethyl substituent. 
Energy minimised using Chem3D.  
 
6.2 Development of inhibitors containing a 1H-pyrrolo[3,2-b]pyridin-7(4H)-one  
core 
 
 
6.2.1 Rationale  
 
In order to further probe the ERK5 ATP binding site, the synthesis of novel inhibitors 
with a core 1H-pyrrolo[3,2-b]pyridin-7(4H)-one bicycle was investigated. The 
compounds were to incorporate either a 2,6-difluoro-, 2,3-dichloro-, 2-chloro-6-fluoro- 
or 2-bromo-6-fluoro benzoyl group and a 3- or 4-pyridyl side chain, based on previous 
SARs. These compounds were docked in the first generation ERK2-based homology 
model (Figure 50). They all introduce rigidity around the core pyrrole ring as well as 
removing the amide NH. It has been shown previously that the amide NH is not 
necessary for inhibitory activity against ERK5, as compounds synthesised without this 
moiety retained potency. Removal of a methylene group from the amide side chain had 
improved potency against ERK5 (chapter 4, section 4.2). This suggested that increasing 
A 
 
B 
 
C 
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the rigidity of inhibitors is beneficial and hence, the introduction of rigidity via 
incorporation of a new planar bicyclic core was postulated to be a valid strategy for 
improvement of ERK5 inhibitory activity. Initially, inhibitors with a methylpyridyl 
group and without the methylene group were proposed for synthesis in order to compare 
ERK5 inhibitory activity.  
 
 
 
 
 
 
 
 
 
 
Figure 50. Compound 332 docked into the ERK2-derived homology model developed 
by CRT-DL. 
 
6.2.2 Synthesis of 1H-pyrrolo[3,2-b]pyridin-7(4H)-one inhibitors 
 
The first synthetic step was based on a literature procedure using toluenesulfonylmethyl 
isocyanide (TosMIC) (333) in a reaction with ethyl acrylate to give ethyl 1H-pyrrole-3-
carboxylate 334 (Scheme 53).
139
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Scheme 53. Reagents and conditions: (i) ethyl acrylate, NaH, Et2O, RT, 3 h; (ii)  LiOH, 
THF, 60 
o
C, 18 h; (iii) DPPA, NEt3, 
t
BuOH, 30 
o
C, 18 h; (iv) diethyl 2-
(bromomethylene)malonate, Pd2(dba)3, Xantphos, K3PO4, toluene, 120 
o
C, 18 h; (v) 
LiOH (aq), THF, 60 
o
C, 18 h; (vi) POCl3, reflux, 3 h; (vii)  appropriate benzoyl 
chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (viii) pyridine N-oxide, conditions TBC; (ix) 
conditions TBC; (x) conditions TBC. 
 
 
The reaction appeared to work well, but despite purification by chromatography, an 
impurity remained. The impurity was thought to be the Michael addition product (340; 
Figure 51) from the reaction of 334 with remaining ethyl acrylate as confirmed by the 
detection of the correct mass by LC-MS. Due to this problem, and also the potential 
issues that may have arisen with the Curtius rearrangement in step (iii), an alternative 
approach was conducted. 
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Figure 51. Michael addition product from reaction of 334 with ethyl acrylate. 
 
 
The first step of the alternative route was the substitution of the 3-bromo group of TIPS 
protected 3-bromopyrrole 341 using diethyl 2-(aminomethylene)malonate (Scheme 54).  
 
 
 
Scheme 54. Reagents and conditions: (i) diethyl 2-(aminomethylene)malonate, see 
Table 38; (ii) LiOH (aq), THF, 60 
o
C, 18 h; (iii) POCl3, reflux, 3 h; (iv) appropriate 
benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (v) pyridine N-oxide, conditions TBC; 
(vi) conditions TBC; (vii) conditions TBC. 
 
 
The substitution with diethyl 2-(aminomethylene)malonate was attempted using a 
variety of conditions, including acid-catalysed aromatic substitution in TFE (Table 38). 
The reaction was unsuccessful when performed in TFE alone, and when TFA was used 
to catalyse the reaction. The next attempted approach was to use Buchwald coupling 
conditions.
140
 This was attempted using both conventional and microwave heating, and 
in each case 342 was not obtained. 
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Table 38. Attempted conditions for step (i) Scheme 54.
140
 
 
Entry 
Heating 
Method 
Temp. 
(
o
C) 
Solvent 
Time 
(h) 
Catalyst Ligand Base Result 
1 MW 160 TFE 0.25 - - - No rxn 
2 MW 160 TFE 0.25 TFA - - No rxn 
3 MW 100 Dioxane 0.5 Pd(OAc)2 BINAP Cs2CO3 No rxn 
4 MW 150 Dioxane 0.5 Pd(OAc)2 BINAP Cs2CO3 Degradation 
5 Conv. 100 Dioxane 18 Pd(OAc)2 BINAP Cs2CO3 Degradation 
6 Conv. 110 Toluene 18  Pd2(dba)3 BINAP Cs2CO3 No rxn 
 
Problems had been encountered previously with Buchwald coupling of 2-bromopyrrole 
with amines (Chapter 4), therefore reversal of the coupling partners was investigated.  
Starting with 3-bromopyrrole 341 (Scheme 55), Buchwald coupling with benzophenone 
imine was performed. The Buchwald coupling in this case was postulated to be more 
favourable due to the electron-rich nature of the amine coupling partner. Once coupled, 
the imine could be hydrolysed to leave the free amine in the 3-position of the pyrrole 
ring. 3-Aminopyrrole 345 could then be coupled with diethyl 2-
(bromomethylene)malonate. Unfortunately the coupling with benzophenone imine was 
not successful and an alternative method of accessing the 3-aminopyrrole was sought.  
 
 
Scheme 55. Reagents and conditions: (i) benzophenone imine, Pd(OAc)2, Cs2CO3, 
BINAP, 100 
o
C, 5 h; (ii) 1 M HCl, THF, RT, 15 min; (iii) diethyl 2-
(bromomethylene)malonate, Pd2(dba)3, Xantphos, K3PO4, toluene, 120 
o
C, 18 h; (iv) 
LiOH (aq), THF, 60 
o
C, 18 h; (v) POCl3, reflux, 3 h; (vi) appropriate benzoyl chloride, 
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AlCl3, DCM, 0 
o
C to RT, 18 h; (vii) pyridine N-oxide, conditions TBC; (viii) conditions 
TBC; (ix) conditions TBC. 
 
A literature procedure using isoxazole (346) and diethyl 2-aminomalonate 
hydrochloride to form ethyl 3-amino-1H-pyrrole-2-carboxylate (347), which goes via 
the mechanism shown in Scheme 56 was conducted.
141
 This route was attractive since 
the 3-amino group was installed directly for use in the subsequent Buchwald reaction. 
The 2-ethylcarboxylate group could also be utilised at a later stage to form the bicycle.  
 
 
 
Scheme 56. Proposed mechanism of reaction of isoxazole with diethyl 2-
aminomalonate.
141
  
 
 
Ethyl 3-amino-1H-pyrrole-2-carboxylate (347) was synthesised in 85% yield (Scheme 
57). Buchwald reaction with ethyl 3-bromoacrylate was attempted using both 
conventional heating at 120 
o
C for 18 h and microwave irradiation at 120 
o
C for 30 min. 
Unfortunately, the reaction was unsuccessful in both cases.   
 
 
183 
 
 
 
Scheme 57. Reagents and conditions: (i) (a) EtOH, NaOEt, 0 
o
C, 45 min; (b) AcOH, 
diethyl 2-aminomalonate hydrochloride, NaOAc, RT, 18 h; (c) EtOH, NaOEt, RT, 18 h 
(d) AcOH, RT, 5min; (ii) ethyl 3-bromoacrylate, Pd2(dba)3, Xantphos, K3PO4, toluene, 
120 
o
C, 18 h; (iii) LiOH (aq), THF, 60 
o
C, 18 h; (iv) POCl3, reflux, 3 h; (v) appropriate 
benzoyl chloride, AlCl3, DCM, 0 
o
C to RT, 18 h; (vi) pyridine N-oxide, conditions 
TBC; (vii) conditions TBC; (viii) conditions TBC. 
 
Due to the lack of success with the synthesis and the discovery of potent inhibitors 
without the methylene group in the amide side chain (Chapter 4), a new synthetic 
strategy was employed focussing on bicyclic inhibitors without a methylene group. An 
alternative synthetic route was attempted as shown in Scheme 58, starting with 
commercially available 4-chloro-3-nitropyridine (350). The first step involved 
substitution of the chloro- group using sodium methoxide and proceeded smoothly to 
produce 351 in 96% yield. Attempts to introduce a bromo- substituent into the 5-
position of the pyridine ring were unsuccessful. The first conditions attempted were 
NBS in MeCN and heating under microwave irradiation, based on a literature procedure 
for bromination of 4-methoxypyridine.
142
 The reaction failed to produce 352, and 
starting material 351 was recovered.  Reaction of 351 with bromine in H2O and heating 
to 50 
o
C for 2 h was also unsuccessful. This procedure was based on a literature method 
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for bromination of 4-hydroxy-3-nitropyridine.
143
 The reason for the lack of success in 
brominating 4-methoxy-3-nitropyridine (351) could be the directionality of the bulky 
methoxide substituent influenced by the 3-nitro- substituent impeding the introduction 
of a large bromine atom. In 4-methoxypyridine, the methoxide substituent won’t 
prevent bromination since there is no substituent in the 3-position of the ring. In 4-
hydroxy-3-nitropyridine, bromination is able to occur since the 4-hydroxy- group is less 
sterically hindered than a 4-methoxy substituent.  
 
 
 
Scheme 58. Reagents and conditions: (i) Na, MeOH, dioxane, reflux, 2.5 h; (ii) NBS, 
MeCN, MW, 100 
o
C, 1 h or Br2, H2O, 50 
o
C, 2 h; ( (iii) vinylmagnesium bromide, THF, 
-78 
o
C, 5 h; (iv) appropriate boronic acid, Pd(PPh3)4, Na2CO3, dioxane:water (9:1), 110 
o
C, 18 h; (v) appropriate benzoyl chloride, AlCl3, DCM, RT, 18 h; (vi) TMSI, DCM, 
RT, 3 h. 
 
A slightly modified synthetic route was employed starting from 4-hydroxy-3-
nitropyridine (354) (Scheme 60). Bromination according to a literature procedure using 
bromine in water afforded 355 in 90% yield.
143
 Reaction of 355 with POCl3 under 
microwave irradiation at 140 
o
C for 15 min produced 356 in 89% yield. Substitution of 
the 4-chloro- substituent of 356 using sodium methoxide provided 352 in 86% yield. 
Although starting from 4-hydroxy-3-nitropyridine and progressing through 3 steps to 
obtain 3-bromo-4-methoxy-5-nitropyridine (352) added an extra step into the synthesis 
of pyrrolopyridone targets, the steps were high yielding and proceeded without the need 
for purification. The next step of the synthesis utilised a Bartoli-type cyclisation to form 
azaindole 353 from reaction of 352 with vinyl magnesium bromide. The Bartoli 
cyclisation was originally reported for the synthesis of indoles from nitrobenzene 
derivatives.  It was reported that reaction of a variety of 2-substituted nitrobenzenes 
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with 3 equivalents of vinylmagnesium bromide afforded the corresponding 7-substituted 
indoles in good yield.
144
 The postulated mechanism of the reaction is shown in Scheme 
59. In the first step of the reaction, the nitro group of the nitroarene is attacked by the 
Grignard reagent at one of the oxygen atoms to produce intermediate A. Elimination of 
the magnesium enolate affords the nitrosoarene B, which undergoes an inverse 1,2-
addition by a second equivalent of Grignard reagent.  The resulting N-aryl-O-vinyl 
hydroxylamino magnesium salt C is then set up for a [3,3]-sigmatropic rearrangement 
leading to intermediate D. Ring closure of D leads to intermediate E, which 
tautomerises to F. The third and final equivalent of the Grignard reagent acts as a base 
to afford the final indole product G.
145-146
 Following on from the success of the Bartoli 
indole synthesis, it was postulated that the reaction could be utilised to synthesise 
azaindoles using the appropriate nitropyridine starting material. It has been 
demonstrated that this approach is successful in producing a range of 4- and 6-
azaindoles in modest yield, and interestingky, larger substituents adjacent to the nitro- 
group improved reaction yield.
147
  
 
 
Scheme 59. Postulated mechanism of Bartoli indole synthesis.
145-146
  
 
The Bartoli approach was applied to 3-bromo-4-methoxy-5-nitropyridine (352) which 
was reacted with vinyl magnesium bromide to afford azaindole 353. Initial attempts 
followed the literature method, which involved addition of an excess of vinyl 
magnesium bromide at -78 
o
C and then warming to -20 
o
C for 8 h.
147
 The desired 
azaindole 353 was produced in 15% yield, which was comparable to the closest 
analogue in the literature (4-methoxy-5-nitropyridine, which gave the corresponding 
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azaindole in 11% yield).
147
 Attempts to improve the reaction yield by slow addition of 
vinyl magnesium bromide over 3 h with the use of a syringe pump were not successful. 
However, performing the reaction at -78 
o
C over 5 h without warming to -20 
o
C, 
increased the reaction yield to 40%.  Reaction of azaindole 353 with either 4-pyridyl- or 
3-pyridyl- boronic acid under Suzuki-Miyaura conditions afforded either 357 or 358 in 
75% yield each. Friedel-Crafts acylation of intermediates 357 and 358 was attempted 
with the four desired benzoyl chlorides using 2.5 equivalents of aluminium trichloride. 
This was unsuccessful, and it was found that similar reactions had been performed in 
the literature, but required a larger number of equivalents of aluminium trichloride. At 
least 3-5 equivalents were required since the aluminium could chelate to the two 
nitrogen atoms in the azaindole ring and would not be available for the Friedel-Crafts 
reaction.
148
 Repeating the reactiosn with 5.5 equivalents of aluminium trichloride and 5 
equivalents of benzoyl chloride was successful in producing the required products (359-
366). Purification of compounds 359-366 was difficult since the methoxy group was 
partly demethylated during the Friedel-Crafts reaction, and the two products were 
difficult to separate via chromatography. In light of this, it was decided not to isolate 
intermediates 359-366 and to perform the subsequent demethylation reaction with 
trimethylsilyl iodide to give the final products 367-374. Again, purification problems 
were encountered due to the presence of the methoxy intermediates remaining after the 
demethylation reaction. As such, the final products were purified by semi-preparative 
HPLC. Overall, compounds 367-374 were produced in low yields (21-30%) over two 
steps. 
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Scheme 60. Reagents and conditions: (i) Br2, H2O, 50 
o
C, 2 h; (ii) POCl3, N,N-
diethylaniline, MW, 140 
o
C, 15 min; (iii) Na, MeOH, RT, 2.5 h; (iv) vinylmagnesium 
bromide, THF, -78 
o
C, 5 h; (v) appropriate boronic acid, Pd(PPh3)4, Na2CO3, 
dioxane:water (9:1), 110 
o
C, 18 h; (vi) appropriate benzoyl chloride, AlCl3, DCM, RT, 
18 h; (vii) TMSI, DCM, RT, 3 h.  
 
 
6.3.3 ERK5 Inhibitory activity of 1H-pyrrolo[3,2-b]pyridin-7(4H)-one 
inhibitors 
 
Compounds 367-374 were sent for biological evaluation, and the results are shown in 
Table 39.  
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Table 39. Biological Results for 367-374. 
 
 
 
Compound R R’ ERK5; IC50 (µM) p38α; IC50 (µM) 
371 
  
38 ± 4.0 
(n = 2) 
14 ± 0.79 
(n = 2) 
367 
  
>120 
6.7 ± 0.67 
(n = 2) 
372 
  
46 ± 5.8 
(n = 2) 
42 ± 1.1 
(n = 2) 
368 
  
7.4 ± 3.4 
(n = 2) 
ND 
374 
  
11 ± 1.2 
(n = 2) 
5.7 ± 0.16 
(n = 2) 
370 
  
6.2 ± 0.05 
(n = 2) 
4.8 ± 0.94 
(n = 2) 
373 
  
>120 ND 
 
 
Disappointingly, ERK5 inhibition was reduced compared to inhibitors in the pyrrole 
carboxamide series. In addition, selectivity over p38α was diminished. It had been 
postulated that the incorporation of a bicyclic core may increase rigidity and lock the 2 
carbonyl groups into favourable conformations for binding, but the lack of potency and 
selectivity exhibited for ERK5 suggests that this is not the case. The lack of activity and 
loss of selectivity observed for these compounds meant further investigation into 
bicyclic analogues was ceased. The final analogue, 369 was produced in too small 
quantity to be purified by semi-preparative HPLC and was therefore not sent for 
biological evaluation. 
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Chapter 7. Conclusions and future work 
7.1 Conclusions 
 
SAR studies around the pyrrole carboxamide hit scaffold (A) were undertaken in order 
to improve ERK5 inhibitory activity. Homology modelling based on both the ERK2 and 
p38α crystal structures was used to guide structure-based design in the absence of a 
crystal structure of ERK5.  
 
 
 
Modification of the amide moiety led to the discovery that removal of a methylene 
group from the side chain resulted in an almost 3-fold improvement in ERK5 inhibitory 
activity compared to the initial hit compound (Figure 52). Shortening of the amide side 
chain was also shown to improve selectivity for ERK5 over closely related MAPK 
p38α.  
 
 
Figure 53. Increase in potency and selectivity observed for 127 compared to 53. 
 
Modification of the aroyl group also led to an improvement in selectivity for ERK5 over 
p38α. Introduction of a different halogen atom (i.e. chloro or bromo) into the 2-position 
of the aromatic ring conferred good potency and retained selectivity for ERK5 over 
p38α. Compound 151 was selected for in vitro and in vivo pharmacokinectic (PK) 
studies with promising results [in vitro PK; solubility >100 µM, PPB = 94% and in vivo 
PK; oral bioavailability = 68% and t1/2 = 65 min (p.o. mice)]. In vivo efficacy studies 
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were also encouraging, suggesting that compound 151 may have potential as an anti-
angiogenic and anti-proliferative agent.  
  
 
 
Despite the promising in vitro and in vivo PK results obtained for compound 151, inhibition 
of CYP450 enzymes was identified when 151 was tested against a panel of five isoforms. 
Replacement of the pyridyl moiety was investigated in order to improve CYP450 
inhibition profiles. Synthesis of a series of compounds with various substituted pyridyl, 
pyrimidyl or pyridazyl rings was conducted. The SARs revealed compounds with a 
pyrimidyl moiety to be potent inhibitors of ERK5 (IC50 <5 M) with excellent CYP450 
inhibition profiles when tested against a panel of CYP450 isoforms, exemplified by 
compound 182.  
 
 
 
More recent modifications to the aroyl substituent found that introduction of a 2,3,6-tri-
substituted aromatic ring led to a 12-fold increase in potency against ERK5. 
Modifications were made based upon the identification of a lipophilic pocket in the 
second-generation homology model (based on p38α). Interestingly, compound 295 was 
identified as the first inhibitor with a sub-100 nM ERK5 inhibitory activity.  
191 
 
 
 
Attempts to access a lipophilic pocket in the ERK5 binding site via substitution at the 3-
position of the core pyrrole ring were not successful. The ERK5 inhibitory activity of all 
compounds containing a substituent at the 3-position of the pyrrole ring was reduced 
(all IC50 >30 μM) and selectivity for ERK5 over p38α diminished. 
 
The replacement of the pyrrole by a pyrrolopyridone bicyclic core was attempted to 
increase the rigidity and reduce entropy of the ERK5 inhibitors. Unfortunately, although 
the bicyclic inhibitors were synthetically challenging, they were not active against 
ERK5 (all IC50 >5 μM) and showed complete loss of selectivity for ERK5 over p38α.  
 
The pyrrole carboxamide series has progressed from the hit-to-lead to the lead 
optimisation phase of drug development with a significant 30-fold improvement in 
ERK5 potency. The CYP450 inhibition profile has also been improved along with the 
selectivity of inhibitors for ERK5 over p38α. Further studies are currently being 
undertaken in order to find an inhibitor suitable for pre-clinical evaluation. 
 
7.2 Future work 
 
In order to identify a compound suitable for pre-clinical evaluation, studies are ongoing 
to further improve ERK5 potency and ADME properties. Compound 295 was shown to 
be an extremely interesting lead compound (ERK5; IC50 = 0.07 µM), but suffered from 
low aqueous solubility. In order to address this problem, future work will investigate the 
incorporation of water-solubilising groups (e.g. piperidine) onto the amide side-chain of 
inhibitors containing the 2,4,6-trisubstituted aroyl motif (Figure 53).  
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Figure 53. Introduction of water-solubilising groups onto the amide side-chain of 295. 
 
Introduction of a 3-bromo substituent onto the aroyl ring was tolerated (300, ERK5; 
IC50 =  0.07 µM). Further investigation into the incorporation of larger substituents in 
the position will be carried out. The bromo substituent can be utilised for the synthesis 
of further analogues via palladium-mediated coupling reactions (Figure 54). It may also 
be possible to introduce more polar, water-solubilising groups into this position using 
the bromo- substituent as a precursor.  
 
 
Figure 54. Introduction of substituents into the 3-position of the aroyl ring using the 3-
bromo substituent.  
 
A p38α-derived homology model identified a lipophilic pocket in the ERK5 ATP 
binding site. However, attempts to access this pocket via substitution at the 3-position of 
the core pyrrole ring were unsuccessful. It may be possible to access the identified 
pocket via substitution of the amide NH or substitution of the ortho position of the 
pyridyl ring in the amide side-chain (Figure 55). Inhibitors will be synthesised in order 
to investigate this hypothesis.  
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Figure 55. p38α-derived homology model highlighting the presence of a lipophilic 
pocket (in blue)  and potential inhibitors to be synthesised to exploit this region of the 
ERK5 binding site.  
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Chapter 8. Experimental  
 
8.1 Safety 
 
All procedures were conducted in line with the school of Chemistry safety policy. 
COSHH risk assessments were completed prior to beginning any experiment.  
 
8.2 Solvents and Reagents  
 
Chemicals were purchased from Sigma-Aldrich, Alfa Aesar and Apollo Scientific 
unless otherwise stated. SureSeal™ or Acroseal™ bottles of anhydrous solvents were 
purchased from Sigma-Aldrich or Acros, respectively. Deuterated solvents used for the 
determination of NMR spectra were purchased from Sigma-Aldrich. Unless otherwise 
stated, reactions were carried out under an inert atmosphere of nitrogen.  
 
8.3 Column chromatography  
 
Purification using column chromatography was achieved using a Biotage automated 
flash purification system with UV monitoring at 298 nm and collection at 254 nm. 
Biotage automated chromatography pre-packed silica cartridges were used in most 
cases. Where stated, the purification of some compounds was performed using Biotage 
C18 reversed phase silica columns, which have octadecyl (end-capped) functionalised 
silica or Biotage KP-NH cartridges were used for the separation of highly polar 
compounds. 
 
Where necessary semi-preparative HPLC was carried out using one of the following 
machines: (i) Varian Prostar Modular HPLC system with a binary pumping system, UV 
detector and fraction collector, controlled by Varian Star software, or (ii) Agilent 1200 
HPLC system with a binary pump, autosampler, fraction collector and diode array 
detector, controlled by Agilent ChemStation software. 
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8.4 Microwave assisted synthesis 
 
Where stated, reactions were carried out under microwave irradiation in sealed 
microwave vials with the use of a Biotage Initiator Sixty with a robotic sample bed. 
Reactions were irradiated at 2.45 GHz, and were able to reach temperatures between 60 
and 250 
o
C. Heating was at a rate of 2-5 
o
C/s and the pressure was able to reach 20 bar.  
8.5 Analytical Techniques  
 
Melting points were measured using a Stuart Scientific SMP3 apparatus. 
1
H NMR 
spectra were obtained using a Bruker Avance III 500 spectrometer using a frequency of 
500 MHz. 
13
C and 
19
F NMR spectra were acquired using the Bruker Avance III 500 
spectrometer operating at a frequency of 125 MHz, and 470 MHz, respectively. The 
abbreviations for spin multiplicity are as follows: s = singlet; d = doublet; t = triplet; q = 
quartet, quin = quintet, sept = septet and m = multiplet. Combinations of these 
abbreviations are employed to describe more complicated splitting patterns (e.g. dd = 
doublet of doublets) and where broadening of the peak is observed, spin multiplicity is 
accompanied by the prefix br = broad. 
 
LC-MS analyses were conducted using a Waters Acquity UPLC system with PDA and 
ELSD. When a 2 min gradient was used, the sample was eluted on Acquity UPLC BEH 
C18, 1.7µm, 2.1 x 50mm, with a flow rate of 0.6 mL/min using 5-95% 0.1% formic 
acid/MeCN. Analytical purity of compounds was determined using Waters XTerra 
RP18, 5 μm (4.6 × 150 mm) column at 1 mL/min using either 0.1% aqueous ammonia 
and acetonitrile or 0.1% aqueous formic acid and acetonitrile with a gradient of 5-100% 
over 15 min.  
 
FTIR spectra were measured using a Bio-Rad FTS 3000MX diamond ATR apparatus. 
UV spectra were recorded on a Hitachi U-2800A spectrophotometer and were 
performed in ethanol. HRMS were provided by the ESPRC National Mass 
Spectrometry Service, University of Wales, Swansea. 
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8.6 Biological assays  
 
8.5.1 ERK5 IMAP
TM
 assay (This assay was performed by Ai Ching Wong at CRT-
DL) 
 
The assay buffer was prepared using 0.01% Tween
®
-20 5x stock, supplied as part of 
IMAP
TM
 FP Progressive Binding System Kit (Molecular Devices R7436) and diluted to 
1x using miliQ H2O. 1 µL of a 1M DTT stock was added for every 1 mL of 1x assay 
buffer to give a final concentration of 1 mM DTT.  
 
ERK5 was expressed and purified at CRT-DL by Leon Pang and Sue Young. Aliquots 
were stored at –80 C. The ERK5 working solution was used at a 1 in 1 in 350 final 
dilution in assay buffer. A 1:175 dilution of ERK5 stock solution was performed in 1x 
assay buffer. For 1 plate, 13 µL of ERK5 stock was added to 2262 µL of 1x assay 
buffer.  
 
To prepare the ATP/substrate working solution for one plate, ATP disodium salt (90 µL, 
20 mM) (Sigma A7699) and FAM-EGFR-derived peptide (15 µL, 100 µM) 
(LVEPLTPSGEAPNQ(K-5FAM)-COOH) (Molecular Devices RP7129; reconstituted 
in miliQ H2O to a stock concentration of 100 µL; stored at -20C) was added to 2295 
µL of 1x assay buffer. 
 
To prepare the IMAP
TM
 binding solution for one plate 20.5 µL of IMAP
™
 binding 
reagent stock, 1476 µL of 1x binding buffer A (60%), and 984 µL of binding buffer B 
(40%) (IMAP™ FP Progressive screening express kit (Molecular Devices R8127) was 
added to 9819.5 µL of milliQ H2O. 
 
1 µL of inhibitor (in 60:40 H2O/DMSO) or control/blanks (60:40 H2O/DMSO) were 
dry-spotted into the relevant wells of a 384-well assay plate using the MATRIX 
PlateMate

 Plus. 5 µL of ERK5 working solution was added to test and control wells, 
and 5 µL of 1x assay buffer added to blanks; 4 µL of ATP/substrate working solution 
was added to all wells using a Matrix multichannel pipette. The plate was sealed using 
DMSO resistant clear seal and incubated for 2 h at 37 C. 1 µL of the kinase reaction 
mixture from the first plate was dry spotted into a second 384-well assay plate using the 
MATRIX PlateMate

 Plus. 9 µL of assay buffer was added, followed by 30 µL of 
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IMAP
™
 binding solution using a multichannel pipette. The plate was incubated at RT in 
darkness for 2 h. The assay plate was then read on an Analyst HT plate reader 
(Molecular Devices) using the settings described below:  
Measurement mode = Fluorescence polarisation; Method ID = ERK5; Integration time 
= 100 ms; Excitation filter = Fluorescein 485-20; Emission filter = 530-25; Dichroic 
mirror = 505 nm; Plate definition file = Corning 384 black fb; Z-height = 5.715 mm 
(middle); G-factor = 1; Attenuator = out; Detector counting = Smartread+; Sensitivity = 
2. 
 
 
8.5.2 p38α LANCE assay  (This assay was performed by Ai Ching Wong at 
CRT-DL)  
 
1x assay buffer was prepared consisting of the following reagents; 250 mM 
tris(hydroxymethyl)aminomethane (Tris) pH 7.5, 25 mM MgCl2, 2.5 mM ethylene 
glycol tetraacetic acid (EGTA), 10 mM DTT and 0.05% Triton X100 in milliQ H2O 
(NB: 1x buffer final assay concentrations were 5x lower than stated above). 
 
The p38α/SAPK2 working solution was prepared using active N-terminal GST-tagged 
recombinant full length protein (Millipore 14-251) supplied as a 10 µg/4 µL stock. This 
was diluted to a 10 µg/40 µL (1 µM) concentration by addition of 156 µL of Tris/HCl 
(pH 7.5, 50 mM), NaCl (150 mM), EGTA (0.1 mM), Brij-35 surfactant (0.03%), 
glycerol (50%) and 0.1% 2-mercaptoethanol (0.1%). The final dilution was dependent 
on activity of the enzyme batches. The p38α concentration used in the assay was 1 nM. 
A 2x working stock solution (2 nM, 500 fold dilution of 1 µM stock) in 1x assay buffer 
was prepared. For one plate, 9.4 µL of p38α (1 µM) was added to 1870.6 µL of milliQ 
H2O.  
 
The ATP/substrate working solution for one plate used ATP disodium salt (17.5 µL, 
200 mM stock), (Sigma A7699) and Ulight-MBP Peptide (50 µL, 5 µM stock) (Perkin 
Elmer TRF0109), which were added to 400 µL of 5x assay buffer and 1532.5 µL of 
milliQ H2O. 
 
The EDTA/antibosy detection reagrent for one plate consisted of; 84 µL of 
ethylenediaminetetraacetic acid (EDTA) (0.5 M) (Sigma E4378-100G) and 27 µL of 
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Europium-anti-phospho-MBP antibody (0.625 µM) (Perkin Elmer) added to 420 µL of 
LANCE detection buffer (1x) and 3669 of milliQ H2O. 
 
1 µL of compound (in 80:20 H2O/DMSO) or control/blank (80:20 H2O/DMSO) was 
dry-spotted into the relevant wells of a 384-well assay plate using the MATRIX 
PlateMate

 Plus. 5 µL of p38α working solution was added to test and control wells, 
and 5 µL of assay buffer added to blanks; 4 µL of ATP/substrate working solution was 
added to all wells using a Thermo Multidrop Combi or Matrix multichannel pipette. The 
plate was sealed using DMSO resistant clear seal and incubated for 1 h at 37 C. 10 µL 
of the EDTA/antibody working solution was added to all wells using a Thermo 
Multidrop Combi or Matrix multichannel pipette. The plate was incubated at RT in 
darkness for 2 h. The assay plate was then read on a PheraStar microplate reader using 
the settings described below: 
Pherastar: Measurement mode = TRF; Method ID = LANCE HTRF ERK5; Optic 
Module: 337, 665, 620 nm. Focal Height = 6.0, Positioning delay, 0.1 sec, Number of 
flashes per well = 100, Integration start = 60 µs, Integration time = 200 µs, 
Simultaneous dual emission, Ratio multiplicator = 1000. 
 
 
8.5.3 Dual-luciferase reporter assay  (This assay was performed by Dr Pamela 
Lochhead at the Babraham Institute)  
 
Agar plates for bacterial colony growth were prepared using 250 mL of lysogeny broth 
(LB) agar spiked with 250 µL of an antibacterial agent (kanomycin or ampicillin), and, 
using a sterile pipette, 25 mL of spiked LB agar was transferred into 12 petri dishes.  
Transformed bacterial colonies were grown as follows: to a polypropylene tube was 
added 48 µL of E. coli in glycerol stock (prepared in-house at the Babraham Institute), 
and 2 µL of either the Gal4-Luciferase or MEK5D DNA plasmid. The resulting mixture 
was incubated at 0 
o
C for 15 min. Bacteria were subjected to stress by heating at 42 
o
C 
for 30 sec, then returning to 0 
o
C. 200 µL of LB agar was added at 0 
o
C, and the 
resulting mixture was incubated with shaking for 30 min to 1 h at 37 
o
C.  
 
At 37 
o
C, 250 µL of the solution containing Gal4-Luciferase transformed bacteria was 
transferred onto one LB agar/kanomycin plate. 250 µL of the solution containing 
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MEK5D transformed bacteria was transferred onto one LB agar/ampicillin plate. Agar 
plates were incubated for 24 h at 37 
o
C for bacterial colony growth.  
 
To a conical flask was added 100 mL LB agar, 100 µL of the relevant antibiotic, and a 
sample of the bacterial colonies from the relevant petri dish. The flasks were incubated 
for a further 24 h at 37 
o
C, with stirring (150-170 rpm). 
 
For DNA purification, 2 x 50 mL portions of the incubated bacteria in agar obtained 
were transferred into 50 mL Falcon tubes and subjected to centrifugation at 6000 G for 
15 min. DNA plasmids were isolated in aqueous media from the remaining bacterial 
pellet using a Qiagen Plasmid Plus Midi Kit, according to kit instructions. 
 
In order to quantify the DNA, concentration of the purified aqueous DNA was 
determined using a NanoDrop 1000 spectrophotometer. DNA stock solutions were at 
2419.4 ng/µL and 1965.6 ng/µL for Gal-4-Luciferase and MEK5D plasmid stocks 
respectively. All other DNA plasmid stocks used were prepared in house at the 
Babraham Institute by Dr Pamela Lochhead. 
 
Cell Maintenance 
HEK293 cells were grown as adherent colonies on tissue culture dishes in Dulbecco’s 
Modified Eagle Medium (DMEM) tissue culture medium (Gibco
®
 41966) containing L-
glutamine (2 mM, Gibco
®
 1499), penicillin/streptomycin (100 µg/mL, PAA P11-010), 
foetal bovine serum (FBS) (10%, PAA A15-151) as additives. 
 
Penicillin and streptomycin are antibacterial agents which minimise the risk of bacterial 
infection occurring in cell culture. FBS is a serum supplement, which contains growth 
factors that promote eukaryotic cell growth. L-glutamine is a nutrient which supports 
the growth of cells which have high energy demands, such as cells which synthesise 
large amounts of proteins and/or nucleic acids or those which use glucose inefficiently. 
 
Trypsinizing of Adherent Cell Colonies 
Cells were regularly passaged in order to maintain optimum colony sizes on plates. In 
order to do this, and to harvest cells for use in the dual-luciferase reporter assay, 
adherent cells were lifted from tissue culture dishes. Cell media was removed via 
aspiration, and the cell monolayer was washed with phosphate buffered saline (PBS) 
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solution (10 mL), which was then aspirated. The cells were lifted from the plate through 
incubation at 37 
o
C for 5-10 min with 1 mL trypsin (0.5% trypsin-EDTA (1x), Gibco
®
 
15400054). 
PBS (10x): NaCl (4% w/v), KCl (0.1% w/v), Na2HPO4.7H2O (0.6% w/v), KH2PO4 
(0.1% w/v), NaN3 (0.01% w/v). 
 
Reverse Transfection of HEK293 cells 
Preparation of EGFP Control (C3) Working Solution (For 1 x 96 well plate) 
To a 50 mL Falcon tube was added 250 µL Opti-MEM
®
 growth media (reduced serum 
medium, Invitrogen 31985) and the following DNA plasmids: MEF2D-Gal4 (2.5 µL, 
0.25 mg/mL stock), Gal4-Luc (2.5 µL, 1.25 mg/mL stock), Renilla Luciferase (2.5 µL, 
0.1 mg/mL stock), EGFP construct, containing no MEK5D (0.25 µL, 0.5 mg/mL stock), 
and HA-ERK5 wt (2.5 µL, 0.5 mg/mL stock). To this mixture was then added 5 µL of 
Lipofectamine™ 2000 transfection reagent (Invitrogen 11668) and complexation 
allowed for 15-20 min. 
 
Preparation of EGFP-MEK5D (5D) Working Solution (For 1 x 96 well plate) 
To a 50 mL Falcon tube was added 1500 µL Opti-MEM
®
 growth media (reduced serum 
medium, Invitrogen 31985), and the following DNA plasmids: MEF2D-Gal4 (15 µL, 
.25 mg/mL stock), Gal4-Luc (15 µL, 1.25 mg/mL stock), Renilla Luciferase (15 µL, 0.1 
mg/mL stock), EGFP-MEK5D construct (1.5 µL, 0.5 mg/mL stock), HA-ERK5 wt (15 
µL, 0.5 mg/mL stock). To this mixture was then added 30 µL of Lipofectamine™ 2000 
transfection reagent (Invitrogen 11668) and complexation allowed for 15-20 min. 
 
Preparation of HEK293 Cells for Reverse Transfection 
Trypsinized HEK293 cells were re-suspended in 19 mL of fresh cell media and counted 
using haemocytometry. Cells were then diluted with fresh cell media to achieve a final 
cell concentration of 2 x 10
5 
cells/mL. 1237.5 µL and 7425 µL of this cell media was 
added to the C3 and 5D working solutions respectively. 100 µL of the transfected cells 
were then aliquoted into the appropriate wells in a 96-well opaque sided tissue culture 
plate, and incubated at 37 
o
C for 6 h. 
 
Addition of Compounds to HEK293 Cells 
Each compound supplied was prepared as a 10 mM working solution in DMSO, from 
which the following stocks were prepared in DMSO: 3.33 mM, 1 mM, 0.11 mM and 10 
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µM. 4 compounds was assayed per 96-well plate. For each compound, 1 mL of growth 
media was added to eight 1.5 mL Eppendorf
®
 tubes. 6 µL of DMSO was added to two 
tubes for C3 and blank 5D wells, and 6 µL of the relevant compound stock solution was 
added to the 6 remaining tubes. BIX02189 was added to each plate in varying 
concentrations as an indicator of assay reliability. Solutions of drug in media were 
thoroughly mixed, and 100 µL of the relevant compound was transferred (in triplicate) 
to the 96-well plate containing transfected HEK293 cells using an electronic 
multichannel pipette with variable tip spacing. Sealed plates were incubated at 37 
o
C for 
24 h. Final compound concentrations were as follows; 30 µM, 10 µM, 3 µM, 1 µM and 
0.3 µM. 
 
Assay Plate Lysis 
15 mL of 1x passive lysis buffer (PLB) was prepared using 5x PLB (Dual-Luciferase 
Reporter Assay System, Promega
®
 E1960), diluting with H2O. Assay plates prepared 
were removed from the incubator and the growth media removed by aspiration. 20 µL 
of 1x PLB was dispensed into each well and the plates shaken for 10 min. Assay plates 
were sealed and  stored at -80 
o
C overnight.  
 
Quantification of Cellular Inhibition of ERK5 
Cellular inhibition of ERK5 was quantified using the Dual-Luciferase® Reporter Assay 
System (Promega
®
 E1960). Luciferase assay buffer/Luciferase assay substrate and Stop 
and Glo
®
 assay buffer/Stop and Glo
®
 substrate were prepared according to kit 
instructions. 100 µL of the Luciferase system was added to each well using a 
multichannel pipette, before analysis using an EG&G Berthold Microlumat Plus 
luminometer. 100 µL of the Stop and Glo
®
 system was subsequently added, and the 
plate was analysed once again by luminometer. Raw data was processed using 
Microsoft Excel, enabling generation of IC50 values for each compound. IC50 values 
obtained are based on the means of 3 experiments. Each data point is the mean of 3 
values ± standard deviation to produce one curve using Microsoft Excel. IC50 values 
were determined by eye. 
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8.5.4 EGF-stimulated HeLa cell assay  (This assay was performed by Lan-Zhen 
Wang at the NICR) 
 
HeLa cells were serum starved overnight followed by treatment with ERK5 inhibitors 
for 1 h. Cells were then stimulated with 100 ng/ml EGF for 10 min. The cells were 
harvested and lysed at 4
o
C for 5–10 min in Laemmli buffer containing Halt protease and 
phosphate inhibitors (Pierce). The lysates were boiled for 10 min at 100
o
C. Twenty 
microliters sample was run on 6% Tris–glycine gels and transferred to nitrocellulose. 
Western blotting was done with ERK5 antibody (Cell signalling #3372S). The IC50 was 
calculated from densitometry of top bands. 
8.7 General Procedures 
 
The following general procedures were employed for the syntheses of structurally 
similar compounds. 
 
General Procedure A – Friedel Crafts acylation 
 
 
Aluminium chloride (2.5 equiv.) was added to DCM (2.5 mL/mmol pyrrole) at 0 
o
C, 
followed by the appropriate benzoyl chloride or acid anhydride (2.0 equiv.). Methyl 2-
pyrrole carboxylate (1.0 equiv.) was then added, and the resulting mixture was stirred at 
0 
o
C for 1 h before being warmed to RT and left to stir overnight. The mixture was 
quenched with a 1.0 M aqueous solution of HCl until effervescence ceased, and the 
resulting mixture was extracted using DCM (5 mL/mmol pyrrole). The combined 
organic extracts were washed with a saturated aqueous solution of NaHCO3, followed 
by water and a saturated brine solution (5 mL/mmol pyrrole) respectively. The organic 
layer was then dried over Na2SO4, filtered, and the filtrate concentrated in vacuo. The 
crude product was purified by medium pressure flash chromatography (MPLC).  
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General Procedure B – Ester hydrolysis 
 
The pyrrole ester (1.0 equiv.) was dissolved in THF (8 mL/mmol pyrrole) and solution 
of LiOH (20 equiv.) in water (13.0 mL/mmol pyrrole) was added.  The resulting 
mixture was heated at 60 
o
C overnight. The mixture was then cooled and acidified using 
a 1.0 M aqueous solution of HCl to pH 3-4, causing a precipitate. The solid was 
extracted into EtOAc (2 x 50 mL/mmol pyrrole), and the combined organic layers were 
washed with water followed by brine (50 mL/mmol pyrrole respectively) before being 
dried over Na2SO4. The filtrate was concentrated in vacuo. 
 
 
General Procedure C - Amide Coupling with CDI 
 
The pyrrole carboxylic acid (1.0 equiv.) was dissolved in THF (5 mL/mmol pyrrole) 
before carbonyldiimidazole (2.0 equiv.) was added. The reaction mixture was then 
heated at reflux for 3 h. After this time, the reaction mixture was cooled to 50 
o
C before 
the amine (2.5 equiv.) was added and the mixture heated for a further 3 h. The reaction 
mixture was then cooled to RT (20 
o
C) and left to stir overnight. The mixture was then 
diluted with EtOAc (50 mL/mmol pyrrole), and subsequently washed with water, and 
brine (50 mL/mmol pyrrole) respectively and extracted with EtOAc (3 x 30 mL/mmol 
pyrrole). The combined organic extracts were dried over Na2SO4 and the filtrate 
concentrated in vacuo. Purification was achieved using MPLC. 
 
 
 
 
 
 
 
 
 
 
 
204 
 
General Procedure D - Amide coupling with PCl3 
 
The carboxylic acid (1.0 equiv.) was dissolved in MeCN (5 mL/mmol pyrrole) before 
the relevant amine (2.5 equiv.) was added followed by phosphorus trichloride (1.0 
equiv.). The mixture was then heated using microwave irradiation at 150 
o
C for 5 min. 
The reaction was then quenched with a few drops of H2O and the solvent removed in 
vacuo. The residue was re-dissolved in EtOAc (50 mL/mmol pyrrole) and washed with 
a saturated aqueous solution of NaHCO3 (50 mL/mmol pyrrole) before being extracted 
into EtOAc (3 x 30 mL/mmol pyrrole). The combined organic extracts were dried over 
Na2SO4, and the filtrate concentrated was in vacuo to afford the crude product, which 
was purified by MPLC. 
 
 
General Procedure E – Boc deprotection  
 
The Boc-protected piperidine (1.0 equiv.) was dissolved in DCM (6 mL/mmol pyrrole) 
before TFA (6 mL/mmol pyrrole) was added, followed by Et3SiH (2.5 equiv.) The 
reaction mixture was then allowed to stir at RT for 1 h before the solvent was removed 
in vacuo. The residue was then dissolved in EtOAc (50 mL/mmol pyrrole) before being 
washed with saturated aqueous solution of NaHCO3 (3 x 50 mL/mmol pyrrole) and 
extracted into EtOAc (3 x 30 mL/mmol pyrrole). The organic extracts were combined, 
dried over Na2SO4 and concentrated in vacuo. 
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General Procedure F – Friedel-Crafts acylation of pyrrolopyridines 
followed by TMSI demethylation 
 
The  azaindole (1.0 equiv.) was dissolved in DCM (5 mL/mmol pyrrole) before the 
appropriate benzoyl chloride (5.0 equiv.) was added followed by AlCl3 (5.5 equiv.) and 
the resulting mixture was then stirred at 0 
o
C for 1 h before being warmed to RT (20 
o
C) 
and left to stir overnight. The mixture was then quenched with MeOH until 
effervescence ceased, and then the solvent was removed in vacuo. The resulting residue 
was re-dissolved in EtOAc and purified by MPLC. After purification a mixture of 
methoxypyridine and pyridone was isolated and this was taken up in DCM (5 mL/mmol 
pyrrole) before TMSI was added (6.0 equiv.) and the mixture was then left to stir at RT 
(20 
o
C) for 3 h. MeOH was added and the solvent removed in vacuo. EtOAc (50 
mL/mmol pyrrole) was added and the organic fraction was washed with water (2 x 50 
mL/mmol pyrrole), dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by semi-preparative HPLC.  
 
8.8 Experimental data 
 
4-(2,6-Difluorobenzoyl)-N-(4-sulphamoylphenyl)-1H-pyrrole-2-carboxamide (61) 
 
 
4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol) was 
dissolved in acetonitrile (5 mL). Pyridine (32 µL, 0.40 mmol) was then added followed 
by cyanuric trifluoride (14 µL, 0.16 mmol). The mixture was allowed to stir for 30 min 
at RT before sulphanilamide (172 mg, 1.00 mmol) was added and the reaction mixture 
was left to stir at RT overnight. Brine was added and the product was extracted into 
EtOAc (2 x 10 mL). The combined organic extracts were dried over Na2SO4 and the 
206 
 
solvent removed in vacuo. Purification was achieved by MPLC (silica, 2-30% MeOH in 
EtOAc) to give the title compound as a white solid (62 mg, 38%); Rf = 0.82 (10% 
MeOH in EtOAc); M.p.: 310-311 
oC; λmax (EtOH)/nm: 284, 233; νmax/cm
-1
: 3362, 3253, 
3123, 2636, 2045, 1669 (CO), 1635 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.26-
7.30 (4H, m, H-3’, H5’ and SO2NH2), 7.54-7.56 (2H, m, H-3 and H-5), 7.64 (1H, dddd, 
J = 6.8, 6.9,  8.4 and 8.5 Hz, H-4’), 7.80 (2H, d, J = 8.9 Hz, p-subs. H-Ar), 7.90 (2H, J 
= 8.9 Hz, p-subs. H-Ar), 10.34 (1H, s, CONH), 12.72 (1H, br s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ 111.0 (C-Ar), 111.9 (C-Ar), 114.0 (C-Ar), 117.8 (C-Ar), 118.5 (C-
Ar), 120.5 (C-3), 125.4 (C2 and C-5), 129.0 (C-4), 132.5 (C-Ar), 133.6 (C-Ar), 158.7 
(JCF = 245.5 Hz, CF), 164.1 (CONH), 185.6 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -
115.4; LRMS (ES
+
) m/z 406.20 [M+H]
+
; HRMS m/z calcd for C18H14F2N3O4S [M+H]
+
 
406.0658, found 406.0658. 
 
1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine (68) 
 
 
4-Nitrophenol (1.00 g, 7.19 mmol) was dissolved in DMF (20 mL). K2CO3 (2.78 g, 20.1 
mmol) was then added and the resulting yellow mixture was stirred for 15 min at RT. 1-
(2-Chloroethyl)pyrrolidine hydrochloride (2.20 g, 12.94 mmol) was added and the 
reaction was heated to 80 
o
C for 2 h, before the solvent was removed in vacuo. Water 
(100 mL) was added to the resulting residue, which was extracted with DCM (4 x 40 
mL). The combined organic layers were washed with a saturated aqueous solution of 
NaHCO3 (3 x 30 mL), dried over Na2SO4 and the solvent removed in vacuo. The title 
compound was obtained as a yellow oil (1.10 g, 65%); Rf = 0.10 (100% EtOAc); λmax 
(EtOH)/nm 305, 221; νmax/cm
-1
 2951, 2787, 2449, 1921, 1599 (NO2); 
1
H NMR (500 
MHz, DMSO-d6) δ 1.45 (4H, pent., J = 3.1 Hz, (CH2)2-pyrrolidine),  2.25-2.29 (4H, m, 
N(CH2)2 -pyrrolidine), 2.58 (2H, t,  J = 5.8 Hz, CH2), 3.98 (2H, t,  J = 5.8 Hz, CH2), 
6.92 (2H, d, J = 7.1 Hz, H-Ar), 7.96 (2H, d, J = 7.1 Hz, H-Ar);  
13
C NMR (125 MHz, 
DMSO-d6) δ 23.2 (CH2)2-pyrrolidine), 54.0 N(CH2)2-pyrrolidine), 54.1 (NCH2), 67.9 
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(CH2O), 115.1 (C-Ar), 118.1 (C-Ar), 125.8 (C-Ar), 127.0 (C-Ar), 163.9 (C-Ar); LRMS 
(ES
+
) m/z 237.1 [M+H]
+
. 
 
4-(2-(Pyrrolidin-1-yl)ethoxy)aniline (66) 
 
 
1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine (68) (400 mg, 1.69 mmol) was dissolved in 
AcOH (10 mL) before zinc powder (1.10 g, 16.9 mmol) was added and the reaction was 
left to stir at RT overnight. The mixture was then filtered through a pad of Celite, and 
the AcOH was removed in vacuo before water was added and the solution neutralised 
using ammonia. The product was extracted using EtOAc (3 x 20 mL) before the organic 
layers were combined, dried over Na2SO4 and the solvent removed in vacuo to give the 
title compound as a brown oil (320 mg, 92%); Rf = 0.23 (30% MeOH in DCM); λmax 
(EtOH)/nm 294, 233; νmax/cm
-1
 3414 (NH2), 3015, 2600, 2162, 1573; 
1
H NMR (500 
MHz, MeOD) δ 1.74-1.77 (4H, m, (CH2)2-pyrrolidine), 2.64-2.66 (4H, m, N(CH2)2-
pyrrolidine), 2.82 (2H, t,  J = 5.5 Hz, CH2), 3.95 (2H, t,  J = 5.5 Hz, CH2), 6.60 (2H, d, J 
= 7.1 Hz, H-Ar), 6.65 (2H, d, J = 7.1 Hz, H-Ar);  
13
C NMR (125 MHz, MeOD) δ 23.0 
(CH2)2-pyrrolidine), 53.9 (N(CH2)2-pyrrolidine), 54.1 (NCH2), 66.4 (CH2O), 114.9 (C-
Ar), 115.6 (C-Ar), 142.6 (C-Ar), 149.6 (C-Ar); LRMS (ES
+
) m/z 207.2 [M+H]
+
.  
 
Methyl 4-(4-isopropoxybenzoyl)-1H-pyrrole-2-carboxylate (72) 
 
 
4-Isopropoxybenzoic acid (500 mg, 2.8 mmol) was dissolved in THF (7 mL). SOCl2 
(0.61 mL, 8.4 mmol) was then added followed by DMF (20 µL, 0.28 mmol). The 
mixture was then stirred at RT for 3 h, before being concentrated in vacuo. The residue 
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was dissolved in DCM (4 mL) and the reaction was carried out according to general 
procedure A, using methyl pyrrole-2-carboxylate (69) (175 mg, 1.4 mmol), and AlCl3 
(467 mg, 3.5 mmol). The crude residue was purified by MPLC (silica, 2-100% EtOAc 
in petrol) followed by an additional NaHCO3 wash to give the title compound as an 
orange solid (270 mg, 67%); Rf = 0.41 (10% EtOAc in petrol); M.p 112-113 
oC; λmax 
(EtOH)/nm 293, 229; νmax/cm
-1
 3293, 2979, 2560, 2159, 2017, 1720 (CO2Me), 1599 
(CO), 1552; 
1
H NMR (500 MHz, DMSO-d6) δ 1.10 (6H, d, J = 6.0 Hz, CH(CH3)2), 
3.58 (3H, s, OCH3), 4.53 (1H, sept., J = 6.0 Hz,  CH(CH3)2), 6.82 (2H, d, J = 6.9 Hz, H-
Ar), 6.92 (1H, dd, J = 1.6 and 3.2 Hz, H-3), 7.34 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 
7.57 (2H, d, J = 6.9 Hz, H-Ar), 12.45 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) 
δ 21.7 (CH(CH3)2), 51.2 (CH3), 69.5 (CH(CH3)2), 114.9 (C-3), 116.3 (C-Ar), 124.6 (C-2 
and C-5), 130.6 (C-4), 130.9 (C-Ar), 131.3 (C-Ar), 160.4 (C-Ar), 161.3 (CO2Me), 187.4 
(CO);  LRMS (ES
+
) m/z 288.2 [M+H]
+
; HRMS m/z calcd for C16H19NO4 [M+H]
+
 
288.1230, found 288.1235. 
 
4-(4-Isopropoxybenzoyl)-1H-pyrrole-2-carboxylic acid (73)  
 
 
Compound 73 was synthesised according to general procedure B, using methyl 4-(4-
isopropoxybenzoyl)-1H-pyrrole-2-carboxylate (72) (200 mg, 0.70 mmol), LiOH (335 
mg, 14.00 mmol) in water (9 mL) and THF (8 mL) to give the title compound as a pale 
yellow solid (187 mg, 98%); Rf = 0.42 (5% MeOH in EtOAc); M.p. 185 
oC (dec.); λmax 
(EtOH)/nm 293, 254, 231; νmax/cm
-1
 3661, 3036, 2607, 2357, 2084, 1619 (CO2H), 1598 
(CO); 
1
H NMR (500 MHz, DMSO-d6) δ 1.37 (6H, d, J = 6.1 Hz,  CH(CH3)2), 4.80 (1H, 
sept., J = 6.1 Hz, CH(CH3)2), 7.10 (2H, d, J = 8.9 Hz, H-Ar), 7.15 (1H, dd, J = 1.7 and 
3.2 Hz, H-3), 7.56 (1H, dd, J = 1.7 and 3.2, H-5), 7.84 (2H, d, J = 8.9 Hz, H-Ar), 12.54 
(1H, br s, OH), 12.84 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 21.7 
(CH(CH3)2), 69.5 (CH(CH3)2), 115.0 (C-3), 115.5 (C-Ar), 124.5 (C-2 and C-5), 128.3 
(C-4), 130.9 (C-Ar), 131.0 (C-Ar), 160.6 (C-Ar), 161.6 (C-Ar), 187.6 (CO2H); LRMS 
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(ES
+
) m/z 274.1 [M+H]
+
; HRMS m/z calcd for C15H13NO4 [M-H]
-
 272.0928, found 
272.0932. 
 
2,5-Dioxopyrrolidin-1-yl 4-(4-isopropoxybenzoyl)-1H-pyrrole-2-carboxylate (74) 
 
 
4-(4-Isopropoxybenzoyl)-1H-pyrrole-2-carboxylic acid (73) (100 mg, 0.37 mmol) was 
dissolved in EtOAc (5 mL) at 0 
o
C. DCC (82 mg, 0.40 mmol) was then added followed 
by N-hydroxysuccinimide (46 mg, 0.40 mmol). The resulting yellow mixture was left to 
stir at 0 
o
C for 2 h before being warmed to RT and being left to stir for 18 h. The cream 
suspension was filtered through a pad of Celite and the filtrate concentrated in vacuo to 
give the title compound as an orange oil (135 mg, 99%); Rf = 0.47 (50% EtOAc in 
Petrol); λmax (EtOH)/nm 277, 229; νmax/cm
-1
 3242, 2981, 2594, 1728 (CON), 1597 (CO); 
1
H NMR (500 MHz, CDCl3) δ 1.30 (6H, d, J = 6.1 Hz, CH(CH3)2), 2.82 (4H, s, 2 x 
CH2), 4.59 (1 H, sept., J = 6.1 Hz, CH(CH3)2), 6.86 (2H, d, J = 8.9 Hz, H-Ar), 7.49 
(1H, br s, H-3), 7.63 (1H, br s, H-5), 7.76 (2H, d, J = 8.9 Hz, H-Ar), 10.36  (1 H, br s, 
NH); 
13
C NMR (125 MHz, CDCl3) δ 21.8 (CH(CH3)2), 25.6 (2 x CH2), 70.2 
(CH(CH3)2), 115.5 (C-3), 120.5 (C-Ar), 125.5 (C-2 and C-5), 128.8 (C-4), 131.6 (C-Ar), 
155.8 (C-Ar), 161.6 (C-Ar), 169.6 (C-Ar), 172.2 (2 x CO), 188.6 (CON);  LRMS (ES
+
) 
m/z 371.1 [M+H]
+
; HRMS m/z calcd for C19H19N2O6 [M+H]
+
 371.1243, found 
371.1241. 
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4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75)  
 
 
Compound 75 was synthesised according to general procedure B, using methyl 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylate (76) (450 mg, 1.70 mmol), LiOH (0.81 g, 
34.00 mmol) in water (22 mL) and THF (14 mL) to give the title compound as a pale 
orange solid (424 mg, 99%); Rf = 0.41 (10% EtOAc in petrol); M.p. 197-198 
o
C; λmax 
(EtOH)/nm 283, 232; νmax/cm
-1
 3772, 3024, 2779, 2612, 2539, 1705 (CO2H), 1624 (CO) 
; 
1
H NMR (500 MHz, DMSO-d6) δ 7.05 (1H, br s, H-3), 7.29-7.33 (2H, m, H-Ar), 7.57 
(1H, dd, J = 1.4 and 3.0 Hz, H-5), 7.64-7.70 (1H, dddd, J = 6.7, 6.8, 8.4 and 8.5 Hz, H-
Ar), 12.77 (1H, br s, NH), 12.97 (1H, br s, OH); 
13
C NMR (125 MHz, DMSO-d6) δ, 
112.1 (C-Ar), 114.2 (C-3), 125.8 (C-2 and C-5), 129.8 (C-4), 132.3 (C-Ar), 158.8 (d, 
JCF = 245.5 Hz, CF), 159.6 (CO2H), 181.7 (CO);  
19
F NMR (470 MHz, DMSO-d6) δ -
114.2;  LRMS (ES
+
) m/z 371.1 [M+H]
+
; HRMS m/z calcd for C12H6F2NO4 [M-H]
-
 
250.0321, found 250.0325. 
 
4-(2,6-Difluorobenzoyl)-N-(4-hydroxyphenyl)-1H-pyrrole-2-carboxamide (76)  
 
 
Compound 76 was synthesised according to general procedure C, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol), 
carbonyldiimidazole (129 mg, 0.80 mmol), 4-aminophenol (109 mg, 1.0 mmol) and 
THF (4 mL). The crude residue was purified by MPLC (silica, 2-60% EtOAc in petrol) 
followed by recrystallisation from EtOAc to give the title compound as a beige solid (73 
mg, 54%); Rf = 0.78 (5% MeOH in EtOAc); M.p 232-233 
oC; λmax (EtOH)/nm 245, 216; 
νmax/cm
-1
 3673, 3297 (OH), 2520, 2159, 2017, 1621 (CO), 1543 (CONH); 
1
H NMR 
(500 MHz, MeOD) δ 6.60 (2 H, d, J = 8.9 Hz, NH-H-Ar), 6.94 -6.98 (2H, m, H-Ar) 
7.23 (1H, br s, H-3), 7.25 (2 H, d, J = 8.9 Hz, NH-H-Ar), 7.29 (1H, br s, H-5), 7.39 (1H, 
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dddd, J = 6.4, 6.5, 8.5 and 8.6 Hz, H-4’); 13C NMR (125 MHz, MeOD) δ 111.8 (C-Ar), 
113.1 (C-Ar), 116.3 (C-Ar), 123.4 (C-3), 124.1 (C-2 and C-5), 127.9 (C-4), 130.2 (C-
Ar), 131.2 (C-Ar), 133.1 (C-Ar), 155.7 (C-Ar), 160.7 (d, JCF = 251.0 Hz, CF), 161.8 
(CONH), 184.8 (CO); 
19
F NMR (470 MHz, MeOD) δ -115.4; LRMS (ES+) m/z 343.0 
[M+H]
+
; HRMS m/z calcd for C18H11F2N2O3 [M-H]
-
 341.0743, found 341.0747. 
 
4-(2,6-Difluorobenzoyl)-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-pyrrole-2-
carboxamide (77) 
 
4-(2,6-Difluorobenzoyl)-N-(4-hydroxyphenyl)-1H-pyrrole-2-carboxamide (76) (50 mg, 
0.15 mmol) was dissolved in DMF (1 mL) before potassium carbonate (58 mg, 0.42 
mmol) was added. The mixture was left to stir at RT for 15 min before 1-(2-
chloroethyl)pyrrolidine.HCl (50 mg, 0.27 mmol) was added. The mixture was placed in 
the microwave at 100 
o
C for 30 min, before further 1-(2-chloroethyl)pyrrolidine.HCl 
(13 mg, 0.075 mmol) and potassium carbonate (10 mg, 0.075 mmol) were added and 
the reaction was placed back in the microwave for a further 15 min. The mixture was 
diluted with EtOAc (8 mL) and washed with water followed by brine (8 mL/mmol 
pyrrole, respectively) before the organic extract was dried over Na2SO4, and the filtrate 
concentrated in vacuo. The crude product was purified by MPLC (NH silica, 2-30% 
MeOH in EtOAc) to give the pure compound as a cream solid (23 mg, 35%); Rf = 0.57 
(NH silica, 10% MeOH in EtOAc); M.p.: 146-147 
o
C;  λmax (EtOH)/nm: 274, 231; 
νmax/cm
-1
: 3353, 3326, 2354, 2075, 1766 (CO), 1632 (CONH); 
1
H NMR (500 MHz, 
MeOD) δ 1.76-1.83 (4H, m, 2 x pyrrolidine CH2), 2.73 (4H, br s, 2 x pyrrolide N-CH2), 
3.07 (2H, t, J = 6.6 Hz, CH2), 4.51 (2H, t, J = 6.6 Hz, CH2), 6.66 (2H, d, J = 8.9 Hz, p-
subs. H-Ar), 6.99-7.04 (2H, m, H-3’ and H-5’), 7.28 (1H, br s, H-3), 7.30 (2H, d, J = 8.9 
Hz, p-subs. H-Ar),  7.45 (1H, dddd, J = 6.4, 6.5, 8.5 and 8.6 Hz, H-4’), 7.52 (1H, d, J = 
1.45 Hz, H-5); 
13
C NMR (125 MHz, MeOD) δ 24.2 (2 x pyrrolidine CH2), 55.5 (2 x 
pyrrolide N-CH2), 57.35 (CH2), 113.0 (CH2), 114.7 (C-Ar), 116.3 (C-Ar), 124.3 (C-3), 
125.9 (C-5 and C-2), 129.6 (C-4), 131.2 (C-Ar), 133.3 (C-Ar), 135.5 (C-Ar), 155.8 (C-
Ar), 159.8 (C-Ar), 159.9 (C-Ar), 161.3 (C-Ar), 161.9 (CONH), 184.1 (CO); 
19
F NMR 
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(470 MHz, MeOD) δ -115.1; LRMS (ES+) m/z 440.19 [M+H]+;  HRMS m/z calcd for 
C24H25F2N3O3 [M+H]
+
 440.1782, found 440.1783. 
 
4-(2,6-Difluorobenzoyl)-N-(4-methoxyphenyl)-1H-pyrrole-2-carboxamide (78) 
 
 
Compound 78 was synthesised according to general procedure C, using 4-(2,6-
Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol), 
carbonyldiimidazole (129 mg, 0.80 mmol), p-anisidine (123 mg, 1.0 mmol) and THF (4 
mL). The reaction mixture was diluted with EtOAc, acidified to pH 6 using a 1.0 M 
aqueous solution of HCl and the resulting mixture washed according to general 
procedure C. The crude residue was purified by MPLC (silica, 0-1% MeOH in EtOAc) 
followed by recrystallisation from EtOAc to give the title compound as a beige solid (73 
mg, 54%); Rf = 0.88 (5% MeOH in EtOAc); M.p. 241-242 
oC; λmax (EtOH)/nm 285, 
259, 233; νmax/cm
-1
 3352, 3193, 1997, 1621 (CO), 1504 (CONH); 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.75 (3 H, s, CH3), 6.93 (2 H, d, J = 9.1 Hz, NH-H-Ar), 7.28 (2 H, t, J = 
7.7 Hz, H-Ar), 7.48 (2 H, br s, H-3 and H-5), 7.59-7.67 (3 H, m, H-Ar + NH-H-Ar), 
9.96 (1H, s, CONH),  12.61 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 55.2 
(CH3), 110.7 (C-Ar), 112.1 (C-Ar), 113.8(C-Ar), 117.7 (C-Ar), 118.0 (C-Ar) 121.7 (C-
3), 125.8 (C2 and C-5), 128.7 (C-4), 131.8 (C-Ar), 132.1 (C-Ar), 157.7 (JCF = 248.5 Hz, 
CF), 159.7 (CONH), 181.8 (CO); 
19
F NMR (470 MHz, MeOD) δ -114.2; LRMS (ES+) 
m/z 357.1 [M+H]
+
; HRMS m/z calcd for C19H15F2N2O2 [M+H]
+
 357.1043, found 
357.1043. 
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Methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (79)  
 
 
Compound 79 was synthesised according to general procedure A, using methyl pyrrole-
2-carboxylate (69) (400 mg, 3.2 mmol), DCM (7 mL), 2,6-difluorobenzoyl  chloride 
(0.8 mL, 6.4 mmol) and AlCl3 (1.07 g, 8.0 mmol). The crude compound was purified by 
MPLC (silica, 2-100% EtOAc in petrol) followed by a final wash with NaHCO3 to 
remove remaining starting material. The  title compound was obtained as an orange 
solid (558 mg, 66%); Rf = 0.46 (10% EtOAc in petrol); M.p. 131-132 
oC; λmax 
(EtOH)/nm 281, 232; νmax/cm
-1
 3335, 2919, 2563, 2224, 2021, 1733 (CO2Me), 1628 
(CO); 
1
H NMR (500 MHz, DMSO-d6) δ 3.81 (3H, s, CH3), 7.04-7.06 (1H, m, H-3), 
7.24-7.28 (2H, m, H-Ar), 7.59-7.65 (2H, m, H-5 and H-Ar), 12.92 (1H, br s, NH); 
13
C 
NMR (125 MHz, DMSO-d6) δ 51.7 (CH3), 112.1 (C-Ar), 114.7 (C-Ar), 124.6 (C-3), 
125.9 (C-2 and C-5), 130.3 (C-4), 132.3 (C-Ar), 159.5 (d, JCF = 259.3 Hz, CF), 160.4 
(CO2Me), 181.6 (CO);  
19
F NMR (470 MHz, DMSO-d6) δ -114.2; LRMS (ES
+
) m/z 
266.0 [M+H]
+
; HRMS m/z calcd for C13H10F2NO3 [M+H]
+
 266.0623, found 266.0629. 
 
4-(2,6-Difluorobenzoyl)-N-phenyl-1H-pyrrole-2-carboxamide (80) 
 
 
Compound 80 was synthesised according to general procedure C, using 4-(2,6-
Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol), 
carbonyldiimidazole (129 mg, 0.80 mmol), aniline (91 µL, 1.0 mmol) and THF (4 mL). 
The reaction mixture was diluted with EtOAc, acidified to pH 3-4 using a 1.0 M 
aqueous solution of HCl and the resulting mixture washed according to general 
procedure C. The crude product was purified by MPLC (silica, 2-60% EtOAc in petrol) 
followed by recrystalllisation from EtOAc to give the title compound as a white solid 
(65 mg, 50%); Rf = 0.85 (5% MeOH in EtOAc); M.p. 272-273 
oC; λmax (EtOH)/nm 259; 
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νmax/cm
-1
 3345, 3218, 2805, 2352, 1621 (CO), 1534 (CONH); 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.1 (1 H, t, J = 7.5 Hz, NH-H-Ar), 7.23-7.25 (2H, m, NH-H-Ar), 7.33-7.37 
(2 H, m, NH-H-Ar), 7.27 (1 H, br s, H-3), 7.50 (1 H, br s, H-5), 7.63 (1H, dddd, J = 6.5, 
6.8, 8.4 and 8.5 Hz, H-4’), 7.71 (2H, d, J = 8.4 Hz, H-Ar), 10.03 (1H, s, CONH),  12.62 
(1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.1 (C-Ar), 112.3 (C-Ar), 117.8 
(C-Ar), 120.1 (C-3), 125.8 (C-2 and C-5), 128.7 (C-4), 129.1 (C-Ar), 132.2 (C-Ar), 
138.8 (C-Ar), 158.3 (d, JCF = 250.1 Hz, CF), 159.6 (CONH), 181.8 (CO); 
19
F NMR 
(470 MHz, MeOD) δ -114.2; LRMS (ES+) m/z 327.0 [M+H]+; HRMS m/z cald for 
C18H13F2N2O2 [M+H]
+
 327.0940, found 327.0942. 
 
2,2,2-Trifluoroethyl 4-nitrobenzenesulfonate (82) 
 
 
DMAP (28 mg, 0.23 mmol) and NEt3 (0.96 mL, 6.9 mmol) were dissolved in TFE (2 
mL) at RT, before 4-nitrobenzene-1-sulfonyl chloride (0.50 g, 2.3 mmol) was added. 
The reaction was left to stir for 1 h before the solvent was removed in vacuo. The 
resulting residue was dissolved in DCM (10 mL) and washed with an aqueous solution 
of HCl (0.05 M, 10 mL) followed by water (10 mL). The organic extract was dried over 
Na2SO4 and the solvent removed in vacuo to give the pure product as a pale yellow solid 
(0.57 g, 87%); Rf = 0.70 (50% EtOAc in Petrol); M.p.: 88-89 
o
C (lit.
99
 80-81 
o
C)  λmax 
(EtOH)/nm: 248; νmax/cm
-1
: 3115, 1782, 1543 (NO2); 
1
H NMR (500 MHz, CDCl3) δ 
4.43 (2H, q, J = 7.9 Hz  CH2), 8.08 (2H, d, J = 8.4 Hz, H-Ar), 8.37 (2H, d, J = 8.4 Hz, 
H-Ar), 
1
H NMR (500 MHz, MeOD) δ 65.0 (OCH2CF3), 122.7 (CF3), 129.4 (C-Ar), 
140.8 (C-Ar), 151.2 (C-Ar); 
19
F NMR (470 MHz, MeOD) δ -83.8; LRMS (ES+) m/z 
285.90 [M+H]
+
. 
 
2,2,2-Trifluoroethyl 4-aminobenzenesulfonate (83) 
 
 
2,2,2-Trifluoroethyl 4-nitrobenzenesulfonate (82) (200 mg, 0.70 mmol) was dissolved 
in a 4:1 MeOH:H2O solution (5 mL) before sodium dithionite (486 mg, 2.8 mmol) was 
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added and the mixture was placed in the microwave for 15 min at 100 
o
C.  The solvent 
was removed in vacuo and the residue dissolved in EtOAc (20 mL) and washed with 
water (2 x 20 mL). The organic extract was dried over Na2SO4 and the solvent was 
removed in vacuo to give the title compound as a white solid (146 mg, 82%); Rf = 0.53 
(50% EtOAc in Petrol); M.p.: 110-111 
oC; λmax (EtOH)/nm: 272; νmax/cm
-1
: 3484 (NH2), 
3379, 1625, 1598; 
1
H NMR (500 MHz, CDCl3) δ 4.23 (2H, q, J = 7.9 Hz CH2), 4.27 
(2H, br s, NH2), 6.64 (2H, d, J = 8.9 Hz, H-Ar), 7.59 (2H, d, J = 8.9 Hz, H-Ar); 
13
C 
NMR (125 MHz, CDCl3) δ 64.4 (OCH2CF3), 114.1 (C-Ar), 122.0 (CF3), 124.7 (C-Ar), 
130.5 (C-Ar), 152.1 (C-Ar); 
19
F NMR (470 MHz, MeOD) δ -73.80; LRMS (ES+) m/z 
256.1 [M+H]
+
.  
 
4-(2,6-Difluorobenzoyl)-N-(4-methoxybenzyl)-1H-pyrrole-2-carboxamide (86)   
 
 
Compound 86 was synthesised according to general procedure C using, 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol), 
carbonyldiimidazole (129 mg, 0.80 mmol), p-methoxybenzylamine (0.130 mL, 1.00 
mmol) and THF (4 mL) to afford the crude product, which was purified by MPLC 
(silica, 2-30% MeOH in EtOAc) to give the title compound as a pale yellow solid (121 
mg, 82%); Rf = 0.88 (5% MeOH in EtOAc); M.p.: 179-180 
oC; λmax (EtOH)/nm: 283, 
233; νmax/cm
-1
: 3372, 3154, 2280, 1610 (CO), 1577 (CONH); 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.59 (3H, s, CH3), 4.22 (2H, d, J = 6.0 Hz, CH2), 6.75 (2H, d, J = 8.7 Hz, 
p-subs. H-Ar), 7.07 – 7.12 (5H, m, H-5’, H-3’, H-3 and p-subs. H-Ar), 7.26 (1H, s, H-
5), 7.47 (1H, dddd, J = 6.7, 6.8, 8.4 and 8.5 Hz, H-4’), 8.68 (1H, t, J = 6.0 Hz, CONH), 
12.33 (1H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ 41.0 (CH2), 55.0 (OCH3), 110.0 
(C-Ar), 112.0 (C-Ar), 112.3 (C-Ar), 113.6 (C-Ar), 113.7 (C-Ar), 125.6 (C-3), 128.3, 
128.6 (C-2 and C-5), 131.4 (C-4), 132.1 (C-Ar), 157.6 (C-Ar), 158.2 (C-Ar), 159.7 
(CONH), 181.8 (CO) ; 
19
F NMR (470 MHz, MeOD) δ -115.0; LRMS (ES+) m/z 370.90 
[M+H]
+
 HRMS m/z calcd for C20H17F2N2O3 [M+H]
+
 371.1204, found 371.1202. 
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4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxamide (87) 
 
 
4-(2,6-Difluorobenzoyl)-N-(4-methoxybenzyl)-1H-pyrrole-2-carboxamide (86) (50 mg, 
0.14 mmol) was dissolved in TFA (2 mL) and left to stir for 18 h at RT, before the 
solvent was removed in vacuo. The residue was dissolved in EtOAc (20 mL) and 
washed with NaHCO3 (3 x 20 mL) before organic extract was dried over Na2SO4 and 
the solvent removed in vacuo to give the title compound as a cream solid (34 mg, 97%); 
Rf = 0.62 (5% MeOH in EtOAc); M.p.: 150-151 
oC λmax (EtOH)/nm: 284, 232; νmax/   
cm
-1
: 3364, 3222, 2282, 1606 (CO), 1600 (CONH); 
1
H NMR (500 MHz, MeOD) δ 6.99 
– 7.01 (2H, m, H-3’ and H-5’), 7.13 (1H, br s, H-3), 7.29 (1H, br s, H-5), 7.43 (1H, 
dddd, J = 6.5, 6.6, 8.6 and 8.7 Hz, H-4’); 13C NMR (125 MHz, CDCl3) δ 109.9 (C-Ar), 
110.4 (C-Ar), 113.6 (C-Ar), 120.0 (C-3), 127.9, 129.7 (C-2 and C-5), 130.2 (C-4), 131.0 
(C-Ar), 155.4 (C-Ar), 160.0 (CONH2), 185.0 (CO); 
19
F NMR (470 MHz, MeOD) δ -
112.3 LRMS (ES
+
) m/z 251.10 [M+H]
+
; HRMS m/z calcd for C12H9F2N2O2 [M+H]
+
 
251.0627, found 251.0629. 
 
tert-Butyl (4-(4-isopropoxybenzoyl)-1H-pyrrol-2-yl)carbamate (89) 
 
 
4-(4-Isopropoxybenzoyl)-1H-pyrrole-2-carboxylic acid (73) (137 mg, 0.50 mmol) was 
dissolved in 
t
BuOH (10 mL) at 25 
o
C. NEt3 (0.146 mL, 1.05 mmol) was added followed 
by the dropwise addition of diphenylphosphoryl azide (DPPA) (0.119 mL, 0.55 mmol). 
The reaction mixture was gently heated at 30 
o
C and left to stir overnight. The solvent 
was removed in vacuo to give the crude product, which was purified by MPLC (silica, 
2-15% MeOH in EtOAc) to give the title compound as a brown oil (170 mg, 99%); Rf = 
0.84 (10% MeOH in EtOAc); λmax (EtOH)/nm 300, 230; νmax/cm
-1
 3332, 3158, 2975, 
2167, 1741 (CO2
t
Bu), 1595 (CO); 
1
H NMR (500 MHz, DMSO-d6) δ 1.32 (6H, d, J = 
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6.1 Hz, CH(CH3)2), 1.53 (9H, s, C(CH3)3), 4.76 (1H, sept.,  J = 6.1 Hz,  CH(CH3)2), 
7.23 (1H, br s, H-3), 7.35 (2H, d, J = 7.4 Hz, H-Ar), 7.74 (1H, br s, H-5), 7.79 (2H, d, J 
= 7.4 Hz, H-Ar), 12.99 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 21.7 
(CH(CH3)2), 27.7 (C(CH3)3), 69.6 (CH(CH3)2), 80.6 (C(CH3)3), 115.0 (C-Ar), 115.1 (C-
Ar), 118.0 (C-Ar), 119.9 (C-3), 128.3 (C-2 and C-5), 128.7 (C-4), 131.1 (C-Ar), 131.4 
(C-Ar), 160.6 (CO2
t
Bu), 187.6 (CO); LRMS (ES
+
) m/z 345.1 [M+H]
+
.  
 
(5-Amino-1H-pyrrol-3-yl)(4-isopropoxyphenyl)methanone (90) 
 
 
(4-(4-Isopropoxybenzoyl)-1H-pyrrol-2-yl)carbamic acid (91) (50 mg, 0.17 mmol) was 
dissolved in ethanol (5 mL) and heated to reflux for 30 min. The mixture was then 
concentrated in vacuo to give the title compound as a cream solid (37 mg, 90%); Rf = 
0.43 (50% EtOAc in petrol); M.p. 98-99 
oC; λmax (EtOH)/nm 293, 228; νmax/cm
-1
 3519 
(NH2), 3293, 2979, 2367, 1721, 1599 (CO), 1553; 
1
H NMR (500 MHz, CDCl3) δ 1.31 
(6H, d, J = 6.0 Hz CH(CH3)2), 3.82 (2H, s, NH2), 4.58 (1H, sept., J = 6.0 Hz, 
CH(CH3)2), 6.87 (2H, d, J = 8.8 Hz, H-Ar), 7.27 (1H, br s, H-3), 7.48 (1H, br s, H-5), 
7.77 (2H, d, J = 8.8 Hz, H-Ar), 9.56 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ 
22.0 (CH(CH3)2), 70.1 (CH(CH3)2), 115.1 (C-Ar), 116.7 (C-Ar), 123.5 (C-3), 126.2 (C-
2 and C-5), 127.7 (C-4), 131.4 (C-Ar), 161.4 (C-Ar), 189.0 (CO); LRMS (ES
+
) m/z 
245.3 [M+H]
+
.  
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[4-(4-Isopropoxybenzoyl)-1H-pyrrol-2-yl]carbamic acid (91) 
 
 
tert-Butyl (4-(4-isopropoxybenzoyl)-1H-pyrrol-2-yl)carbamate (89) (266 mg, 0.77 
mmol) was dissolved in TFA  (6 ml) and stirred at RT for 1 h. The resulting mixture 
was concentrated in vacuo before being dissolved in DCM and washed with a saturated 
aqueous solution of NaHCO3, dried using Na2SO4 and the solvent removed in vacuo. 
The title compound was obtained as a cream solid (53 mg, 28%); Rf = 0.31 (50% 
EtOAc in petrol); M.p. 105-106 
oC; λmax (EtOH)/nm 300, 230; νmax/cm
-1
 3296, 2979, 
2551, 2160, 1721 (NHCO2H), 1600 (CO) ; 
1
H NMR (500 MHz, CDCl3) δ 1.31 (6H, d, J 
= 6.1 Hz CH(CH3)2), 4.58 (1H, sept., J = 6.1 Hz, CH(CH3)2 ), 6.87 (2H, d, J = 7.0 Hz, 
H-Ar), 7.27 (1H, dd, J = 1.7 and 3.0 Hz, H-3), 7.48 (1H, dd, J = 1.7 and 3.2 Hz, H-5), 
7.78 (2H, d, J = 7.0 Hz, H-Ar), 9.77 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 
23.0 (CH(CH3)2), 77.0 (CH(CH3)2), 115.7 (C-Ar), 116.7 (C-3), 127.7 (C-2 and C-5), 
127.7 (C-4), 131.5 (C-Ar), 155.7 (CO2H), 161.5 (C-Ar), 189.1 (CO); LRMS m/z 289.1 
[M+H]
+
. 
 
Methyl 4-(4-isopropoxybenzoyl)-1-(phenylsulfonyl)-1H-pyrrole-2-carboxylate (92) 
 
 
Methyl 4-(4-isopropoxybenzoyl)-1H-pyrrole-2-carboxylate (72) (150 mg, 0.52 mmol) 
was dissolved in DCM (6 mL) before NEt3 (152 µL, 1.1 mmol) was added followed by 
phenylsulfonyl chloride (139 µL, 1.1 mmol). The mixture was left to stir at RT for 3 h 
before being quenched with water and the product extracted with DCM (3 x 10 mL). 
The combined organic extracts were washed with a saturated aqueous solution of 
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NaHCO3 (2 x 10 mL) before being dried over Na2SO4 and the solvent removed in 
vacuo. The crude product was purified by MPLC (silica, 2-60% EtOAc in petrol) to 
give the title compound as a white solid (100 mg, 65%) ;Rf = 0.77 (10% MeOH in 
EtOAc); M.p.: 135-136 
oC; λmax (EtOH)/nm: 294, 233; νmax/cm
-1
: 2977, 2366, 1730, 
1598; 
1
H NMR (500 MHz, CDCl3) δ 1.40 (6H, d, J = 6.2 Hz, OCH(CH3)2), 3.77 (3H, s, 
OCH3), 4.68 (1H, sept. J = 6.2 Hz, OCH(CH3)2), 6.97 (2H, d, J = 8.9 Hz, H-2’ and H-
6’), 7.47 (1H, d, J = 2.0 Hz, H-3), 7.55-7.58 (2H, m, H-Ar), 7.64-7.69 (1H, m, H-Ar), 
7.87 (2H, d, J = 8.9 Hz, H-3’ and H-5’), 8.02-8.04 (2H, m, sulfonyl H-Ar), 8.21 (1H, d, 
J = 2.0 Hz, H-5); 
13
C NMR (125 MHz, CDCl3) δ 22.0 (OCH(CH3)2), 52.1 (OCH3), 70.3 
(OCH(CH3)2), 115.3 (C-3 and C-4), 123.2 (C-2 and C-5), 128.6 (C-Ar), 129.0 (C-Ar), 
131.6 (C-Ar), 132.4 (C-Ar), 134.4 (C-Ar), 169.6 (CO2Me), 189.6 (CO); LRMS (ES
+
) 
m/z 428.20 [M+H]
+
; HRMS m/z calcd for C22H22NO6S [M+H]
+
 428.1162, found 
428.1162. 
 
Methyl 4-(2,6-difluorobenzoyl)-1-(phenylsulfonyl)-1H-pyrrole-2-carboxylate (93) 
 
 
Methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (79) (100 mg, 0.38 mmol) 
was dissolved in DCM (6 mL) before triethylamine (59 µL, 0.42 mmol) was added 
followed by phenylsulfonyl chloride (53 µL, 0.42 mmol). The mixture was left to stir 
for 3 h before being quenched with water and the product extracted with DCM (3 x 10 
mL). The combined organic extracts were washed with a saturated aqueous solution of 
NaHCO3 (2 x 10 mL) before being dried over Na2SO4 and the solvent removed in 
vacuo. The crude product was purified by MPLC (silica, 2-60% EtOAc in petrol) to 
give the title compound as a white solid (133 mg, 60%); Rf = 0.75 (10% MeOH in 
EtOAc); M.p.: 122-123 
oC; λmax (EtOH)/nm: 233; νmax/cm
-1
: 3144, 3086, 2953, 1746 
(CO2Me), 1663 (CO); 
1H NMR (500 MHz, MeOD) δ 3.88 (3H, s, OCH3), 7.11-7.14 
(2H, m, H-Ar), 7.18 (1H, d, J = 2.1 Hz, H-3), 7.56 (1H, dddd, , J = 6.3, 6.4, 8.5 and 8.6 
Hz, H-4’), 7.63-7.67 (2H, m, H-3’ and H-5’), 7.76-7.79 (1H, m, sulfonyl H-Ar), 8.07-
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8.09 (2H, m, sulfonyl H-Ar), 8.21 (1H, d, J = 2.1 Hz, H-5); 
13
C NMR (125 MHz, 
DMSO-d6) δ 52.4(OCH3), 112.7 (C-3 and C-4), 120.17 (C-2), 125.2 (C-5), 126.2 (C-
Ar), 128.5 (C-Ar), 129.5 (C-Ar), 133.4 (C-Ar), 134.3 (C-Ar), 135.3 (C-Ar), 136.6 (C-
Ar), 159.9 (CO2Me), 181.5 (CO) LRMS (ES
+
) m/z 406.20 [M+H]
+
; HRMS m/z calcd 
for C19H14F2NO3S [M+H]
+
 406.0555, found 406.0555. 
 
1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrrole (101)  
 
 
Sodium hydride (60% in mineral oil; 155 mg, 6.5 mmol) was suspended in DMF (5 mL) 
before pyrrole (0.4 mL, 6.0 mmol) was added at 0
o
C. The mixture was stirred for 10 
min before (2-(chloromethoxy)ethyl)trimethylsilane (1.0 mL, 6.0 mmol) was added 
dropwise. The mixture was allowed to warm to RT and stirred for 1 h. The mixture was 
then poured onto a 10% aqueous solution of NaHCO3 (20 mL) and the product was 
extracted using Et2O (3 x 10 mL). The combined organic extracts were washed with 
water followed by brine before being dried over Na2SO4 and the solvent removed in 
vacuo. The crude product was purified by MPLC (silica, 50% EtOAc in petrol) to give 
the title compound as an orange oil (0.71g, 60%); Rf = 0.63 (10% MeOH in EtOAc);  
λmax (EtOH)/nm: 213; νmax/cm
-1
: 2953, 2896, 1554; 
1
H NMR (500 MHz, DMSO-d6) δ 
0.02 (9H, s, Si(CH3)3), 0.85 (2H, t, J = 8.0 Hz, CH2), 3.46 (2H, t, J = 8.0 Hz, CH2), 5.24 
(2H, s, CH2) 6.09-6.10 (2H, m, H-2 and H-5), 6.89-6.90 (2H, m, H-3 and H-4); 
13
C 
NMR (125 MHz, DMSO-d6) δ 17.1 (Si(CH3)3), 54.9 (CH2), 64.6 (CH2), 77.4 (CH2), 
108.6 (C-3 and C-4), 121.2 (C-2 and C-5); LRMS (ES
+
) m/z 198.20 [M+H]
+
. 
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2-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole (102) 
 
 
1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrrole (101) (50 mg, 0.25 mmol) was 
dissolved in THF (2 mL) at 0 
o
C before N-bromosuccinimide (46 mg, 0.26 mmol) was 
added slowly. The mixture was allowed to stir for 15 min before being poured onto a 
saturated aqueous solution of NaHCO3. The product was extracted into Et2O (2 x 10 
mL) and the combined organic extracts were washed with brine before being dried over 
Na2SO4 and the solvent removed in vacuo. The crude product was dissolved in DCM 
(10 mL) and passed through a plug of silica to give the title compound as a pale yellow 
oil (54 mg, 99%); Rf = 0.68 (10% MeOH in EtOAc);  λmax (EtOH)/nm: 216; νmax/cm
-1
: 
2952, 2362, 1974, 1671; 
1
H NMR (500 MHz, CDCl3) δ 0.02 (9H, s, Si(CH3)3), 0.90-
0.93 (2H, m, CH2), 3.51-3.54 (2H, m, CH2), 5.25 (2H, s, CH2), 6.19 (1H, d, J = 1.2 Hz, 
H-3), 6.20 (1H, s, H-4), 6.85-6.87 (1H, m, H-5); 
13
C NMR (125 MHz, CDCl3) δ 17.8 
(Si(CH3)3), 30.3 (CH2), 60.4 (CH2), 65.8 (CH2), 109.1 (C-3), 111.7 (C-4), 122.7 (C-5); 
LRMS (ES
+
) m/z 276.2 [M+H]
+
. 
 
2-(1-(Phenylsulfonyl)-1H-pyrrol-2-yl)isoindoline-1,3-dione (111) 
 
 
N-(Phenylsulfonyl) pyrrole (50 mg, 0.24 mmol) was dissolved in DCM (4 mL) before 
N-chlorophthalimide (44 mg, 0.24 mmol) and NaHCO3 (39 mg, 0.46 mmol) were 
added. The mixture was stirred in the dark at RT overnight. Further DCM was added to 
the mixture before it was washed with water followed by a saturated aqueous solution 
of brine (10 mL respectively). The organic extract was dried over Na2SO4 and the 
solvent was removed in vacuo to give the crude product, which was purified by MPLC 
(silica, 2-60% EtOAc in petrol) to give the title compound as a beige solid (6 mg, 7%); 
Rf = 0.14 (10% EtOAc in petrol); M.p.: 210-211 
o
C (lit.
149
 212-213 
o
C) λmax (EtOH)/nm: 
263; νmax/cm
-1
: 3107, 2917, 1788 (CON), 1729 (CON) ,; 
1
H NMR (500 MHz, CDCl3) δ 
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6.31 (1H, dd, J = 1.6 and 3.5 Hz, H-3), 6.35 (1H, dd, J = 3.5 and 3.8 Hz, H-4), 7.29 (1H, 
dd, J = 1.8 and 3.5 Hz, H-5), 7.38-7.42 (2H, m, sulfonyl H-Ar), 7.53-7.56 (1H, m, 
sulfonyl H-Ar), 7.65 (2H, dd, J = 1.1 and 8.5 Hz, phthalimide H-Ar), 7.74-7.78 (2H, m, 
sulfonyl H-Ar), 7.86-7.89 (2H, m, phthalimide H-Ar); 
13
C NMR (125 MHz, CDCl3) δ 
111.7 (C-3), 115.5 (C-4), 119.9 (C-5), 123.2 (C-Ar), 124.1 (C-Ar), 127.3 (C-Ar), 129.3 
(C-Ar), 131.8 (C-Ar), 134.3 (C-2), 134.7 (C-Ar), 138.6 (C-Ar), 167.0 (NCO); LRMS 
(ES
+
) m/z  353.20 [M+H]
+
. 
 
2-(1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrrol-2-yl)isoindoline-1,3-dione (114) 
 
 
1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrrole (101) (50 mg, 0.25 mmol) was 
dissolved in DCM (4 mL) before N-chlorophthalimide (44 mg, 0.24 mmol) and 
NaHCO3 (39 mg, 0.46 mmol) were added. The mixture was stirred in the dark at RT 
overnight. The mixture was diluted with DCM (30 mL) before it was washed with water 
followed by a saturated aqueous solution of brine (10 mL respectively). The organic 
extracts were dried over Na2SO4 and the solvent removed in vacuo to give the crude 
product, which was purified by MPLC (silica, 2-60% EtOAc in petrol) giving the title 
compound as a brown solid (42 mg, 49%); Rf = 0.78 (10% MeOH in EtOAc); M.p.: 
205-206 
o
C; λmax (EtOH)/nm: 262; νmax/cm
-1
: 3609, 3277, 2950, 1787 (CON), 1728 
(CON); 
1
H NMR (500 MHz, CDCl3) δ 0.00 (9H, s, Si(CH3)3), 0.84-0.87 (2H, m, CH2), 
3.41-3.45 (2H, m CH2), 5.25 (2H, s, CH2), 6.33-6.38 (2H, m, H-3 and H-4), 6.93 (1H, 
dd, J = 1.9 and 3.2 Hz, H-5), 7.86-7.90 (2H, m, H-Ar), 8.01-8.05 (2H, m, H-Ar);
 13
C 
NMR (125 MHz, CDCl3) δ 17.7 (Si(CH3)3), 65.7 (CH2), 72.5 (CH2), 76.0 (CH2), 108.2 
(C-3), 109.5 (C-4), 122.5 (C-5), 124.0 (C-2), 131.9 (C-Ar), 134.5 (C-Ar), 167.6 
(phthalimide CO);
 
LRMS (ES
+
) m/z 343.30 [M+H]
+
; HRMS m/z calcd for 
C18H23N2O3Si [M+H]
+
 343.1477, found 343.1477.  
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Potassium (E)-2,3-dicyanoprop-1-en-1-olate (121) 
 
 
Succininitrile (2.0 g, 24.8 mmol), was dissolved in toluene (15 mL) before 
t
BuOH (1.5 
mL) and ethyl formate (2.0 mL, 24.8 mmol) were added at 0 
o
C. Slow addition of 
t
BuOK (2.8 g, 24.8 mmol) caused formation of a beige precipitate. The mixture was 
allowed to warm to RT and left to stir for 4 h before the precipitate was filtered and 
washed with a 1:1 mixture of EtOH:Et2O. After drying under vacuum, the pure product 
was obtained as a beige solid (3.0 g, 20.5 mmol, 84%); Rf = 0.20 (10% MeOH in 
EtOAc); M.p.: 199-200 
o
C (lit.
150
 205-210 
o
C); λmax (EtOH)/nm 249.0; νmax/cm
-1
 2824 
(CN), 1565 (CO), 1367, 1265; 
1
H NMR (500 MHz, DMSO-d6) δ 3.06 (2H, s, CH2), 
8.29 (1H, s, CH);  
13
C NMR (125 MHz, DMSO-d6) δ 12.5 (CH2), 61.0 (CCN), 120.5 
(CH2CN), 128.6 (CCN), 173.7 (CHO); LRMS (ES
+
) m/z 108.2 [M+H]
+
.  
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5-Amino-1-(4-methoxybenzyl)-1H-pyrrole-3-carbonitrile (122) 
 
 
Potassium (E)-2,3-dicyanoprop-1-en-1-olate (121) (2.0 g, 13.6 mmol), was dissolved in 
EtOH (15 mL). Acetic acid (4 mL) was added followed by p-methoxybenzylamine (1.9 
mL, 14.4 mmol) and the solution was stirred at reflux for 45 min. After cooling to RT, 
KOH (4.7 g, 84.0 mmol) was added in ethanol (15 mL) and the mixture was heated to 
reflux for a further 2.5 h. Upon cooling, the solvent was removed in vacuo and the 
residue was dissolved in EtOAc, before being washed with water. The organic extracts 
were separated, dried over Na2SO4 and the solvent removed in vacuo to give the crude 
product which was purified by MPLC (silica; 0-60% EtOAc in petrol ) to give the pure 
product as a brown solid (2.2 g, 9.68 mmol, 70%); Rf = 0.33 (50% EtOAc in petrol); 
M.p. 155-156 
o
C; λmax (EtOH)/nm 270.5, 226.0; νmax/cm
-1
 3315 (NH2), 2191 (CN), 
1640, 1609, 1510; 
1
H NMR (500 MHz, CDCl3) δ 2.98 (2H, br s, NH2), 3.73 (3H, s, 
OCH3), 4.86 (2H, s, CH2), 5.66 (1H, d, J = 1.8 Hz, H-3), 6.79 (1H, d, J = 1.8 Hz, H-5), 
6.80 (2H, d, J = 8.6 Hz, H-Ar), 6.97 (2H, d, J = 8.6 Hz, H-Ar);  
13
C NMR (125 MHz, 
DMSO-d6) δ 47.5 (CH2), 55.1 (CH3), 90.3 (C-4), 113.9 (C-3), 117.9 (CN), 122.4 (C-2), 
128.8 (C-5), 139.5, 153.2, 153.6 (C-Ar); LRMS (ES
+
) m/z 226.2 [M-H]
-
; HRMS m/z 
calcd for C13H13N3O [M-H]
-
 226.0988, found 226.0988.  
 
1-(4-Methoxybenzyl)-5-(phenylamino)-1H-pyrrole-3-carbonitrile (123) 
 
 
5-Amino-1-(4-methoxybenzyl)-1H-pyrrole-3-carbonitrile (122) (320 mg, 1.41 mmol) 
was dissolved in dioxane (12 mL) before bromobenzene (96 µL, 0.96 mmol) and 
caesium carbonate (627 mg, 1.92 mmol) were added. The mixture was degassed for 15 
min before Pd2(dba)3 (9 mg, 0.01 mmol) and Xantphos (11 mg, 0.02 mmol) were added 
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and the mixture was degassed again for a further 20 min. The reaction was heated to 
100 
o
C for 18 h before being cooled, filtered through Celite, diluted with EtOAc and 
washed with water followed by brine. The organic extract was dried over Na2SO4 and 
the solvent removed in vacuo to give the crude product which was purified by MPLC 
(0-40% EtOAc in petrol ) to afford the pure compound as a white solid (321 mg, 1.06 
mmol, 75%); Rf = 0.52 (50% EtOAc in petrol); M.p. 83-84 
o
C; λmax (EtOH)/nm 229.5; 
νmax/cm
-1
: 3358 (NH), 2200 (CN), 1603, 1590, 1513; 
1
H NMR (500 MHz, CDCl3) δ 
3.73 (3H, s, OCH3), 4.79 (2H, s, CH2), 4.90 (2H, br s, NH2), 6.20 (1H, dd, J = 0.9 and 
1.9 Hz, H-3), 6.51 (2H, d, J = 8.8 Hz, benzyl H-Ar), 6.77-6.80 (3H, m, H-Ar), 6.94 (2H, 
d, J = 8.8 Hz, benzyl H-Ar), 6.99 (1H, d, J = 1.9 Hz, H-5), 7.11-7.14 (2H, m, H-Ar);  
13
C NMR (125 MHz, DMSO-d6) δ 48.1 (CH2), 55.0 (CH3), 89.5 (C-4), 104.4 (C-3), 
113.3 (CN), 113.9, 117.0, 118.3, 126.2, 128.9 (C-Ar), 129.1 (C-5), 132.1 (C-2), 146.6, 
158.7 (C-Ar); LRMS (ES
+
) m/z 304.3 [M+H]
+
; HRMS m/z calcd for C19H17N3O [M-H]
-
 
302.1299, found 302.1299. 
 
4-(Imino(phenyl)methyl)-1-(4-methoxybenzyl)-N-phenyl-1H-pyrrol-2-amine (124)  
 
Mg turnings (24 mg, 0.98 mmol) were covered in THF (3 mL) before bromobenzene 
(68 µL, 0.65 mmol) was added followed by an iodine crystal to encourage turbidity and 
initiate reflux. After 30 min, 1-(4-Methoxybenzyl)-5-(phenylamino)-1H-pyrrole-3-
carbonitrile (123) was added (100 mg, 0.33 mmol) in THF (1.0 mL). The mixture was 
then heated to reflux for 18 h. Upon cooling to RT HCl (1.0 M aqueous solution) was 
added until effervescence ceased. The product was extracted using EtOAc, dried over 
Na2SO4 and the solvent removed in vacuo to afford the pure product as a green solid 
(112 mg, 0.29 mmol 90%);  Rf = 0.45 (5% MeOH in EtOAc); M.p. 131-132 
o
C; λmax 
(EtOH)/nm 227; νmax/cm
-1
: 2997 (NH), 1596 (CNH), 1512; 
1
H NMR (500 MHz, CDCl3) 
δ 3.73 (3H, s, CH3), 4.79 (2H, s, CH2), 4.93 (1H, br s, NH), 6.20 (1H, d, J = 1.9 Hz, H-
3), 6.51 (2H, d, J = 8.8 Hz, p-subs H-Ar), 6.77-6.79 (3H, m, H-Ar), 6.94 (2H, d, J = 8.8 
Hz, p-subs H-Ar), 6.99 (1H, d, J = 1.9 Hz, H-5), 7.11-7.13 (2H, m, H-Ar), 7.26-7.29 
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(3H, m, H-Ar), 7.35-7.38 (1H, m, H-Ar), 7.51-7.53 (1H, m H-Ar); 
13
C NMR (125 MHz, 
CDCl3) δ 27.4 (CH2), 55.3 (CH3), 104.1 (C-3), 107.5 (C-4), 113.9, 114.4, 119.9 (C-Ar), 
125.7 (C-5), 128.8 (C-2), 129.5, 143.2 (C-Ar), 158.8 (CNH); LRMS (ES
+
) m/z 382.3 
[M+H]
+
; HRMS m/z calcd for C25H24N3O [M+H]
+
 382.1914, found 382.1912. 
 
(1-(4-Methoxybenzyl)-5-(phenylamino)-1H-pyrrol-3-yl)(phenyl)methanone (125) 
 
 
4-(Imino(phenyl)methyl)-1-(4-methoxybenzyl)-N-phenyl-1H-pyrrol-2-amine (124) (160 
mg, 0.42 mmol) was dissolved in H2SO4 (1.0 M aqueous solution, 5 mL, 5.0 mmol) and 
heated to reflux for 2 h. After cooling, the mixture was neautralised using a 2.0 M 
aqueous solution of NaOH and the product was extracted using EtOAc. The organic 
extracts were combined, dried over Na2SO4 and the solvent removed in vacuo. The 
crude product was purified using MPLC  (silica; 0-80% EtOAc in petrol ) to give the 
pure product as a beige solid (136 mg, 0.35 mmol, 85%); Rf = 0.66 (5% MeOH in 
EtOAc); M.p. 135-136 
o
C; λmax (EtOH)/nm: 342; νmax/cm
-1
 3409 (NH), 1669 (CO), 
1512; 
1
H NMR (500 MHz, CDCl3) δ 3.72 (3H, s, CH3), 4.83 (2H, s, CH2), 4.94 (1H, br 
s, NH), 6.48 (1H, br s, H-3), 6.56 (2H, d, J = 8.7 Hz, 2 x p-subs H-Ar), 6.76-6.79 (2H, 
m, H-Ar), 6.96 (2H, d, J = 8.7 Hz, 2 x p-subs H-Ar), 7.10-7.14 (2H, m, H-Ar), 7.16 (1H, 
d, J = 2.0 Hz, H-5), 7.36-7.39 (3H, m, H-Ar), 7.43-7.46 (1H, m, H-Ar), 7.45-7.47 (2H, 
m, H-Ar);  LRMS (ES
+
) m/z 383.3 [M+H]
+
; HRMS m/z calcd for C25H23N2O2 [M+H]
+
 
383.1010, found 383.1012. 
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4-(2,6-Difluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (127) 
 
 
Compound 127 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol), 
carbonyldiimidazole (129 mg, 0.80 mmol), 4-aminopyridine (94 mg, 1.00 mmol) and 
THF (4 mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a white solid (50 mg, 38%); Rf = 0.52 
(5% MeOH in EtOAc); M.p.: 290 
oC (dec.); λmax (EtOH)/nm: 292, 271; νmax/cm
-1
: 3655, 
3368, 2585, 2235, 2019, 1588 (CO), 1506 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 
7.26-7.30 (2H, m, H-3’ and H-5’); 7.57 (1H, s, H-3), 7.58 (1H, s, H-5),  7.64 (1H, dddd, 
J = 6.7, 6.8, 8.4 and  8.5 Hz, H-4’), 7.75 (2H, d, J = 6.4 Hz, CH-pyridine), 8.47 (2H, d, 
J = 6.4 Hz, CH-N-pyridine), 10.36 (1H, s, CONH), 12.78 (1H, br s, NH); 
13
C NMR 
(125 MHz, MeOD) δ 112.1 (C-Ar), 112.2 (C-Ar), 112.4 (C-Ar), 113.7 (C-Ar), 122.0 
(C-3), 125.9 (C-2 and C-5), 129.9 (C-4), 145.6 (C-Ar), 150.3 (C-Ar), 157.7 (C-Ar), 
159.6 (C-Ar) 159.7 (CONH), 181.8 (CO); 
19
F NMR (470 MHz, MeOD) δ -114.1; 
LRMS (ES
+
) m/z 328.10 [M+H]
+
; HRMS m/z calcd for C17H12F2N3O2 [M+H]
+
 
328.0890, found 328.0890. 
 
4-(2,6-Difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (128) 
 
 
Compound 128 was synthesised according to general procedure C, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 3-aminopyridine (47 mg, 0.50 mmol) and 
THF (2 mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a white solid (23 mg, 35%); Rf = 0.78 
(5% MeOH in EtOAc); M.p.: 160-161 
o
C;  λmax (EtOH)/nm: 290, 240; νmax/cm
-1
: 3243, 
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3021, 2437, 1622 (CO), 1538 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.04-7.07 
(2H, m, H-3’ and H-5’), 7.15 – 7.17 (1H, m, H-3), 7.30-7.32 (2H, m, CH-pyridine), 7.41 
(1H, dddd, J = 6.8, 6.9, 8.5 and 8.6 Hz, H-4’), 7.90-7.93 (1H, m, H-5), 8.08 (1H, dd, J = 
1.5 and 4.7 Hz, CH-pyridine), 8.67 (1H, d, J = 2.5 Hz CH-N-pyridine), 10.02 (1H, t, 
CONH), 12.50 (1H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ 112.9 (C-Ar), 113.1, (C-
Ar), 122.6 (C-3), 125.2 (C-2 and C-5), 128.0 (C-4), 129.5 (C-Ar), 130.6 (C-Ar), 133.2 
(C-Ar), 136.4 (C-Ar), 137.5 (C-Ar), 142.4 (C-Ar), 145.1 (C-Ar), 160.9 (CONH), 184.7 
(CO);
 19
F NMR (470 MHz, MeOD) δ -115.4; LRMS (ES+) m/z 328.30 [M+H]+; HRMS 
m/z calcd for C17H12F2N3O2 [M+H]
+
 328.0894, found 328.0895. 
 
4-(2,6-Difluorobenzoyl)-N-(4-fluorophenyl)-1H-pyrrole-2-carboxamide (129)  
 
Compound 129 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 4-fluoroaniline (48 µL, 0.50 mmol) and THF 
(2mL) to afford the crude product, which was purified by MPLC (silica, 2-30% MeOH 
in EtOAc, then NH silica, 0-10% MeOH in EtOAc) to give the title compound as a pale 
yellow solid (46 mg, 67%); Rf = 0.85 (10% MeOH in EtOAc); M.p.: 278-279 
oC; λmax 
(EtOH)/nm: 258, 200; νmax/cm
-1
: 3369, 3240, 3123, 2362, 2182, 1635 (CO), 1507 
(CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.18-7.21 (2H, m, benzoyl H-3’and H-5’); 
7.26-7.29 (2H, m, p-subs. H-Ar), 7.50 (2H, br s, H-3 and H-5), 7.63 (1H, dddd, J = 6.6, 
6.7, 8.4 and 8.5, H-4’), 7.62-7.73 (2H, m, p-subs. H-Ar), 10.11 (1H, s, CONH), 12.66 
(1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.1 (C-Ar), 112.4 (C-Ar), 115.3 
(C-pyridine), 117.8 (C-Ar), 121.8 (C-3), 125.8 (C-2 and C-5), 128.4 (C-pyridine), 129.2 
(C-4), 132.2 (C-Ar), 135.1 (C-pyridine), 158.3 (d, JCF = 254.3 Hz, CF), 159.2 (CONH), 
181.9 (CO); 
19
F NMR (470 MHz, MeOD) δ -114.2, -121.5; LRMS (ES+) m/z 345.20 
[M+H]
+
; HRMS m/z calcd for C18H12F3N2O2 [M+H]
+
 328.0890, found 328.0890.  
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N-(3-Aminophenyl)-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamide (130) 
 
 
Compound 130 was synthesised according to general procedure C using, 4-(2,6-
Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 1,3-phenylenediamine (54 mg 0.50 mmol) 
and THF (2mL) to afford the crude product, which was purified using MPLC (silica, 2-
30% MeOH in EtOAc then NH silica, 0-20% MeOH in EtOAc) to give the title 
compound as a beige solid (45 mg, 66%); Rf = 0.60 (10% MeOH in EtOAc); M.p.: 210 
o
C (dec.); λmax (EtOH)/nm: 239; νmax/cm
-1
: 3353 (NH2), 3204, 3123, 2963, 1620 (CO), 
1539 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 6.41 (1H, d, J = 8.3 Hz, H-Ar), 6.71 
(1H, d, J = 8.3 Hz, H-Ar), 6.93-6.96 (2H, m, H-Ar and H-4’), 7.05 (1H, t, J = 8.3 Hz, H-
Ar),  7.10-7.12 (2H, m, H-3 and H-5), 7.34 – 7.40 (2H, m, H-3’ and H-5’), 7.53 (1H, br 
s, CONH), 9.74 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 112.1 (C-Ar), 112.5 
(C-Ar), 116.3 (C-pyridine), 118.3 (C-Ar), 121.8 (C-3), 126.1 (C-2 and C-5), 129.4 (C-
pyridine), 131.0 (C-4), 133.6 (C-Ar), 138.4 (C-pyridine), 156.2 (d, JCF = 255.5 Hz, CF), 
162.3 (CONH), 181.7 (CO); 
19F NMR (470 MHz, MeOD) δ -112.2; LRMS (ES+) m/z 
342.30 [M+H]
+
; HRMS m/z calcd for C18H14F2N3O2 [M+H]
+
 342.1050, found 
342.1051. 
 
N-(4-Aminophenyl)-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamide (131) 
 
 
Compound 131 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 1,4-phenylenediamine (43 mg,  0.40 mmol) 
and THF (2mL) to afford the crude product, which was purified using MPLC (silica, 2-
30% MeOH in EtOAc then NH silica, 0-100% EtOAc in petrol) and semi-preparitive 
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HPLC (C-18 silica; 5-100% acetonitrile in water (0.1% formic acid)) to give the title 
compound as a white solid (27 mg, 40%); Rf = 0.66; M.p.: 208 
oC (dec.); λmax 
(EtOH)/nm: 233; νmax/cm
-1
: 3250 (NH2), 3120, 2237, 1789 (CO), 1624 (CONH); 
1
H 
NMR (500 MHz, CDCl3) δ 6.55 (2H, d, J = 8.7 Hz, p-subs. H-Ar), 7.25-7.28 (2H, m, H-
3’ and H-5’), 7.31 (2H, d, J = 8.7 Hz, p-subs. H-Ar), 7.42 (1H, br s, H-3), 7.62 (1H, 
dddd, J = 6.7, 6.8, 8.7 and 8.8 Hz, H-4’), 8.18 (1H, br s, H-5), 9.70 (1H, br s, CONH), 
12.50 (1H, br s, NH);
 13
C NMR (125 MHz, DMSO-d6) δ 111.4 (C-Ar), 113.8 (C-Ar), 
115.9 (C-pyridine), 122.7 (C-3), 125.9 (C-2 and C-5), 130.0 (C-pyridine), 131.4 (C-4), 
133.5 (C-Ar), 135.6 (C-pyridine), 159.3 (d, JCF = 246.3 Hz, CF), 159.9 (CONH), 182.0 
(CO); 
19
F NMR (470 MHz, CDCl3) δ -114.2; LRMS (ES
+
) m/z 342.20  [M+H]
+
; HRMS 
m/z calcd for C18H14F2N3O2 [M+H]
+
 342.1051, found 342.1051. 
 
tert-Butyl 4-(4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate (132) 
 
Compound 132 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 4-amino-1-Boc-piperidine (100 mg, 0.50 
mmol) and THF (2mL) to afford the crude product, which was purified using MPLC 
(silica, 2-30% MeOH in EtOAc) to give the title compound as a beige solid (50 mg, 
57%); Rf = 0.71 (10% MeOH in EtOAc); M.p.: 159-160 
oC; λmax (EtOH)/nm: 286, 238; 
νmax/cm
-1
: 3509, 3175, 3005, 2944, 1763 (CO2
t
Bu), , 1622 (CO), 1564 (CONH);
 1
H 
NMR (500 MHz, MeOD) δ 1.48 (9H, s, 3 x CH3), 1.85-1.92 (4H, m, 2 x CH2), 3.64-
3.69 (1H, m, CH), 3.96-4.03 (4H, m, 2 x CH2N), 7.10-7.14 (2H, m, H-3’ and H-5’); 
7.24 (1H, d,  J = 1.50 Hz, H-3), 7.43 (1H, d,  J = 1.50 Hz, H-5),  7.56 (1H, dddd, J = 
6.4, 6.5, 8.6 and 8.7   Hz, H-4’); 13C NMR (125 MHz, MeOD) δ 30.8 (3 x CH3), 33.1 (2 
x CH2), 34.9 (2 x CH2), 48.7 (NHCH), 50.7 (CH(CH3)3), 81.3 (C-Ar), 81.4 (C-Ar), 
112.8 (C-Ar), 114.8 (C-3), 115.0 (C-2 and C-5), (128.3 (C-4), 156.6 (C-Ar), 159.3 
(CONH), 161.8 (CO2
t
Bu), 184.5 (CO); 
19
F NMR (470 MHz, MeOD) δ -115.4; LRMS 
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(ES
+
) m/z 432.40 [M+H]
+
; HRMS m/z calcd for C22H26F2N3O4 [M+H]
+
 434.1887, found 
434.1888. 
 
N-Cyclohexyl-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamide (133) 
 
 
Compound 133 was synthesised according to general procedure C, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), cyclohexylamine (57 µL, 0.50 mmol) and 
THF (2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc  then NH silica, 0-100% EtOAc in petrol) to give the title compound 
as a white solid (50 mg, 75%); Rf = 0.88 (10% MeOH in EtOAc); M.p.: 269-270 
o
C; 
λmax (EtOH)/nm: 287, 236; νmax/cm
-1
: 3123, 3062, 2929, 2851, 1974, 1620 (CO), 1568 
(CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.32-1.37 (2H, m, CH2), 1.66-1.70 (2H, m, 
CH2), 1.90-1.93 (2H, m, CH2), 3.42-3.43 (2H, m, CH2), 3.81-3.88 (1H, m, CH), 5.75 
(1H, d,  1.65-1.69, J = 9.5 Hz), 6.91-6.94 (3H, m, H-3’, H-5’ and H-3), 7.26 (1H, d, J = 
1.5 Hz, H-5), 7.34 (1H, dddd, J = 6.4, 6.5, 8.5 and 8.6 Hz, H-4’); 13C NMR (125 MHz, 
CDCl3) δ 14.2 (CH2), 24.8 (CH2), 33.2 (CH2), 48.5 (CH), 108.2 (C-Ar), 111.8 (C-Ar), 
112.0 (C-Ar), 124.5 (C-3), 127.5 (C-2 and C-5), 131.5 (C-4), 171.2 (CONH), 181.9 
(CO);
 19
F NMR (470 MHz, CDCl3) δ -112.3; LRMS (ES
+
) m/z 333.30 [M+H]
+
; HRMS 
m/z calcd for C18H19F2N2O2 [M+H]
+
 333.1412, found 333.1413. 
 
N-Cycloheptyl-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamide (134) 
 
 
Compound 134 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), cycloheptylamine (64 µL,  0.50 mmol) and 
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THF (2 mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc then NH silica, 0-100% EtOAc in petrol) to give the title compound as 
a white solid (51 mg, 73%); Rf = 0.87 (10% MeOH in EtOAc); M.p.: 199-200 
oC; λmax 
(EtOH)/nm: 287, 236; νmax/cm
-1
: 3356, 3167, 2921, 2854, 1617 (CO), 1566 (CONH); 
1
H 
NMR (500 MHz, CDCl3) δ 1.45-1.57 (8H, m, 4 x CH2), 1.84-1.94 (2H, m, CH2), 3.40-
3.58 (2H, m CH2), 4.02-4.07 (1H, m, CH), 5.88 (1H, d, 1.32-1.37 (2H, m, CH2), 1.66-
1.70 (2H, m, CH2), 1.90-1.93 (2H, m, CH2), 3.42-3.43 (2H, m, CH2), 3.81-3.88 (1H, m, 
CH), 5.75 (1H, d, J = 9.5 Hz, CONH), 6.90-6.94 (3H, m, H-3’, H-5’ and H-3), 7.25 
(1H, br s, H-5), 7.34 (1H, dddd, J = 6.5, 6.6, 8.5 and 8.6 Hz, H-4’), 9.95 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ 24.0 (CH2), 28.1 (CH2), 35.8 (CH2), 51.4 (CH), 108.5 
(C-Ar), 111.9 (C-Ar), 112.0 (C-Ar), 127.1 (C-Ar), 127.9 (C-3), 128.5 (C-2 and C-5), 
131.4 (C-4), 178.8 (CONH), 182.5 (CO);
 19
F NMR (470 MHz, DMSO-d6) δ -112.4; 
LRMS (ES
+
) m/z 347.30 [M+H]
+
; HRMS m/z calcd for C19H21F2N2O2 [M+H]
+
 
347.1569, found 357.1571. 
 
4-(2,6-Difluorobenzoyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrrole-2-carboxamide 
(135) 
 
Compound 135 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 4-aminotetrahydro-2H-pyran (52 µL 0.50 
mmol) and THF (2mL) to afford the crude product, which was purified using MPLC 
(silica, 2-30% MeOH in EtOAc)  to give the title compound as a white solid (48 mg, 
72%); Rf = 0.66 (10% MeOH in EtOAc); M.p.: 241-242 
oC; λmax (EtOH)/nm: 288, 236; 
νmax/cm
-1
: 3355, 3131, 2954, 2851, 1621 (COAr), 1537 (CONH); 
1
H NMR 470 MHz, 
DMSO-d6) δ 1.47-1.55 (2H, m, CH2-THP), 1.71-1.74  (2H, m, CH2-THP), 3.34-3.39 
(2H, m, CH2-O-THP), 3.85-3.87 (2H, m, CH2-O-THP), 3.90-3.98 (1H, m, CH), 7.24-
7.27 (3H, m, H-3’, H-5’ and H-3), 7.28 (1H, br s, H-5), 7.61 (1H, dddd, J = 6.8, 6.9, 8.5 
and 8.6 Hz, H-4’), 8.20 (1H, d, J = 7.9 Hz, CONH), 12.47 (1H, br s, NH); 13C NMR 
(125 MHz, DMSO-d6) δ 35.6 (2 x CH2), 36.0 (2 x CH2), 49.0 (NHCH), 82.0 (C-Ar), 
83.4 (C-Ar), 113.2 (C-Ar), 120.8 (C-3), 123.6 (C-2 and C-5), 128.4 (C-4), 155.2 (d, JCF 
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= 250.1 Hz, CF), 161.3 (CONH), 185.6 (CO);
 19
F NMR (470 MHz, DMSO-d6) δ -114.3; 
LRMS (ES
+
) m/z 335.20 [M+H]
+
; HRMS m/z calcd for C17H17F2N2O3 [M+H]
+
 
335.1203, found 335.1203. 
 
4-(2,6-Difluorobenzoyl)-N-(pyrrolidin-3-yl)-1H-pyrrole-2-carboxamide (136) 
 
 
Compound 136 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), 3-aminopyrrolidine (44 µL 0.50 mmol) and 
THF (2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a cream solid (45 mg, 70%); Rf = 0.24 
(10% MeOH in EtOAc); M.p.: 206-207 
o
C; λmax (EtOH)/nm: 285, 236; νmax/cm
-1
: 3333 
(NH), 2918, 2117, 1997, 1622 (CO), 1588 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 
1.60-2.04 (2H, m, CH2), 3.39-3.75 (4H, m, 2 x CH2), 3.82-3.84 (1H, m CH), 6.95 (1H, 
d, J = 1.1 Hz, H-3), 7.23-7.27 (2H, m, H-3’ and H-5’), 7.33 (1H, d, J = 1.1 Hz, H-5), 
7.61 (1H, dddd, J = 6.7, 6.8, 8.5 and 8.6 Hz, H-4’); 13C NMR (125 MHz, DMSO-d6) δ 
35.6 (2 x CH2), 42.0 (CH2), 50.1 (NHCH), 85.6 (C-Ar), 91.0 (C-Ar), 114.6 (C-Ar), 
121.8 (C-3), 125.6 (C-2 and C-5), 130.1 (C-4), 159.7 (d, JCF = 246.1 Hz, CF), 159.9 
(CONH), 183.4 (CO);
 19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 
320.30 [M+H]
+
; HRMS m/z calcd for C16H16F2N3O2 [M+H]
+
 320.1209, found 
320.1210. 
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4-(2,6-Difluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide (137) 
 
 
tert-Butyl4-(4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate (132) (30 mg, 0.07 mmol) was dissolved in TFA (3 mL) and stirred at RT 
for 30 min. The solvent was removed in vacuo and the residue was dissolved in EtOAc 
before being washed with a saturated aqueous solution of NaHCO3 (20 mL). The 
organic extract was dried over Na2SO4 and the solvent removed in vacuo to afford the 
crude compound as a white solid, which was purified by recrystallisation from MeOH 
(20 mg, 0.06 mmol , 87%); Rf = 0.50 (10% MeOH in EtOAc); M.p.: 150-151 
oC; λmax 
(EtOH)/nm: 286, 237; νmax/cm
-1
: 3313 (NH), 2974, 2873, 1773 (CO), 1650 (CONH); 
1
H 
NMR (500 MHz, CDCl3) δ 0.88-0.92 (4H, m, 2 x CH2-piperidine) 1.19-1.35 (5H, m, 2 x 
CH2-N-piperidine and CH-piperidine),  7.49-7.53 (2H, m, H-3’ and H-5’), 7.60-7.63 
(1H, m, H-4’), 7.82 (1H, br s, H-3), 7.84 (1H, br s, H-5); 13C NMR (125 MHz, CDCl3) δ 
38.1 (2 x CH2), 39.0 (2 x CH2), 48.2 (NHCH), 91.0 (C-Ar), 96.7 (C-Ar), 114.1 (C-Ar), 
121.7 (C-3), 125.9 (C-2 and C-5), 129.9 (C-4), 156.1 (d, JCF = 256.4 Hz, CF), 164.2 
(CONH), 186.9 (CO);
 19
F NMR (470 MHz, MeOD) δ -112.3; LRMS (ES+) m/z 334.30 
[M+H]
+
; HRMS m/z calcd for C17H18F2N3O2 [M+H]
+
 334.1364, found 334.1365.  
 
4-(4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridine 1-oxide (138) 
 
 
4-(2,6-Difluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (127) was 
dissolved in DCM (2 mL) before m-CPBA (65%, 38 mg, 0.22 mmol) was added and the 
reaction was stirred at RT for 18 h. The reaction mixture was diluted with DCM and 
washed with an aqueous saturated solution of NaHSO3. The organic extract was dried 
over Na2SO4, and the solvent removed in vacuo to give the crude product. Purification 
was achieved using MPLC (silica, 0-20% MeOH in EtOAc) to give the title compound 
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as a white solid (30 mg, 65%); Rf = 0.64 (5% MeOH in EtOAc); M.p.: 255 
o
C (dec.); 
λmax (EtOH)/nm: 315; νmax/cm
-1
: 3304, 3120, 2829, 1657 (CO), 1628 (CONH); 
1
H NMR 
(500 MHz, DMSO-d6) δ 7.26-7.30 (2H, m, H-3’ and H-5’), 7.54 (1H, br s, H-3), 7.56 
(1H, br s, H-5), 7.65 (1H, dddd, J = 6.7, 6.8, 8.6 and 8.7 Hz, H-4’), 7.78 (2H, d, J = 6.2 
Hz, CH-pyridine), 8.15 (2H, d, J = 6.2 Hz, CH-N-pyridine), 10.50 (1H, s, CONH), 
12.79 (1H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ 112.0 (C-Ar), 112.2 (C-Ar), 
112.5, (C-Ar), 121.0 (C-3), 125.9 (C-2 and C-5), 129.9 (C-4), 145.6 (C-pyridine), 150.3 
(C-pyridine), 157.7 (C-pyridine), 159.6 (C-pyridine) 159.7 (CONH), 181.8 (CO); δF 
19
F 
NMR (470 MHz, DMSO-d6) δ -114.1; LRMS (ES
+
) m/z 344.20 [M+H]
+
; HRMS m/z 
calcd for C17H12F2N3O3 [M+H]
+
 344.0831, found: 344.0832. 
 
3-(4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridine 1-oxide (139) 
 
 
4-(2,6-Difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (128) (30 mg, 0.09 
mmol) was dissolved in DCM (2 mL) before m-CPBA (65%, 38 mg, 0.22 mmol) was 
added and the reaction was stirred at RT for 18 h. The reaction mixture was diluted with 
DCM and washed with an aqueous saturated solution of NaHSO3. The organic extracts 
were dried over Na2SO4, and the solvent was removed in vacuo to give the crude 
product. Purification was achieved using MPLC (silica, 0-20% MeOH in EtOAc) to 
give the title compound as a white solid (23 mg, 77%); Rf = 0.60 (5% MeOH in 
EtOAc); M.p. 250 
o
C (dec); λmax (EtOH)/nm 231.0; νmax/cm
-1
 2199, 2126, 1623 (CO), 
1609 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.25-7.28 (2 H, m, H-3’ and H-4’), 
7.40 (1H, dd, J = 6.4 and 8.7 Hz, CH-pyridine), 7.53 ( 1H, br s, H-3), 7.56 (1H, br-s, H-
5), 7.59 (1H, d, J = 6.4 Hz, CH-pyridine), 7.64 (1H, dddd,  J = 6.4, 6.5, 8.1 and 8.2 Hz, 
H-Ar), 7.98 (1H, d, J = 6.4 Hz, CH-N-pyridine), 8.81 (1H, s, CH-N-pyridine), 10.35 (1 
H, s, CONH), 12.79 (1 H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.0 (C-Ar), 
112.2 (C-Ar), 112.6, (C-Ar), 123.1 (C-3), 126.0 (C-2 and C-5), 130.0 (C-4), 147.9 (C-
pyridine), 150.2 (C-pyridine), 157.6 (C-pyridine), 159.6 (C-pyridine) 160.1 (CONH), 
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185.1 (CO);  
19
F NMR (470 MHz, DMSO-d6) δ -114.1; LRMS (ES
+
) m/z 344.3 [M+H]
+
; 
HRMS m/z calcd for C17H12F2N3O3 [M-H]
-
 342.0688, found 342.0689. 
 
(4-(2,6-Difluorobenzoyl)-1H-pyrrol-2-yl)(morpholino)methanone (140) 
 
 
Compound 140 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), morpholine (44 µL, 0.50 mmol) and THF 
(2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a white solid (45 mg, 70%); Rf = 0.71 
(10% MeOH in EtOAc);  M.p.: 210-211 
oC; λmax (EtOH)/nm: 284, 233; νmax/cm
-1
: 3241, 
2959, 2867, 1656 (CO), 1598 (CON); 
1
H NMR (500 MHz, DMSO-d6) δ 3.62-3.64 (4H, 
m, 2 x CH2-N-morpholine), 3.67-3.69 (4H, m, 2 x CH2-O-morpholine), 6.90 (1H, brs, 
H-3), 7.23-7.26 (2H, m, H-3’and H-5’), 7.38 (1H, br s, H-5),  7.61 (1H, dddd, J = 6.7, 
6.8, 8.6 and 8.7 Hz, H-4’), 12.43 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 
40.1 (2 x C-N-morpholine), 66.1 (2x C-O-morpholine), 110.7 (C-Ar), 112.1 (C-Ar), 
112.3 (C-Ar), 125.3 (C-3), 126.9 (C-2 and C-5), 129.0 (C-4), 129.0 (C-Ar), 160.5 
(CON), 181.6 (CO); 
19
F NMR (470 MHz, MeOD) δ -115.5; LRMS (ES+) m/z 321.20 
[M+H]
+
; HRMS m/z calcd for C17H15F2N2O3 [M+H]
+
 321.1050, found 321.1049. 
 
(4-(2,6-Difluorobenzoyl)-1H-pyrrol-2-yl)(piperidin-1-yl)methanone (141) 
 
 
Compound 141 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), piperidine (49 µL, 0.50 mmol) and THF 
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(2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc then NH silica, 0-100% EtOAc in petrol) to give the title compound as 
a white solid (30mg, 47%); Rf = 0.68 (10% MeOH in EtOAc); M.p.: 200-201 
oC; λmax 
(EtOH)/nm: 286, 236, 201; νmax/cm
-1
: 3766, 3012, 2933, 2419, 2117, 1644 (CO), 1587 
(CON); 
1
H NMR 470 MHz, MeOD) δ 1.65-1.69 (4H, m, 2 x CH2-piperidine), 1.75-1.79 
(2H, m, CH2-piperidine), 3.80 (4H, br s, 2 x CH2-N-piperidine), 6.95 (1H, d, J = 1.6 Hz, 
H-3), 7.10 – 7.15 (2H, m, H-3’ and H-5’), 7.36 (1H, br s, H-5), 7.57 (1H, dddd, J = 6.4, 
6.5, 8.5 and 8.6 Hz, H-4’); 13C NMR (125 MHz, MeOD) δ 25.5 (CH2-piperidine), 27.2 
(CH2-piperidine), 49.6 (CH2-N-piperidine), 112.9 (C-Ar), 113.0 (C-Ar), 127.3 (C-2 and 
C-5), 128.5 (C-3), 130.1 (C-4), 133.2 (C-Ar), 139.8 (C-Ar), 161.8 (CON), 184.6 (CO);
 
19
F NMR (470 MHz, MeOD) δ -115.4; LRMS (ES+) m/z 321.20 [M+H]+; HRMS m/z 
calcd for C17H17F2N2O2 [M+H]
+
 319.1258, found 319.1256. 
 
(4-(2,6-Difluorobenzoyl)-1H-pyrrol-2-yl)(piperazin-1-yl)methanone (142) 
 
 
Compound 142 was synthesised according to general procedure C using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), piperazine (43 mg, 0.50 mmol) and THF 
(2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a white solid (50 mg, 78%); Rf = 0.12 
(10% MeOH in EtOAc); M.p.: 201-202 
o
C; λmax (EtOH)/nm: 287, 236; νmax/cm
-1
: 3303 
(NH), 2594, 2362, 2159, 2010, 1622 (CO), 1601 (CON); 
1
H NMR (500 MHz, DMSO-
d6) δ 2.86-2.88 (4H, m, 2 x CH2), 3.76 (4H, br s, 2 x CH2), 6.89-6.92 (2H, m, H-3’ and 
H-5’), 6.95 (1H, br s, H-3), 7.19 (1H, br s, H-5), 7.35 (1H, dddd, J = 6.6, 6.7, 8.5 and 
8.6 Hz, H-4’), 10.67 (1H, br s, NH); 13C NMR (125 MHz, MeOD) δ 46.2 (4 x CH2), 
111.8 (C-Ar), 126.6, 126.8 (C-2 and C-5), 128.2 (C-4), 131.4 (C-Ar), 158.6 (C-Ar), 
160.6 (C-Ar), 160.9 (CON), 182.5 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -112.4; 
LRMS (ES
+
) m/z 320.30 [M+H]
+
; HRMS m/z calcd for C16H16F2N3O2 [M+H]
+
 
320.1028, found 320.1027. 
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(4-(2,6-Difluorobenzoyl)-1H-pyrrol-2-yl)(pyrrolidin-1-yl)methanone (143) 
 
 
Compound 143 was synthesised according to general procedure C using 4-(2,6-
Difluorobenzoyl)-1H-pyrrole-2-carboxylic  (75) (50 mg, 0.20 mmol), 
carbonyldiimidazole (65 mg, 0.40 mmol), pyrrolidine (42 µL 0.50 mmol) and THF (2 
mL) to afford the crude product, which was purified using MPLC (silica, 2-30% MeOH 
in EtOAc)  to give the title compound as a white solid (54 mg, 90%); Rf = 0.52 (10% 
MeOH in EtOAc); M.p.: 228 
oC (dec.); λmax (EtOH)/nm: 286, 234; νmax/cm
-1
: 3227, 
2958, 2870, 2162, 1973, 1677 (CO), 1644 (CON); 
1
H NMR (500 MHz, DMSO-d6) δ 
1.82-1.85 (2H, m , CH2-pyrrolidine), 1.94-1.97 (2H, m, CH2-pyrrolidine), 3.48-3.51 
(2H, m, CH2-N-pyrrolidine), 3.71-3.73 (2H, m, CH2-N-pyrrolidine),  6.97 (1H, d, J = 
1.3 Hz, H-3), 7.22-7.24 (2H, m, H-3’ and H-5’) 7.33 (1H, br s, H-5), 7.62 (1H, dddd, J 
= 6.6, 6.7, 8.6 and 8.7 Hz, H-4’), 12.37 (1H, br s, NH); 19F NMR (470 MHz, DMSO-d6) 
δ -114.3; LRMS (ES+) m/z 305.20 [M+H]+; HRMS m/z calcd for C16H15F2N2O2 [M+H]
+
 
305.1098, found 305.1096.  
 
4-(2,6-Difluorobenzoyl)-N-(3-fluorophenyl)-1H-pyrrole-2-carboxamide (144) 
 
 
Compound 144 was synthesised according to general procedure D, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
3-fluoroaniline (48 µL, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford the crude 
product. Purification was achieved by recrytallisation from MeOH to give the title 
compound as a white solid (45 mg, 65%); Rf = 0.51 (10% MeOH in EtOAc); M.p.: 285-
286 
oC; λmax (EtOH)/nm: 261; νmax/cm
-1
: 3225, 2338, 2121, 1623 (CO), 1610 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 6.89-6.93 (1H, m, H-Ar), 7.25-7.28 (2H, m, H-3’ and 
H-5’), 7.37 (1H, q, J  = 7.8 Hz, H-Ar), 7.50-7.52 (3H, m, H-3, H- 5 and H-Ar), 7.63 
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(1H, dddd,  J  =  6.8, 6.9, 8.4 and 8.5 Hz, H-4’),  7.71-7.74 (2H, m, H-Ar), 10.21 (1 H, 
s, CONH) 12.69 (1 H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.0 (C-Ar), 
112.5 (C-Ar), 116.3 (C-pyridine), 118.5 (C-Ar), 120.9 (C-3), 125.6 (C-2 and C-5), 
129.4 (C-pyridine), 130.1 (C-4), 133.6 (C-Ar), 136.2 (C-pyridine), 156.4 (d, JCF = 255.1 
Hz, CF), 159.3 (d, JCF = 256.3 Hz, CF), 159.2 (CONH), 181.9 (CO)
 19
F NMR (470 
MHz, DMSO-d6) δ -112.4, -114.2; LRMS (ES
-
) m/z 343.10 [M-H]
-
; HRMS m/z calcd 
for C18H12F5N2O2 [M+H]
+
 345.0845, found 385.0845. 
 
4-(2,6-Difluorobenzoyl)-N-(2,6-difluorophenyl)-1H-pyrrole-2-carboxamide (145) 
 
 
Compound 145 was synthesised according to general procedure D, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
2,6-difluoroaniline (54 µL, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol).  The title compound 
was obtained after work up, without further purification, as a white solid (60 mg, 83%); 
Rf = 0.75 (10% MeOH in EtOAc); M.p.: 215 
o
C (dec.); λmax (EtOH)/nm: 286, 240; 
νmax/cm
-1
: 3291, 3042, 2934, 2598, 2062, 2006, 1618 (CO), 1608 (CONH); 
1
H NMR 
(500 MHz, DMSO-d6) δ 6.89-6.91 (1H, m, H-3), 7.10-7.18 (4H, m, H-Ar, H-3’ and H-
5’), 7.26-7.32 (1H, m H-4’), 7.36 (1H, br s, H-5), 7.48-7.54 (1H, m, H-Ar), 9.72 (1H, s, 
CONH), 12.62 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.5 (C-Ar), 111.6 
(C-Ar), 111.7 (C-Ar), 111.8 (C-Ar) 126.7 (C-3), 126.9 (C-2 and C-5), 130.6 (C-4), 
157.7 (C-Ar), 159.1, (C-Ar), 159.7 (CONH), 179.9 (CO);
 19
F NMR (470 MHz, DMSO-
d6) δ -114.3, -117.8; LRMS (ES
+
) m/z 363.20 [M+H]
+
; HRMS m/z calcd for 
C18H11F4N2O2 [M+H]
+
 363.0748, found 363.0749. 
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4-(2,6-Difluorobenzoyl)-N-(4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide 
(146) 
 
Compound 146 was synthesised according to general procedure D, using 4-(2,6-
Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
4-(trifluoromethyl)aniline (63 µL, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 2-60% MeOH in EtOAc) 
followed by recrytallisation from MeOH to give the title compound as a white solid (50 
mg, 64%); Rf = 0.75 (10% MeOH in EtOAc); M.p.: 299 
oC (dec.); λmax (EtOH)/nm: 
297; νmax/cm
-1
: 3359, 3254, 3122, 1668, (CO) 1633 (CONH); 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.26-7.29 (2H, m, H-3’ and H-5’), 7.53 (1H, s, H-3), 7.57 (1H, s, H-5), 
7.64 (1H, dddd, J = 6.4, 6.5, 8.8 and 8.9 Hz, H-4’), 7.72 (2H, d, J = 8.9 Hz, p-subs. H-
Ar), 7.97 (2H, d, J = 8.9 Hz, p-subs.  H-Ar), 10.34 (1H, s, CONH), 12.72 (1H, br s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.0 (C-Ar), 112.4 (C-Ar), 113.1 (C-Ar), 
119.8 (CF3), 121.0(C-3), 124.9 (C-2 and C-5), 129.2 (C-Ar), 129.5 (C-Ar), 129.9 (C-4), 
133.0 (C-Ar), 138.8 (C-Ar), 157.6 (C-Ar), 159.7 (CONH), 181.8 (CO);
 19
F NMR (470 
MHz, DMSO-d6) δ -60.3, -114.1; LRMS (ES
+
) m/z 395.40 [M+H]
+
; HRMS m/z calcd 
for C19H12F5N2O2 [M+H]
+
 395.0810, found 395.0809.  
 
4-(2,6-Difluorobenzoyl)-N-(3-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide 
(147) 
 
Compound 147 was synthesised according to general procedure D, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid  (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
3-(trifluoromethyl)aniline (63 µL, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 2-60% MeOH in EtOAc) 
followed by recrytallisation from MeOH to give the title compound as a white solid (45 
mg, 57%); Rf = 0.76 (10% MeOH in EtOAc); M.p.: 290 
oC (dec.); λmax (EtOH)/nm: 292, 
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264; νmax/cm
-1
: 3362, 3223, 2296, 1624 (CO), 1541 (CONH); 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.26-7.30 (2H, m, H-3’ and H-5’), 7.55 (2H, br s, H-3 and H-Ar), 7.60 
(1H, t, J = 8.1 Hz, H-Ar), 7.64 (1H, dddd, J = 6.5, 6.6, 8.8 and 8.9 Hz, H-4’), 8.04 (1H, 
d, J = 8.1 Hz, H-Ar), 8.18 (1H, br s, H-5), 10.4 (1H, s, CONH), 12.72 (1h, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.7 (C-Ar), 112.2 (C-Ar), 112.3 (C-Ar), 119.7 
(CF3), 123.4 (C-3), 125.9 (C-2 and C-5), 129.2 (C-Ar), 129.5 (C-Ar), 129.9 (C-4), 132.3 
(C-Ar). 139.7 (C-Ar), 157.6 (C-Ar), 158.7 (C-Ar), 159.7 (CONH),  181.8 (CO);
 19
F 
NMR (470 MHz, DMSO-d6) δ -69.3, -114.1; LRMS (ES
+
) m/z 395.40 [M+H]
+
; HRMS 
m/z calcd for C19H12F5N2O2 [M+H]
+
 395.0811, found 395.0811. 
 
4-(2,6-Difluorobenzoyl)-N-(3-sulfamoylphenyl)-1H-pyrrole-2-carboxamide (148) 
 
 
Compound 148 was synthesised according to general procedure D, using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
3-aminobenzenesulfonamide (86 mg, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford 
the crude product. Purification was achieved by recrytallisation from MeOH to give the 
title compound as a white solid (61 mg, 75%); Rf = 0.65 (10% MeOH in EtOAc); M.p.: 
309 
oC (dec.); λmax (EtOH)/nm: 295, 256; νmax/cm
-1
: 3345, 3228, 3215, 2343, 1621 
(CO), 1532 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.21-7.24 (2 H, m, H-3’ and H-
5’), 7.33-7.38 (3 H, m, H-Ar), 7.49-7.50 (1 H, m, H-Ar), 7.54-7.60 (1H, m, H-4’),  7.91 
(1 H, d, J = 3.5 Hz, H-3), 8.37 (1H, br s, H-5), 10.42 (1 H, s, CONH) 12.67 (1 H, br s, 
NH);
 13
C NMR (125 MHz, CDCl3) δ 111.5 (C-Ar), 111.7 (C-Ar), 112.4 (C-Ar), 116.5 
(C-Ar), 118.9 (C-Ar), 121.6 (C-3), 129.0 (C-2 and C-5), 129.2 (C-4), 140.3 (C-Ar), 
144.5 (C-Ar), 157.7 (C-Ar), 159.6 (CONH), 183.8 (CO);
 19
F NMR (470 MHz, DMSO-
d6) δ -114.3; LRMS (ES
+
) m/z 406.20 [M+H]
+
; HRMS m/z calcd for C18H14F2N3O4S 
[M+H]
+
 406.0661, found 406.0661. 
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4-(2,6-Difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide 
(149) 
 
Compound 149 was synthesised according to general procedure D using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
4-amino-N-methylpiperidine (51 µL, 0.4 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford 
the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in 
EtOAc) to give the pure compound as a beige solid (50 mg, 72%); Rf = 0.65 (5% MeOH 
in EtOAc); M.p. 170-171 
o
C; λmax (EtOH)/nm 286.0, 236.0; νmax/cm
-1
 2947 (NMe), 
1748, 1617 (CO), 1529 (CONH);  
1
H NMR (500 MHz, DMSO-d6) δ 1.48-1.56 (2H, m, 
CH2), 1.73 (2H, d, J = 11.5 Hz, CH2), 1.93 (2H, t,  J = 11.5 Hz, CH2N), 2.16 (3H, s, 
NCH3), 2.74 (2H, d, J = 11.5 Hz, CH2N), 3.64-3.71 (1H, m, CH), 7.18 (1H, br s, H-3), 
7.23-7.26 (2H, m, H-3’ and H-5’), 7.34 (1H, br s, H-5), 7.59 (1H, dddd, J  = 6.3, 6.4, 
8.4 and 8.5 Hz, H-4’), 8.01 (1 H, br s, CONH) 12.39 (1 H, br s, NH); 13C NMR (125 
MHz, MeOD) δ 30.9 (2 x CH2), 44.6 (CH3), 46.2 (CH), 54.9 (2 x CH2N), 112.1 (C-Ar), 
112.9 (C-Ar), 113.1 (C-Ar), 122.3 (C-3), 129.8 (C-2 and C-5), 133.2 (C-4), 133.3 (C-
Ar), 159.7 (CON), 162.1 (d, JCF = 250.2 Hz, CF), 184.0 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 348.3 [M+H]
+
; HRMS m/z calcd for 
C18H20F2N3O2 [M+H]
+
 348.1521, found 348.1520. 
 
Methyl 4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxylate (152) 
 
 
Compound 152 was synthesised according to general procedure A using methylpyrrole-
2-carboxylate (400 mg, 3.20 mmol), DCM (7 mL), AlCl3 (1.07 g, 8.00 mmol) and 2,3-
dichlorobenzoyl chloride (1.34 g, 6.40 mmol) to afford the crude product. Purification 
was achieved using MPLC (0-80% EtOAc in petrol) to give the pure compound as a 
white solid (681 mg, 71%); Rf = 0.60 (50% EtOAc in petrol); M.p. 183-184 
o
C; λmax 
(EtOH)/nm 284.5, 233.0; νmax/cm
-1
 3285, 1691 (CO2Me), 1657 (CO), 1561; 
1
H NMR 
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(500 MHz, DMSO-d6) δ 3.80 (3H, s, CH3), 7.02 (1H, dd, J = 1.6 and 2.3 Hz, H-3), 7.44-
7.50 (3H, m, H-5 and H-Ar), 7.79 (1H, dd, J = 1.8 and 8.0 Hz, H-Ar), 12.85 (1H, br s, 
NH);  
13
C NMR (500 MHz, DMSO-d6) δ  51.7 (CH3), 115.0 (C-3), 124.3 (C-2), 124.7 
(C-5), 126.9 (C-4), 127.5 (C-Ar), 128.6 (C-Ar), 130.4 (C-Ar), 131.5 (C-Ar), 132.6 (C-
Ar), 141.3 (C-Ar), 160.3 (CO2Me), 187.2 (CO); LRMS (ES
+
) m/z 296.1 [M-H]
-
; HRMS 
m/z calcd for C13H10
35
Cl2NO3 [M+H]
+
 298.0037, found 298.0037. 
 
Methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (153)  
 
 
Compound 153 was synthesised according to general procedure A using methylpyrrole-
2-carboxylate (3.00 g, 23.80 mmol), DCM (40 mL), AlCl3 (7.93 g, 59.50 mmol) and 2-
chloro-6-fluorobenzoyl chloride (6.40 mL, 47.60 mmol to afford the crude product. 
Purification was achieved using MPLC (0-80% EtOAc in petrol) to give the pure 
compound as a white solid (4.20 g, 63%); Rf = 0.48 (50% EtOAc in petrol); M.p. 183-
184 
o
C; λmax (EtOH)/nm 282, 232; νmax/cm
-1
 3224, 1732 (CO2Me), 1639 (CO), 1563; 
1
H 
NMR (500 MHz, DMSO-d6) δ 7.00 (1H, s, H-3), 7.37-7.40 (1H, m, H-5’), 7.46 (1H, d, 
J = 8.2 Hz, H-3’), 7.54 (1H, dd, J = 1.5 and 3.3 Hz, H-5), 7.58 (1H, ddd, J = 6.3, 8.4 
and 8.4 Hz, H-4’); 13C NMR (125 MHz, DMSO-d6) δ 51.7 (CH3), 114.6 (C-3), 115.0 (d, 
JCF = 21.6Hz, C-Ar), 124.5 (C-5), 125.3 (C-2), 125.8 (d, JCF = 3.6 Hz, C-Ar), 127.8 (d, 
JCF = 22.8 Hz, C-Ar), 130.1 (C-4), 130.3 (d, JCF = 5.8 Hz, C-Ar), 131.9 (d, JCF = 9.2 Hz, 
C-Ar), 158.6 (d, JCF = 247.7 Hz, CF) 160.2 (CO2Me), 183.7 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) δ  -114.0; LRMS (ES
+
) m/z 282.3 [M+H]
+
; HRMS m/z calcd for 
C13H10
35
ClFNO3 [M+H]
+
 282.0328, found 282.0331. 
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Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (154)  
 
 
2-Bromo-6-fluorobenzoic acid (2.0 g, 9.13 mmol) was dissolved in THF (20 mL) and 
SOCl2 (1.98 mL, 27.39 mmol) was added followed by DMF (71 µL, 0.91 mmol). The 
mixture was stirred at RT for 3 h before the solvent was removed in vacuo. The 
resulting residue was dissolved in DCM (20 mL) before AlCl3 (1.83 g, 13.70 mmol) 
was added followed by methylpyrrole-2-carboxylate (571 mg, 4.57 mmol) and the 
mixture was stirred at RT for 18 h. Work up was achieved according to general 
procedure A and the crude product was purified using MPLC (0-80% EtOAc in petrol) 
to give the pure compound as a white solid (1.16 g, 80%); Rf = 0.51 (50% EtOAc in 
petrol); M.p.: 185-186 
o
C; λmax (EtOH)/nm 280; νmax/cm
-1
 3229, 1731 (CO2Me), 1638 
(CO), 1563; 
1
H NMR (500 MHz, DMSO-d6) δ 3.80 (3H, s, CH3), 7.00 (1H, s, H-3), 
7.39-7.43 (1H, m, H-5’), 7.50 (1H, ddd, J = 6.3, 8.3 and 8.3 Hz, H-4’), 7.52 (1H, s, H-
5), 7.59 (1H, d, J = 8.3 Hz, H-3’), 12.90 (1H, br s, NH);  13C NMR (125 MHz, DMSO-
d6) δ  51.6 (CH3),  114.7 (C-3), 115.4 (d, JCF = 21.6 Hz, C-Ar), 118.9 (d, JCF = 5.4 Hz, 
C-Ar), 124.5, 125.0 (C-2 and C-5), 128.8 (d, JCF = 3.3 Hz, C-Ar), 130.4 (C-4), 132.2 (d, 
JCF = 8.2 Hz, C-Ar), 158.4 (d, JCF = 248.2 Hz, CF), 160.3 (CO2Me), 184.6 (CO); 
19
F 
NMR (470 MHz, DMSO-d6) δ -113.6; LRMS (ES
+
) m/z 328.1 [M+H]
+
; HRMS m/z 
calcd for C13H10
79
BrFNO3 [M+H]
+
 325.9823, found 325.9830. 
 
4-(2,3-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) 
 
 
Compound 155 was synthesised according to general procedure B using methyl 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylate (152) (600 mg, 2.01 mmol), LiOH (963 mg, 
40.20 mmol) in water (26 mL) and THF (15 mL) to afford the pure product as a white 
solid (595 mg, 99%); Rf = 0.40 (5% MeOH in EtOAc); M.p. 209-210 
o
C; λmax 
(EtOH)/nm: 281.5, 229.5; νmax/cm
-1
 3286, 1686 (CO2H), 1654 (CO), 1559; 
1
H NMR 
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(500 MHz, DMSO-d6) δ 6.97 (1H, br s, H-3), 7.38 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 
7.45 (1H, dd, J = 1.7 and 7.6 Hz, H-Ar), 7.46-7.50 (1H, m, H-Ar); 7.79 (1H, dd, J = 1.7 
and 7.6 Hz, H-Ar), 12.65 (1H, s, CO2H), 12.88 (1H, br s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 114.6 (C-3), 124.6 (C-5), 125.6 (C-2), 126.9 (C-4), 127.5 (C-Ar), 128.5 
(C-Ar), 130.0 (C-Ar), 131.4 (C-Ar), 132.3 (C-Ar), 141.5 (C-Ar), 161.3 (CO2H), 187.2 
(CO); LRMS (ES
+
) m/z 283.2 [M-H]
-
; HRMS m/z calcd for C12H7
35
Cl2NO3 [M+H]
+
 
281.9733, Found: 281.9735. 
 
4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156)  
 
 
Compound 156 was synthesised according to general procedure B using methyl 4-(2-
chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (153) (4.00 g, 14.20 mmol), LiOH 
(6.81 g, 284.00 mmol) in water (150 mL) and THF (100 mL) to afford the pure product 
as a white solid (3.75 g, 99%); Rf = 0.36 (5% MeOH in EtOAc); M.p. 209-210 
o
C; λmax 
(EtOH)/nm 281, 233; νmax/cm
-1
 3306, 1638 (CO2H), 1556 (CO); 
1
H NMR (500 MHz, 
DMSO-d6) δ 6.95 (1H, s, H-3), 7.35-7.40 (1H, m, H-5’), 7.44-7.46 (2H, m, H-3’ and H-
5), 7.57 (1H, ddd, J = 6.4, 8.4 and 8.6 Hz, H-4’), 12.69 (1H, br s, NH);  13C NMR (125 
MHz, DMSO-d6) δ 114.0 (C-3), 114.9 (d, JCF = 21.6Hz, C-Ar), 125.2 (C-5), 125.2 (d, 
JCF = 3.2 Hz, C-Ar), 126.1 (C-2), 127.8 (d, JCF = 6.6 Hz, C-Ar), 129.5 (C-4), 130.3 (d, 
JCF = 6.5 Hz, C-Ar), 131.8 (d, JCF = 9.3 Hz, C-Ar), 158.5 (d, JCF = 247.7 Hz, CF), 161.4 
(CO2H), 183.7 (CO);
 19
F NMR (470 MHz, DMSO-d6) δ -114.0; LRMS (ES
+
) m/z 268.3 
[M+H]
+
; HRMS m/z calcd for C12H6
35
ClFNO3 [M-H]
-
 266.0026, found 266.0019. 
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4-(2-Bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157)  
 
Compound 157 was synthesised according to general procedure B using methyl 4-(2-
bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (154) (1.00 g, 3.06 mmol), LiOH 
(1.46 g, 61.12 mmol) in water (40 mL) and THF (25 mL) to afford the pure product as a 
white solid (949 mg, 99%); Rf = 0.40 (5% MeOH in EtOAc); M.p. 210-211 
o
C; λmax 
(EtOH)/nm 281; νmax/cm
-1
 3342, 1690 (CO2H), 1648 (CO), 1561; 
1
H NMR (500 MHz, 
DMSO-d6) δ 6.94 (1H, s, H-3), 7.39-7.43 (2H, m, H-5 and H-5’), 7.50 (1H, ddd, J = 6.3, 
8.4 and 8.4 Hz, H-4’), 7.59 (1H, d, J = 8.4 Hz, H-Ar), 12.69 (1H, br s, NH), 12.81 (1H, 
br s, CO2H);  
13
C NMR (125 MHz, DMSO-d6) δ 114.1 (C-3), 115.3 (d, JCF = 21.4 Hz, 
C-Ar), 118.9 (d, JCF = 5.0 Hz, C-Ar), 124.9 (C-5), 126.0 (C-2), 128.8 (d, JCF = 2.8 Hz, 
C-Ar), 129.6 (C-4), 129.8 (d, JCF = 23.2 Hz, C-Ar), 132.1 (d, JCF = 8.5 Hz, C-Ar), 158.3 
(d, JCF = 247.9 Hz, CF), 161.3 (CONH), 184.6 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ 
-113.8; LRMS (ES
+
) m/z 312.2 [M-H]
-
; HRMS m/z calcd for C12H6
79
BrFNO3 [M-H]
-
 
309.9521, found 309.9516. 
 
4-(2,6-Difluorobenzoyl)-N-(pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (158) 
 
Compound 158 was synthesised according to general procedure D using 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (50 mg, 0.2 mmol), MeCN (1 mL), 
4-aminopyrimidine (48 mg, 0.5 mmol)  and PCl3 (17 µL, 0.2 mmol) to afford the crude 
product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) to 
give the pure compound as a white solid (50 mg, 76%); Rf = 0.68 (5% MeOH in 
EtOAc); M.p. 278-279 
o
C; λmax (EtOH)/nm 296.0, 246.0; νmax/cm
-1
: 2976, 2863, 2118, 
1641 (CO), 1553 (CONH0; 
1
H NMR (500 MHz, DMSO-d6) δ 7.26-7.29 (2H, m, H-3’ 
and H-5’), 7.60-7.67 (2H, m, H-4’ and CH-pyrimidine), 7.79 (1H, br s, H-3), 8.29 (1H, 
dd, J = 1.5  and 6.0 Hz, CH-pyrimidine), 7.69 (1H, d, J = 6.0 Hz, CH-pyrimidine), 8.92 
(1H, br s, H-5), 11.16 (1H, br s, CONH), 12.79 (1H, br s, NH); 
13
C NMR (125 MHz, 
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DMSO-d6) δ 110.5 (C-Ar), 112.1 (d, JCF = 21.2 Hz, C-Ar), 114.2 (C-Ar), 122.3 (C-3), 
127.2 (C-2 and C-5), 132.2 (C-4), 158.7 (d, JCF = 203.1 Hz, CF), 159.5 (CON), 181.9 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -115.4; LRMS (ES
+
) m/z 329.3 [M+H]
+
; 
HRMS m/z calcd for C16H10F2N4O2 [M+H]
+
 329.0844, found: 329.0845. 
 
4-(2,3-Dichlorobenzoyl)-N-(pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (159) 
 
 
Compound 159 was synthesised according to general procedure D using 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (152) (75 mg, 0.25 mmol), MeCN (1.5 
mL), 4-aminopyrimidine (60 mg, 0.63 mmol) and PCl3 (22 µL, 0.25 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a yellow solid (65 mg, 0.18 mmol, 72%); Rf = 0.70 (5% 
MeOH in EtOAc); M.p. 199-200 
o
C; λmax (EtOH)/nm 297.0, 238.0; νmax/cm
-1
 3119, 
2336, 2168, 1646 (CO), 1552 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.47-7.53 
(3H, m, H-Ar), 7.74 (1H, br s, H-3), 7.81 (1H, dd, J = 1.8  and 6.0 Hz, CH-pyrimidine), 
8.18 (1H, dd, J = 1.8 and 6.0 Hz, CH-pyrimidine), 8.69 (1H, d, J = 6.0 Hz, CH-
pyrimidine) 8.92 (1H, br s, H-5), 11.14 (1H, br s, CONH), 12.76 (1H, br s, NH); 
13
C 
NMR (125 MHz, DMSO-d6) δ 110.4 (C-Ar), 114.6 (C-Ar), 124.8 (C-3), 127.0 (C-2 and 
C-5), 128.6 (C-4), 130.2 (C-Ar), 131.4 (C-Ar), 132.3 (C-Ar), 141.6 (C-Ar), 158.2 (C-
Ar), 170.3 (CON), 187.4 (CO; LRMS (ES
+
) m/z 361.3 [M+H]
+
; HRMS m/z calcd for 
C16H10
35
Cl2N4O2 [M+H]
+
 361.0258, found 361.0258. 
 
 
 
 
 
 
  
248 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (160) 
 
 
Compound 160 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-aminopyrimidine (89 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a white solid (76 mg, 60%); Rf = 0.66    (5% MeOH in 
EtOAc); M.p. 205-206 
o
C; λmax (EtOH)/nm 293.0, 241.0; νmax/cm
-1
 3123, 2961, 2159, 
1976, 1636 (CO), 1555 (CONH), 1497; 
1
H NMR (500 MHz, DMSO-d6) δ 7.39-7.43 
(1H, m, H-3’), 7.47-7.79 (1H, m, H-5’), 7.57-7.62 (2H, m, H-4’ and CH-pyrimidine), 
7.74 (1H, s, H-3), 8.18 (1H, dd, J = 1.2 and 5.8 Hz, CH-pyrimidine), 8.69 (1H, d, J = 
5.8 Hz, CH-pyrimidine), 8.92 (1H, d, J = 1.0 Hz, H-5), 11.14 (1H, s, CONH), 12.82 
(1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 110.5 (C-Ar), 114.1 (C-Ar), 114.9 (C-
Ar), 115.0 (d, JCF = 21.9 Hz, C-Ar), 125.5 (C-3), 125.8 (C-2 and C-5), 131.8 (C-4), 
158.2 (d, JCF = 204.1 Hz, CF), 174.0 (CON), 184.0 (CO); 
19
F NMR (470 MHz, DMSO-
d6) δ -114.4; LRMS (ES
+
) m/z 345.2 [M+H]
+
; HRMS m/z calcd for C16H10
35
ClFN4O2 
[M+H]
+
 345.0553, found 345.0554. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyrimidin-4-yl)-1H-pyrrole-2-carboxamide (161) 
 
 
Compound 161 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (150 mg, 0.48 mmol), MeCN (2 
mL), 4-aminopyrimidine (114 mg, 1.20 mmol) and PCl3 (42 µL, 0.48 mmol) to afford 
the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in 
EtOAc) to give the pure compound as a white solid (116 mg, 62%); Rf = 0.70 (5% 
MeOH in EtOAc); M.p. 210-211 
o
C; λmax (EtOH)/nm 294.0, 242.0; νmax/cm
-1
 3119, 
2968, 1639 (CO), 1572 (CONH), 1500; 
1
H NMR (500 MHz, DMSO-d6) δ 7.42-7.45 
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(1H, m, H-5’), 7.51 (1H, ddd, J = 6.0, 8.4 and 8.4 Hz, H-4’), 7.56 (1H, s, CH-
pyrimidine), 7.60-7.62 (1H, m, H-Ar), 7.74 (1H, s, H-3), 8.18 (1H, dd, J = 1.4 and 5.8 
Hz, CH-pyrimidine), 8.69 (1H, d, J = 5.8 Hz, CH-pyrimidine), 8.92 (1H, s, H-5), 11.35 
(1H, s, CONH), 12.89 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 110.5, 114.2 (C-
Ar), 115.2 (d, JCF = 21.9 Hz, C-Ar), 119.0 (d, JCF = 5.3 Hz, C-Ar), 125.1 (C-3), 127.3 
(C-2 and C-5), 128.8 (C-4), 129.8, 130.0 (d, JCF = 21.9 Hz, C-Ar), 132.1, 158.2 (d, JCF = 
247.3 Hz, CF), 174.5 (CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ       -
113.7; LRMS (ES
+
) m/z 391.2 [M+H]
+
; HRMS m/z calcd for C16H10
79
BrFN4O2 [M+H]
+
 
389.0048, found 389.0048. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2,6-dimethylpyridin-4-yl)-1H-pyrrole-2-
carboxamide (162) 
 
 
Compound 162 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-amino-2,6-methylpyridine (226 mg, 1.86 mmol) and PCl3 (32 µL, 0.37 mmol) 
with microwave irradiation at 150 
o
C for 45 min, to afford the crude product. 
Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) to give the 
pure compound as a beige solid (69 mg, 50%); Rf = 0.65 (5% MeOH in EtOAc); M.p. 
250 
o
C (dec.); λmax (EtOH)/nm 295.5, 271.5; νmax/cm
-1
 3199, 3122, 2945, 2799, 1599 
(CO), 1570 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 2.39 (6H, s, 2 x CH3), 7.40-
7.43 (3H, m, H-3’ and 2 x CH-pyridine), 7.48-7.52 (3H, m, H-3, H-5 and H-5’), 7.60 
(1H, ddd, J = 6.3, 8.4 and 8.4 Hz, H-4’), 10.16 (1H, s, CONH), 12.69 (1H, s, NH); 13C 
NMR (125 MHz, DMSO-d6) δ 24.1 (2 x CH3), 105.9 (2 x C-pyridine), 110.0, 112.1 (C-
Ar), 115.0 (d, JCF = 20.9 Hz, C-Ar), 125.3 (C-3), 125.9 (C-5), 128.2 (C-2), 129.6 (C-4), 
131.8 (d, JCF = 9.5 Hz, C-Ar), 146.3 (C-Ar), 157.6 (2 x C-N-pyridine), 158.5 (d, JCF = 
248.1 Hz, CF), 158.9 (CON), 186.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; 
LRMS (ES
+
) m/z 372.3 [M+H]
+
; HRMS m/z calcd for C19H15
35
ClFN3O2 [M+H]
+
 
372.0913 found 372.0913. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(2,6-dimethylpyridin-4-yl)-1H-pyrrole-2-
carboxamide (163) 
 
Compound 163 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 4-amino-2,6-methylpyridine (98 mg, 0.80 mmol) and PCl3 (28 µL, 0.32 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a cream solid (82 mg, 62%); Rf = 0.71   (5% 
MeOH in EtOAc); M.p. 220 
o
C (dec.); λmax (EtOH)/nm 388.5, 294.5, 271.5; νmax/cm
-1
 
3350, 1641 (CO), 1595 (CONH), 1556, 1522; 
1
H NMR (500 MHz, DMSO-d6) δ 2.39 
(6H, s, 2 x CH3), 7.41 (2H, s, 2 x pyridine CH), 7.44-7.46 (1H, m, H-5’), 7.48 (1H, s, H-
3), 7.51-7.54 (2H, m, H-3 and H-4’), 7.62 (1H, d, J = 8.0 Hz, H-3’), 10.16 (1H, s, 
CONH), 12.68 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 24.1 (2 x CH3), 110.0 ( 
2 x C-pyridine), 112.1 (C-3), 115.4 (d, JCF = 21.8 Hz, C-Ar), 119.0 (d, JCF = 4.5 Hz, C-
Ar), 124.9 (C-2 and C-5), 128.0 (C-4), 128.9 (d, JCF = 2.9 Hz, C-Ar), 129.6 (d, JCF = 
21.8 Hz, C-Ar), 132.2 (d, JCF = 9.2 Hz, C-Ar), 157.6 (2 x C-N-pyridine), 158.4 (d, JCF = 
247.7 Hz, CF), 158.9 (CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; 
LRMS (ES
+
) m/z 417.2 [M+H]
+
; HRMS m/z calcd for C19H15
79
BrFN3O2 [M+H]
+
 
416.0405, found 416.0404. 
 
 4-(2-Chloro-6-fluorobenzoyl)-N-(2-methylpyridin-4-yl)-1H-pyrrole-2-carboxamide 
(164) 
 
Compound 164 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-amino-2-methylpyridine (101 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a pale yellow solid (79 mg, 60%); Rf = 0.60 
(5% MeOH in EtOAc); M.p. 230-231 
o
C; λmax (EtOH)/nm 345.0, 294.0, 271.0; νmax/cm
-1
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3365, 1635, 1607 (CO), 1560 (CONH), 1509, 1446;
 1
H NMR (500 MHz, DMSO-d6) δ 
2.44 (3H, s, CH3), 7.39-7.43 (1H, m, H-5’), 7.48 (1H, d,  J = 8.1 Hz, H-3’), 7.51 (1H, s, 
H-3), 7.53 (1H, s, H-5), 7.56-7.62 (3H, m, H-4’ and 2 x CH-pyridine), 8.33 (1H, d, J = 
5.5 Hz, CH-N-pyridine) 10.25 (1H, s, CONH), 12.73 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 24.3 (CH3), 111.1 (C-Ar), 112.0(C-Ar), 114.9 (d, JCF = 22.4 Hz, C-Ar), 
125.3 (C-3), 125.8 (C-2 and C-5), 128.1 (C-4), 129.7 (C-pyridine), 130.4 (C-Ar),  131.8 
(d, JCF = 8.4 Hz, C-Ar), 145.9 (C-pyridine), 149.6 (C-pyridine), 158.9 (d, JCF = 241.7 
Hz, CF), 173.5 (CON), 183.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS 
(ES
+
) m/z 358.3 [M+H]
+
; HRMS m/z calcd for C18H13
35
ClFN3O2 [M+H]
+
 358.0756, 
found 358.0756. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-(2-methylpyridin-4-yl)-1H-pyrrole-2-carboxamide 
(165) 
 
Compound 165 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 4-amino-2-methylpyridine (86 mg, 0.80 mmol) and PCl3 (28 µL, 0.32 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as an orange solid (88 mg, 69%); Rf = 0.63 (5% 
MeOH in EtOAc); M.p. 205-206 
o
C; λmax (EtOH)/nm 345.0, 295.5, 274.0; νmax/cm
-1
 
3118, 2966, 1643, 1600 (CO), 1553 (CONH), 1502; 
1
H NMR (500 MHz, DMSO-d6) δ 
2.48 (3H, s, CH3), 7.42-7.46 (1H, m, H-5’), 7.50-7.56 (3H, m, CH-pyridine and H-4’ 
and H-3), 7.61 (1H, d, J = 8.2 Hz, H-3’), 7.67-7.69 (2H, m, H-5 and CH-pyridine), 8.38 
(1H, d, J = 5.7 Hz, CH-N-pyridine) 10.44 (1H, s, CONH), 12.77 (1H, s, NH); 
13
C NMR 
(125 MHz, DMSO-d6) δ 23.3 (CH3), 111.5 (C-Ar), 112.5 (C-Ar), 115.3 (d, JCF = 22.5 
Hz, C-Ar), 125.0 (C-3), 127.8 (C-2 and C-5), 128.9 (C-4), 130.0 (C-Ar), 132.2 (d, JCF = 
9.3 Hz, C-Ar), 157.5 (C-Ar), 159.0 (d, JCF = 246.7 Hz, CF), 171.0 (CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 403.3 [M+H]
+
; HRMS m/z 
calcd for C18H13
79
BrFN3O2 [M+H]
+
 402.0250, found 402.0250. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(2-methylpyridin-3-yl)-1H-pyrrole-2-carboxamide 
(166) 
 
Compound 166 was synthesised according to general procedure D using 4-(2-chloro-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156) (150 mg, 0.56 mmol), 3-amino-2-
methylpyridine (152 mg, 1.40 mmol), PCl3 (49 µL, 0.56 mmol) and MeCN (2 mL). The 
crude product was purified by MPLC (0-80% EtOAc in petrol) The product was 
obtained as a pale orange solid (120 mg, 60%); Rf = 0.58 (5% MeOH in EtOAc); M.p. 
235-236 
oC; λmax (EtOH)/nm 240, 289; νmax/cm
-1
: 3266, 1635 (CO), 1557 (CONH), 
1518; 
1
H NMR (500 MHz, DMSO-d6) δ 2.44 (3H, s, CH3), 7.28 (1H, dd, J = 4.4 and 7.9 
Hz, CH-pyridine),  7.38-7.48 (4H, m, H-3, CH-pyridine, H-3’ and H-5’), 7.58 (1H, ddd, 
J = 6.3, 8.1 and 8.1 Hz, H-4’), 7.73 (1H, s, H-5), 8.93 (1H, d, J = 4.4 Hz, CH-N-
pyridine), 9.90 (1H, s, CONH), 12.66 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 
20.7 (CH3), 106.1(C-pyridine), 114.1 (C-Ar), 115.2 (C-Ar), 119.0 (C-3), 125.1 (C-2 and 
C-5), 127.4 (C-4), 128.8 (C-pyridine), 132.2 (C-pyridine), 158.4 (d, JCF = 251.0 Hz, 
CF), 159.4 (CONH), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS 
(ES
+
) m/z 358.2 [M+H]
+
; HRMS m/z calcd for C18H13
79
ClFN3O2  [M+H]
+ 
358.0758, 
found 358.0758.  
 
4-(2-Bromo-6-fluorobenzoyl)-N-(2-methylpyridin-3-yl)-1H-pyrrole-2-carboxamide 
(167) 
 
Compound 167 was synthesised according to general procedure D using 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157) (150 mg, 0.48 mmol), 3-amino-2-
methylpyridine (129 mg, 1.20 mmol), PCl3 (42 µL, 0.48 mmol) and MeCN (2 mL). The 
crude product was purified by MPLC (0-80% EtOAc in petrol) The product was 
obtained as a cream solid (104 mg, 52%); Rf = 0.62 (5% MeOH in EtOAc); M.p. 204-
205 
oC; λmax (EtOH)/nm 237, 289; νmax/cm
-1
: 3171, 1637 (CO), 1520 (CONH); 
1
H NMR 
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(500 MHz, DMSO-d6) δ 2.44 (3H, s, CH3), 7.28 (1H, dd, J = 4.7 and 7.9 Hz, CH-
pyridine),  7.40-7.45 (3H, m, H-3, H-5 and H-5’), 7.51 (1H, ddd, J = 6.4, 8.7 and 8.7 
Hz, H-4’), 7.61 (1H, d, J = 7.8 Hz, H-3’), 7.72 (1H, d, J = 7.9 Hz, CH-pyridine), 8.34 
(1H, dd, J = 1.4 and 4.7 Hz, CH-N-pyridine), 9.91 (1H, s, CONH), 12.66 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 21.6 (CH3), 110.2 (C-pyridine), 114.9 (C-Ar), 116.0 
(C-Ar), 122.0 (C-3), 126.5 (C-2 and C-5), 128.3 (C-4), 128.9 (C-Ar), 132.2 (C-yridine), 
138.9 (C-pyridine), 158.9 (d, JCF = 249.6 Hz, CF), 159.5 (CON), 189.9 (CO); 
19
F NMR 
(470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 400.1 [M-H]
-
; HRMS m/z calcd for 
C18H13
81
BrFN3O2 [M+H]
+ 
402.0246, found 402.0246. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(6-methylpyridin-3-yl)-1H-pyrrole-2-carboxamide 
(168) 
 
Compound 168 was synthesised according to general procedure D using 4-(2-chloro-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156) (150 mg, 0.56 mmol), 5-amino-2-
methylpyridine (152 mg, 1.40 mmol), PCl3 (49 µL, 0.56 mmol) and MeCN (2 mL). The 
crude product was purified by MPLC (0-80% EtOAc in petrol) The product was 
obtained as a pale orange solid (104 mg, 52%); Rf = 0.57 (5% MeOH in EtOAc); M.p. 
234-235 
oC; λmax (EtOH)/nm 239, 286; νmax/cm
-1
: 3271, 1633 (CO), 1519 (CONH), 
1496; 
1
H NMR (500 MHz, DMSO-d6) δ 2.25 (3H, s, CH3), 7.33 (1H, d, J = 4.9 Hz, CH-
pyridine),  7.39-7.48 (4H, m, H-3, H-5, H-3’ and H-5’), 7.58 (1H, ddd, J = 6.2, 8.3 and 
8.3 Hz, H-4’), 8.32 (1H, d, J = 4.9 Hz, CH-pyridine), 8.46 (1H, s, CH-N-pyridine), 9.95 
(1H, s, CONH), 12.67 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 20.8 (CH3), 
106.2 (C-pyridine), 115.0 (C-Ar), 115.2 (C-Ar), 121.0 (C-3) , 125.1 (C-2 and C-5), 
127.5 (C-4), 129.0 (C-pyridine), 132.2 (C-pyridine), 159.4 (d, JCF = 248.6 Hz, CF), 
160.1 (CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 
358.2 [M+H]
+
; HRMS m/z calcd for C18H13
79
ClFN3O2 [M+H]
+ 
358.0758, found 
358.0758. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(6-methylpyridin-3-yl)-1H-pyrrole-2-carboxamide 
(169) 
 
Compound 169 was synthesised according to general procedure D using 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157) (150 mg, 0.48 mmol), 3-amino-2-
methylpyridine (129 mg, 1.20 mmol), PCl3 (42 µL, 0.48 mmol) and MeCN (2 mL). The 
crude product was purified by MPLC (0-80% EtOAc in petrol) The product was 
obtained as an orange solid (121 mg, 0.30 mmol, 63%); Rf = 0.65 (5% MeOH in 
EtOAc); M.p. 206-207 
oC; λmax (EtOH)/nm 226, 379; νmax/cm
-1
: 3255, 1621 (CO), 1552 
(CONH), 1524; 
1
H NMR (500 MHz, DMSO-d6) δ 2.25 (3H, s, CH3), 7.33 (1H, d, J = 
5.1 Hz, CH-pyridine),  7.42 (1H, s, H-3), 7.43-7.45 (2H, m, H-5 and H-5’), 7.51 (1H, 
ddd, J = 6.2, 8.3 and 8.3 Hz, H-4’), 7.61 (1H, d, J = 7.9 Hz, H-3’), 8.32 (1H, d, J = 5.1 
Hz, CH-pyridine), 8.46 (1H, s, CH-N-pyridine), 9.96 (1H, s, CONH), 12.66 (1H, s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) δ 20.7 (CH3), 109.5 (C-pyridine), 113.2 (C-Ar), 
114.1 (C-Ar), 114.9 (C-Ar), 119.9 (C-3), 125.5 (C-2 and C-5), 128.4 (C-4), 129.4 (C-
Ar), 129.8 (C-pyridine), 132.3 (C-pyridine), 159.6 (d, JCF = 254.6 Hz, CF), 160.4 
(CONH), 186.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 
400.1 [M-H]
-
; HRMS m/z calcd for C18H13
81
BrFN3O2 [M+H]
+ 
402.0250, found 
402.0250. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(6-fluoropyridin-3-yl)-1H-pyrrole-2-carboxamide 
(170) 
 
Compound 170 was synthesised according to general procedure D using 4-(2-chloro-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), 5-amino-2-
fluoropyridine (103 mg, 0.93 mmol), PCl3 (32 µL, 0.37 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a cream solid (66 mg, 50%); Rf = 0.42 (5% DCM in MeOH); M.p. 267-
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oC; λmax (EtOH)/nm 247, 292, 379; νmax/cm
-1
: 3246, 1624, 1561 (CO), 1526 
(CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.21 (1H, dd, J = 3.3 and 9.0 Hz, CH-
pyridine),  7.39-7.43 (1H, m, H-3’), 7.46-7.49 (3H, m, H-5’, H-3 and H-5), 7.59 (1H, 
ddd, J = 6.1, 8.4 and 8.4 Hz, H-4’), 8.26-8.29 (1H, m, CH-pyridine), 8.54 (1H, s, CH-N-
pyridine), 10.30 (1H, s, CONH), 12.74 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 
109.5 (C-pyridine), 113.0 (C-Ar), 120.5 (C-Ar), 120.8 (C-3), 126.1 (C-2 and C-5), 
126.5 (C-pyridine), 130.4 (C-4), 135.6 (C-Ar), 140.0 (C-pyridine), 149.5 (d, JCF = 245.0 
Hz, CF), 153.0 (d, JCF = 256.2 Hz, CF), 163.0 (CON), 189.2 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) δ -114.0, -74.1; LRMS (ES
+
) m/z 362.30 [M+H]
+
; HRMS m/z calcd for 
C17H10
35
ClF2N3O2 [M+H]
+ 
362.0508, found 362.0508.  
 
4-(2-Bromo-6-fluorobenzoyl)-N-(6-fluoropyridin-3-yl)-1H-pyrrole-2-carboxamide 
(171) 
 
Compound 171 was synthesised according to general procedure D using 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.37 mmol), 5-amino-2-
fluoropyridine (103 mg, 0.93 mmol), PCl3 (32 µL, 0.37 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a cream solid (58 mg, 45%); Rf = 0.46 (5% DCM in MeOH); M.p. 270-
271 
oC; λmax (EtOH)/nm 258, 290, 379; νmax/cm
-1
: 3237, 1624 (CO), 1561 (CONH), 
1526; 
1
H NMR (500 MHz, DMSO-d6) δ 7.21 (1H, dd, J = 3.2 and 8.9 Hz, CH-pyridine),  
7.42-7.46 (3H, m, H-5’, H-3 and H-5), 7.52 (1H, ddd, J = 6.0, 8.3 and 8.3 Hz, H-4’), 
7.62 (1H, d, J = 8.3 Hz, H-3’),  8.26-8.30 (1H, m, CH-pyridine), 8.54 (1H, s, CH-N-
pyridine), 10.33 (1H, s, CONH), 12.72 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 
108.4 (C-pyridine), 114.0 (C-Ar), 120.9 (C-Ar), 121.0 (C-3), 125.9 (C-2 and C-5), 
126.7 (C-pyridine), 131.0 (C-4), 136.6 (C-Ar), 143.2 (C-pyridine), 150.1 (d, JCF = 245.0 
Hz, CF), 153.6 (d, JCF = 256.2 Hz, CF), 162.1 (CON), 191.0 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) δ -113.8, -74.3; LRMS (ES
+
) m/z 406.30 [M+H]
+
; HRMS m/z calcd for 
C17H10
79
BrF2N3O2 [M+H]
+ 
405.9999, found 405.9999.  
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4-(2-Chloro-6-fluorobenzoyl)-N-(pyridazin-4-yl)-1H-pyrrole-2-carboxamide (172) 
 
 
Compound 172 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-aminopyridazine (88 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a beige solid (82 mg, 65%); Rf = 0.51 (5% MeOH in 
EtOAc); M.p. 200-202 
o
C; λmax (EtOH)/nm 345.0, 296.0; νmax/cm
-1
 3088, 1636, 1551 
(CO), 1519 (CONH), 1445;
 1
H NMR (500 MHz, DMSO-d6) δ 7.39-7.42 (1H, m, H-5’), 
7.48 (1H, d,  J = 8.3 Hz, H-3’), 7.54 (1H, s, H-3), 7.57 (1H, s, H-5), 7.60 (1H, ddd, J = 
6.3, 8.3 and 8.3 Hz, H-4’), 8.05 (1H, dd, J = 2.7 and 5.9 Hz, CH-pyridazine), 9.06 (1H, 
dd, J = 1.0 and 5.9 Hz, CH-N-pyridazine) 9.47 (1H, dd, J = 1.0 and 2.7 Hz, CH-N-
pyridazine),  10.58 (1H, s, CONH), 12.87 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) 
δ 112.8 (C-pyridazine), 114.0 (C-Ar), 114.9 (d, JCF = 21.8 Hz, C-Ar), 115.1 (C-Ar), 
120.4 (C-3), 125.9 (C-2 and C-5), 131.9 (C-4), 138.1 (d, JCF = 9.0 Hz, C-Ar), 143.9 (C-
N-pyridazine), 151.4 (d, JCF = 243.8 Hz, CF), 177.7 (CON), 186.8 (CO); 
19
F NMR (470 
MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 345.2 [M+H]
+
; HRMS m/z calcd for 
C16H10
35
ClFN4O2 [M+H]
+
 345.0553, found 345.0554. 
 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridazin-4-yl)-1H-pyrrole-2-carboxamide (173) 
 
 
Compound 173 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 4-aminopyridazine (76 mg, 0.80 mmol) and PCl3 (28 µL, 0.37 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a orange solid (76 mg, 61%); Rf = 0.56 (5% MeOH in 
EtOAc); M.p. 199-200 
o
C; λmax (EtOH)/nm 298.5; νmax/cm
-1
 3119, 1988, 1637 (CO), 
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1600 (CONH), 1552, 1520; 
1
H NMR (500 MHz, DMSO-d6) δ 7.43-7.46 (1H, m, H-5’), 
7.50-7.55 (3H, m, H-3, H-5 and H-4’), 7.62 (1H, d,  J = 7.8 Hz, H-3’), 8.05 (1H, dd, J = 
2.7 and 6.0 Hz, CH-pyridazine), 9.06 (1H, d, J = 6.0Hz, CH-N-pyridazine) 9.48 (1H, 
dd, J = 1.0 and 2.7 Hz, CH-N-pyridazine),  10.58 (1H, s, CONH), 12.86 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 112.8 (C-pyridazine), 114.0(C-Ar), 115.5 (d, JCF = 
21.9 Hz, C-Ar), 124.4 (C-3), 126.8 (C-2 and C-5), 128.9 (C-4), 138.1 (d, JCF = 8.6 Hz, 
C-Ar), 140.7 (C-N-pyridazine), 143.6 (C-Ar), 151.4 (d, JCF = 248.8 Hz, CF), 173.6 
(CON), 186.6 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 391.2 
[M+H]
+
; HRMS m/z calcd for C16H10
35
ClFN4O2 [M+H]
+
 389.0035, found 389.0034. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-chloropyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (174) 
 
Compound 174 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-amino-2-chloropyrimidine (120 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a white solid (77 mg, 0.20 mmol, 55%); Rf = 
0.65 (5% MeOH in EtOAc); M.p. 215-216 
o
C; λmax (EtOH)/nm 301.0, 243.0; νmax/cm
-1
 
3112, 2978, 1645 (CO), 1554 (CONH), 1498; 
1
H NMR (500 MHz, DMSO-d6) δ 7.39-
7.43 (1H, m, H-5’), 7.48 (1H, d,  J = 7.8 Hz, H-3’), 7.57-7.62 (2H, m, H-3 and H-4’) 
7.77 (1H, s, H-5), 8.18 (1H, d, J = 5.8 Hz, CH-pyrimidine), 8.63 (1H, d, J = 5.8 Hz, 
CH-N-pyrimidine), 11.49  (1H, s, CONH), 12.85 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 109.1 (C-pyrimidine), 113.0 (C-Ar), 114.8 (d, JCF = 22.4Hz, C-Ar), 115.0 
(C-Ar), 125.8 (C-3), 126.9 (C-2 and C-5), 130.1 (C-4), 149.2 (C-N-pyrimidine), 160.2 
(C-Ar), 161.0 (d, JCF = 243.6 Hz, CF), 169.0 (C-pyrimidine), 176.1 (CON), 180.4 (CO);
 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 379.2 [M+H]
+
; HRMS m/z 
calcd for C16H9
35
Cl2FN4O2 [M+H]
+
 379.0152, found 379.0152. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(2-chloropyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (175) 
 
Compound 175 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 4-amino-2-chloropyrimidine (104 mg, 0.80 mmol) and PCl3 (28 µL, 0.32 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a white solid (78 mg, 58%); Rf = 0.69 (5% 
MeOH in EtOAc); M.p. 218-219 
o
C; λmax (EtOH)/nm 298.5, 241.5; νmax/cm
-1
 3278, 
1646, 1555, 1498; 
1
H NMR (500 MHz, DMSO-d6) δ 7.44 (1H, dd,  J = 1.0 and 9.0 Hz, 
H-5’), 7.52 (1H, ddd,  J = 6.2, 8.2 and 8.2 Hz, H-4’), 7.60-7.63 (2H, m, H-3 and H-3’) 
7.76 (1H, s, H-5), 8.18 (1H, d, J = 5.8 Hz, CH-pyrimidine), 8.62 (1H, d, J = 5.8 Hz, 
CH-N-pyrimidine), 11.50  (1H, s, CONH), 12.84 (1H, s, NH);
  13
C NMR (125 MHz, 
DMSO-d6) δ 109.1 (C-pyrimidine), 114.8 (C-Ar), 115.2, (C-Ar), 115.8 (d, JCF = 21.0 
Hz, C-Ar), 120.8 (C-3), 125.2 (C-2 and C-5), 128.8 (C-4), 143.2 (C-N-pyrimidine), 
159.4 (C-Ar), 161.0 (d, JCF = 235.4 Hz, CF), 162.0 (C-pyrimidine), 170.4 (CON), 180.4 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 425.1 [M+H]
+
; 
HRMS m/z calcd for C16H9
79
Br
35
ClFN4O2 [M+H]
+
 422.9647, found 422.9647. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2,6-dimethylpyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (176) 
 
Compound 176 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (150 mg, 0.56 mmol), MeCN (2 
mL), 4-amino-2,6-dimethylpyrimidine (172 mg, 1.40 mmol) and PCl3 (49 µL, 0.56 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as an orange solid (100 mg, 48%); Rf 
= 0.54 (5% MeOH in EtOAc); M.p. 220-221 
o
C; λmax (EtOH)/nm 243.0, 293.5; νmax/cm
-
1
 3130, 1653 (CO), 1553 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 2.45 (3H, s, CH3), 
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2.54 (3H, s, NCH3N), 7.41 (1H, dd, J = 1.0 and 9.0 Hz, H-5’), 7.48 (1H, d, J  = 8.1 Hz, 
H-3’), 7.57-7.61 (2H, m, H-4’ and H-3), 7.75 (1H, s, H-5), 7.96 (CH-pyrimidine), 11.20 
(CONH), 12.78 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 20.7 (CH3), 59.7 
(NCH3N), 106.2 (C-pyrimidine), 114.3 (C-Ar), 114.8 (d, JCF = 21.8 Hz, C-Ar), 115.0 
(C-Ar), 125.4 (C-Ar), 127.2 (C-3), 129.9 (C-2 and C-5), 130.4 (C-4), 131.8 (d, JCF = 9.0 
Hz, C-Ar), 157.6 (d, JCF = 248.7 Hz, CF), 143.4 (C-N-pyrimidine), 159.5 (CON), 184.0 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 373.3 [M+H]
+
; 
HRMS m/z calcd for C18H15
35
ClFN4O2 [M+H]
+
 373.0862, found 373.0861. 
 
 4-(2-Bromo-6-fluorobenzoyl)-N-(2,6-dimethylpyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (177)  
 
Compound 177 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (150 mg, 0.48 mmol), MeCN (2 
mL), 4-amino-2,6-dimethylpyrimidine (147 mg, 1.20 mmol) and PCl3 (42 µL, 0.48 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as a cream solid (110 mg, 55%); Rf = 
0.67 (5% MeOH in EtOAc); M.p. 215-216 
o
C; λmax (EtOH)/nm 242.5, 295.5; νmax/cm
-1
 
3127, 1652, 1601 (CO), 1553 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 2.42 (3H, s, 
CH3), 2.50 (3H, s, NCH3N), 7.41 (1H, dd, J = 1.0 and 9.0 Hz, H-5’),  7.51 (1H, ddd, J = 
6.3, 8.1 and 8.1 Hz, H-4’), 7.55 (1H, s, H-3), 7.61 (1H, d, J  = 8.1 Hz, H-3’), 7.73 (1H, 
s, H-5), 7.90 (CH-pyrimidine), 11.04 (CONH), 12.73 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 20.7 (CH3), 59.7 (NCH3N), 106.1 (C-pyrimidine), 114.1 (C-Ar), 115.2 (d, 
JCF = 21.8 Hz, C-Ar), 119.0 (d, JCF = 4.6 Hz, CF), 125.1 (C-Ar), 127.4 (C-3), 128.8 (C-
2 and C-5), 132.2 (C-4), 149.2 (C-N-pyrimidine), 159.4 (CON), 184.9 (CO); 
19
F NMR 
(470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 415.2 [M-H]
-
; HRMS m/z calcd for 
C18H15
81
BrFN4O2 [M+H]
+
 417.0357, found 417.0359. 
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Pyrimidin-5-amine (180) 
 
5-Amino-4,6-dichloropyrimidine (500 mg, 3.05 mmol) was dissolved in MeOH (30 
mL) before NH4HCOO (1.92 g, 30.5 mmol) was added followed by Pd/C (50 mg, 0.1% 
w/w). The resulting mixture was heated to reflux for 1 h. Upon cooling, the reaction 
was filtered through Celite and the solvent removed in vacuo. The crude product was 
purified by MPLC (silica; 0-20% MeOH in DCM) to give the product as a yellow solid 
(232 mg, 80%); Rf = 0.32 (10% MeOH in DCM); M.p. 168-169 
o
C (lit. 165-166 
o
C); 
λmax (EtOH)/nm 314, 245; νmax/cm
-1
: 3178 (NH2), 1662, 1554; 
1
H NMR (500 MHz, 
DMSO-d6) δ 5.54 (2H, br s, NH2), 8.09 (2H, s, H-4 and H-6), 8.35 (1H, s, H-2); 
13
C 
NMR (125 MHz, DMSO-d6) δ 141.4 (C-4 and C-6), 143.0 (C-5), 146.7 (C-2); LRMS 
(ES
+
) m/z 96.1 [M+H]
+
. 
 
2-Methylpyrimidin-5-amine (181) 
 
 
 
5-Amino-4,6-dichloro-2-methylpyrimidine (3.0 g, 16.9 mmol) was dissolved in MeOH 
(100 mL) before ammonium formate (10.6 g, 169 mmol) was added followed by Pd/C 
(300 mg, 10% w/w). The reaction was heated to reflux for 1 h before cooling and being 
filtered through celite. The solvent was removed in vacuo and the crude mixture was 
purified by MPLC (0-20% MeOH in DCM) to give the title compound as a beige oil 
(1.48 g, 80%); Rf = 0.35 (10% MeOH in DCM); λmax (EtOH)/nm 244, 317; νmax/cm
-1
: 
3016 (NH2), 2118, 1635, 1555; 
1
H NMR (500 MHz, DMSO-d6) δ 2.39 (3H, s, CH3), 
5.28 (2H, br s, NH2), 8.01 (2H, s, C-pyrimidine), 8.43 (1H, s, C-pyrimidine);
13
C NMR 
(125 MHz, DMSO-d6) δ 22.0 (CH3), 140.1 (C-pyrimidine), 145.2 (C-N-pyrimidine), 
157.0 (N-C-N-pyrimidine); LRMS (ES
+
) m/z 110.1 [M+H]
+
. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide (182)  
 
 
Compound 181 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 5-aminopyrimidine (180) (88 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as an orange solid (100 mg, 79%); Rf = 0.52 (5% 
MeOH in EtOAc); M.p. 227 
o
C (dec.); λmax (EtOH)/nm 262.0, 292.0; νmax/cm
-1
 2960, 
2862, 1968, 1637 (CO), 1529 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.42 (1H, dd,  
J = 1.0 and 9.0 Hz, H-5’), 7.48 -7.50 (2H, m, H-3’ and H-3), 7.55 (1H, s, H-5), 7.60 
(1H, ddd,  J = 6.3, 8.3 and 8.3 Hz, H-4’), 8.92 (1H, s, N-CH-N-pyrimidine), 9.13 (2H, s, 
2 x CH-N-pyrimidine), 10.44  (1H, s, CONH), 12.93 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 112.1 (C-pyrimidine), 114.9 (C-Ar), 115.1 (d, JCF = 23.4 Hz, C-Ar), 125.3 
(C-Ar), 125.9 (C-3), 127.6 (C-2 and C-5), 129.7 (C-4), 130.4 (d, JCF = 22.8 Hz, C-Ar), 
131.9 (d, JCF = 8.6 Hz, C-Ar), 134.3 (C-N-pyrimidine), 147.8 (C-Ar), 153.2 (d, JCF = 
245.2 Hz, CF), 158.8 (CON), 183.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; 
LRMS (ES
+
) m/z 344.2 [M+H]
+
; HRMS m/z calcd for C16H11
35
ClFN4O2 [M+H]
+
 
345.0549, found 345.0550. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-methylpyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (183) 
 
Compound 183 was synthesised according to general procedure D using 4-(2-chloro-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), 2-
Methylpyrimidin-5-amine (181) (102 mg, 0.93 mmol), PCl3 (32 µL, 0.37 mmol) and 
MeCN (2 mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to 
give the title compound as a yellow solid (53 mg, 0.14 mmol, 40%); Rf = 0.45 (5% 
DCM in MeOH); M.p. 270 
oC (dec.); λmax (EtOH)/nm 268, 290, 379; νmax/cm
-1
: 3320, 
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1637 (CO), 1516 (CONH); 
1
H NMR (500 MHz, MeOD) δ 2.68 (3H, s, CH3), 7.25-7.28 
(1H, m, H-5’),  7.40 (1H, d, J = 8.5 Hz, H-3’), 7.44 (1H, d, J = 1.5 Hz, H-3), 7.49 (1H, 
d, J = 1.5 Hz, H-5), 7.53 (1H, ddd, J = 6.1, 8.5 and 8.5 Hz, H-4’), 9.07 (2H, s, CH-
pyrimidine); 
13
C NMR (125 MHz, MeOD) δ 25.0 (CH3), 108.4 (C-pyrimidine), 115.0 
(C-Ar), 121.9 (C-Ar), 122.0 (C-3), 126.5 (C-2 and C-5), 127.2 (C-pyrimidine), 131.0 
(C-4), 135.6 (C-Ar), 143.2 (C-N-pyridine), 156.7 (N-C-N-pyrimidine), 154.6 (d, JCF = 
253.2 Hz, CF), 159.8 (CON), 187.0 (CO);
19
F NMR (470 MHz, DMSO-d6) δ -115.3; 
LRMS (ES
+
) m/z 359.2 [M+H]
+
; HRMS m/z calcd for C17H12
35
ClFN4O2 [M+H]
+ 
359.0710, found 359.0710.  
 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide (184) 
 
 
Compound 181 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 5-aminopyrimidine (180) (76 mg, 0.80 mmol) and PCl3 (28 µL, 0.32 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as an orange solid (75 mg, 60%); Rf = 0.56 (5% 
MeOH in EtOAc); M.p. 220-221 
o
C; λmax (EtOH)/nm 293.0; νmax/cm
-1
 3339, 1721, 1628 
(CO), 1528 (CONH);
 1
H NMR (500 MHz, DMSO-d6) δ 7.43-7.46 (2H,  H-5’ and H-3), 
7.50 -7.54 (2H, m, H-4’ and H-5), 7.60 (1H, d,  J = 7.9 Hz, H-3’), 8.92 (1H, s, N-CH-N-
pyrimidine), 9.13 (2H, s, 2 x CH-N-pyrimidine), 10.45  (1H, s, CONH), 12.83 (1H, s, 
NH); δC 
13
C NMR (125 MHz, DMSO-d6) δ 112.2 (C-pyrimidine), 115.3 (d, JCF = 21.8 
Hz, C-Ar), 119.0 (d, JCF = 4.5 Hz, C-Ar), 125.0 (C-Ar), 127.6 (C-3), 128.9 (C-2 and C-
5), 129.7 (C-4), 132.2 (d, JCF = 8.4 Hz, C-Ar), 134.3 (d, JCF = 21.8 Hz, C-Ar), 147.8 (C-
N-pyrimidine), 153.2 (N-C-N-pyrimidine), 157.5 (C-Ar), 158.8 (d, JCF = 236.8 Hz, CF) 
159.4 (CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS (ES
+
) m/z 
391.2 [M+H]
+
; HRMS m/z calcd for C16H11
79
BrFN4O2 [M+H]
+
 389.0047, found 
389.0044. 
 
 
263 
 
4-(2-Bromo-6-fluorobenzoyl)-N-(2-methylpyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (185) 
 
Compound 185 was synthesised according to general procedure D using 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), 2-
Methylpyrimidin-5-amine (181) (87 mg, 0.80 mmol), PCl3 (28 µL, 0.32 mmol) and 
MeCN (2 mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to 
give the title compound as a yellow solid (51 mg, 0.13 mmol, 40%); Rf = 0.48 (5% 
DCM in MeOH); M.p. 280 
oC (dec.); λmax (EtOH)/nm 294, 379; νmax/cm
-1
: 3326, 1632 
(CO), 1600 (CONH), 1536, 1443, 1242; 
1
H NMR (500 MHz, MeOD) δ 2.68 (3H, s, 
CH3), 7.28-7.32 (1H, m, H-5’),  7.43-7.49 (3H, m, H-3’, H-3 and  H-5), 7.54-7.58 (1H, 
m, H-4’), 9.06 (2H, s, CH-pyrimidine); 13C NMR (125 MHz, MeOD) δ 30.0 (CH3), 
109.9 (C-pyrimidine), 116.0 (C-Ar), 120.8 (C-Ar), 121.5 (C-3), 125.6 (C-2 and C-5), 
128.2 (C-pyrimidine), 130.1 (C-4), 136.2 (C-Ar), 145.6 (C-N-pyridine), 155.5 (N-C-N-
pyrimidine), 153.1 (d, JCF = 245.3 Hz, CF), 164.0 (CON), 190.0 (CO);
19
F NMR (470 
MHz, DMSO-d6) δ -115.3; LRMS (ES
+
) m/z 403.3 [M+H]
+
; HRMS m/z calcd for 
C17H12
79
BrFN4O2 [M+H]
+ 
403.0203, found 403.0202. 
 
2-Methoxypyrimidin-4-amine (187) 
 
 
Sodium (78 mg, 3.40 mmol) was dissolved in MeOH (8 mL) and this was allowed to 
stir at RT for 15 min before 4-amino-2-chloropyrimidine (400 mg, 3.10 mmol) in 
MeOH (4 mL) was added. The reaction was heated to 50 
o
C for 4 h before being cooled 
and water added. The product was extracted into EtOAc and the combined organic 
layers were dried over Na2SO4. The solvent was removed in vacuo and the crude 
product purified by MPLC (silica; 0-10% MeOH in DCM) to give the pure product as a 
white solid (349 mg, 90%) Rf = 0.25 (5% MeOH in DCM); M.p. 167-168 
o
C (lit. 168-
169 
o
C); λmax (EtOH)/nm 272, 228; νmax/cm
-1
 3157 (NH2), 1652, 1594, 1557; 
1
H NMR 
(500 MHz, DMSO-d6) δ 3.15 (3H, s, CH3), 6.13 (1H, d, J = 5.70 Hz, CH-pyrimidine), , 
6.91 (2H, br s, NH2), 7.92 (1H, d, J = 5.70 Hz, CH-N-pyrimidine);  
13
C NMR (125 
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MHz, DMSO-d6) δ 53.5 (CH3), 99.3 (C-5), 156.7 (C-6), 165.3 (C-2); LRMS (ES
+
) m/z 
126.1 [M+H]
+
. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-oxo-1,2-dihydropyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (188)  
 
Compound 188 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (156) (100 mg, 0.37 mmol), MeCN (2 
mL), 4-amino-2-methoxypyrimidine (187) (116 mg, 0.93 mmol) and PCl3 (32 µL, 0.37 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as a cream solid (40 mg, 30%); Rf = 
0.45 (5% MeOH in EtOAc); M.p. 199-200 
o
C; λmax (EtOH)/nm 298.0; νmax/cm
-1
 3332, 
1676 (CO), 1637 (CONH), 1553 (NCONH), 1513, 1449; 
1
H NMR (500 MHz, DMSO-
d6) δ 7.22 (1H, br s, H-3), 7.38-7.42 (1H, m, H-5’), 7.47 (1H, d, J = 8.1 Hz, H-3’), 7.56-
7.61 (2H, m, pyrimidone CH and H-4’), 7.70 (1H, br s, H-5), 7.85 (1H, d, J = 6.0 Hz, 
pyrimidone CH), 11.04 (1H, br s, CONH), 11.60 (1H, br s, pyrimidone NH), 12.77 (1H, 
br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 95.2 (C-pyrimidone), 114.5 (C-Ar), 114.8 
(C-Ar), 115.0 (d, JCF = 20.8 Hz, C-Ar), 125.5 (C-Ar), 125.8 (C-3), 130.3 (C-2 and C-5), 
131.8 (C-4), 157.6 (C-pyrimidone-C and CO-pyrimidone), 159.7 (C-pyrimidone and 
CON), 184.9 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.3; LRMS (ES
+
) m/z 361.2 
[M+H]
+
; HRMS m/z calcd for C16H11
35
ClFN4O3 [M+H]
+
 361.0500, found 361.0500. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(2-oxo-1,2-dihydropyrimidin-4-yl)-1H-pyrrole-2-
carboxamide (189) 
 
Compound 189 was synthesised according to general procedure D using 4-(2-bromo-6-
fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid (157) (100 mg, 0.32 mmol), MeCN (2 
mL), 4-amino-2-methoxypyrimidine (187) (100 mg, 0.80 mmol) and PCl3 (28 µL, 0.32 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as a cream solid (60 mg, 45%); Rf = 
0.47 (5% MeOH in EtOAc); M.p. 195-196 
o
C; λmax (EtOH)/nm 262.0, 295.0, 305.0; 
νmax/cm
-1
 3348, 1677 (CO), 1637 (CONH), 1554 (NCONH), 1516; 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.23 (1H, br s, H-3), 7.41-7.44 (1H, m, H-5’), 7.50 (1H, ddd, J = 6.3, 8.2 
and 8.2 Hz, H-4’), 7.55 (1H, br s, pyrimidone CH), 7.60 (1H, d, J = 6.3 Hz, H-3’), 7.72 
(1H, br s, H-5), 7.86 (1H, d, J = 6.3 Hz, pyrimidone CH), 11.02 (1H, br s, CONH), 
11.60 (1H, br s, pyrimidone NH), 12.79 (1H, br s, NH); 
19
F NMR (470 MHz, DMSO-
d6) δ -113.7; LRMS (ES
+
) m/z 405.2 [M+H]
+
; HRMS m/z calcd for C16H11
79
BrFN4O3 
[M+H]
+
 404.9993, found 404.9996. 
 
tert-Butyl 6-nitro-1H-indazole-1-carboxylate (191) 
 
 
6-Nitroindazole (1.00 g, 6.13 mmol) was suspended in DCM (25 mL) before 
triethylamine (0.855 mL, 6.13 mmol) was added followed by Boc2O (1.34 g, 6.13 
mmol). The mixture was left to stir at RT for 18 h before being quenched with water (20 
mL). The product was extracted using DCM (3 x 30 mL), the combined organic 
fractions dried over Na2SO4 and the solvent removed in vacuo. The crude product was 
purified by MPLC (0-10% EtOAc in petrol) to give the desired product as a yellow 
solid (1.48 g, 92%); M.p. 132-133 
o
C (lit.
151
 134-136 
o
C) ; λmax (EtOH)/nm 277, 325; 
νmax/cm
-1
: 3067, 2122, 1737 (CO2
t
Bu), 1532 (NO2); 
1
H NMR (500 MHz, DMSO-d6) δ 
1.69 (9H, s, 3 x CH3), 8.15-8.22 (2H, m, H-4 and H-5), 8.65 (1H, br s, H-7), 8.88 (1H, 
br s, H-3);
13
C NMR (125 MHz, DMSO-d6) δ 28.1 (C(CH3)3), 77.1 (C(CH3)3), 111.1 (C-
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Ar), 118.6 (C-Ar), 121.8 (C-Ar), 129.1 (C-Ar), 138.8 (C-Ar), 138.9 (C-Ar), 148.1 (C-
Ar), 180.7 (CO2
t
Bu); LRMS (ES
+
) m/z 264.2 [M+H]
+
. 
 
tert-Butyl 6-amino-1H-indazole-1-carboxylate (192) 
 
 
tert-Butyl 6-nitro-1H-indazole-1-carboxylate (191) (500 mg, 1.90 mmol) was dissolved 
in THF (38 mL) and the solution was flowed through the H-cube on full H2 mode at a 
rate of 1 mL/min continuously for 2.5 h. The solvent was removed in vacuo and the 
crude mixture was purified by MPLC (0-50% EtOAc in petrol) to give the product as a 
pale yellow solid (399 mg, 90%); M.p. 170-173 
o
C (lit.
151
 171-172 
o
C); λmax (EtOH)/nm 
277, 328; νmax/cm
-1
: 3065 (NH2), 2096, 1742 (CO2
t
Bu), 1565; 
1
H NMR (500 MHz, 
DMSO-d6) δ 1.65 (9H, s, 3 x CH3), 5.20 (2H, br s, NH2), 8.10-8.19 (2H, m, H-4 and H-
5), 8.71 (1H, br s, H-7), 8.89 (1H, br s, H-3);
13
C NMR (125 MHz, DMSO-d6) δ 28.1 
(C(CH3)3), 77.1 (C(CH3)3), 111.1 (C-Ar), 118.6 (C-Ar), 121.8 (C-Ar), 129.1 (C-Ar), 
138.8 (C-Ar), 138.9 (C-Ar), 148.1 (C-Ar), 180.7 (CO2
t
Bu); LRMS (ES
+
) m/z 234.2 
[M+H]
+
. 
 
4-(2-Chloro-6-fluorobenzoyl)-N-(1H-indazol-6-yl)-1H-pyrrole-2-carboxamide (195) 
 
 
Compound 195 was synthesised according to general procedure C using 4-(2-chloro-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (156) (150 mg, 0.56 mmol), CDI (182 mg, 
1.12 mmol), tert-Butyl 6-amino-1H-indazole-1-carboxylate (192) (327 mg, 1.40 mmol) 
and THF (4 mL). The crude product was purified by MPLC (0-8% MeOH in DCM). 
After initial purification, a crude mixture remained and this was dissolved in TFA (2 
mL) and allowed to stir at RT for 1.5 h. The solvent was removed in vacuo and the 
residue re-dissolved in EtOAc (10 mL) and washed with a saturated aqueous solution of 
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NaHCO3 (3 x 10 mL). The organic fraction was dried over Na2SO4 and the solvent 
removed in vacuo. The crude mixture was purified by MPLC (0-8% MeOH in DCM) to 
give the pure product as a pale yellow solid (32 mg, 16% yield); Rf = 0.40 (5% DCM in 
MeOH); M.p. 215-216 
oC; λmax (EtOH)/nm 250, 305; νmax/cm
-1
: 3322, 3124, 1630 (CO), 
1558 (CONH), 1511; 
1
H NMR (500 MHz, DMSO-d6) δ 7.34 (1H, d, J = 8.0 Hz, H-3’),  
7.39-7.44 (2H, m, H-3 and H-5’), 7.48 (1H, d, J = 9.0 Hz, Indazole-H-Ar), 7.59 (1H, 
ddd, J = 5.8, 8.3 and 8.3 Hz, H-4’), 7.70 (1H, d, J = 9.0 Hz, Indazole-H-Ar), 7.99 (1H, 
s, Indazole-H-Ar), 8.20 (1H, s, Indazole-H-Ar), 10.14 (1H, s, CONH), 12.65 (1H, s, 
NH), 12.94 (1H, s, Indazole-NH); 
19
F NMR (470 MHz, DMSO-d6) δ -113.7; LRMS 
(ES
+
) m/z 383.20 [M+H]
+
; HRMS m/z calcd for C19H12
35
ClFN4O2 [M+H]
+ 
383.0709, 
found 383.0709.  
 
4-(2-Bromo-6-fluorobenzoyl)-N-(1H-indazol-6-yl)-1H-pyrrole-2-carboxamide (196) 
 
 
Compound 196 was synthesised according to general procedure C using 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (157) (150 mg, 0.48 mmol), CDI (155 mg, 
0.96 mmol), tert-Butyl 6-amino-1H-indazole-1-carboxylate (192) (280 mg, 1.20 mmol) 
and THF (4 mL). The crude product was purified by MPLC (0-8% MeOH in DCM). 
After initial purification, a crude mixture remained and this was dissolved in TFA (2 
mL) and allowed to stir at RT for 1.5 h. The solvent was removed in vacuo and the 
residue re-dissolved in EtOAc (10 mL) and washed with a saturated aqueous solution of 
NaHCO3 (3 x 10 mL). The organic fraction was dried over Na2SO4 and the solvent 
removed in vacuo. The crude mixture was purified by MPLC (0-8% MeOH in DCM) to 
give the pure product as a pale yellow solid (32 mg, 16% yield); Rf = 0.40 (5% DCM in 
MeOH); M.p. 215-216 
oC; λmax (EtOH)/nm 250, 305; νmax/cm
-1
: 3271, 3116, 1631 (CO), 
1597 (CONH), 1562, 1442; 
1
H NMR (500 MHz, DMSO-d6) δ 7.35 (1H, d, J = 8.0 Hz, 
H-3’),  7.42-7.46 (2H, m, H-3 and H-5’), 7.49-7.54 (2H, m, H-5 and H-4’), 7.62 (1H, d, 
J = 8.9 Hz, Indazole-H-Ar), 7.69 (1H, d, J = 8.9 Hz, Indazole-H-Ar), 7.99 (1H, s, 
Indazole-H-Ar), 8.19 (1H, s, Indazole-H-Ar), 10.16 (1H, s, CONH), 12.64 (1H, s, NH), 
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12.94 (1H, s, Indazole-NH); 
19
F NMR (470 MHz, DMSO-d6) δ -114.6; LRMS (ES
+
) 
m/z 425.10 [M-H]
-
; HRMS m/z calcd for C19H12
81
BrFN4O2 [M+H]
+ 
427.0202, found 
427.0202.  
4-(4-Isopropoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (199) 
 
 
Compound 199 was synthesised according to general procedure C, using 4-(4-
isopropoxybenzoyl)-1H-pyrrole-2-carboxylic acid (73) (150 mg, 0.55 mmol), 
carbonyldiimidazole (178 mg, 1.10 mmol), 4-picolylamine (139 µL, 1.38 mmol) and 
THF (3 mL). The crude residue was purified by MPLC (silica, 2-30% MeOH in EtOAc) 
followed by recrystallisation from EtOAc to give the title compound as a yellow solid 
(153 mg, 77%); Rf = 0.16 (50% MeOH in EtOAc); M.p. 242-243 
oC (dec.); λmax 
(EtOH)/nm 294; νmax/cm
-1
: 3210, 2606, 2162, 2028, 1632 (CO), 1533 (CONH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.31 (6H, d, J = 6.0 Hz, CH(CH3)2), 4.48 (2H, br d, J = 
6.0 Hz, CH2), 4.82 (1H, sept., J = 6.0 Hz, CH(CH3)2), 7.05 (2H, d, J = 8.8 Hz, H-Ar), 
7.31 (2H, d,  J = 6.0 Hz, CH-pyridine), 7.40 (1H, d, J = 1.5 Hz, H-3), 7.44 (1H, d, J = 
1.5 Hz, H-5), 7.80 (2H, d, J = 8.8 Hz, H-Ar), 8.51 (2H, d, J = 6.0 Hz, CH-N-pyridine), 
9.04 (1H, t, J = 6.0 Hz, CONH), 12.34 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) 
δ 21.7 (CH(CH3)2), 41.1 (CH2), 69.5 (CH(CH3)2), 111.7(C-Ar), 115.0 (C-Ar), 122.1 (C-
3), 122.7 (C-pyridine), 124.2 (C-2 and C-5), 127.2 (C-4), 130.9 (C-Ar), 131.1 (C-Ar), 
135.1 (C-Ar), 148.6 (C-pyridine), 149.5 (C-pyridine), 149.5 (C-pyridine), 160.5 
(CONH), 187.6 (CO); LRMS (ES
+
) m/z 364.3 [M+H]
+
; HRMS m/z calcd for 
C21H22N3O3 [M+H]
+ 
364.1660, found 364.1661.  
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4-(4-Methoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (200) 
 
 
Compound 200 was synthesised according to general procedure C, using 4-(4-
methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (205) (200 mg, 0.81 mmol), 
carbonyldiimidazole (263 mg, 1.62 mmol), 4-picolylamine (205 μL, 2.01 mmol) and 
THF (4 mL). The crude residue was purified by MPLC (silica, 2-30% MeOH in EtOAc) 
followed by recrystallisation from MeOH to give the title compound as a cream solid 
(200 mg, 74%); Rf = 0.38 (10% MeOH in EtOAc); M.p. 221-222 
oC; λmax (EtOH)/nm 
292, 241; νmax/cm
-1
 3315, 3036, 2956, 2840, 1730 (CO), 1598 (CONH); 
1
H NMR (500 
MHz, DMSO-d6) δ 3.63 (3H, s, CH3),  4.25 (2H, br d, J = 6.0 Hz, CH2), 6.85 (2H, d, J 
= 8.8 Hz, H-Ar), 7.08 (2H, d,  J = 6.0 Hz, CH-pyridine), 7.17 (1H, d, J = 1.3 Hz, H-3), 
7.21 (1H, d, J = 1.3 Hz, H-5), 7.60 (2H, d, J = 8.8 Hz, H-Ar), 8.29 (2H, d, J = 6.0 Hz, 
CH-N-pyridine), 8.74 (1H, t, J = 6.0 Hz, CONH), 12.09 (1H, br s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ, 55.4 (CH3), 59.7 (CH2), 111.6 (C-Ar), 113.7 (C-Ar), 122.1 (C-3), 
124.1 (C-pyridine), 127.2 (C-2 and C-5), 130.8 (C-4), 148.6 (C-pyridine), 149.5 (C-
pyridine), 160.4 (C-Ar), 162.1 (CONH), 187.9 (CO); LRMS (ES
+
) m/z 336.2 [M+H]
+
; 
HRMS m/z calcd for C19H18N3O3 [M+H]
+ 
336.1334, found 336.1336. 
 
N-(Pyridin-4-ylmethyl)-4-(4-(trifluoromethoxy)benzoyl)-1H-pyrrole-2-
carboxamide (201) 
 
Compound 201 was synthesised according to general procedure C, using 4-(4-
(trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid (206) (100 mg, 0.33 mmol), 
carbonyldiimidazole (107 mg, 0.66 mmol), 4-picolylamine (83 µL, 0.83 mmol) and 
THF (3 mL). The crude residue was purified by MPLC (silica, 2-30% MeOH in EtOAc) 
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and the title compound obtained as a cream solid (120 mg, 94%); Rf = 0.41 (5% MeOH 
in EtOAc); M.p. 204 
oC (dec.); λmax (EtOH)/nm 292, 242; νmax/cm
-1
 3466, 3360, 3207, 
2555, 2199, 2012, 1699 (CO), 1618 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 0.25 
(2H, br d, J = 6.0 Hz, CH2), 7.05 (2H, d,  J = 6.0, CH-pyridine), 7.15-7.16 (1 H, m, H-
3), 7.26 (1H, d, J = 1.5 Hz, H-5), 7.28 (2H, d, J = 8.0 Hz, H-Ar), 7.68 (2H, d, J = 8.0 
Hz, H-Ar), 8.27 (2H, d,  J = 6.0 Hz, CH-N-pyridine), 8.74 (1H, t, J = 6.0 Hz, CONH), 
12.20 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 59.7 (CH2) , 111.5 (C-Ar), 
120.7 (C-3), 122.1 (C-pyridine), 124.1 (C-2 and C-5), 128.1 (CF3), 130.8 (C-4), 138.1 
(C-Ar), 148.5 (C-pyridine), 149.5 (C-pyridine), 150.5 (C-Ar), 160.3 (CONH), 187.9 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -56.6; LRMS (ES
+
) m/z  390.3 [M+H]
+
; 
HRMS m/z calcd for C19H15F3N3O3 [M+H]
+ 
390.1067, found 390.1067. 
 
Methyl 4-(4-methoxybenzoyl)-1H-pyrrole-2-carboxylate (203)  
 
 
Compound 203 was synthesised according to general procedure A, using methyl 
pyrrole-2-carboxylate, 69 (400 mg, 3.20 mmol), DCM (7 mL), 4-methoxybenzoyl 
chloride (1.09 g, 6.40 mmol) and AlCl3 (1.07 g, 8.0 mmol). The crude residue was 
purified by MPLC (silica, 2-100% EtOAc in petrol) followed by a final wash with 
NaHCO3 to remove remaining starting material.  The title compound was obtained as a 
yellow solid (641 mg, 77%); Rf = 0.42 (50% EtOAc in Petrol); M.p.: 150-151 
o
C (dec.); 
λmax (EtOH)/nm: 291, 227; νmax/cm
-1
: 3301, 2567, 2366, 2144, 1697 (CO2Me), 1590 
(CO); 
1
H NMR (500 MHz, DMSO-d6) δ 3.82 (3H, s, COOCH3), 3.86 (3H, s, OCH3), 
7.09 (2H, d, J = 8.9 Hz H-Ar), 7.50 (1H, dd, J = 1.7 and 3.2 Hz, H-3), 7.58 (1H, dd, J = 
1.7 and 3.3 Hz, H-5), 7.83 (2H, d, J = 8.9 Hz, H-Ar), 12.70 (1H, br s, NH); 
13
C NMR 
(125 MHz, DMSO-d6) δ 51.5 (CH3), 55.4 (CH3), 113.8 (C-Ar), 115.9 (C-Ar), 123.2 (C-
3), 124.6 (C-2 and C-5), 128.9 (C-4), 130.9 (C-Ar), 131.1 (C-Ar), 160.5 (C-Ar), 162.3 
(CO2Me), 187.6 (CO); LRMS (ES
+
) m/z 259.3 [M+H]
+
; HRMS m/z calcd for 
C14H14NO4 [M+H]
+
 260.0920, found 260.0917. 
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Methyl 4-(4-(trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylate (204)  
 
 
Compound 204 was synthesised using general procedure A using methyl pyrrole-2-
carboxylate, 69 (200 mg, 1.60 mmol), DCM (5 mL), 4-(trifluoromethoxy)benzoyl 
chloride (0.50 mL, 3.20 mmol) and AlCl3 (533 mg, 4.00 mmol). The crude residue was 
purified by MPLC (silica, 2-100% EtOAc in petrol) and the title compound obtained as 
a cream solid (393 mg, 78%); Rf = 0.51 (10% EtOAc in petrol); M.p.: 133-134 
o
C 
(dec.); λmax (EtOH)/nm: 289, 240; νmax/cm
-1
: 3219, 2958, 2368, 1695 (CO2Me), 1623 
(CO); 
1
H NMR (500 MHz, DMSO-d6) δ 4.05 (3H, s, CH3), 7.41 (1H, dd, J = 1.7 and 3.9 
Hz, H-3), 7.77 (2H, d, J = 8.0 Hz, H-Ar), 7.87 (1H, dd, J = 1.7 and 3.9 Hz, H-5), 8.17 
(2H, d, J = 8.0 Hz, H-Ar), 13.05 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 
51.6 (CH3), 115.8, 118.9 (C-Ar), 121.04 (C-Ar), 123.7 (C-3), 124.1 (C-2 and C-5), 
129.7 (C-4), 130.9 (CF3) , 137.6 (C-Ar), 150.6 (C-Ar), 160.5 (CO2Me), 187.6 (CO); 
19
F 
NMR (470 MHz, DMSO-d6) δ -56.6; LRMS (ES
+
) m/z 314.1 [M+H]
+
; HRMS m/z calcd 
for C14H12F3NO4 [M+H]
+
 314.0635, found 314.0641. 
 
4-(4-Methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (205)  
 
 
Compound 205 was synthesised using general procedure B, using methyl 4-(4-
methoxybenzoyl)-1H-pyrrole-2-carboxylate (203) (350 mg, 1.34 mmol), LiOH (0.64 g, 
26.8 mmol) in water (18 mL) and THF (14 mL) to give the title compound as a cream 
solid (277 mg, 84%); Rf = 0.15 (10% MeOH in EtOAc); M.p.: 171-172 
oC; λmax 
(EtOH)/nm: 292, 227; νmax/cm
-1
: 3256, 2912, 1678 (CO2H), 1600 (CO); 
1
H NMR (500 
MHz, DMSO-d6) δ 3.91 (3H, s, CH3), 7.13 (2H, d, J = 8.9 Hz H-Ar), 7.15 (1H, dd, J = 
1.7 and 3.1 Hz, H-3), 7.57 (1H dd, J = 1.7 and 3.3 Hz, H-5), 7.87 (2H, d, J = 8.9 Hz, H-
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Ar), 12.56 (1H, br s, OH), 12.85 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 55.4 
(CH3), 113.8 (C-Ar), 115.5 (C-4), 124.5 (C-2 and C-5), 128.4 (C-4), 130.9 (C-Ar), 
131.3 (C-Ar), 161.6 (C-Ar), 162.2 (CO2H), 187.7 (CO); LRMS (ES
+
) m/z 246.0 
[M+H]
+
; HRMS m/z calcd for C13H10NO4 [M-H]
-
 244.0615, found 244.0620. 
 
4-(4-(Trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid (206)  
 
 
Compound 206 was synthesised according to general procedure B, using methyl 4-(4-
(trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylate (204) (200 mg, 0.64 mmol), 
LiOH (305 mg, 1.72 mmol) in water (9 mL) and THF (8 mL) to give the title compound 
as a cream solid (150 mg, 78%); Rf = 0.61 (5% MeOH in EtOAc); M.p.: 155-156 
o
C 
(dec.); λmax (EtOH)/nm: 235; νmax/cm
-1
: 3277, 2898, 2572, 2362, 1685 (CO2H), 1554 
(CO); 
1
H NMR (500 MHz, DMSO-d6) δ 7.17 (1H, dd, J = 1.7 and 3.3 Hz, H-3), 7.62 
(2H, d, J = 7.9 Hz, H-Ar), 7.62 (1H, dd, J = 1.7 and 3.3 Hz, H-5), 7.98 (2H, d, J = 7.9 
Hz, H-Ar), 12.68 (1H, br s, OH), 12.93 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) 
δ 115.4 (C-Ar), 120.7 (C-Ar), 123.9 (C-3), 125.0 (C-2 and C-5), 129.3 (C-4), 130.9 
(CF3), 137.7 (C-Ar), 161.5 (CO2H), 187.7 (CO); δF (470 MHz, DMSO-d6)/ppm: -56.6; 
LRMS (ES
+
) m/z 300.3 [M+H]
+
; HRMS m/z calcd for C13H9F3NO4 [M+H]
+
 298.0333, 
found 298.0337. 
 
Methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (209) 
 
 
Compound 209 was synthesised according to general procedure A, using methyl 
pyrrole-2-carboxylate (69) (400 mg, 3.2 mmol), DCM (7 mL), trichloroacetyl chloride 
(0.718 mL, 6.4 mmol) and AlCl3 (1.07 g, 8.0 mmol). The crude residue was purified by 
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MPLC (silica, 2-100% EtOAc in petrol) and the title compound obtained as a peach 
solid (770 mg, 89%); Rf = 0.66 (50% EtOAc in Petrol); M.p. 116-117 
o
C (lit.
152
 118-119 
oC); λmax (EtOH)/nm 289, 236; νmax/cm
-1
 3271, 2608, 1695 (CO2Me), 1680 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ 3.63 (3H, s, CH3),  7.15 (1H, dd, J = 1.8 and 3.2 Hz, H-
3), 7.76 (1H, dd, J = 1.8 and 3.5 Hz, H-5), 12.92 (1H, br s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 51.6 (CH3), 114.9 (CCl3), 116.9 (C-3), 123.9 (C-2 and C-5), 131.9 (C-4), 
160.0 (CO2Me), 181.1 (CO); LRMS (ES
+
) m/z  270.9 [M+H]
+
. 
 
Methyl 4-benzoyl-1H-pyrrole-2-carboxylate (211) 
 
 
Methyl 4-(2,2,2-trifluoroacetyl)-1H-pyrrole-2-carboxylate (213) (50 mg, 0.23 mmol) 
was dissolved in THF (1.0 mL) at -78 
o
C before phenylmagnesium bromide (1.0 M in 
THF) (0.32 mL, 0.32 mmol) was added cautiously to give a yellow solution, which was 
stirred at -78 
o
C for 3 h before being allowed to warm to RT and stirred for a further 2 h. 
The reaction was then quenched with a 0.01M solution of HCl and the mixture was 
extracted with Et2O (3 x 30 mL). The combined organic layers were washed with brine 
(70 mL), dried over Na2SO4 and the solvent removed in vacuo. The crude residue was 
purified by recrystallisation from EtOAc to afford the title compound as a white solid 
(20 mg, 38%); Rf = 0.71 (50% EtOAc in petrol); M.p. 149-150 
o
C (lit.
153
 118-119 
o
C) 
λmax (EtOH)/nm 288; νmax/cm
-1
 3354, 2521, 2161, 2029, 1701 (CO2Me), 1684 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ 3.71 (3H, s, CH3),  6.72 (1H, br s, H-3), 6.84 (1H, br s, 
H-5), 7.23-7.25 (3H, m, H-Ar), 7.45 (2H, d, J = 8.2 Hz, H-Ar); 
13
C NMR (125 MHz, 
DMSO-d6) δ 51.9 (CH3), 115.9 (C-3), 124.0 (C-2 and C-5), 128.5 (C-4), 128.8 (C-Ar), 
128.8 (C-Ar), 129.3 (C-Ar), 138.9 (C-Ar), 157.4 (CO2Me), 189.8 (CO); LRMS (ES
+
) 
m/z  229.1 [M+H]
+
. 
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Methyl 4-(2,2,2-trifluoroacetyl)-1H-pyrrole-2-carboxylate (213) 
 
 
Compound 213 was synthesised according to general procedure A, using methyl 
pyrrole-2-carboxylate (69) (400 mg, 3.20 mmol), DCM (7 mL), trifluoracetic anhydride 
(0.890 mL, 6.4 mmol) and AlCl3 (1.07 g, 8.00 mmol). The crude residue was purified 
by MPLC (silica, 2-100% EtOAc in petrol) and the title compound obtained as a white 
solid (531 mg, 2.4 mmol, 75%); Rf = 0.38 (10% EtOAc in petrol); M.p. 112-113 
o
C; 
λmax (EtOH)/nm 283, 233; νmax/cm
-1
 3252, 2360, 1687 (CO2Me), 1561 (CO); 
1
H NMR 
(500 MHz, DMSO-d6) δ  3.71 (3H, s, CH3), 7.14 (1H, br s, H-3), 7.86 (1H, br s, H-5), 
13.16 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 51.9 (CH3), 115.3 (C-3), 117.5 
(CF3), 117.6 (C-2), 125.2 (C-5), 131.5 (C-4), 160.0 (CO2Me), 174.3 (CO); 
19
F NMR 
(470 MHz, DMSO-d6) -72.9; LRMS (ES
+
) m/z  221.0 [M+H]
+
. 
 
1-(4-(Difluoromethoxy)phenyl)-1-phenylethanol (216) 
 
 
Mg turnings (33 mg, 1.40 mmol) were covered with diethyl ether (4 mL) at RT and 1-
(bromo-4-difluoromethoxy)benzene (0.123 mL, 0.90 mmol) was added carefully with 
stirring . A crystal of iodine was added until boiling was observed, and the reaction was 
left to stir for 15 min before acetophenone (97 µL, 0.83 mmol) was added and the 
reaction left for 5 h. The mixture was quenched with 0.01 M HCl solution and extracted 
with Et2O (3 x 30 mL). The combined organic extracts were washed with brine before 
being dried over Na2SO4 and the solvent removed in vacuo to give the title compound 
as an orange oil (175 mg, 80%); Rf = 0.46 (10% MeOH in EtOAc);  λmax (EtOH)/nm: 
201; νmax/cm
-1
: 3365 (OH), 2959, 2159, 1963, 1654; 
1
H NMR (500 MHz, MeOD) δ 2.37 
(3H, s, CH3), 6.79 (1H, t, J = 73.6 Hz, CHF2), 7.05 (2H, d, J = 8.5 Hz, H-Ar), 7.44-7.48 
(5H, m, H-Ar), 7.96 (2H, d, J = 8.5 Hz, H-Ar); 
13
C NMR (125 MHz, MeOD) δ 26.9 
(CH3), 62.0 ((Ar)2C(CH3)OH), 115.4 (C-Ar), 117.5 (C-Ar), 119.2 (C-Ar), 122.3 (C-Ar), 
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128.8 (C-Ar), 133.4 (C-Ar), 134.5 (C-Ar), 138.3 (C-Ar), 151.9 (OCHF2);  
19
F NMR 
(470 MHz, DMSO-d6) δ -83.0; LRMS (ES
+
) m/z 265.30 [M+H]
+
. 
 
4-(4-Hydroxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (217) 
 
 
Compound 217 was synthesised according to general procedure C using 4-(4-
hydroxybenzoyl)-1H-pyrrole-2-carboxylic acid (218) (50 mg, 0.22 mmol), 
carbonyldiimidazole (71 mg, 0.44 mmol), 4-picolylamine (56 µL, 0.56 mmol) and THF 
(2mL) to afford the crude product, which was purified using MPLC (silica, 2-30% 
MeOH in EtOAc) to give the title compound as a white solid (23 mg, 32%); Rf = 0.25 
(10% MeOH in EtOAc); M.p.: 201-202 
o
C; λmax (EtOH)/nm: 235; νmax/cm
-1
: 3298, 
3001, 2945, 2830, 1710 (CO), 1593 (CONH); 
1
H NMR (500 MHz, MeOD) δ 4.50 (2H, 
s, CH2), 6.79 (2H, d, J = 7.8 Hz, p-subs. H-Ar), 7.24 (1H, d, J = 1.57 Hz, H-3), 7.31 
(2H, d, J = 5.1 Hz, CH-pyridine), 87.42 (1H, d, J = 1.57 Hz, H-5), 7.69 (2H, d, J = 7.8 
Hz, p-subs. H-Ar), 8.39 (2H, br s, CH-N-pyridine); 
13
C NMR (125 MHz, MeOD) δ 45.2 
(CH2), 114.1 (C-Ar), 123.2 (C-3), 125.7 (C-pyridine), 125.9 (C-2 and C-5), 131.6 (C-4), 
132.0 (C-Ar), 145.6 (C-pyridine), 146.2 (C-pyridine), 151.3 (C-pyridine), 159.2 (C-Ar), 
164.5 (CONH), 191.6 (CO); LRMS (ES
+
) m/z 322.30 [M+H]
+
;  HRMS m/z cald for 
C18H13F2N2O2 [M+H]
+
 322.1189, found 322.1191.  
 
4-(4-Hydroxybenzoyl)-1H-pyrrole-2-carboxylic acid (218)  
 
 
4-(4-Methoxybenzoyl)-1H-pyrrole-2-carboxylic acid (205) (100 mg, 0.41 mmol) was 
dissolved in BBr3 (1.0M in DCM, 5 mL) at 0 
o
C.  The reaction was allowed to warm to 
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RT overnight. The mixture was quenched with water and neutralised using a 2M 
aqueous solution of NaOH. The product was extracted with EtOAc (20 mL) and the 
organic extract dried over Na2SO4 and the solvent removed in vacuo. Purification was 
achieved using MPLC (silica, 2-20% MeOH in DCM) to give the pure product as a pale 
yellow solid (75 mg, 79%); Rf = 0.10 (10% MeOH in EtOAc); M.p.: 160-161 
o
C; λmax 
(EtOH)/nm: 234; νmax/cm
-1
: 3406 (OH), 2371, 2135, 1710 (CO2H), 1614 (CO); 
1
H NMR 
(500 MHz, DMSO-d6) δ 6.69 (1H, d, J = 1.7 Hz, H-3), 6.79 (2H, d, J = 8.5 Hz, H-Ar), 
7.14 (1H, d, J = 1.7 Hz, H-5), 7.65 (2H, d, J = 8.5 Hz, H-Ar); 
13
C NMR (125 MHz, 
DMSO-d6) δ 117.3 (C-Ar), 123.9 (C-3), 125.0 (C-2), 128.6 (C-5), 131.0 (C-4), 130.8 
(C-Ar), 131.6 (C-Ar), 132.9 (C-Ar), 159.0 (C-Ar), 164.6 (CO2H), 184.0 (CO); LRMS 
(ES
+
) m/z 230.20 [M-H]
-
; HRMS m/z calcd for C12H8NO4 [M-H]
-
 230.0453, found 
230.0459.  
 
Methyl 4-(3-(trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylate (220) 
 
 
Compound 220 was synthesised according to general procedure A, using methyl 
pyrrole-2-carboxylate (69) (200 mg, 1.60 mmol), DCM (4 mL), 3-
trifluoromethoxybenzoyl chloride (0.52 mL, 3.20 mmol) and AlCl3 (533 mg, 4.00 
mmol) to give the crude compound, which was purified by MPLC (silica, 2-100% 
EtOAc in petrol) to give the title compound as a cream solid (394 mg, 79%); Rf = 0.29 
(50% EtOAc in Petrol); M.p.: 99-101 
oC (dec.); λmax (EtOH)/nm: 285, 238; νmax/cm
-1
: 
3355, 3184, 3064, 2157, 2028, 1713 (CO2Me), 1637 (CO); 
1
H NMR (500 MHz, 
DMSO-d6) δ 3.87 (3H, s, CH3), 7.21 (1H, dd, J = 1.8 and 3.2 Hz, H-3), 7.67-7.72 (4H, 
m, H-5 and H-Ar), 7.88 (1H, d, J = 7.5 Hz, H-Ar), 12.88 (1H, br s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ 51.5 (CH3), 115.8 (C-Ar), 121.1 (C-Ar), 123.9 (C-Ar), 124.2 (C-3), 
127.6 (C-2 and C-5), 130.8 (C-4), 133.2 (CF3), 140.8 (C-Ar), 148.3 (C-Ar), 160.4 (C-
Ar), 165.9 (CO2Me), 187.3 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -56.8; LRMS (ES
-
) 
m/z 314.3 [M+H]
+
; HRMS m/z calcd for C14H11F3NO4 [M+H]
+
 314.0635, found 
314.0637. 
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4-(3-(Trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylic acid (221) 
 
 
Compound 221 was synthesised according to general procedure B, using methyl 4-(3-
(trifluoromethoxy)benzoyl)-1H-pyrrole-2-carboxylate (220) (200 mg, 0.64 mmol), 
LiOH (305 mg, 1.72 mmol) in water (9 mL) and THF (8 mL) to give the title compound 
as a cream solid (163 mg, 85%); Rf = 0.28 (50% MeOH in EtOAc); M.p.: 145-146 
o
C; 
λmax (EtOH)/nm: 288, 235; νmax/cm
-1
: 3226, 2923, 2559, 1683 (CO2H), 1626 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ 7.12 (1H, dd, J = 1.7 and 3.2 Hz, H-3), 7.57, (1H, dd, J = 
1.7 and 3.4 Hz, H-5), 7.64 - 7.67 (3H, m, H-Ar), 7.84 (1H, d, J = 7.5 Hz, H-Ar), 12.65 
(1H, br s, OH), 12.91 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 115.3 (C-Ar), 
119.1 (C-Ar), 120.5 (C-Ar), 121.1 (C-Ar), 123.8 (C-3), 125.2 (C-2), 127.6 (C-5), 129.3 
(C-4), 130.8 (CF3), 141.0 (C-Ar), 148.3 (C-Ar), 161.4 (CO2H), 187.4 (CO); 
19
F NMR 
(470 MHz, DMSO-d6) δ -56.8; LRMS (ES
-
) m/z 298.1 [M-H]
-
 HRMS m/z calcd for 
C13H7F3NO4 [M-H]
-
 298.0333, found 298.0324. 
 
1H-Pyrrole-2-carboxylic acid (222) 
 
 
Compound 222 was synthesised according to general procedure B, using methyl 
pyrrole-2-carboxylate (69) (400 mg, 3.1 mmol), LiOH (1.48 g, 62 mmol) in water (40 
mL) and THF (14 mL) to give the title compound as a cream solid (348 mg, 98%); Rf = 
0.31 (5% MeOH in EtOAc); M.p 197-198 
o
C (lit.
154
 190 
oC); λmax (EtOH)/nm 262; 
νmax/cm
-1
 3348, 2989, 2907, 2624, 1649 (CO2H), 1437; 
1
H NMR (500 MHz, DMSO-d6) 
δ 6.16-6.18 (1H, m, H-4), 6.74 (1H, ddd, J = 3.6, 2.5 and 1.5 Hz, H-3), 6.98-7.00 (1H, 
m, H-5); 
13
C NMR (125 MHz, DMSO-d6) δ 70.2 (C-4), 110.6 (C-3), 116.7 (C-2), 124.5 
(C-5), 164.5 (CO2H); LRMS (ES
+
) m/z  112.0 [M+H]
+
. 
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N-(Pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (223) 
 
 
Compound 223 was synthesised according to general procedure C, using 1H-pyrrole-2-
carboxylic acid (250 mg, 2.25 mmol), carbonyldiimidazole (730 mg, 4.50 mmol), 4-
picolylamine (0.569 mL, 5.63 mmol) and THF (6 mL). The crude residue was purified 
by MPLC (silica, 2-30% MeOH in EtOAc) and the title compound obtained as a cream 
solid (403 mg, 89%); Rf = 0.31 (5% MeOH in EtOAc); M.p 165-166 
o
C (lit.
154
 170-171 
oC); λmax (EtOH)/nm 264; νmax/cm
-1
 3216, 3072, 2922, 1561 (CONH), 1407; 
1
H NMR 
(500 MHz, DMSO-d6) δ 4.25 (2H, d, J = 6.0 Hz, CH2), 5.91 (1H, t, J = 3.5 Hz H-4), 
6.64, (1H, d, J = 3.5, H-3), 6.57 (1H, br s, H-5) 7.08 (2H, d, J = 5.6 Hz, CH-pyridine), 
8.29 (2H, d, J = 5.6 Hz, CH-N-pyridine), 8.42 (1H, t, J = 6.0 Hz, CONH), 11.30 (1H, br 
s, NH);
 13
C NMR (125 MHz, DMSO-d6) δ 42.1 (CH2), 109.3 (C-4), 110.1 (C-3), 122.1 
(C-pyridine), 125.3 (C-2 and C-5), 147.6 (C-pyridine), 150.1 (C-pyridine), 
161.2(CONH) LRMS (ES
+
) m/z 202.1 [M+H]
+
.  
 
N-(Pyridin-4-ylmethyl)-4-(3-(trifluoromethoxy)benzoyl)-1H-pyrrole-2-
carboxamide (224) 
 
 
Compound 224 was synthesised according to general procedure A, using N-benzyl-1H-
pyrrole-2-carboxamide (223) (100 mg, 0.50 mmol), 3-(trifluoromethoxy)benzoyl 
chloride (0.162 mL, 1.00 mmol), DCM (4 mL), and AlCl3 (167 mg, 1.25 mmol). The 
crude residue was purified by reversed phase MPLC (C18 silica, 1-50% MeOH (1% 
formic acid) in H2O (1% formic acid)) and the title compound obtained as a dark red 
solid (163 mg, 84%); Rf = 0.89 (5% MeOH in EtOAc); M.p 203 
oC (dec.); λmax 
(EtOH)/nm 241; νmax/cm
-1
 3232, 2924, 2362, 2188,1650 (CO), 1560 (CONH); 
1
H NMR 
(500 MHz, MeOD) δ 4.59 (2 H, br d, J = 5.9 Hz, CH2), 7.24 (1 H, br s, H-3), 7.40-7.41 
(2 H, m,  H-5 and H-Ar), 7.49-7.52 (1 H, m, H-Ar), 7.54 (1 H, s, H-Ar), 7.62 (2H, d, J = 
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6.1 Hz, CH-pyridine), 7.70 (1H, d, J = 8.0 Hz, H-Ar), 8.51 (2H, d, J = 6.1 Hz, CH-N-
pyridine),  8.93 (1H, t, J = 5.9 Hz, CONH); 
13
C NMR (125 MHz, MeOD) δ 43.3 (CH2), 
113.1 (C-Ar), 122.1 (C-3), 125.4 (C-pyridine), 125.7 (C-2 and C-5), 128.7 (CF3), 130.1 
(C-4), 131.6 (C-Ar), 142.6 (C-pyridine), 145.7 (C-pyridine), 150.6 (C-pyridine), 158.2 
(C-Ar), 163.1 (CONH), 190.7 (CO); 
19
F NMR (470 MHz, MeOD) δ -56.8; LRMS (ES+) 
m/z 390.3 [M+H]
+
; HRMS m/z calcd for C19H15F3N3O3 [M+H]
+
 390.1054, found 
390.1053. 
 
Methyl 4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylate (228)  
 
 
Compound 228 was synthesised according to general procedure A using methylpyrrole-
2-carboxylate (69) (400 mg, 3.20 mmol), DCM (7 mL), AlCl3 (1.07 g, 8.00 mmol) and 
2-(trifluoromethyl)benzoyl chloride (0.94 mL, 6.40 mmol) to afford the crude product. 
Purification was achieved using MPLC (0-80% EtOAc in petrol) to give the pure 
compound as a pale yellow solid (800 mg, 84%); Rf = 0.48 (50% EtOAc in petrol); M.p. 
143-144 
o
C; λmax (EtOH)/nm 279.0, 231.5; νmax/cm
-1
 3282, 1710 (CO2Me), 1642 (CO), 
1556,; 
1
H NMR (500 MHz, DMSO-d6) δ 3.80 (3H, s, CH3), 6.98 (1H, s, H-3), 7.39 (1H, 
s, H-5), 7.59 (1H, d, J = 7.3 Hz, H-Ar), 7.73-7.80 (2H, m, H-Ar), 7.87 (1H, d, J = 7.3 
Hz, H-Ar), 12.82 (1H, s, NH);  
13
C NMR (125 MHz, DMSO-d6) δ 51.6 (CH3), 115.1 
(C-3), 124.1 (CF3), 126.6 (C-2 and C-5), 128.1 (C-4), 129.9 (C-Ar), 130.1 (C-Ar), 132.3 
(C-Ar), 160.3 (CO2Me), 188.8 (CO); LRMS (ES
+
) m/z 296.1 [M-H]
-
; 
19
F NMR (470 
MHz, DMSO-d6) δ -56.8; HRMS m/z calcd for C14H11F3NO3 [M-H]
-
 296.0539, found 
296.0538. 
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Methyl 4-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylate (229)  
 
 
Compound 229 was synthesised according to general procedure A using methylpyrrole-
2-carboxylate (69) (400 mg, 3.20 mmol), DCM (7 mL), AlCl3 (1.07 g, 8.00 mmol) and 
2-fluoro-6-(trifluoromethyl)benzoyl chloride (0.99 mL, 6.40 mmol) to afford the crude 
product. Purification was achieved using MPLC (0-80% EtOAc in petrol) to give the 
pure compound as a pale yellow solid (604 mg, 60%); Rf = 0.56 (50% EtOAc in petrol); 
M.p. 148-149 
o
C; λmax (EtOH)/nm 275.0, 231.5; νmax/cm
-1
 3274, 1699 (CO2Me), 1657 
(CO), 1563,; 
1
H NMR (500 MHz, CDCl3) δ 3.80 (3H, s, CH3), 7.07 (1H, s, H-3), 7.27-
7.31 (1H, m, H-Ar), 7.36 (1H, dd, J = 1.8 and 3.3 Hz, H-5), 7.47-7.51 (2H, m, H-Ar), 
9.44 (1H, s, NH); 
13
C NMR (125 MHz, CDCl3) δ  52.0 (CH3), 115.4 (C-3), 119.5 (CF3), 
122.3 (C-2 and C-3), 124.5 (C-4), 127.3 (C-Ar), 131.0 (C-Ar), 131.1 (C-Ar), 158.3 (d, 
JCF = 246.8, CF), 161.0 (CO2Me), 181.3 (CO); 
19
F NMR (470 MHz, CDCl3) δ -113.2, -
58.2,; LRMS (ES
+
) m/z 316.2 [M+H]
+
; HRMS m/z calcd for C14H8F4NO3 [M-H]
-
 
316.0596, found 316.0596.  
 
4-(2-(Trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylic acid (230)  
 
 
Compound 230 was synthesised according to general procedure B using methyl 4-(2-
(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylate (69) (450 mg, 1.43 mmol), LiOH 
(685 mg, 28.60 mmol) in water (18 mL) and THF (12 mL) to afford the pure product as 
a white solid (430 mg, 99%); Rf = 0.40 (5% MeOH in EtOAc); M.p. 210-211 
o
C; λmax 
(EtOH)/nm 274.0, 231.0; νmax/cm
-1
 3350, 1650 (CO2H), 1564 (CO); 
1
H NMR (500 
MHz, DMSO-d6) δ 6.93-6.94 (1H, m, H-3), 7.31 (1H, dd, J = 1.5 and 3.4 Hz, H-5), 7.58 
(1H, d, J = 7.6 Hz, H-Ar), 7.72-7.79 (2H, m, H-Ar), 7.88 (1H, d, J = 7.6 Hz, H-Ar), 
12.62 (1H, s, CO2H), 12.88 (1H, br s, NH);  
13
C NMR (500 MHz, DMSO-d6) δ 114.7 
(C-3), 125.2 (C-2), 125.4 (C-5), 125.8 (C-Ar), 126.0 (CF3), 126.6 (C-Ar), 128.1 (C-Ar), 
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129.5 (C-4), 130.1, 132.3, 138.8 (C-Ar), 161.4 (CO2H), 188.9 (CO); 
19
F NMR (470 
MHz, DMSO-d6) δ -58.0; LRMS (ES
+
) m/z 282.1 [M-H]
-
; HRMS m/z calcd for 
C13H8F3NO3 [M-H]
-
 282.0384, found 282.0387. 
 
4-(2-Fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylic acid (231)  
 
 
Compound 231 was synthesised according to general procedure B using methyl 4-(2-
fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylate (69) (450 mg, 1.43 
mmol), LiOH (685 mg, 28.60 mmol) in water (18 mL) and THF (12 mL) to afford the 
pure product as a white solid (430 mg, 99%); Rf = 0.35 (5% MeOH in EtOAc); M.p. 
210-211 
o
C; λmax (EtOH)/nm 274.0, 231.0; νmax/cm
-1
 3350, 1650 (CO2H), 1564 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ  6.95 (1H, s, H-3), 7.46 (1H, s, H-5), 7.69-7.73 (2H, m, 
H-3’ and H-5’), 7.77 (1H, ddd, J = 5.4, 8.0 and 8.0 Hz, H-4’), 12.69 (1H, s, NH), 12.99 
(1H, s, COOH);  
13
C NMR (125 MHz, DMSO-d6) δ 114.0 (C-3), 120.4 (d, JCF = 22.2 
Hz, C-Ar), 121.9, 122.7 (C-2 and C-5), 123.0 (q, JCF = 273.5 Hz, CF3), 125.8 (C-Ar), 
126.9 (d, JCF = 24.2 Hz, C-Ar), 127.6 (d, JCF = 31.0 Hz, C-Ar), 129.5 (C-4), 132.0 (d, 
JCF = 9.4 Hz, C-Ar), 158.3 (d, JCF = 240.6 Hz, CF-Ar), 161.3 (CO2H), 184.1 (CO); 
19
F 
NMR (470 MHz, DMSO-d6) δ -114.7, -57.0; LRMS (ES
+
) m/z 302.20 [M+H]
+
; HRMS 
m/z calcd for C13H7F4NO3 [M-H]
-
 300.0289, found 300.0280. 
 
N-(Pyridin-3-yl)-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide (232) 
 
 
Compound 232 was synthesised according to general procedure D using 4-(2-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (230) (50 mg, 0.18 mmol), 
MeCN (1 mL), 3-aminopyridine (42 mg, 0.44 mmol)  and PCl3 (16 µL, 0.18 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
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in EtOAc) to give the pure compound as a white solid (25 mg, 38%); Rf = 0.57 (5% 
MeOH in EtOAc); M.p. 197-198 
o
C; λmax (EtOH)/nm 235, 291; νmax/cm
-1
: 2362, 2050, 
2000, 1635 (CO), 1533 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.34 (1 H, s, H-3),  
7.40-7.43 (1 H, m, CH-pyridine), 7.50 (1H, s, CH-pyridine),  7.62 (1 H, d, J = 7.5 Hz,  
H-6’), 7.75-7.83 (2 H, m, H-4’ and H-5’), 7.90 (1H, d, J = 7.5 Hz, H-3’), 8.15-8.17 (1H, 
m, CH-N-pyridine), 8.31 (1H, d, J = 5.9 Hz, CH-N-pyridine), 10.25 (1 H, s, CONH), 
12.63 (1 H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 114.2 (2 x C-pyridine), 120.1 
(C-3), 126.9 (C-2 and C-5), 130.2 (C-4), 131.4 (C-Ar), 131.6 (C-Ar), 132.9 (C-Ar), 
135.6 (C-Ar), 137.7 (C-Ar), 143.4 (C-Ar), 145.6 (2 x C-N-pyridine), 148.1(C-pyridine), 
161.5 (CONH), 189.1 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -56.8; LRMS (ES
+
) m/z 
358.2 [M-H]
-
;
 
HRMS m/z calcd for C18H12F3N3O2 [M+H]
+
 360.0954, found: 360.0959. 
 
4-(2,3-Dichlorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (233) 
 
 
Compound 233 was synthesised according to general procedure D using 4-(2,3-
Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) (50 mg, 0.17 mmol), MeCN (1 
mL), 3-aminopyridine (39 mg, 0.42 mmol)  and PCl3 (15 µL, 0.17 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a beige solid (45 mg, 75%); Rf = 0.61 (5% MeOH in 
EtOAc); M.p. 199-200 
o
C; λmax (EtOH)/nm 292; νmax/cm
-1
 3356, 2365, 2163, 2026, 1641 
(CO), 1526 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.37 (1 H, dd, J = 4.9 and 8.2 
Hz, H-Ar), 7.42 (1H, s, H-3), 7.47-7.53 (3 H, m, 2 x H-Ar and H-5), 7.79 (1 H, dd, J  =  
1.4 and 7.5 Hz, CH-pyridine), 8.13-8.16 (1H, m,  CH-pyridine),  8.29 (1 H, dd, J = 1.4 
and 4.7 Hz,  CH-N-pyridine), 8.90 (1 H, d, J = 2.4 Hz,  CH-N-pyridine), 10.22 (1 H, s, 
CONH), 12.67 (1 H, br s, NH);
 13
C NMR (125 MHz, MeOD) δ  114.1 (2 x C-pyridine), 
123.4 (C-3), 125.1, 126.0 (C-2 and C-5), 129.9 (C-4), 130.1 (C-Ar), 131.5 (C-Ar), 132.8 
(C-Ar), 135.9 (C-Ar), 138.1 (C-Ar), 143.6 (C-Ar), 145.0 (2 x C-N-pyridine), 146.2 (C-
pyridine), 159.8 (CONH), 187.6 (CO);   LRMS (ES
+
) m/z 359.0 [M+H]
+
; HRMS m/z 
calcd for C17H10
35
Cl2N3O2 [M-H]
-
 358.0161, found: 358.0161.  
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N-(Pyridin-4-yl)-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide (234)  
 
 
Compound 234 was synthesised according to general procedure D using 4-(2-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (230) (50 mg, 0.18 mmol), 
MeCN (1 mL), 4-aminopyridine (42 µL, 0.44 mmol)  and PCl3 (16 µL, 0.18 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a white solid (35  mg, 0.10 mmol, 58%); Rf = 
0.60 (5% MeOH in EtOAc); M.p. 175-176 
o
C; λmax (EtOH)/nm 271, 292; νmax/cm
-1
: 
3343, 3115, 2977, 1732 (CO), 1624 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.35 (1 
H, s, H-3), 7.53 (1 H, s, H- 5), 7.62 (1H, d,  J  =  7.8 Hz, H-Ar),  7.74 (2 H, d, J = 6.5 
Hz,  CH-pyridine), 7.76-7.82 (2H, m, H-Ar), 7.91 (1H, d,  J  =  7.8 Hz, H-Ar) 8.46 (2 H, 
d, J = 6.5 Hz,  CH-N-pyridine), 10.33 (1 H, s, CONH) 12.67 (1 H, br s, NH); 
19
F NMR 
(470 MHz, DMSO-d6) δ -56.8; LRMS (ES
+
) m/z 360.3 [M+H]
+
; HRMS m/z calcd for 
C18H12F3N3O2 [M+H]
+
 360.0954, found: 360.0959. 
 
4-(2,3-Dichlorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (235) 
 
 
Compound 235 was synthesised according to general procedure D using 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) (50 mg, 0.17 mmol), MeCN (1 
mL), 4-aminopyridine (39 mg, 0.42 mmol)  and PCl3 (15 µL, 0.17 mmol) to afford the 
crude product. Purification was achieved using MPLC (silica, 0-10% MeOH in EtOAc) 
to give the pure compound as a white solid (40 mg, 67%); Rf = 0.60 (5% MeOH in 
EtOAc); M.p. 251-252 
o
C; λmax (EtOH)/nm 272, 293; νmax/cm
-1
: 2588, 2342, 2160, 
2018, 1636 (CO), 1591 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 7.45-7.56 (4 H, m, 
2 x H-Ar, H-3 and H-5), 7.74 (2H, d,  J  =  5.9 Hz, CH-pyridine),  7.80 (2 H, dd, J = 2.4 
and 7.8 Hz,  H-Ar), 8.46 (2 H, d, J = 5.9 Hz,  CH-N-pyridine), 10.33 (1 H, s, CONH) 
12.71 (1 H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ  113.2 (2 x C-pyridine), 125.3 
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(C-3), 126.7, 127.9 (C-2 and C-5), 129.2 (C-4), 129.9 (C-Ar), 131.1 (C-Ar), 132.7 (C-
Ar), 134.8 (C-Ar), 137.5 (C-Ar), 142.4 (C-Ar), 143.2 (2 x C-N-pyridine), 145.2 (C-
pyridine), 160.9 (CONH), 190.6 (CO); LRMS (ES
+
) m/z 359.3 [M+H]
+
; HRMS m/z 
calcd for C17H12
35
Cl2N3O2 [M+H]
+
 359.0215, found: 359.0214.  
 
N-(3-Aminophenyl)-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide 
(236) 
 
Compound 236 was synthesised according to general procedure D using 4-(2-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (230) (50 mg, 0.18 mmol), MeCN 
(1 mL), 1,3-phenylenediamine (48 mg, 0.44 mmol)  and PCl3 (16 µL, 0.18 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a white solid (37 mg, 55%); Rf = 0.50 (5% 
MeOH in EtOAc); M.p. 205 
o
C (dec.); λmax (EtOH)/nm 236; νmax/cm
-1
: 3337 (NH2), 
2360, 1611 (CO), 1557 (CONH); 
1
H NMR (500 MHz, MeOD) δ 6.52 (1H, d, J = 7.7 Hz, 
H-Ar), 6.94 (1H, d, J = 7.7 Hz, H-Ar), 7.06-7.09 (1H, m, H-Ar), 7.13-7.14 (1H, m, H-
Ar), 7.33 (1H, d, J = 1.5 Hz, H-3), 7.39 (1H, d, J = 1.5 Hz, H-5), 7.57 (1H, d, J = 7.1 Hz, 
H-6’), 7.71-7.78 (2H, m, H-4’ and H-5’), 7.85 (1H, d, J = 7.1 Hz, H-3’); 13C NMR (125 
MHz, MeOD) δ 109.2, 112.0, 112.5, 112.8, 127.2, 127.7 (C-Ar), 127.8 (C-3), 129.5 (C-2 
and C-5), 130.3 (C-4), 130.5 (C-Ar), 131.1 (C-Ar), 133.0 (C-Ar), 140.2 (C-Ar), 149.3 
(C-Ar), 160.8 (CON), 192.4 (CO); 
19
F NMR (470 MHz, MeOD) δ -59.4; LRMS (ES+) 
m/z 374.3 [M+H]
+
; HRMS m/z calcd for C19H14F3N3O2Na [M+Na]
+
 396.0928, found 
396.0928. 
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N-(3-Aminophenyl)-4-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-
carboxamide (237) 
 
Compound 237 was synthesised according to general procedure D using 4-(2-fluoro,6-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (231) (50 mg, 0.17 mmol), 
MeCN (1 mL), 1,3-phenylenediamine (45 mg, 0.42 mmol)  and PCl3 (15 µL, 0.17 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as a beige solid (30 mg, 45%); Rf = 
0.45 (5% MeOH in EtOAc); M.p. 251-252 
o
C; λmax (EtOH)/nm 238; νmax/cm
-1
 2364 
(NH2), 2336, 1615 (CO), 1559 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ  6.31 (1H, d, 
J = 8.3 Hz, H-Ar), 6.84 (1H, d, J = 8.3 Hz, H-Ar), 6.93-6.97 (1H, m, H-4’), 7.00-7.01 
(1H, m, H-Ar), 7.38 (1H, br s, H-3), 7.46 (1H, br s, H-5), 7.71-7.82 (3H, m, H-3’, H-5’ 
and H-Ar), 9.75 (1H, br s, CONH), 12.52 (1H, br s, NH); 
13
C NMR (125 MHz, MeOD) 
δ  109.2 (C-Ar), 112.0 (C-Ar), 112.9 (C-Ar), 120.9 (C-3), 121.0 (d, JCF = 22.8 Hz, C-
Ar), 123.5 (C-Ar), 127.9 (C-2 and C-5), 128.9 (d, JCF = 22.8 Hz, C-Ar), 130.0 (C-Ar), 
130.3 (C-Ar), 130.6 (C-Ar), 132.8 (d, JCF = 8.9 Hz, C-Ar), 140.2 (C-Ar), 149.3 (C-Ar), 
160.3 (d, JCF = 243.5 Hz, CF-Ar), 160.7 (CON), 187.2 (CO);  
19
F NMR (470 MHz, 
DMSO-d6) δ -114.4, -57.0; LRMS (ES
+
) m/z 392.4 [M+H]
+
; HRMS m/z calcd for 
C19H13F4N3O2 [M+H]
+
 392.1018, found 392.1019. 
 
N-(3-Aminophenyl)-4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxamide (238)  
 
 
Compound 238 was synthesised according to general procedure D using 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) (50 mg, 0.17 mmol), MeCN (1 
mL), 1,3-phenylenediamine (45 mg, 0.42 mmol)  and PCl3 (15 µL, 0.17 mmol). The 
reaction was performed at 100 
o
C. Purification of the crude product was achieved using 
MPLC (silica, 0-10% MeOH in EtOAc) to give the pure compound as a beige solid (35 
mg, 52%); Rf = 0.58 (5% MeOH in EtOAc); M.p. 251-252 
o
C; λmax (EtOH)/nm 216; 
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νmax/cm
-1
: 3333 (NH2), 3123, 2160, 2023, 1596 (CO), 1557 (CONH); 
1
H NMR (500 
MHz, MeOD) δ 6.52 (1H, d, J = 7.5 Hz, H-Ar), 6.94 (1H, d, J = 7.5 Hz, H-Ar), 7.06-
7.09 ( 1H, m, H-Ar), 7.13-7.14 (1H, m, H-Ar), 7.39-7.41 (2H, m, H-6’ and H-3), 7.42 
(1H, d, J = 2.2 Hz, H-5), 7.44-7.47 (1H, m, H-4’), 7.70 (1H, dd, J = 1.6 and 8.0 Hz, H-
5’), 8.55 (1H, br s, CONH); 13C NMR (500 MHz, MeOD) δ 109.2 (C-Ar), 112.0 (C-Ar), 
112.5 (C-Ar), 112.8 (C-Ar), 128.0 (C-3), 129.2 (C-2 and C-5), 129.9 (C-4), 130.3 (C-
Ar), 130.6 (C-Ar), 132.6 (C-Ar), 134.8 (C-Ar), 140.2 (C-Ar), 149.6 (C-Ar), 160.8 
(CON), 180.0 (CO); LRMS (ES
+
) m/z 372.2 [M-H]
-
; HRMS m/z calcd for 
C18H13
35
Cl2N3O2 [M+H]
+
 374.0461, found 374.0461. 
 
N-(3-Sulfamoylphenyl)-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide 
(239) 
 
Compound 239 was synthesised according to general procedure D using 4-(2-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (230) (50 mg, 0.18 mmol), 
MeCN (1 mL), 3-aminobenzenesulfonamide (75 mg, 0.44 mmol)  and PCl3 (16 µL, 0.18 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the title compound as a white solid (40 mg, 51%); Rf = 
0.55 (5% MeOH in EtOAc); M.p. 301-302 
o
C; λmax (EtOH)/nm 292; νmax/cm
-1
: 3400, 
3013, 2948, 2775, 2112, 1777, 1706 (CO), 1670 (CONH); 
1
H NMR (500 MHz, DMSO-
d6) δ  7.33 (1 H, s, H-3), 7.37 (2H, br s, SO2NH2), 7.53-7.55 (3H, m, H-3’, H-5’ and H-
6’), 7.62 (1H, d, J = 7.5 Hz, H-Ar), 7.74-7.77 (2H, m, H-Ar), 7.90 (1H, d, J = 7.5 Hz, 
H-Ar), 7.96-7.99 (1H, m, H-4’),  8.28 (1 H, s, H- 5), 10.32 (1 H, s, CONH) 12.55 (1 H, 
br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ  112.1 (C-Ar), 117.0 (C-Ar), 120.4 (C-3), 
125.4 (C-2 and C-5), 130.1 (C-4), 139.2 (C-Ar), 139.8 (C-Ar), 157.4 (CON), 177.1 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -56.8; LRMS (ES
+
) m/z 436.0 [M-H]
-
;
 
HRMS 
m/z calcd for C19H14F3N3O4SNa [M+Na]
+
 455.0990, found 455.0991. 
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4-(2-Fluoro-6-(trifluoromethyl)benzoyl)-N-(3-sulfamoylphenyl)-1H-pyrrole-2-
carboxamide (240) 
 
Compound 240 was synthesised according to general procedure D using 4-(2-fluoro,6-
trifluoromethylbenzoyl)-1H-pyrrole-2-carboxylic acid (231) (50 mg, 0.17 mmol), 
MeCN (1 mL), 3-aminobenzenesulfonamide (72 mg, 0.42 mmol)  and PCl3 (17 µL, 0.17 
mmol) to afford the crude product. Purification was achieved using MPLC (silica, 0-
10% MeOH in EtOAc) to give the pure compound as a pale yellow solid (57 mg, 75%); 
Rf = 0.53 (5% MeOH in EtOAc); M.p. 263-264 
o
C; λmax (EtOH)/nm 291; νmax/cm
-1
: 
3201, 2667, 2339, 1650 (CO), 1559 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ  7.37 
(2 H, s, SO2NH2), 7.47 (1 H, s, H-3), 7.52 (1 H, s,H- 5), 7.52 (2H, d,  J  =  7.6 Hz, H-
Ar),  7.72-7.82 (3H, m, H-3’, H-4’ and H-5’), 7.96-7.98 (1H, m, H-Ar), 8.26 (1H, s, H-
Ar),  10.31 (1 H, s, CONH) 12.65 (1 H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ  
111.4 (C-Ar), 116.9 (C-Ar), 122.7 (C-3), 125.8 (C-2 and C-5), 129.4(C-4), 139.2 (C-
Ar), 144.6 (C-Ar), 157.4 (CON), 177.1 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -56.9, -
114.6; LRMS (ES
+
) m/z 456.3 [M+H]
+
; HRMS m/z calcd for C19H13F4N3O4S [M-H]
-
 
454.0483, found 454.0483.  
 
4-(2,3-Dichlorobenzoyl)-N-(3-sulfamoylphenyl)-1H-pyrrole-2-carboxamide (241) 
 
 
Compound 241 was synthesised according to general procedure D using 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) (50 mg, 0.17 mmol), MeCN (1 
mL), 3-aminobenzenesulfonamide (72 mg, 0.42 mmol)  and PCl3 (15 µL, 0.17 mmol) to 
afford the crude product. Purification was achieved using MPLC (silica, 0-10% MeOH 
in EtOAc) to give the pure compound as a beige solid (43 mg, 57%); Rf = 0.62 (5% 
MeOH in EtOAc); M.p. 261-262 
o
C; λmax (EtOH)/nm: 236; νmax/cm
-1
 3346, 2853, 1622 
(CO), 1558 (CONH), 1532; 
1
H NMR (500 MHz, DMSO-d6) δ 7.40 (2H, br s, SO2NH2), 
7.43 (1H, s, H-3), 7.47-7.55 (5H, m, 2 x H-Ar, H-4’, H-5’ and H-6’), 7.81 (1H, dd, J = 
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2.0 and 7.6 Hz, H-Ar), 7.98-8.00 (1H, m, H-Ar), 8.27 (1H, s, H-Ar), 10.35 (1H, s, 
CONH), 12.69 (1H, s, NH); 
13
C NMR (125 MHz, MeOD) δ 112.8 (C-Ar), 113.0 (C-
Ar), 115.5 (C-Ar), 119.2 (C-Ar), 122.4 (C-3), 124.8 (C-2 and C-5), 130.6 (C-4), 132.7 
(C-Ar), 145.5 (C-Ar), 150.1 (CON), 176.6 (CO); LRMS (ES
+
) m/z 438.2 [M+H]
+
; 
HRMS m/z calcd for C18H13
35
Cl2N3O4S [M+H]
+
 435.9923, found 435.9923. 
 
tert-Butyl-4-(4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamido)piperidine-
1-carboxylate (242)  
 
Compound 242 was synthesised according to general procedure C using 4-(2- 
(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylic acid (230) (100 mg, 0.35 mmol), 
THF (4 mL), 4-amino-1-boc-piperidine (176 mg, 0.88 mmol)  and CDI (113 mg, 0.70 
mmol). Purification of the crude product was achieved using MPLC (silica, 0-10% 
MeOH in EtOAc) to give the pure compound as a yellow solid (134 mg, 82%); Rf = 
0.61 (5% MeOH in EtOAc); M.p. 195-196 
o
C; λmax (EtOH)/nm 236.0, 282.5; νmax/cm
-1
 
3183, 1620 (CO2
t
Bu), 1568 (CO), 1534 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.25-
1.33 (2H, m, CH2),  1.40 (9H, s, 3 x CH3), 1.84-1.88 (2H, m, CH2), 2.74-2.82 (2H, m, 
CH2N), 3.94-4.05 (3H, m, CH2N and CH), 7.03 (1H, dd, J = 1.3 and 2.4 Hz,  H-3); 7.09 
(1H, dd, J = 1.3 and 3.2 Hz, H-5), 7.39 (1H, d, J = 7.1 Hz, H-6’), 7.52-7.57 (2H, m, H-
4’ and H-5’), 7.69 (1H, d, J = 7.1 Hz, H-3’), 10.02 (1H, br s, NH); 13C NMR (125 MHz, 
CDCl3) δ  28.4 (3 x CH3), 32.0 (2 x CH2), 47.0 (2 x CH2N), 79.8 (CH), 109.3 (C-Ar), 
122.5 (C-3), 126.6 (C-Ar), 126.7, 126.8 (C-5 and C-5), 127.9 (C-Ar), 128.2 (C-Ar), 
129.7 (C-Ar), 131.4 (C-4), 139.0 (C-Ar), 154.6 (CO2
t
Bu), 159.8 (CON), 189.9 (CO); 
19
F 
NMR (470 MHz, CDCl3) δ -59.0; LRMS (ES
+
) m/z 482.40 [M-H]
-
; HRMS m/z calcd for 
C23H27F3N3O4 [M+H]
+
 483.2210, found 483.2210. 
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tert-Butyl-4-(4-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (243)  
 
Compound 243 was synthesised according to general procedure C using 4-(2-fluoro, 6-
(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylic acid (231) (100 mg, 0.33 mmol), 
THF (4 mL), 4-amino-1-boc-piperidine (165 mg, 0.83 mmol)  and CDI (108 mg, 0.66 
mmol). Purification of the crude product was achieved using MPLC (silica, 0-10% 
MeOH in EtOAc) to give the pure compound as a peach solid (119 mg, 75%); Rf = 0.60 
(5% MeOH in EtOAc); M.p. 190-191 
o
C; λmax (EtOH)/nm 236.0, 274.5; νmax/cm
-1
: 3242, 
1623 (CO2
t
Bu), 1568 (CO), 1537 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.27-1.36 
(2H, m, CH2),  1.39 (9H, s, 3 x CH3), 1.86-1.90 (2H, m, CH2), 2.80-2.83 (2H, m, 
CH2N), 3.96-4.04 (3H, m, CH2N and CH), 6.96-6.97 (1H, m, H-3); 7.15 (1H, dd, J = 
1.3 and 3.2 Hz, H-5), 7.28-7.31 (2H, m, H-3’ and H-5’), 7.48-7.53 (1H, m, H-4’), 9.92 
(1H, br s, NH); 
13
C NMR (500 MHz, MeOD) δ 28.4 (3 x CH3), 32.1 (2 x CH2), 47.1 (2 
x CH2N), 79.8 (CH), 108.6, 119.6 (d, JCF = 22.9 Hz, C-Ar), 119.7 (C-3), 122.3 (C-Ar), 
127.1 (C-2 and C-5), 127.7, 128.0 (C-Ar), 131.1 (C-4), 131.5 (d, JCF = 8.1 Hz, C-Ar), 
154.7 (d, JCF = 243.1 Hz, CF), 159.6 (CO2
t
Bu), 160.0 (CON), 184.9 (CO); 
19
F NMR 
(470 MHz, MeOD) δ  -113.2, -58.1; LRMS (ES+) m/z 482.4 [M-H]-; HRMS m/z calcd 
for C23H26F4N3O4 [M+H]
+
 484.1235, found 484.1230. 
 
tert-Butyl 4-(4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate (244)  
 
Compound 244 was synthesised according to general procedure C using 4-(2,3-
dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (155) (100 mg, 0.35 mmol), THF (4 
mL), 4-amino-1-boc-piperidine (175 mg, 0.88 mmol)  and CDI (114 mg, 0.70 mmol). 
Purification of the crude product was achieved using MPLC (silica, 0-10% MeOH in 
EtOAc) to give the pure compound as a white solid (131 mg, 80%); Rf = 0.65 (5% 
MeOH in EtOAc); M.p. 185-186 
o
C; λmax (EtOH)/nm 236.5, 287.0; νmax/cm
-1
: 3158, 
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1686 (CO2
t
Bu), 1621 (CO), 1571 (CONH), 1537; 
1
H NMR (500 MHz, DMSO-d6) δ 
1.41 (9H, s, 3 x CH3), 1.67-1.77 (4H, m, 2 x CH2), 3.50-3.56 (1H, m, CH), 3.67-3.84 
(4H, m, 2 x CH2N), 7.17 (1H, d, J = 1.3 Hz, H-3); 7.27 (1H, d, J = 1.3 Hz, H-5), 7.42 
(1H, dd, J = 1.5 and 8.0 Hz, H-Ar), 7.47-7.45 (1H, m, H-Ar), 7.48 (1H, dd, J = 1.5 and 
8.0 Hz, H-Ar), 8.10 (1H, d, J = 7.7 Hz, CONH), 12.02 (1H, br s, NH); 
13
C NMR (125 
MHz, CDCl3) δ  28.4 (3 x CH3), 32.1 (2 x CH2), 47.1 (2 x CH2N), 79.8 (CH), 109.0 (C-
Ar), 123.9 (C-3), 126.4 (C-2 and C-5), 127.4 (C-Ar), 127.9 (C-Ar), 131.5 (C-4), 141.5 
(C-Ar), 159.5 (CO2
t
Bu), 163.7 (CON), 184.2 (CO); LRMS (ES
+
) m/z 464.3 [M-H]
-
; 
HRMS m/z calcd for C22H26
35
Cl2N3O4 [M+H]
+
 466.1295, found 466.1294. 
 
N-(Piperidin-4-yl)-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide (245) 
 
Compound 245 was synthesised according to general procedure E using tert-Butyl 4-(4-
(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-carboxylate (230) 
(40 mg, 0.09 mmol), TFA (1.0 mL), Et3SiH (34 µL, 0.10 mmol) and DCM (2 mL). The 
pure product was obtained as a white solid (30 mg, 97%); Rf = 0.48 (5% MeOH in 
EtOAc); M.p. 233-134 
o
C; λmax (EtOH)/nm 236, 341; νmax/cm
-1
 3311 (NH), 2939, 2833, 
2671, 1626 (CO), 1617 (CONH); 
1
H NMR (500 MHz, MeOD) δ  1.30-1.38 (2H, m, 
CH2), 1.69 (2H, d, J = 10.3 Hz, CH2), 2.46-2.48 (2H, m, CH2N), 2.10 (2H, d, J = 10.3 
Hz, CH2N), 3.72-3.79 (1H, m, CH), 7.15 (2H, br s, H-3 and H-5), 7.55 (1H, d, J = 7.3 
Hz, H-6’), 7.70-7.78 (2H, m, H-4’ and H-5’), 7.85 (1H, d, J = 7.3 Hz, H-3’), 8.03 (1H, 
br s, CONH); 
13
C NMR (125 MHz, CDCl3) δ  33.0 (2 x CH2), 49.2 (2 x CH2N), 79.9 
(CH), 110.5 (C-Ar), 123.4 (C-3), 128.0 (C-Ar), 126.8 (C-5 and C-5), 128.1 (C-Ar), 
128.5 (C-Ar), 129.9 (C-Ar), 131.0 (C-4), 140.1 (C-Ar), 164.1 (CON), 184.2 (CO);  
19
F 
NMR (470 MHz, MeOD) δ -56.8; LRMS (ES+) m/z 366.3 [M+H]+; HRMS m/z calcd for 
C18H19F3N3O2 [M+H]
+
 366.1423, found 366.1424. 
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4-(2-Fluoro-6-(trifluoromethyl)benzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-
carboxamide (246) 
 
Compound 246 was synthesised according to general procedure E using tert-Butyl 4-(4-
(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate (231) (40 mg, 0.08 mmol), TFA (1.0 mL), Et3SiH (34 µL, 0.20 mmol) and 
DCM (2 mL). the pure product was obtained as a white solid (20 mg, 65%); Rf = 0.45 
(5% MeOH in EtOAc); M.p. 225-227 
o
C; λmax (EtOH)/nm 236; νmax/cm
-1
: 2815 (NH), 
2106, 1720 (CO), 1615 (CONH); 
1
H NMR (500 MHz, MeOD) δ  1.34-1.42 (2H, m, 
CH2), 1.79 (2H, d, J = 11.9 Hz, CH2), 2.52-2.57 (2H, m, CH2N), 2.95 (2H, d, J = 11.9 
Hz, CH2N), 3.77-3.83 (1H, m, CH),  7.05 (1 H, s, H-3), 7.21 (1 H, s,H- 5), 7.39-7.42 
(1H, m, H-4’), 7.52-7.61 (2H, m, H-3’ and H-4’); 13C NMR (125 MHz, MeOD) δ 33.3 
(2 x CH2), 44.7 (2 x CH2N), 58.4 (CH), 112.3 (C-Ar), 120.8 (C-3), 123.5 (C-2 and C-5), 
127.8 (C-4), 131.3 (C-Ar), 132.6 (C-Ar), 159.5 (C-Ar), 161.4 (C-Ar), 162.6 (CONH), 
186.9 (CO); 
19
F NMR (470 MHz, MeOD) δ -59.6, -115.8; LRMS (ES+) m/z 384.3 
[M+H]
+
; HRMS m/z calcd for C18H17F4N3O2 [M+H]
+
 392.1018, found 392.1019. 
4-(2,3-Dichlorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide (247) 
 
 
Compound 247 was synthesised according to general procedure E using tert-Butyl 4-(4-
(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-carboxylate (155) (20 
mg, 0.04 mmol), TFA (0.50 mL), Et3SiH (17 µL, 0.10 mmol) and DCM (1 mL). the 
pure product was obtained as a white solid (12 mg, 0.03 mmol, 80%); Rf = 0.55 (5% 
MeOH in EtOAc); M.p.    251 
o
C (dec.); λmax (EtOH)/nm: 236, 288; νmax/cm
-1
 3411 
(NH), 3310, 2114, 1632 (CO), 1601 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 1.28-
1.38 (2H, m, CH2), 1.69 (2H, d, J = 12.3 Hz, CH2), 2.45-2.48 (2H, m, CH2N), 2.95 (2H, 
d, J = 12.3 Hz, CH2N), 3.71-3.81 (1H, m, CH), 7.18 (1H, br s, H-3), 7.25 (1H, br s, H-
5), 7.42 (1H, d, J = 7.3 Hz, H-Ar), 7.47-7.50 (2H, m, H-Ar), 7.77 (1H, d, J = 7.3 Hz, H-
Ar), 8.06 (1H, br s, CONH); 
13
C NMR (125 MHz, DMSO-d6) δ 36.0 (2 x CH2), 45.6 (2 
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x CH2N), 59.9 (CH), 113.0 (C-Ar), 121.2 (C-3), 123.6 (C-2 and C-5), 129.2 (C-4), 
131.4 (C-Ar), 133.5 (C-Ar), 158.4 (C-Ar), 162.1 (C-Ar), 164.2 (CONH), 184.7 (CO); 
LRMS (ES
+
) m/z 367.2 [M+H]
+
; HRMS m/z calcd for C17H18
35
Cl2N3O2 [M+H]
+
 
366.0775, found: 366.0775. 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (268)  
 
Compound 268 was synthesised according to general procedure A using methyl pyrrole-
2-carboxylate (69) (2.00 g, 16.0 mmol), 3-chloro-2,6-difluorobenzoyl chloride (6.74 g, 
32.0 mmol), AlCl3 (5.33 g, 40.0 mmol) and DCM (40 mL). The crude mixture was 
purified by MPLC (0-50% EtOAc in petrol) to give the pure product as a white solid 
(4.50 g, 94%); Rf = 0.45 (5% MeOH in EtOAc); M.p. 187-188 
o
C; λmax (EtOH)/nm 234, 
283; νmax/cm
-1
: 3256,1694 (CO2Me), 1650 (CO), 1614, 1560; 
1
H NMR (500 MHz, 
CDCl3) δ 3.82 (3H, s, CH3), 6.88-6.92 (1H, m, H-5’),  7.15 (1H, br s, H-3), 7.41 (1H, 
dddd, J = 6.8, 6.9, 8.5 and 8.6 ,H-4’), 7.43 (1H, br s, H-5), 9.74 (1H, br s, NH); 13C 
NMR (125 MHz, CDCl3) δ 52.1 (CH3), 112.6 (C-Ar), 112.8 (C-Ar), 115.6 (C-Ar), 
124.6 (C-3), 128.2 (C-2 and C-5), 131.8 (C-4), 131.9 (C-Ar), 155.1 (d, JCF = 245.3 Hz, 
CF), 162.2 (d, JCF = 219.7  Hz, C-Ar), 166.0 (CO2Me), 191.0 (CO);
19
F NMR (470 
MHz, CDCl3) δ -113.4, -112.6; LRMS (ES
+
) m/z 300.6 [M+H]
+
; HRMS m/z calcd for 
C13H9
35
ClF2NO3 [M+H]
+ 
300.0240, found 300.0242. 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (269)  
 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (268) (500 mg, 1.67 
mmol) was dissolved in THF (5 mL) at 0 
o
C before potassium tert-butoxide (225 mg, 
2.00 mmol) was added and the mixture was stirred for 10 min. SEM chloride (0.354 
mL, 2.00 mmol) was added and the mixture was allowed to warm to RT overnight. The 
product was extracted with ethyl acetate and washed with water followed by brine. The 
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combined organic extracts were dried over Na2SO4 and the solvent was removed in 
vacuo. The product was purified using MPLC (0-50% ethyl acetate in petrol) to give the 
title product as a colourless oil (0.68 g, 95%); Rf = 0.55 (5% MeOH in EtOAc); λmax 
(EtOH)/nm 234, 279; νmax/cm
-1
: 2952, 1716 (CO2Me), 1660 (CO), 1578, 1542; 
1
H NMR 
(500 MHz, CDCl3) δ 0.00 (1H, s, Si(CH3)3), 0.93-0.96 (2H, m, CH2), 3.57-3.61 (2H, m, 
CH2), 3.86 (3H, s, CH3), 5.73 (2H, s, CH2O), 6.98-7.01 (1H, m, H-5’), 7.33 (1H, br s, 
H-3), 7.50 (1H, dddd, J = 6.7, 6.8, 8.6 and 8.7 ,H-4’), 7.57 (1H, br s, H-5); 13C NMR 
(125 MHz, CDCl3) δ 17.8 (Si(CH3)3), 51.7 (2 x CH2), 67.0 (CH3), 76.8 (CH2O), 112.6 
(C-Ar), 112.7 (C-Ar), 119.0 (C-Ar), 124.2 (C-3), 124.6 (C-2 and C-5), 131.7 (C-4), 
131.8 (C-Ar), 132.7 (C-Ar), 154.8 (d, JCF = 246.0 Hz, CF), 157.2 (d, JCF = 218.4  Hz, C-
Ar), 160.8 (CO2Me), 180.9 (CO);
19
F NMR (470 MHz, CDCl3) δ -113.5, -112.8; LRMS 
(ES
+
) m/z 430.8 [M+H]
+
; HRMS m/z calcd for C19H23
35
ClF2NO4Si [M+H]
+ 
430.1051, 
found 430.1051. 
 
Methyl 4-(3-ethyl-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (270)  
 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (269) (150 mg, 0.35 mmol) was dissolved in dioxane (3 mL), 
along with ethyl boronic acid (78 mg, 1.05 mmol) and Cs2CO3 (171 mg, 0.53 mmol). 
The mixture was degassed for 20 min before dichloro [1,1' bis(di-tert-
butylphosphino)]ferrocene palladium (II) (22 mg, 0.035 mmol) was added and it was 
degassed for a further 20 min. The reaction was heated under microwave irradiation for 
90 min at 150 
o
C before being filtered through Celite and the solvent removed in vacuo. 
The crude product was purified by MPLC (0-20% EtOAc in petrol) to give the 
compound as a pale yellow oil (88 mg, 60%); Rf = 0.54 (5% MeOH in EtOAc);  λmax 
(EtOH)/nm 235, 279; νmax/cm
-1
: 2953, 1719 (CO2Me), 1660 (CO), 1543; 
1
H NMR (500 
MHz, CDCl3) δ 0.00 (1H, s, Si(CH3)3), 0.93-0.96 (2H, m, CH2), 1.26 (3H, t, J = 7.5 Hz, 
CH2CH3), 2.70 (2H, q, J = 7.5 Hz, CH2CH3),  3.57-3.60 (2H, m, CH2), 3.87 (3H, s, 
CH3), 5.73 (2H, s, CH2O), 6.91-6.95 (1H, m, H-5’), 7.26-7.30 (1H, m, H-4’), 7.36 (1H, 
294 
 
br s, H-3), 7.56 (1H, br s, H-5); 
13
C NMR (125 MHz, CDCl3) δ 14.3 (CH2CH3), 17.8 
(Si(CH3)3), 51.7 (2 x CH2), 52.0 (CH2CH3), 66.0 (CH3), 75.0 (CH2O), 111.3 (C-Ar), 
111.8 (C-Ar), 119.2 (C-Ar), 123.9 (C-3), 125.1 (C-2 and C-5), 127.5 (C-4), 131.2 (C-
Ar), 132.8 (C-Ar), 156.7 (d, JCF = 247.5 Hz, CF), 161.0 (CO2Me), 168.1 (d, JCF = 220.4  
Hz, C-Ar), 182.8 (CO);
19
F NMR (470 MHz, CDCl3) δ -117.5, -119.6; LRMS (ES
+
) m/z 
424.4 [M+H]
+
; HRMS m/z calcd for C21H28F2NO4Si [M+H]
+ 
424.1750, found 
424.1752. 
Methyl 4-(3-ethyl-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (271) 
 
 
Methyl 4-(3-ethyl-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (270) (145 mg, 0.34 mmol) was dissolved in THF (1 mL) before 
TBAF (0.7 mL, 1.0 M in THF) was added and the reaction was heated to 65 
o
C for 18 h. 
Upon cooling to RT the solvent was removed in vacuo. The crude product was purified 
by MPLC (0-8 % MeOH in DCM) to give the pure product as a colourless oil (65 mg, 
65%); Rf = 0.42 (5% MeOH in EtOAc);  λmax (EtOH)/nm 236, 278; νmax/cm
-1
: 2952, 
1720 (CO2Me), 1668 (CO), 1541; 
1
H NMR (500 MHz, CDCl3) δ 1.27 (3H, t, J = 7.4 
Hz, CH2CH3), 2.71 (2H, q, J = 7.4 Hz, CH2CH3), 3.87 (3H, s, CH3), 6.91-6.95 (1H, m, 
H-5’), 7.26-7.30 (1H, dddd, J = 6.6, 6.7, 8.6 and 8.7 ,H-4’), 7.35 (1H, br s, H-3), 7.58 
(1H, br s, H-5), 9.65 (1H, s, NH); 
13
C NMR (125 MHz, CDCl3) δ 14.6 (CH2CH3), 49.0 
(CH2CH3), 65.0 (CH3), 112.3 (C-Ar), 112.6 (C-Ar), 120.1 (C-Ar), 123.6 (C-3), 126.6 
(C-2 and C-5), 129.5 (C-4), 131.2 (C-Ar), 132.7 (C-Ar), 153.1 (d, JCF = 245.1 Hz, CF), 
163.0 (CO2Me), 167.2 (d, JCF = 216.8  Hz, C-Ar), 186.0 (CO);
19
F NMR (470 MHz, 
CDCl3) δ -117.6, -119.1; LRMS (ES
+
) m/z 294.2 [M+H]
+
; HRMS m/z calcd for 
C15H14F2NO3 [M+H]
+ 
294.1852, found 294.1856. 
 
  
295 
 
4-(3-Ethyl-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (272) 
 
 
Compound 272 was synthesised according to general procedure B using, Methyl 4-(3-
ethyl-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (271) (60 mg, 0.20 mmol), THF (3 
mL), LiOH (96 mg) in H2O (3 mL). The pure product was obtained as a white solid (55 
mg, 98%);  Rf = 0.35 (5% MeOH in EtOAc); M.p. λmax (EtOH)/nm 235, 280; νmax/cm
-1
: 
2969, 1715 (CO2H), 1659 (CO), 1536; 
1
H NMR (500 MHz, DMSO-d6) δ 1.27 (3H, t, J 
= 7.5 Hz, CH2CH3), 2.74 (2H, q, J = 7.5 Hz, CH2CH3), 7.07 (1H, s, H-3), 7.23-7.27 
(1H, m, H-5’), 7.55-7.61 (2H, m, H-5 and H-4’), 12.76 (1H, s, NH), 13.03 (1H, br s, 
CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 15.0 (CH2CH3), 48.1 (CH2CH3), 111.6 (C-
Ar), 112.0 (C-Ar), 121.1 (C-Ar), 123.4 (C-3), 126.2 (C-2 and C-5), 129.5 (C-4), 132.2 
(C-Ar), 132.7 (C-Ar), 154.1 (d, JCF = 248.1 Hz, CF), 166.2 (d, JCF = 214.4  Hz, C-Ar), 
168.0 (CO2H), 185.6 (CO);
19
F NMR (470 MHz, CDCl3) δ -117.6, -119.7; LRMS (ES
+
) 
m/z 278.2 [M-H]
-
; HRMS m/z calcd for C14H10F2NO3 [M-H]
- 
278.0634, found 
278.0626. 
 
(3-Ethyl-2,6-difluorophenyl)(5-((pyridin-3-ylamino)methyl)-1H-pyrrol-3-
yl)methanone (273) 
 
Compound 273 was synthesised according to general procedure D using 4-(3-Ethyl-2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (272) (70 mg, 0.25 mmol), 3-
aminopyridine (59 mg, 0.63 mmol), PCl3 (22 µL, 0.25 mmol) and MeCN (1 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) followed by (C-18 silica, 
1:1 MeCN (0.1% formic acid):H20 (0.1% formic acid) followed by semi-prep. HPLC 
(C-18 silica; 5-100% acetonitrile in water (0.1% formic acid)) to give the title 
compound as a white solid (15 mg, 13%); Rf = 0.43 (5% DCM in MeOH); M.p. 255-266 
oC; λmax (EtOH)/nm 253, 294; νmax/cm
-1
: 3233, 3121, 2970, 2923, 1625 (CO), 1536 
(CONH); 
1
H NMR (500 MHz, MeOD) δ 1.15 (3H, t, J = 7.6 Hz, CH2CH3),  2.62 (2H, q, 
J = 7.6 Hz, CH2CH3), 6.92-6.96 (1H, m, H-Ar), 7.31-7.35 (2H, m, H-Ar and CH-
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pyridine), 7.37 (1H, s, H-3), 7.39 (1H, s, H-5), 8.13 (1H, d, J = 6.6 Hz, CH-pyridine), 
8.18 (1H, br s, CH-N-pyridine), 8.80 (1H, br s, CH-N-pyridine);
 13
C NMR (125 MHz, 
MeOD) δ14.8 (CH2CH3), 22.7 (CH2CH3), 112.5 (d, J = 21.8 Hz, C-Ar), 112.7 (C-Ar), 
119.0 (C-3), 125.3 (C-5), 128.0 (C-2), 128.8 (d, J = 16.7 Hz, C-Ar), 129.4 (C-4), 129.6 
(C-pyridine), 132.8 (dd, J = 7.2 and 9.6 Hz, C-Ar), 142.3 (C-pyridine), 145.1 (C-
pyridine), 158.3 (d, JCF = 247.3 Hz, C-F), 158.9 (d, JCF = 243.9 Hz, C-F), 160.9 (CON), 
185.2 (CO); 
19
F NMR (470 MHz, MeOD) δ -119.1, -120.8; LRMS (ES+) m/z 356.4 
[M+H]
+
; HRMS m/z calcd for C18H15F2N4O2 [M+H]
+ 
356.1053, found 356.1056. 
 
4-(3-Ethyl-2,6-difluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide 
(274) 
 
Compound 274 was synthesised according to general procedure D using 4-(3-Ethyl-2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (272) (70 mg, 0.25 mmol), 5-
aminopyrimidine (59 mg, 0.63 mmol), PCl3 (22 µL, 0.25 mmol) and MeCN (1 mL). 
The crude mixture was purified by MPLC (0-8% MeOH in DCM) followed by (C-18 
silica, 1:1 MeCN (0.1% formic acid):H20 (0.1% formic acid) followed by semi-prep. 
HPLC (C-18 silica; 5-100% acetonitrile in water (0.1% formic acid)) to give the title 
compound as a white solid (25 mg, 28%); Rf = 0.43 (5% DCM in MeOH); M.p. 259-
260 
o
C; λmax (EtOH)/nm 267, 291; νmax/cm
-1
: 3332, 3252, 2971, 1665, 1626 (CO), 1589 
(CONH), 1524; 
1
H NMR (500 MHz, DMSO-d6) δ 1.29 (3H, t, J = 7.7 Hz, CH2CH3), 
2.75 (2H, q, J = 7.7 Hz, CH2CH3), 7.27-7.30 (1H, m, H-Ar), 7.57-7.64 (3H, m, H-3, H-5 
and H-Ar), 9.00 (1H, s, CH-pyrimidine), 9.22 (2H, s, 2 x CH-pyrimidine), 10.52 (1H, br 
s, CONH), 12.89 (1H, br s, NH); 
19
F NMR (470 MHz, CDCl3) δ -117.6, -119.7; LRMS 
(ES
+
) m/z 372.3 [M+H]
+
; HRMS m/z calcd for C18H15F2N4O2 [M+H]
+ 
357.1158, found 
357.1158. 
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4-(3-Ethyl-2,6-difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (275) 
 
Compound 275 was synthesised according to general procedure D using 4-(3-Ethyl-2,6-
difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (272) (90 mg, 0.32 mmol), 4-amino-1-
methylpiperidine (76 mg, 0.80 mmol), PCl3 (28 µL, 0.32 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) followed by (C-18 silica, 
1:1 MeCN (0.1% formic acid):H20 (0.1% formic acid) followed by semi-prep. HPLC 
(C-18 silica; 5-100% acetonitrile in water (0.1% formic acid)) to give the title 
compound as a white solid (23 mg, 19%); Rf = 0.35 (5% DCM in MeOH); M.p. 262-
263 
oC; λmax (EtOH)/nm 237, 287; νmax/cm
-1
: 3248, 2929, 1650 (CO), 1591 (CONH), 
1539; 
1
H NMR (500 MHz, CDCl3) δ 1.15 (3H, t, J = 7.5 Hz, CH2CH3), 2.03 (4H, br s, 2 
x CH2), 2.58 (2H, q,  J = 7.5 Hz, CH2CH3), 2.60-2.64 (5H, m, NCH3 + CH2N), 3.32 
(2H, br s, CH2), 6.80-6.84 (1H, m, H-Ar), 7.14-7.20 (1H, m, H-Ar), 7.26 (1H, s, H-3), 
7.61 (1H, s, H-5), 8.44 (1H, br s, CONH), 10.63 (1H, br s, NH); 
13
C NMR (125 MHz, 
CDCl3) δ; 14.3 (CH2CH3), 21.7 (CH2CH3), 29.4 (2 x CH2), 43.8 (NCH3), 44.3 (CH), 
53.7 (2 x CH2N), 111.2 (C-Ar), 111.4 (C-Ar), 117.9 (C-3), 127.1 (C-2 and C-5), 1.27.4 
(d, J = 20.5 Hz, C-Ar), 127.9 (d, J = 4.5 Hz, C-Ar), 131.1 (C-4), 157.3 (d, JCF = 202.1 
Hz, CF), 160.1 (CONH), 167.2 (d, JCF = 214.4  Hz, C-Ar), 183.3 (CO); 
19
F NMR (470 
MHz, CDCl3) δ -116.7,-118.2; LRMS (ES
+
) m/z 376.3 [M+H]
+
; HRMS m/z calcd for 
C20H24F2N3O2 [M+H]
+ 
376.1024, found 376.1023. 
 
Methyl 4-(2,6-difluoro-3-vinylbenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (276) 
 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (269) (1.0 g, 2.32 mmol) was dissolved in THF (18 mL) before 
potassium vinyltrifluoroborate (310 mg, 2.32 mmol) was added followed by Cs2CO3 
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(2.26 g, 6.96 mmol), XPhos (66 mg, 0.12 mmol) and PdCl2 (8 mg, 0.04 mmol) and 
water (2 mL). The reaction was heated to 85 
o
C and left to stir for 1 h. Upon cooling, 
the mixture was filtered through Celite and the solvent removed in vacuo. The crude 
mixture was purified by MPLC (0-30% EtOAc in petrol). The pure product was 
obtained as a cream oil (778 mg, 80%); Rf = 0.56 (5% MeOH in EtOAc); λmax 
(EtOH)/nm 236, 279; νmax/cm
-1
: 2954, 1720 (CO2Me), 1661 (CO), 1544; 
1
H NMR (500 
MHz, CDCl3) δ 0.00 (1H, s, Si(CH3)3), 0.92-0.96 (2H, m, CH2), 3.57-3.60 (2H, m, 
CH2), 3.87 (3H, s, CH3), 5.45 (1H, d, J = 11.2 Hz, vinyl CH), 5.74 (2H, s, CH2O), 5.83 
(1H, d, J = 17.7 Hz, vinyl CH), 6.74 (1H, dd, J = 11.2 and 17.7 Hz, vinyl CH), 6.97-
7.02 (1H, m, H-5’), 7.35 (1H, s, H-3), 7.57 (1H, s, H-5), 7.58-7.60 (1H, m, H-4’); 13C 
NMR (125 MHz, CDCl3) δ (17.8 (Si(CH3)3), 51.7 (2 x CH2), 66.9 (CH3), 76.7 (CH2O), 
111.8 (CH2 vinyl) 111.9 (C-Ar), 112.0 (C-Ar), 112.2 (CH vinyl), 119.1 (C-Ar), 124.0 
(C-3), 125.0 (C-2 and C-5), 127.9 (C-4), 131.2 (C-Ar), 132.8 (C-Ar), 155.0 (d, JCF = 
247.5 Hz, CF), 163.0 (CO2Me), 168.1 (d, JCF = 218.4  Hz, C-Ar), 182.8 (CO); 
19
F NMR 
(470 MHz, CDCl3) δ -113.2, -117.4; LRMS (ES
+
) m/z 422.3 [M+H]
+
; HRMS m/z calcd 
for C12H26F2NO4Si [M+H]
+ 
422.1108, found 424.1110. 
Methyl-4-(2,6-difluoro-3-(prop-1-en-2-yl)benzoyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carboxylate (278) 
 
 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (269) (1.65 g, 3.84 mmol) was dissolved in THF (18 mL) before 
potassium isopropenyltrifluoroborate (568 mg, 3.84 mmol) was added followed by 
Cs2CO3 (3.75 g, 1.5 mmol), XPhos (110 mg, 0.23 mmol) and PdCl2 (14 mg, 0.08 mmol) 
and water (2 mL). The reaction was heated to 85 
o
C and left to stir for 1 h. Upon 
cooling, the mixture was filtered through Celite and the solvent removed in vacuo. The 
crude mixture was purified by MPLC (0-30% EtOAc in petrol). The pure product was 
obtained as a colourless oil (699 mg, 42%); Rf = 0.57 (5% MeOH in EtOAc); λmax 
(EtOH)/nm 235, 280; νmax/cm
-1
: 2965, 1695 (CO2Me), 1653 (CO), 1521; 
1
H NMR (500 
MHz, CDCl3) δ 0.00 (1H, s, Si(CH3)3), 0.92-0.96 (2H, m, CH2), 2.15 (3H, s, CH3), 3.56-
299 
 
3.60 (2H, m, CH2), 3.87 (3H, s, CH3), 5.24 (1H, s, alkene-CH), 5.31 (1H, s, alkene-CH), 
5.72 (2H, s, CH2O), 6.95-6.99 (1H, m, H-5’), 7.36 (1H, s, H-3), 7.56 (1H, s, H-5), 7.59-
7.61 (1H, m, H-4’); 13C NMR (125 MHz, CDCl3) δ 17.5 (Si(CH3)3), 23.0 (CH3), 51.5 (2 
x CH2), 68.0 (OCH3), 77.2 (CH2O), 112.0 (alkene-CH2 ) 112.2 (C-Ar), 112.4 (C-Ar), 
112.8 (C-Ar), 125.0 (C-3), 126.0 (C-2 and C-5), 127.9 (C-4), 131.3 (C-Ar), 134.0 (C-
Ar), 156.0 (d, JCF = 245.5 Hz, CF), 165.0 (CO2Me), 169.0 (d, JCF = 215.4  Hz, C-Ar), 
182.8 (CO); 
19
F NMR (470 MHz, CDCl3) δ -113.2, -117.4; LRMS (ES
+
) m/z 436.2 
[M+H]
+
; HRMS m/z calcd for C22H28F2NO4Si [M+H]
+ 
436.1750, found 436.1747. 
 
Methyl 4-(2,6-difluoro-3-vinylbenzoyl)-1H-pyrrole-2-carboxylate (278) 
 
Methyl 4-(2,6-difluoro-3-vinylbenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylate (276) (730 mg, 1.73 mmol) was dissolved in THF (15 mL) before 
TBAF (3.5 mL, 1.0 M in THF) was added and the reaction was heated to 65 
o
C for 18 h. 
Upon cooling to RT the solvent was removed in vacuo. The crude product was purified 
by MPLC (0-8 % MeOH in DCM) to give the pure product as a colourless oil (332 mg, 
66%); Rf = 0.45 (5% MeOH in EtOAc);  λmax (EtOH)/nm 235, 280; νmax/cm
-1
: 2960, 
1716 (CO2Me), 1656 (CO), 1604;
 1
H NMR (500 MHz, CDCl3) δ 3.86 (3H, s, CH3), 5.39 
(1H, d, J = 11.4 Hz, vinyl CH), 5.76 (1H, d, J = 17.7 Hz, vinyl CH), 6.78 (1H, dd, J = 
11.4 and 17.7 Hz, vinyl CH), 6.94-6.99 (1H, m, H-5’), 7.21 (1H, s, H-3), 7.47 (1H, s, H-
5), 7.54 (1H, dddd, J = 6.8, 6.9, 8.5 and 8.6 Hz, H-4’), 9.84 (1H, br s, NH);; 13C NMR 
(125 MHz, CDCl3) δ 65.2 (CH3), 112.0 (CH2 vinyl) 112.2 (C-Ar), 112.3 (C-Ar), 112.8 
(CH vinyl), 119.5 (C-Ar), 124.0 (C-3), 125.6 (C-2 and C-5), 128.1 (C-4), 132.2 (C-Ar), 
132.8 (C-Ar), 156.0 (d, JCF = 245.6 Hz, CF), 165.2 (CO2Me), 169.1 (d, JCF = 225.4  Hz, 
C-Ar), 182.9 (CO); 
19
F NMR (470 MHz, CDCl3) δ -113.2, -117.4; LRMS (ES
+
) m/z 
292.3 [M+H]
+
. 
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Methyl 4-(2,6-difluoro-3-(prop-1-en-2-yl)benzoyl)-1H-pyrrole-2-carboxylate (279) 
 
 
methyl 4-(2,6-difluoro-3-(prop-1-en-2-yl)benzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrrole-2-carboxylate (277) (350 mg, 0.80 mmol) was dissolved in THF (7 mL) 
before TBAF (1.7 mL, 1.0 M in THF) was added and the reaction was heated to 65 
o
C 
for 18 h. Upon cooling to RT the solvent was removed in vacuo. The crude product was 
purified by MPLC (0-8 % MeOH in DCM) to give the pure product as a colourless oil 
(170 mg, 70%); Rf = 0.46 (5% MeOH in EtOAc);  λmax (EtOH)/nm 236, 282; νmax/cm
-1
: 
3300, 1710 (CO2Me), 1654 (CO), 1596, 1516; 
1
H NMR (500 MHz, CDCl3) δ 2.13 (3H, 
s, CH3), 3.85 (3H, s, OCH3), 5.21 (1H, s, alkene-CH), 5.32 (1H, s, alkene-CH), 6.98-
7.01 (1H, m, H-5’), 7.35 (1H, s, H-3), 7.58 (1H, s, H-5), 7.60-7.64 (1H, m, H-4’); 13C 
NMR (125 MHz, CDCl3) δ 23.0 (CH3), 67.0 (OCH3), 111.9 (alkene-CH2 ) 112.3 (C-
Ar), 112.4 (C-Ar), 113.2 (C-Ar), 124.8 (C-3), 126.7 (C-2 and C-5), 129.5 (C-4), 130.9 
(C-Ar), 133.0 (C-Ar), 153.2 (d, JCF = 249.6 Hz, CF), 164.2 (CO2Me), 169.6 (d, JCF = 
217.4  Hz, C-Ar), 184.6 (CO); 
19
F NMR (470 Hz, CDCl3) δ -114.1, -117.5; LRMS 
(ES
+
) m/z 306.3 [M+H]
+
. 
 
4-(2,6-Difluoro-3-vinylbenzoyl)-1H-pyrrole-2-carboxylic acid (280) 
 
 
Compound 280 was synthesised according to general procedure B using, Methyl 4-(2,6-
difluoro-3-vinylbenzoyl)-1H-pyrrole-2-carboxylate (278) (165 mg, 0.57 mmol), THF (5 
mL), LiOH (271 mg, 11.33 mmol) in H2O (7 mL). The pure product was obtained as a 
white solid (156 mg, 99%); Rf = 0.35 (5% MeOH in EtOAc); M.p. 190-191 
o
C;  λmax 
(EtOH)/nm 236, 280; νmax/cm
-1
: 2965, 1720 (CO2Me), 1658 (CO), 1610; 
1
H NMR (500 
MHz, DMSO-d6) δ 5.41 (1H, d, J = 11.1 Hz, vinyl CH), 5.76 (1H, d, J = 17.5 Hz, vinyl 
CH), 6.87 (1H, dd, J = 11.1 and 17.5 Hz, vinyl CH), 6.95-67.01 (1H, m, H-5’), 7.35 
(1H, s, H-3), 7.48 (1H, s, H-5), 7.60 (1H, dddd, J = 6.6, 6.7, 8.6 and 8.7 Hz, H-4’),  
12.75 (1H, br s, NH) 12.94 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 112.2 
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(CH2 vinyl) 112.3 (C-Ar), 112.4 (C-Ar), 112.8 (CH vinyl), 119.0 (C-Ar), 120.9 (C-3), 
125.4 (C-2 and C-5), 129.5 (C-4), 132.2 (C-Ar), 132.9 (C-Ar), 153.0 (d, JCF = 235.6 Hz, 
CF), 165.2 (CO2H), 169.1 (d, JCF = 225.4  Hz, C-Ar), 183.9 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) δ -113.6, -117.5; LRMS (ES
+
) m/z 276.2 [M-H]
-
 ; HRMS m/z calcd for 
C14H8F2NO3 [M-H]
- 
276.0478, found 276.0469. 
4-(2,6-Difluoro-3-(prop-1-en-2-yl)benzoyl)-1H-pyrrole-2-carboxylic acid (281) 
 
 
Compound 281 was synthesised according to general procedure B using, methyl 4-(2,6-
difluoro-3-(prop-1-en-2-yl)benzoyl)-1H-pyrrole-2-carboxylate (279) (170 mg, 0.56 
mmol), THF (5 mL), LiOH (267 mg, 11.1 mmol) in H2O (7 mL). The pure product was 
obtained as a colourless oil (160 mg, 98%); Rf = 0.37 (5% MeOH in EtOAc);  λmax 
(EtOH)/nm 235, 279; νmax/cm
-1
: 3251, 1715 (CO2H), 1656 (CO),  1524; 
1
H NMR (500 
MHz, CDCl3) δ 2.14 (3H, s, CH3), 5.21 (1H, s, alkene-CH), 5.30 (1H, s, alkene-CH), 
6.96-6.99 (1H, m, H-5’), 7.36 (1H, s, H-3), 7.57 (1H, s, H-5), 7.64 (1H, dddd, J = 6.5, 
6.6, 8.4 and 8.5 Hz, H-4’), 9.75 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) δ 24.1 
(CH3), 112.5 (alkene-CH2 ) 112.6 (C-Ar), 112.8 (C-Ar), 113.0 (C-Ar), 124.0 (C-3), 
126.2 (C-2 and C-5), 130.0 (C-4), 130.8 (C-Ar), 132.1 (C-Ar), 157.2 (d, JCF = 251.2 Hz, 
CF), 166.8 (CO2H), 169.6 (d, JCF = 218.4  Hz, C-Ar), 184.6 (CO); 
19
F NMR (470 Hz, 
CDCl3) δ -11401, -117.5; LRMS (ES
+
) m/z 290.2 [M+H]
+
; HRMS m/z calcd for 
C15H10F2NO3 [M-H]
- 
290.0634, found 290.0624. 
4-(2,6-Difluoro-3-vinylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (282) 
 
 
Compound 282 was synthesised according to general procedure C using 4-(2,6-difluoro-
3-vinylbenzoyl)-1H-pyrrole-2-carboxylic acid (280) (60 mg, 0.21 mmol), 3-
aminopyridine (51 mg, 0.54 mmol), CDI (70 mg, 0.43 mmol) and THF (1 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) followed by (C-18 silica, 
1:1 MeCN (0.1% formic acid):H20 (0.1% formic acid) followed by semi-prep. HPLC 
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(C-18 silica; 5-100% acetonitrile in water (0.1% formic acid)) to give the title 
compound as a white solid (12 mg, 16%); Rf = 0.44 (5% DCM in MeOH); M.p. 255-
256 
oC; λmax (EtOH)/nm 244, 293; νmax/cm
-1
: 3354, 3254, 3121, 1650 (CO), 1597 
(CONH); 
1
H NMR (500 MHz, CDCl3) δ 5.35 (1H, d, J = 11.3 Hz, vinyl CH), 5.73 (1H, 
d, J = 17.6 Hz, vinyl CH), 6.73 (1H, dd, J = 11.3 and 17.6 Hz, vinyl CH), 6.90-6.93 
(1H, m, H-5’), 7.38 (d, J = 2.4 Hz, pyridine-CH), 7.39 (1H, s, H-3), 7.52 (1H, ddd, J = 
6.4, 8.6 and 8.7 Hz, H-4’), 8.04-8.06 (1H, m, pyridine-CH), 8.17 (1H, s, H-5), 8.29 (1H, 
dd, J = 1.4 and 5.0 Hz, pyridine-CH), 8.69 (1H, d, J = 2.4 Hz, pyridine-CH), 9.90 (1H, 
br s, CONH); 
19
F NMR (470 MHz, CDCl3) δ -117.2, -113.1; LRMS (ES
+
) m/z 354.3 
[M+H]
+
; HRMS m/z calcd for C19H14F2N3O2 [M+H]
+ 
354.1049, found 354.1051. 
4-(2,6-Difluoro-3-vinylbenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide 
(283) 
 
4-(2,6-Difluoro-3-vinylbenzoyl)-1H-pyrrole-2-carboxylic acid (280) (60 mg, 0.21 
mmol) was dissolved in acetonitrile (1 mL) before cyanuric fluoride (7 µL, 0.08 mmol) 
and pyridine (17 µL, 0.21 mmol) were added. The mixture was stirred at RT for 30 min 
before 5-aminopyrimidine (50 mg, 0.53 mmol) was added and the reaction was left to 
stir for 18 h. Brine was added and the product was extracted using ethyl acetate. The 
combined organic layers were dried over Na2SO4 and the solvent was removed in 
vacuo. The crude mixture was purified by semi-prep. HPLC (C-18 silica; 5-100% 
acetonitrile in water (0.1% formic acid)) to give the title compound as a white solid (15 
mg, 20%); Rf = 0.39 (5% DCM in MeOH); M.p. 250-251 
oC; λmax (EtOH)/nm 243, 293; 
νmax/cm
-1
: 3333, 3252, 3118, 1626 (CO), 1586 (CONH); 
1
H NMR (500 MHz, DMSO-
d6) δ 5.49 (1H, d, J = 11.4 Hz, vinyl CH), 5.97 (1H, d, J = 17.7 Hz, vinyl CH), 6.84 (1H, 
dd, J  = 11.4 and 17.7 Hz, vinyl CH), 7.26-7.31 (1H, m, H-5’), 7.50 (1H, s, H-3), 7.61 
(1H, s, H-5), 7.85-7.90 (1H, m, H-4’), 8.46 (1H, br s, CONH), 8.91 (1H, s, CH-
pyrimidine), 9.15 (2H, s, 2 x CH-pyrimidine), 10.60 (1H, br s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ 112.5 (C-Ar), 112.6 (CH2 vinyl), 118.2 (C-Ar), 121.7 (C-3), 
125.9(C-2 and C-5), 127.5 (C-4), 129.2 (CH vinyl), 130.1 (C-Ar), 134.4, 141.8 (C-
pyrimidine), 153.5 (d, JCF = 258.7 Hz, CF), 158.9 (CON), 181.7 (CO); 
19
F NMR (470 
MHz, CDCl3) δ -119.5, -114.7; LRMS (ES
+
) m/z 355.3 [M+H]
+
; HRMS m/z calcd for 
C18H13F2N4O2 [M+H]
+ 
355.1001, found 355.1003.4 
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(2,6-Difluoro-3-vinylbenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (284) 
 
Compound 284 was synthesised according to general procedure C using 4-(2,6-difluoro-
3-vinylbenzoyl)-1H-pyrrole-2-carboxylic acid (280) (60 mg, 0.21 mmol), 3-
aminopyridine (51 mg, 0.54 mmol), CDI (70 mg, 0.43 mmol) and THF (1 mL). The 
crude mixture was purified by semi-prep. HPLC (C-18 silica; 5-100% acetonitrile in 
water (0.1% formic acid)) to give the title compound as a white solid (15 mg, 19%); Rf 
= 0.35 (5% DCM in MeOH); M.p. 233-234 
oC; λmax (EtOH)/nm 238, 290; νmax/cm
-1
: 
3366 (NMe), 3261, 3117, 2954, 1588 (CO), 1587 (CONH); 
1
H NMR (500 MHz, 
CDCl3) δ 2.03 (2H, br s, CH2), 2.70 (4H, br s, CH2 and CH2N), 3.4 Hz (5H, s CH2N and 
CH3), 4.09 (2H, br s, CH), 5.32 (1H, d, J = 11.1 Hz, vinyl CH), 5.70 (1H, d, J = 17.6 
Hz, vinyl CH), 6.72 (1H, dd, J = 11.1 and 17.6 Hz, vinyl CH), 6.86-6.89 (1H, m, H-5’), 
7.24 (1H, s, H-3), 7.29 (1H, s, H-5), 7.45-7.49 (1H, m, H-4’), 8.38 (1H, br s, CONH), 
10.79 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ
 
28.0 (2 x CH2), 42.6 (CH), 43.0 
(CH3), 110.5 (CH2 vinyl), 111.0 (C-Ar), 116.1 (C-Ar), 117.1 (CH vinyl), 125.9 (C-3), 
126.9 (C-2 and C-5), 127.1 (C-4), 127.2 (d, JCF = 259.6 Hz, CF), 159.1 (CONH), 181.6 
(CO); 
19
F NMR (470 MHz, CDCl3) δ -117.7, -113.5; LRMS (ES
+
) m/z 374.3 [M+H]
+
; 
HRMS m/z calcd for C20H22F2N3O2 [M+H]
+ 
374.1675, found 374.1677. 
 
4-(2,6-Difluoro-3-(prop-1-en-2-yl)benzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide (285) 
 
4-(2,6-Difluoro-3-(prop-1-en-2-yl)benzoyl)-1H-pyrrole-2-carboxylic acid (281) (167 
mg, 0.57 mmol) was dissolved in acetonitrile (4 mL) before cyanuric fluoride (20 µL, 
0.23 mmol) and pyridine (46 µL, 0.57 mmol) were added. The mixture was stirred at 
RT for 30 min before 3-aminopyridine (135 mg, 1.43 mmol) was added and the reaction 
was left to stir for 18 h. Brine was added and the product was extracted using ethyl 
acetate. The combined organic layers were dried over Na2SO4 and the solvent was 
removed in vacuo. The crude mixture was purified by MPLC (0-8% MeOH in DCM) to 
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give the title compound as a white solid (84 mg, 0.23 mmol, 40%); Rf = 0.45 (5% DCM 
in MeOH); M.p. 269-270 
oC; λmax (EtOH)/nm 237, 293; νmax/cm
-1
: 3258, 2925, 2858, 
1725, 1633 (CO), 1532 (CONH); 
1
H NMR (500 MHz,CDCl3) δ 2.13 (3H, s, CH3), 5.23 
(1H, s, alkene-CH), 5.29 (1H, s, alkene-CH), 6.96-6.70 (1H, m, H-5’), 7.42 (1H, ddd, J 
= 6.5, 8.5 and 8.6 Hz, H-4’), 7.46 (1H, s, H-3), 7.71 (1H, s, H-5), 8.17-8.20 (1H, m, 
pyridine-CH), 8.37 (1H, br s, pyridine-CH), 8.91 (2H, br s, pyridine-CH), 10.47 (1H, br 
s, CONH); 
13
C NMR (125 MHz, CDCl3) δ; 23.0 (CH3), 111.5 (C-Ar), 111.7 (alkene-
CH2), 117.7 (d, JCF = 19.0 Hz, C-Ar), 123.9 (C-3), 127.5 (C-2 and C-5), 128.1 (C-
pyridine), 129.6 (C-4), 131.3 (d, JCF = 9.2 Hz, C-Ar), 135.1 (C-Ar), 138.7 (C-Ar), 141.0 
(C-pyridine), 144.4, 158.3 (CH-N-pyridine), (d, JCF = 242.5 Hz, CF), 158.9 (CH-N-
pyridine), 163.6 (CONH), 183.3 (CO); 
19
F NMR (470 MHz, CDCl3) δ -116.2, -114.1; 
LRMS (ES
+
) m/z 368.3 [M+H]
+
; HRMS m/z calcd for C20H16F2N3O2 [M+H]
+ 
368.1205, 
found 368.1207. 
 
Methyl 4-(2,3-dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (286)  
 
2,3-Dichloro-6-fluorobenzoic acid (2.0 g, 9.57 mmol) was dissolved in THF (20 mL) 
before SOCl2 (2.1 mL, 28.7 mmol) and DMF (74 µL, 0.96 mmol) were added. The 
mixture was stirred at RT for 3 h before the solvent was removed in vacuo. The residue 
was re-dissolved in DCM (10 mL) and AlCl3 (1.91 g, 14.4 mmol) was added followed 
by methyl pyrrole-2-carboxylate (69) (599 mg, 4.79 mmol) and the reaction was carried 
out as for general procedure A. The crude mixture was purified by MPLC (0-50% 
EtOAc in petrol) to give the pure product as a white solid (1.50 g, 99%); Rf = 0.41 (5% 
MeOH in EtOAc); M.p. 185-187 
o
C; λmax (EtOH)/nm 234, 284; νmax/cm
-1
: 3260, 1715 
(CO2Me), 1597 (CO), 1546; 
1
H NMR (500 MHz, CDCl3) δ 3.87 (3H, s, CH3), 6.86-6.87 
(1H, m, H-5’),  7.21 (1H, br s, H-3), 7.50-7.56 (1H, m ,H-4’), 7.58 (1H, br s, H-5), 9.84 
(1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ 42.0 (CH3), 111.9 (C-Ar), 112.4 (C-Ar), 
116.0 (C-Ar), 124.6 (C-3), 128.9 (C-2 and C-5), 132.8 (C-4), 132.9 (C-Ar), 157.6 (d, 
JCF = 246.2 Hz, CF), 167.4 (CO2Me), 190.1 (CO);
19
F NMR (470 MHz, CDCl3) δ -
110.7; LRMS (ES
+
) m/z 317.0 [M+H]
+
; HRMS m/z calcd for C13H9
35
Cl2FNO3 [M+H]
+ 
316.1025, found 316.1029. 
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Methyl 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (287) 
 
Compound 287 was synthesised according to general procedure A using methyl pyrrole-
2-carboxylate (69) (250 mg, 1.99 mmol), 3,6-dichloro-2-fluorobenzoyl chloride (909 
mg, 3.99 mmol), AlCl3 (633 mg, 4.98 mmol) and DCM (10 mL). The crude mixture was 
purified by MPLC (0-50% EtOAc in petrol) to give the pure product as a white solid 
(539 mg, 86%); Rf = 0.42 (5% MeOH in EtOAc); M.p. 186-187 
o
C; λmax (EtOH)/nm 
235, 284; νmax/cm
-1
: 3259, 1704 (CO2Me), 1591 (CO), 1552; 
1
H NMR (500 MHz, 
CDCl3) δ 3.85 (3H, s, CH3), 6.85-6.86 (1H, m, H-5’),  7.20 (1H, br s, H-3), 7.46 (1H, 
ddd, J = 6.9, 8.5 and 8.6, H-4’), 7.50 (1H, br s, H-5), 9.75 (1H, br s, NH); 13C NMR 
(125 MHz, CDCl3) δ 52.1 (CH3), 112.0 (C-Ar), 112.4 (C-Ar), 115.6 (C-Ar), 123.6 (C-
3), 129.1 (C-2 and C-5), 131.8 (C-4), 132.0 (C-Ar), 155.1 (d, JCF = 243.2 Hz, CF), 
166.0 (CO2Me), 189.6 (CO);
19
F NMR (470 MHz, CDCl3) δ -110.3; LRMS (ES
+
) m/z 
316.9 [M+H]
+
; HRMS m/z calcd for C13H9
35
Cl2FNO3 [M+H]
+ 
316.1025, found 
316.1025. 
 
Methyl 4-(2-chloro-6-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate (288) 
 
Compound 288 was synthesised according to general procedure A using methyl pyrrole-
2-carboxylate (69) (500 mg, 3.99 mmol), 2-chloro-6-fluoro-3-methylbenzoyl chloride 
(1.10 mL, 7.98 mmol), AlCl3 (1.33 g, 9.98 mmol) and DCM (10 mL). The crude 
mixture was purified by MPLC (0-50% EtOAc in petrol) to give the pure product as a 
cream solid (706 mg, 60%); Rf = 0.41 (5% MeOH in EtOAc); M.p. 187-188 
o
C; λmax 
(EtOH)/nm 233, 279; νmax/cm
-1
: 3285, 1750 (CO2Me), 1634 (CO), 1521; 
1
H NMR (500 
MHz, CDCl3) δ 2.20 (3H, s, CH3), 3.71 (3H, s, OCH3), 7.05 (1H, s, H-3), 7.10 (1H, s, 
H-5), 7.12-7.15 (1H, m, H-5’),  7.41 (1H, ddd, J = 6.6, 8.4 and 8.5 Hz, H-4’), 9.85 (1H, 
br s, NH); 
13
C NMR (125 MHz, CDCl3) δ 14.3 (CH3), 53.0 (OCH3), 114.1 (C-Ar), 
115.4 (C-Ar), 124.3 (C-3), 126.4 (C-2 and C-5), 127.6 (C-Ar) 129.0 (C-4), 132.0 (C-
Ar), 157.0 (d, JCF = 246.2 Hz, CF), 161.6 (CO2Me), 186.0 (CO);
19
F NMR (470 MHz, 
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CDCl3) δ -116.8; LRMS (ES
+
) m/z 296.8 [M+H]
+
; HRMS m/z calcd for 
C14H12
35
ClFNO3 [M+H]
+ 
296.0489, found 296.0489. 
 
Methyl 4-(6-chloro-2-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate (289) 
 
Compound 289 was synthesised according to general procedure A using methyl pyrrole-
2-carboxylate (69) (500 mg, 3.99 mmol), 2-chloro-6-fluoro-5-methylbenzoyl chloride 
(1.10 mL, 7.98 mmol), AlCl3 (1.33 g, 9.98 mmol) and DCM (10 mL). The crude 
mixture was purified by MPLC (0-50% EtOAc in petrol) to give the pure product as a 
cream solid (1.13 g, 96%); Rf = 0.41 (5% MeOH in EtOAc); M.p. 186-187 
o
C; λmax 
(EtOH)/nm  233, 279; νmax/cm
-1
: 3263, 1711 (CO2Me), 1636 (CO), 1549; 
1
H NMR (500 
MHz, CDCl3) δ 2.20 (3H, s, CH3), 3.69 (3H, s, OCH3),7.05 (1H, s, H-3), 7.06 (1H, s, H-
5), 7.10-7.12 (1H, m, H-5’),  7.37-7.39 (1H, m, H-4’), 9.96 (1H, br s, NH); 13C NMR 
(125 MHz, CDCl3) δ 14.3 (CH3), 52.0 (OCH3), 115.8 (C-Ar), 116.6 (C-Ar), 124.3 (C-
3), 125.1 (C-2 and C-5), 126.9 (C-Ar) 128.5 (C-4), 132.4 (C-Ar), 156.3 (d, JCF = 245.6 
Hz, CF), 161.3 (CO2Me), 185.3 (CO);
19
F NMR (470 MHz, CDCl3) δ -116.8; LRMS 
(ES
+
) m/z 296.8 [M+H]
+
; HRMS m/z calcd for C14H12
35
ClFNO3 [M+H]
+ 
296.0489, 
found 296.0486. 
 
4-(2,3-Dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (290) 
 
Compound 290 was synthesised according to general procedure B using, methyl 4-(2,3-
dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (286) (1.0 g, 3.17 mmol), THF (25 
mL), LiOH (1.52 g, 63.5 mmol) in H2O (40 mL). The pure product was obtained as a 
white solid (948 mg, 98%); Rf = 0.33 (5% MeOH in EtOAc); M.p. 190-191 
o
C; λmax 
(EtOH)/nm 236, 285; νmax/cm
-1
: 3331, 1654 (CO2H), 1593 (CO), 1558; 
1
H NMR (500 
MHz, DMSO-d6) δ 7.02 (1H, s, H-3), 7.43-7.47 (1H, m, H-5’),  7.57 (1H, br s, H-5), 
7.80 (1H, ddd, J = 6.9, 8.6 and 8.7,H-4’), 12.74 (1H, br s, NH), 13.01 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 111.5 (C-Ar), 112.4 (C-Ar), 117.0 (C-Ar), 124.6 (C-
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3), 128.9 (C-2 and C-5), 130.2 (C-4), 132.0 (C-Ar), 156.9 (d, JCF = 250.1 Hz, CF), 
168.2 (CO2H), 189.7 (CO);
19
F NMR (470 MHz, CDCl3) δ -110.4; LRMS (ES
+
) m/z 
301.2 [M-H]
-
; HRMS m/z calcd for C12H5
35
Cl2FNO3 [M-H]
- 
301.1011, found 301.1012. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (291) 
 
Compound 291 was synthesised according to general procedure B using, methyl 4-(3,6-
dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (287) (330 mg, 1.05 mmol), THF 
(8 mL), LiOH (502 mg, 21.0 mmol) in H2O (14 mL). The pure product was obtained as 
a white solid (314 mg, 99%); Rf = 0.32 (5% MeOH in EtOAc); M.p. 190-191 
o
C; λmax 
(EtOH)/nm 234, 279; νmax/cm
-1
: 3267, 1649 (CO2H), 1592 (CO) 1557; 
1
H NMR (500 
MHz, DMSO-d6) δ 7.01 (1H, s, H-3), 7.45-7.48 (1H, m, H-5’),  7.56 (1H, br s, H-5), 
7.77 (1H, ddd, J = 6.7, 8.4and 8.5 ,H-4’), 12.67 (1H, br s, NH), 13.04 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 112.0 (C-Ar), 112.9 (C-Ar), 116.9 (C-Ar), 123.6 (C-
3), 128.9 (C-2 and C-5), 131.2 (C-4), 132.1 (C-Ar), 155.4 (d, JCF = 254.2 Hz, CF), 
169.0 (CO2H), 188.4 (CO);
19
F NMR (470 MHz, CDCl3) δ -110.3; LRMS (ES
+
) m/z 
301.3 [M-H]
-
; HRMS m/z calcd for C12H5
35
Cl2FNO3 [M-H]
- 
301.1056, found 301.1056. 
 
4-(2-Chloro-6-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (292) 
 
Compound 292 was synthesised according to general procedure B using, methyl 4-(2-
chloro-6-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate (288) (400 mg1.33 mmol), 
THF (11 mL), LiOH (637 mg, 26.6 mmol) in H2O (17 mL). The pure product was 
obtained as a cream solid (366 mg, 98%); Rf = 0.31 (5% MeOH in EtOAc); M.p. 195-
196 
o
C; λmax (EtOH)/nm 236, 279; νmax/cm
-1
: 3305, 1780, 1710 (CO2H), 1562 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ 2.27 (3H, s, CH3), 6.96 (1H, s, H-3), 7.34 (1H, s, H-5), 
7.35-7.37 (1H, m, H-5’),  7.41-7.45 (1H, m, H-4’), 12.65 (1H, br s, NH), 13.05 (1H, br 
s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 14.4 (CH3), 115.2 (C-Ar), 115.8 (C-Ar), 
124.6 (C-3), 125.2 (C-2 and C-5), 126.9 (C-Ar), 129.6 (C-4), 131.6 (C-Ar), 155.6 (d, 
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JCF = 250.2 Hz, CF), 165.2 (CO2H), 183.5 (CO);
19
F NMR (470 MHz, CDCl3) δ -117.0; 
LRMS (ES
+
) m/z 280.3 [M-H]
-
; HRMS m/z calcd for C13H8
35
ClFNO3 [M-H]
- 
280.0172, 
found 280.0172. 
 
4-(6-Chloro-2-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (293) 
 
Compound 293 was synthesised according to general procedure B using, methyl 4-(6-
chloro-2-fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate (289) (1.0 g, 3.32 mmol), 
THF (27 mL), LiOH (1.59 g, 66.5 mmol) in H2O (43 mL). The pure product was 
obtained as a cream solid (914 mg, 98%); Rf = 0.30 (5% MeOH in EtOAc); M.p. 196-
197 
o
C; λmax (EtOH)/nm 235, 280; νmax/cm
-1
: 3300, 1753, 1701 (CO2H), 1558 (CO); 
1
H 
NMR (500 MHz, DMSO-d6) δ 2.26 (3H, s, CH3), 6.96 (1H, s, H-3), 7.31 (1H, s, H-5), 
7.33-7.35 (1H, m, H-5’),  7.41-7.45 (1H, m, H-4’), 12.69 (1H, br s, NH), 13.25 (1H, br 
s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ 14.3 (CH3), 114.9 (C-Ar), 115.2 (C-Ar), 
124.0 (C-3), 124.9 (C-2 and C-5), 126.9 (C-Ar), 128.5 (C-4), 132.0 (C-Ar), 155.4 (d, 
JCF = 246.5 Hz, CF), 169.0 (CO2H), 185.6 (CO);
19
F NMR (470 MHz, CDCl3) δ -116.8; 
LRMS (ES
+
) m/z 280.6 [M-H]
-
; HRMS m/z calcd for C13H8
35
ClFNO3 [M-H]
- 
280.0171, 
found 280.0171. 
4-(2,3-Dichloro-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (294) 
 
 
Compound 294 was synthesised according to general procedure D using 4-(2,3-
Dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (290) (100 mg, 0.33 mmol), 3-
aminopyridine (78 mg, 0.83 mmol), PCl3 (29 µL, 0.33 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a white solid (60 mg, 48%); Rf = 0.49 (5% DCM in MeOH); M.p. 265-
266 
oC; λmax (EtOH)/nm 295; νmax/cm
-1
: 3309, 2160, 1636 (CO), 1594 (CONH), 1551; 
1
H NMR (500 MHz, DMSO-d6) δ 7.39 (1H, dd, J = 4.7 and 8.2 Hz, CH-pyridine), 7.48-
7.51 (2H, m, H-5’ and H-3), 7.62 (1H, s, H-5), 7.86 (1H, dd, J = 4.7 and 8.2 Hz, CH-
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pyridine), 8.14 (1H, d, J = 7.3 Hz, H-4’), 8.30 (1H, d, J = 4.7 Hz, CH-pyridine), 8.89 
(1H, s, CH-N-pyridine), 10.24 (1H, s, CONH), 12.70 (1H, br s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ 111.5 (C-Ar), 116.6 (d, J = 23.1 Hz, C-Ar), 123.6 (C-3), 124.7(C-
Ar), 127.0 (C-2 and C-5), 127.9 (C-pyridine), 128.3 (C-pyridine), 130.1 (C-4), 131.9 (d, 
J = 10.7 Hz, C-Ar), 135.5 (C-Ar and C-pyridine), 141.6 (C-N-pyridine), 144.4 (C-N-
pyridine), 156.8 (d, J = 245.3 Hz, CF), 158.7 (CON), 182.9 (CO); 
19
F NMR (470 MHz, 
CDCl3) δ -115.8; LRMS (ES
+
) m/z 378.3 [M+H]
+
; HRMS m/z calcd for 
C17H11
35
Cl2FN3O2 [M+H]
+ 
378.0210, found 378.0210. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (295) 
 
 
Compound 295 was synthesised according to general procedure D using 4-(3,6-
Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (291) (90 mg, 0.30 mmol), 3-
aminopyridine (71 mg, 0.75 mmol), PCl3 (26 µL, 0.30 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a white solid (58 mg, 51%); Rf = 0.50 (5% DCM in MeOH); M.p. 262-
263 
oC; λmax (EtOH)/nm 251, 293; νmax/cm
-1
: 3286, 3114, 3077, 2963, 1636 (CO), 1594 
(CONH), 1529; 
1
H NMR (500 MHz, DMSO-d6) δ 7.39 (1H, dd, J = 4.5 and 7.6 Hz, 
CH-pyridine), 7.52 (1H, br s, H-5’), 7.54 (1H, br s, H-3), 7.64 (1H, s, H-5), 7.78-7.81 
(1H, m, H-4’), 8.14 (1H, d, J = 7.6 Hz, CH-pyridine), 8.30 (1H, d, J = 4.5 Hz, CH-
pyridine), 8.90 (1H, s, CH-N-pyridine), 10.25 (1H, br s, CONH), 12.77 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 111.5 (C-Ar), 119.3 (d, J = 18.7 Hz, C-Ar), 123.6 
(C-3), 124.8 (C-Ar), 126.9 (C-2 and C-5), 128.5 (C-Ar), 129.2 (C-pyridine), 130.30 (C-
Ar), 131.9 (C-4), 135.5 (C-pyridine), 141.6 (C-N-pyridne), 144.4 (C-N-pyridine), 153.8 
(d, JCF = 249.7, CF), 158.7 (CONH), 182.6 (CO); 
19
F NMR (470 MHz, CDCl3) δ -
116.7; LRMS (ES
+
) m/z 378.3 [M+H]
+
 HRMS m/z calcd for C17H11
35
Cl2FN3O2 [M+H]
+ 
378.0210, found 378.0210. 
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4-(2-Chloro-6-fluoro-3-methylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide (296) 
 
Compound 296 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (292) (120 mg, 0.43 mmol), 3-
aminopyridine (100 mg, 1.07 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN (3 mL). The 
crude mixture was purified by MPLC (0-5% MeOH in EtOAc) to give the title 
compound as a white solid (92 mg, 60%); Rf = 0.48 (5% MeOH in EtOAc); M.p. 267-
268 
oC; λmax (EtOH)/nm 243, 292; νmax/cm
-1
: 3249, 3126, 2982, 1629 (CO), 
1532(CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 2.37 (3H, s, CH3), 7.29-7.33 (1H, m, 
H-5’), 7.39 (1H, dd, J = 4.8 and 8.6 Hz, CH-pyridine), 7.46 (1H, br s, H-3), 7.48 (1H, br 
s, H-5), 7.54 (1H, dd, J = 6.5 and 8.5 Hz, H-4’), 8.13-8.15 (1H, m, CH-pyridine), 8.30 
(1H, dd, J = 1.5 and 4.8 Hz, CH-pyridine), 8.90 (1H, d, J = 2.5 Hz, CH-pyridine), 10.20 
(1H, s, CONH), 12.71 (1H, br s, NH; 
13
C NMR (125 MHz, DMSO-d6) δ 19.0 (CH3), 
111.6 (C-Ar), 114.5 (d, J = 20.2 Hz, C-Ar), 123.6 (C-3), 125.3 (C-Ar), 126.9 (C-2 and 
C-5), 128.1 (C-pyridine), 129.3 (C-pyridine), 130.0 (C-4), 132.3 (d, J = 10.7 Hz, C-Ar), 
132.6 (C-Ar), 135.5 (C-pyridine), 141.6 (C-N-pyridine), 144.4 (C-N-pyridine), 156.8 (d, 
J = 246.3 Hz, CF), 158.7 (CONH), 184.3 (CO); 
19
F NMR (470 MHz, CDCl3) δ -118.4; 
LRMS (ES
+
) m/z 358.3 [M+H]
+
; HRMS m/z calcd for C18H14
35
ClFN3O2 [M+H]
+ 
358.0753, found 358.0755. 
 
4-(6-Chloro-2-fluoro-3-methylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide (297) 
 
Compound 297 was synthesised according to general procedure D using 4-(6-chloro-2-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (293) (120 mg, 0.43 mmol), 3-
aminopyridine (100 mg, 1.07 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN (3 mL). The 
crude mixture was purified by MPLC (0-5% MeOH in EtOAc) to give the title 
compound as a pale yellow solid (122 mg, 80%); Rf = 0.50 (5% MeOH in EtOAc); M.p. 
268-269 
oC; λmax (EtOH)/nm 250, 293; νmax/cm
-1
: 3124, 2978, 2858, 1985, 1633 (CO), 
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1533 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 2.29 (3H, s, CH3), 7.36 (1H, d, J = 8.0 
Hz,  H-5’), 7.39 (1H, dd, J = 4.7 and 8.4 Hz, CH-pyridine), 7.45-7.49 (3H, m, H-3, H-5 
and H-4’), 8.13-8.15 (1H, m, CH-pyridine), 8.30 (1H, dd, J = 1.4 and 4.7 Hz, CH-
pyridine), 8.90 (1H, d, J = 2.5 Hz, CH-pyridine), 10.24 (1H, s, CONH), 12.70 (1H, br s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) δ 13.9 (CH3), 111.6 (C-Ar), 123.6 (C-3), 124.1 
(d, J = 20.2 Hz, C-Ar), 125.2 (C-Ar), 127.0 (C-2 and C-5), 127.7 (C-pyridine), 128.1 
(C-pyridine), 129.4 (C-4), 132.8 (d, J = 10.7 Hz, C-Ar), 135.5 (C-Ar), 141.6 (C-
pyridine), 144.4 (C-N-pyridine), 156.8 (d, J = 245.3 Hz, CF), 158.7 (CONH), 184.2 
(CO); 
19
F NMR (470 MHz, CDCl3) δ -118.4; LRMS (ES
+
) m/z 358.3 [M+H]
+
; HRMS 
m/z calcd for C18H14
35
ClFN3O2 [M+H]
+ 
358.0753, found 358.0754. 
 
4-(2,3-Dichloro-6-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide 
(298) 
 
 
 
 
Compound 298 was synthesised according to general procedure D using 4-(2,3-
Dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (290) (100 mg, 0.33 mmol), 5-
aminopyrimidine (79 mg, 0.83 mmol), PCl3 (29 µL, 0.33 mmol) and MeCN (2 mL). 
The crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a white solid (68 mg, 67%); Rf = 0.46 (5% DCM in MeOH); M.p. 259-
260 
oC; λmax (EtOH)/nm 293; νmax/cm
-1
: 3115, 3058, 2971, 1651 (CO), 1590 (CONH), 
1537; 
1
H NMR (500 MHz, DMSO-d6) δ 7.46-7.52 (2H, m, H-3 and H-5’), 7.68 (1H, br 
s, H-5), 7.87 (1H, dd,  J = 5.5 and 9.1 Hz, H-4’), 8.93 (1H, s, CH-pyrimidine), 9.13 (2H, 
s, CH-pyrimidine), 10.45 (1H, br s, CONH), 12.89 (1H, br s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 112.0 (C-Ar), 116.6 (d, J = 23.5 Hz, C-Ar), 124.8 (C-3), 127.8 (C-2 and C-
5), 128.7 (d, J = 6.3 Hz, C-Ar), 131.9 (C-Ar), 132.0 (d, J = 10.3 Hz, C-Ar),  134.3 (C-
pyrimidine), 147.9 (C-N-pyrimidine), 153.2 (N-C-N-pyrimidine), 156.6 (d, JCF = 252.4 
Hz, CF), 158.8 (CON), 182.9 (CO); 
19
F NMR (470 MHz, CDCl3) δ -114.6; LRMS 
(ES
+
) m/z 379.3 [M+H]
+
; HRMS m/z calcd for C16H10
35
Cl2FN4O2 [M+H]
+ 
379.1059, 
found 379.1061. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide 
(299) 
 
Compound 299 was synthesised according to general procedure D using 4-(3,6-
Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (291) (90 mg, 0.30 mmol), 5-
aminopyrimidine (71mg, 0.75 mmol), PCl3 (26 µL, 0.30 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a white solid (53 mg, 47%); Rf = 0.46 (5% DCM in MeOH); M.p. 258-259 
oC; λmax (EtOH)/nm 268, 292; νmax/cm
-1
: 3229, 3063, 2922, 1647 (CO), 1591 (CONH), 
1536; 
1
H NMR (500 MHz, DMSO-d6) δ 7.53-7.55 (2H, m, H-3 and H-5’), 7.69 (1H, br 
s, H-5), 7.79-7.82 (1H, m, H-4’), 8.93 (1H, s, CH-pyrimidine), 9.13 (2H, s, CH-
pyrimidine), 10.45 (1H, br s, CONH), 12.90 (1H, br s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ 111.9 (C-Ar), 116.6 (d, J = 24.5 Hz, C-Ar), 123.8 (C-3), 126.9 (C-2 and C-
5), 128.0 (d, J = 6.5 Hz, C-Ar), 132.9 (C-Ar), 133.0 (d, J = 10.5 Hz, C-Ar),  134.3 (C-
pyrimidine), 148.2 (C-N-pyrimidine), 155.2 (N-C-N-pyrimidine), 157.9 (d, JCF = 245.6 
Hz, CF), 159.6 (CON), 183.6 (CO
 19
F NMR (470 MHz, CDCl3) δ -116.5; LRMS (ES
+
) 
m/z 379.3 [M+H]
+
; HRMS m/z calcd for C16H10
35
Cl2FN4O2 [M+H]
+ 
379.1059, found 
379.1060. 
 
4-(2-Chloro-6-fluoro-3-methylbenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (300) 
 
Compound 300 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (292) (120 mg, 0.43 mmol), 5-
aminopyrimidine (102 mg, 1.08 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN (3 mL). 
The crude mixture was purified by MPLC (0-5% MeOH in EtOAc) to give the title 
compound as a pale yellow solid (77 mg, 50%); Rf = 0.45 (5% MeOH in EtOAc); M.p. 
256-257 
oC; λmax (EtOH)/nm 238, 300; νmax/cm
-1
: 3244, 2943, 2806, 1621 (CO), 1603 
(CONH); 
1
H NMR (500 MHz, MeOD) δ 2.30 (3H, s, CH3), 7.03-7.06 (1H, m, H-5’), 
7.33 (1H, s, H-3), 7.34-7.36 (1H, m, H-4’), 7.37 (1H, s, H-5). 8.77 (1H, s, CH-
pyrimidine), 9.07 (2H, s, CH-pyrimidine); 
13
C NMR (125 MHz, DMSO-d6) δ 59.7 
313 
 
(CH3), 112.1, 114.6 (C-Ar), 125.4 (C-3), 127.6 (C-2 and C-5), 129.5 (C-4), 132.3 (C-
Ar), 134.3, 147.8 (C-pyrimidine), 153.2 (d, JCF = 256.7 Hz, CF), 155.8 (CONH), 184.3 
(CO);
 19
F NMR (470 MHz, MeOD) δ -119.8; LRMS (ES+) m/z 359.1 [M+H]+; HRMS 
m/z calcd for C17H13
35
ClFN4O2 [M+H]
+ 
359.0712, found 359.0711. 
 
4-(6-Chloro-2-fluoro-3-methylbenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (301) 
 
Compound 301 was synthesised according to general procedure D using 4-(6-chloro-2-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (293) (120 mg, 0.43 mmol), 5-
aminopyrimidine (102 mg, 1.08 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN (3 mL). 
The crude mixture was purified by MPLC (0-5% MeOH in EtOAc) to give the title 
compound as a pale yellow solid (95 mg, 62%); Rf = 0.43 (5% MeOH in EtOAc); M.p. 
255-256 
oC; λmax (EtOH)/nm 243, 298; νmax/cm
-1
: 3355, 2941, 2360, 1600 (CO), 1537 
(CONH) , ,; 
1
H NMR (500 MHz, MeOD) δ 2.20 (3H, s, CH3), 7.10 (1H, d, J = 8.5 Hz, 
H-5’), 7.18-7.21 (1H, m, H-4’), 7.28 (1H, d, J = 3.4 Hz, , H-3), 8.04 (1H, s, H-5). 8.85 
(1H, s, CH-pyrimidine), 8.98 (2H, s, CH-pyrimidine), 9.21 (1H, br s, CONH), 10.08 
(1H, br s, NH); 
13
C NMR (125 MHz, MeOD) δ 14.3 (CH3), 111.4 (C-Ar), 124.6 (C-3), 
125.4 (C-2 and C-5), 127.1 (C-4), 130.4, 133.1, 133.8 (C-Ar), 148.0, 153.8 (C-
pyrimidine), 157.5 (d JCF = 254.6 Hz, CF), 159.0 (CONH), 187.0 (CO); 
19
F NMR (470 
MHz, CDCl3) δ -116.5; LRMS (ES
+
) m/z 359.1 [M+H]
+
; HRMS m/z calcd for 
C17H13
35
ClFN4O2 [M+H]
+ 
359.0712, found 359.0711. 
 
4-(2,3-Dichloro-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (302) 
 
Compound 302 was synthesised according to general procedure D using 4-(2,3-
Dichloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (290) (100 mg, 0.33 mmol), 4-
amino-1-methylpiperidine (87 µL, 0.83 mmol), PCl3 (29 µL, 0.33 mmol) and MeCN (2 
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mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the title 
compound as a white solid (66 mg, 50%); Rf = 0.40 (5% DCM in MeOH); M.p. 264-
265 
oC; λmax (EtOH)/nm 237, 285; νmax/cm
-1
: 3204 (NMe), 2940, 2802, 2363, 2188, 
1521 (CO), 1569 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.65-1.67 (2H, m, CH2), 
2.01-2.03 (2H, m, CH2), 2.07-2.19 (2H, m, CH2N),  2.36 (3H, s, NCH3),  2.87-2.90 (2H, 
m, CH2N),  3.51-3.53 (1H, m, CH), 6.04 (1H, br s, CONH), 7.00 (1H, s, H-5), 7.10 (1H, 
dd, J = 7.6 and 8.9 Hz, H-5’), 7.33 (1H, s, H-5), 7.54 (1H, dd, J = 5.2 and 8.9  Hz, H-
4’); 13C NMR (125 MHz, CDCl3) δ 29.7 (2 x CH2), 32.1 (NCH3), 46.2 (CH), 54.4 (2 x 
CH2N), 108.8 (C-Ar), 115.6 (d, J = 28.2 Hz, C-Ar), 126.1 (C-3), 127.9 (C-2 and C-5), 
128.3 (C-4), 129.1 (C-Ar), 131.4 (d, J = 9.8 Hz, C-Ar), 156.7 (d, J = 244.9 Hz, CF), 
159.6 (CON), 183.5 (CO); 
19
F NMR (470 MHz, CDCl3) δ -114.7; LRMS (ES
+
) m/z 
398.3 [M+H]
+
 ; HRMS m/z calcd for C18H19
35
Cl2FN3O3 [M+H]
+ 
398.0833, found 
398.0835. 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (303) 
 
Compound 303 was synthesised according to general procedure D using 4-(3,6-
Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (291) (150 mg, 0.50 mmol), 4-
amino-1-methylpiperidine (130 µL, 1.24 mmol), PCl3 (44 µL, 0.50 mmol) and MeCN 
(3 mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the 
title compound as a peach solid (99 mg, 50%); Rf = 0.39 (5% DCM in MeOH); M.p. 
268-269 
oC; λmax (EtOH)/nm 230, 285; νmax/cm
-1
: 3230 (NMe), 3085, 2981, 1629  (CO), 
1564 (CONH); 
1
H NMR (500 MHz, DMSO-d6) δ 1.80 (2H, br s, CH2), 1.91 (2H, br s, 
CH2), 2.36 (5H, br s, CH2N and CH3), 2.97 (2H, br s, CH2N), 2.98 (1H, br s, CH), 7.25 
(1H, s, H-3), 7.48 (1H, s, H-5), 7.50 (1H, d, J = 8.4 Hz, H-5’), 7.76-7.79 (1H, m, H-4’), 
8.21 (1H, d, J = 7.02 Hz, CONH), 12.51 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-
d6) δ 21.1 (2 x CH2), 44.5 (CH), 45.0 (CH3), 53.5 (2 x CH2N), 119.2 (C-3), 124.5 (C-2 
and C-5), 126.8 (C-4), 129.1 (C-Ar), 131.8 (C-Ar), 153.8 (d, JCF = 254.6 Hz, CF), 159.2 
(CONH), 182.6 (CO); 
19
F NMR (470 MHz, CDCl3) δ -116.8; LRMS (ES
+
) m/z 398.4 
[M+H]
+
; HRMS m/z calcd for C18H19
35
Cl2FN3O3 [M+H]
+ 
398.0833, found 398.0834. 
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4-(2-Chloro-6-fluoro-3-methylbenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (304) 
 
Compound 304 was synthesised according to general procedure D using 4-(2-chloro-6-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (292) (120 mg, 0.43 mmol), 4-
amino-1-methylpiperidine (112 µL, 1.08 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN 
(3 mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the 
title compound as a white solid (85 mg, 52%); Rf = 0.40 (5% MeOH in DCM); M.p. 
260-261 
oC; λmax (EtOH)/nm 235, 282; νmax/cm
-1
: 3361 (NMe), 3119, 2938, 1621 (CO), 
1572 (CONH), 1538; 
1
H NMR (500 MHz, CDCl3) δ 1.69-1.78 (4H, m, 2 x CH2), 2.07 
(2H, br t, J = 11.1 Hz, CH2N), 2.39 (3H, s, NCH3), 2.41 (3H, s, CH3), 2.97 (2H, br d, J 
= 11.1 Hz, CH2N), 3.97-4.04 (1H, m, CH), 6.23 (1H, br d, J = 8.06 Hz, CONH), 7.00-
7.04 (2H, m, H-4’ and H-5’), 7.31 (1H, d, J = 2.4 Hz, H-3), 7.32 (1H, br s, H-5), 10.14 
(1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 19.0 (2 x CH2), 109.9, 114.4 (C-Ar), 
125.0 (C-3), 127.9 (C-2 and C-5), 128.8 (C-4), 132.2, 132.5 (C-Ar), 154.8 (d, JCF = 
255.2 Hz, CF), 159.2 (CONH), 184.3 (CO);
 19
F NMR (470 MHz, CDCl3) δ -117.4; 
LRMS (ES
+
) m/z 377.9 [M+H]
+
; HRMS m/z calcd for C17H13
35
ClFN4O2 [M+H]
+ 
359.0712, found 359.0712. 
 
4-(6-Chloro-2-fluoro-3-methylbenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (305) 
 
Compound 305 was synthesised according to general procedure D using 4-(6-chloro-2-
fluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (293) (120 mg, 0.43 mmol), 4-
amino-1-methylpiperidine (112 µL, 1.08 mmol), PCl3 (38 µL, 0.43 mmol) and MeCN 
(3 mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM) to give the 
title compound as a white solid (78 mg, 48%); Rf = 0.40 (5% MeOH in DCM); M.p. 
262-264 
oC; λmax (EtOH)/nm 236, 284; νmax/cm
-1
: 3242 (NMe), 3064, 2944, 2155, 1741 
(CO), 1623 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.59-1.67 (2H, m, CH2),1.90 (2H, 
br d, J = 11.1 Hz, CH2),  2.14-2.19 (2H, m, CH2N), 2.19 (3H, s, NCH3), 2.27 (3H, s, 
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CH3), 2.83(2H, br d, J = 11.1 Hz, CH2N), 3.86-3.98 (1H, m, CH), 6.57 (1H, br d, J = 7.9 
Hz, CONH), 7.05 (1H, d, J = 8.4 Hz, H-5’), 7.07 (1H, br s, H-3), 7.10-7.13 (1H, m, H-
4’), 7.20 (1H, br s, H-5), 10.97 (1H, br s, NH); 14.3 (CH3), 31.4 (2 x CH2), 45.6 
(NCH3), 45.9 (CH), 54.1 (2 x CH2N), 109.8 (C-3), 124.2 (d, J = 17.6 Hz, C-Ar), 125.0 
(d, J = 3.3 Hz, C-Ar), 127.8 (d, J = 22.5 Hz, C-Ar), 128.3 (C-2 and C-5), 128.4 (C-4), 
128.7 (d, J = 5.2 Hz, C-Ar), 132.3 (d, J = 5.2 Hz, C-Ar), 157.5 (d, J = 248.0 Hz, CF), 
160.1 (CONH), 185.3 (CO); 
19
F NMR (470 MHz, CDCl3) δ -116.8; LRMS (ES
+
) m/z 
378.1 [M+H]
+
; HRMS m/z calcd for C19H22
35
ClFN3O2 [M+H]
+ 
378.1379, found 
378.1380. 
3-Bromo-6-chloro-2-fluorobenzoic acid (307)  
 
Diisopropylamine (0.68 mL, 4.8 mmol) was dissolved in THF (3.5 mL) at -60 
o
C before 
n
BuLi (2.0 mL, 2.4 M in hexane) was added and the mixture was stirred for 30 min. The 
mixture was cooled to -70 
o
C and 1-bromo-4-chloro-2-fluorobenzene (298 µL, 2.4 
mmol) was added and the mixture stirred for 2 h. The mixture was transferred via 
canula to a suspension of solid CO2 in diethyl ether. The mixture was allowed to warm 
to RT before the pH was adjusted to 3 using 1.0 M HCl solution. The product was 
extracted using ethyl acetate and the organic fractions were dried over Na2SO4. The 
solvent was removed in vacuo to give the pure product as a white solid (548 mg, 90%); 
Rf = 0.25 (5% MeOH in DCM); M.p. 156-157 
oC; λmax (EtOH)/nm 231,280; νmax/cm
-1
: 
3081, 1706 (CO2H), 1639, 1590; 
1
H NMR (500 MHz, DMSO-d6) δ 7.40-7.42 (1H, m, 
H-Ar), 7.83-7.87 (1H, m, H-Ar), 14.34 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-
d6) δ 107.3 (C-Ar), 124.6 (C-Ar), 127.1 (C-Ar), 129.6 (C-Ar), 134.7 (C-Ar), 154.9 (d, 
JCF = 256.2 Hz, CF), 162.9 (CO2H); 
19
F NMR (470 MHz, CDCl3) δ -105.5; LRMS 
(ES
+
) m/z 252.4 [M-H]
-
. 
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Methyl 4-(3-bromo-6-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (308) 
 
 
3-Bromo-6-chloro-2-fluorobenzoic acid (307) (0.50 g, 1.97 mmol) was dissolved in 
THF (5 mL) before SOCl2 (429 µL, 5.92 mmol) and DMF (15 µL, 0.20 mmol) were 
added. The mixture was stirred at RT for 3 h before the solvent was removed in vacuo. 
The residue was re-dissolved in DCM (5 mL) and AlCl3 (394 mg, 2.96 mmol) was 
added followed by methyl pyrrole-2-carboxylate 123 mg, 1.00 mmol) and the reaction 
was carried out as for general procedure A. The crude mixture was purified by MPLC 
(0-50% EtOAc in petrol) to give the pure product as a beige oil (314 mg, 87%); Rf = 
0.34 (5% MeOH in DCM); M.p. 185-187 
o
C; λmax (EtOH)/nm 235, 284; νmax/cm
-1
:3265, 
1737 (CO2Me), 1654, (CO) 1558; 
1
H NMR (500 MHz, CDCl3) δ 3.87 (3H, s, CH3), 
6.86-6.89 (1H, m, H-5’),  7.15 (1H, br s, H-3), 7.56 (1H, ddd, J = 6.9, 8.5 and 8.6,H-4’), 
7.61 (1H, br s, H-5), 9.84 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ 52.3 (CH3), 
112.0 (C-Ar), 112.4 (C-Ar), 115.5 (C-Ar), 124.2 (C-3), 128.6 (C-2 and C-5), 131.8 (C-
4), 133.0 (C-Ar), 153.2 (d, JCF = 250.1 Hz, CF), 165.2 (CO2Me), 185.0 (CO);
19
F NMR 
(470 MHz, CDCl3) δ -109.5; LRMS (ES
+
) m/z 361.2 [M+H]
+
; HRMS m/z calcd for 
C13H9
79
Br
35
ClFNO3 [M+H]
+ 
360.1154, found 360.1157. 
 
4-(3-Bromo-6-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (309) 
 
 
Compound 309 was synthesised according to general procedure B using, methyl 4-(3-
bromo-6-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (308) (310 mg, 0.86 
mmol), THF (7 mL), LiOH (412 mg, 17.2 mmol) in H2O (11 mL). The pure product 
was obtained as a cream solid (293 mg, 99%); Rf = 0.31 (5% MeOH in DCM); M.p. 
196-197 
o
C; λmax (EtOH)/nm 236, 284; νmax/cm
-1
:3350, 1740, 1645 (CO2H), 1557 (CO); 
1
H NMR (500 MHz, DMSO-d6) δ 7.01-7.05 (1H, m, H-5’),  7.10 (1H, br s, H-3), 7.54 
(1H, ddd, J = 6.9, 8.5 and 8.6,H-4’), 7.70 (1H, br s, H-5), 12.45 (1H, br s, NH), 12.98 
(1H, br s, CO2H); 
13
C NMR (125 MHz, CDCl3) δ 53.0 (CH3), 112.1 (C-Ar), 112.2 (C-
Ar), 116.0 (C-Ar), 123.9 (C-3), 128.6 (C-2 and C-5), 131.5 (C-4), 133.4 (C-Ar), 153.5 
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(d, JCF = 250.5 Hz, CF), 166.7 (CO2H), 187.0 (CO);
19
F NMR (470 MHz, CDCl3) δ -
109.5; LRMS (ES
+
) m/z 345.5 [M-H]
-
; HRMS m/z calcd for C12H7
79
Br
35
ClFNO3 [M-H]
- 
343.9124, found 343.9124. 
 
4-(3-Bromo-6-chloro-2-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide 
(310) 
 
Compound 310 was synthesised according to general procedure D using 4-(3-bromo-6-
chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (309) (90 mg, 0.26 mmol), 3-
aminopyridine (61 mg, 0.65 mmol), PCl3 (23 µL, 0.26 mmol) and MeCN (3 mL). The 
crude mixture was purified by MPLC (0-5% MeOH in EtOAc) to give the title 
compound as a white solid (64 mg, 58%); Rf = 0.50 (5% MeOH in EtOAc); M.p. 273-
274 
oC; λmax (EtOH)/nm 230, 285; νmax/cm
-1
: 3308, 2396, 2115, 1653 (CO), 1636 
(CONH); 
1
H NMR (500 MHz, MeOD) δ 7.24 (1H, dd, J = 1.3 and 8.7 Hz, H-5’), 7.31-
7.34 (2H, m, H-3 and CH-pyridine), 7.42 (1H, d, J = 1.4 Hz, H-5), 7.66 (1H, dd, J = 7.5 
and 8.9 Hz, H-4’), 8.11-8.14 (1H, m, CH-pyridine), 8.17 (d, J = 4.3 Hz, CH-pyridine), 
8.78 (1H, d, J = 2.3 Hz, CH-N-pyridine); 
13
C NMR (125 MHz, MeOD) δ 112.7 (C-Ar), 
125.3 (C-3), 127.0 (C-Ar), 128.1 (d, JCF = 5.7 Hz, C-Ar), 129.6 (C-2 and C-5), 130.7 
(C-4), 135.9 (C-Ar), 142.3 (C-pyridine), 145.1 (C-pyridine), 156.8 (d, JCF = 245.5 Hz, 
CF), 160.8 (CONH), 185.3 (CO); 
19
F NMR (470 MHz, MeOD) δ -108.8; LRMS (ES+) 
m/z 422.5 [M+H]
+
; HRMS m/z calcd for C17H11
79
Br
35
ClFN3O2 [M+H]
+ 
421.9702, found 
421.9702. 
4-(3-Bromo-6-chloro-2-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (311) 
 
Compound 311 was synthesised according to general procedure D using 4-(3-bromo-6-
chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (309) (90 mg, 0.26 mmol),  5-
aminopyrimidine (62 mg, 0.65 mmol), PCl3 (23 µL, 0.26 mmol) and MeCN (3 mL). 
The crude mixture was purified by MPLC (0-5% MeOH in EtOAc  followed by NH-
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silica, 0-5% MeOH in EtOAc) to give the title compound as a pale yellow solid (33 mg, 
30%); Rf = 0.48 (5% MeOH in EtOAc); M.p. 275-276 
oC; λmax (EtOH)/nm 231-291; 
νmax/cm
-1
:3301, 3031, 2942, 1646 (CO), 1528 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 
7.21 (1H, dd, J = 1.4 and 8.7 Hz, H-5’), 7.41 (1H, d, J = 2.6 Hz, H-3), 7.64 (1H, dd, J = 
7.3 and 8.7 Hz, H-4’), 7.82 (1H, s, H-5), 8.78 (1H, br s, CONH), 8.99 (1H, s, 
pyrimidine-CH), 9.09 (2H, s, pyrimidine-CH), 10.15 (1H, br s, NH); 
13
C NMR (125 
MHz, CDCl3) δ 111.1 (C-Ar), 126.6 (C-3), 127.8 (C-Ar), 130.0 (C-2 and C-5), 133.4 
(C-4), 134.8 (C-Ar), 148.0 (C-N-pyrimidine), 154.2 (d, JCF = 250.1 Hz, CF), 158.6 
(CONH), 184.2 (CO); 
19
F NMR (470 MHz, MeOD) δ -105.7; LRMS (ES+) m/z 422.5 
[M+H]
+
; HRMS m/z calcd for C16H9
79
Br
35
ClFN4O2 [M+H]
+ 
421.9810, found 421.9810. 
3-Bromo-1-(phenylsulfonyl)-1H-pyrrole (313) 
 
 
1-(Phenylsulfonyl)pyrrole (1.00 g, 4.83 mmol) was dissolved in AcOH (9 mL), and Br2 
was added (0.251 mL, 4.83 mmol) as a solution in AcOH (3mL). The mixture was 
heated to reflux for 1 h. Upon cooling water was added (10 mL) and the mixture was 
neutralised using NaOH. The product was extracted using EtOAc (3 x 30 mL) and the 
combined organic extracts were dried over Na2SO4 before the solvent was removed in 
vacuo. The crude product was purified by MPLC (0-10% EtOAc in petrol) to give the 
pure product as a colourless oil that solidified on cooling (0.832 g, 2.90 mmol, 60%); Rf 
= 0.56 (5% MeOH in EtOAc); M.p. 65-66 
o
C (lit.
135
 66.5-67 
o
C) λmax (EtOH)/nm 237; 
νmax/cm
-1
:3140, 1736, 1580, 1529; 
1
H NMR (500 MHz, CDCl3) δ 6.22 (1H, dd, J = 1.6 
and 3.2 Hz, H-4), 7.01-7.02 (1H, m, H-5), 7.09-7.10 (1H, m, H-2), 7.44-7.49 (2H, m, H-
Ar), 7.51-7.59 (1H, m, H-Ar), 7.78-7.82 (2H, m, H-Ar); 
13
C NMR  (125 MHz, CDCl3) δ 
116.4 (C-3), 119.7 (C-4), 120.8 (C-2), 121.3 (C-5), 126.9 (C-Ar), 127.2 (C-Ar), 129.3 
(C-Ar), 129.7 (C-Ar), 134.6 (C-Ar); LRMS (ES
+
) m/z 285.1 [M+H]
+
. 
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Methyl 3-bromo-1-(phenylsulfonyl)-1H-pyrrole-2-carboxylate (314) 
 
 
Diisopropylamine (0.785 µL, 5.60 mmol) was cooled to -78 
0
C before n-BuLi (2.13 M 
in hexane) (2.10 mL, 4.47 mmol) was added dropwise and the mixture was allowed to 
stir at the temperature for 1 h. 3-Bromo-1-(phenylsulfonyl)-1H-pyrrole (313) (0.800 g, 
2.80 mmol) was added in THF (13 mL) and the mixture was allowed to stir at -78 
o
C for 
1 h further. Methyl chloroformate (494 µL, 6.44 mmol) was added dropwise as a 
solution in THF (13 mL) and the reaction was stirred for 30 min before being allowed to 
warm to RT and being quenched with a saturated aqueous solution of NH4Cl (10 mL). 
The product was extracted with EtOAc (3 x 30 mL) and washed with water (50 mL) 
followed by brine (50 mL). The combined organic extracts were dried over Na2SO4 
before being concentrated in vacuo. The crude product was purified by MPLC (0-10% 
EtOAc in petrol ) to give the title compound as a colourless oil that solidified on cooling 
(1.23 g, 3.59 mmol, 80%); Rf = 0.45 (5% MeOH in EtOAc); M.p. 77-78 
o
C (lit.
135
 77-
77.5 
o
C) λmax (EtOH)/nm 246; νmax/cm
-1
:3142, 2120, 1722 (CO2Me), 1533; 
1
H NMR 
(500 MHz, CDCl3) δ 3.72 (3H, s, CH3), 6.33 (1H, d, J = 3.4 Hz, H-4), 7.47-7.50 (3H, m, 
H-5 and H-Ar), 7.57-7.59 (1H, m, H-2), 7.87-7.91 (2H, m, H-Ar); 
13
C NMR  (125 MHz, 
CDCl3) δ 52.4 (CH3), 115.3 (C-3), 123.8 (C-4), 124.8 (C-2), 125.3 (C-5), 126.9 (C-Ar), 
127.9 (C-Ar), 128.1 (C-Ar), 128.8 (C-Ar), 134.2 (C-Ar); LRMS (ES
+
) m/z 344.2 
[M+H]
+
. 
 
(Z)-Ethyl 2-(hydroxyimino)-3-oxobutanoate (317) 
 
 
Ethyl acetoacetate (98 µL, 0.77 mmol) was cooled to 0 
o
C in AcOH (1 mL) before 
sodium nitrite (53 mg, 0.77 mmol) was added as a solution in water (1 mL) and the 
reaction left to stir for 4 h. Water was added (10 mL) and the product was extracted with 
diethyl ether (3 x 10 mL). The combined organic layers washed with brine (20 mL) 
before being dried over Na2SO4. The solvent was removed in vacuo to give the title 
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compound as a pale yellow oil (103 mg, 0.65 mmol 85%); Rf = 0.30 (5% MeOH in 
EtOAc); λmax (EtOH)/nm 299; νmax/cm
-1
:3083, 2925, 2110, 1742 (CO2Et), 1571; 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.56 (3H, t, J = 7.2 Hz, CH2CH3), 2.01 (1H, s, NOH), 
2.50 (3H, s, CH3), 4.50 (2H, q, J = 7.2 Hz, CH2CH3); 
13
C NMR  (125 MHz, DMSO-d6) 
δ 14.7 (CH2CH3), 20.8 (CH3), 60.1 (CH2CH3), 144.0 (CNOH), 166.1 (CO2Et), 196.1 
(CO); LRMS (ES
+
) m/z 160.3 [M+H]
+
. 
 
(Z)-Ethyl 2-(hydroxyimino)-3-oxopentanoate (318) 
 
 
Ethyl propionylacetate (0.49 mL, 3.47 mmol) was cooled to 0 
o
C in AcOH (5 mL) 
before sodium nitrite (239 mg, 3.47 mmol) was added as a solution in water (5 mL) and 
the reaction left to stir for 4 h. Water was added (30 mL) and the product was extracted 
with diethyl ether (3 x 30 mL). The combined organic layers washed with brine (50 mL) 
before being dried over Na2SO4. The solvent was removed in vacuo to give the title 
compound as a yellow oil (0.49 g, 2.84 mmol 82%); Rf = 0.33 (5% MeOH in EtOAc); 
λmax (EtOH)/nm 232; νmax/cm
-1
:3314, 2984, 2942, 1720 (CO2Et), 1688; 
1
H NMR (500 
MHz, DMSO-d6) δ 1.08 (3H, t, J = 7.2 Hz, CH2CH3), 1.31 (3H, t, J = 6.8 Hz, 
OCH2CH3), 2.10 (1H, s, NOH),  2.01 (1H, s, NOH), 2.79 (2H, q, J = 7.2 Hz, CH2CH3), 
4.34 (2H, q, J = 6.8 Hz, OCH2CH3); 
13
C NMR  (125 MHz, DMSO-d6) δ 7.7 (CH2CH3),  
13.9 (OCH2CH3), 62.4 (CH2CH3), 77.1 (OCH2CH3), 150.3 (CNOH), 162.1 (CO2Et), 
197.0 (CO); LRMS (ES
+
) m/z 174.1 [M+H]
+
. 
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(E)-1-(2-Chloro-6-fluorophenyl)-3-(dimethylamino)prop-2-en-1-one (320) 
 
 
 
N,N-Dimethylformamide dimethyl acetal (97 µL, 0.73 mmol) was added dropwise to a 
solution of 2’-chloro-6’-fluoroacetophenone (79 µL, 0.58mmol) in toluene (1 mL) and 
the mixture was heated to reflux for 18 h. Upon cooling, the solvent was removed in 
vacuo and the crude residue was purified by MPLC (0-50% EtOAc in petrol over 24 
column volumes) to give the pure compound as a pale yellow solid (105 mg, 0.46, 
80%); Rf = 0.35 (5% MeOH in EtOAc); λmax (EtOH)/nm 305, 236; νmax/cm
-1
: 3077 
(NMe2), 2920, 2323, 1630 (CO), 1560; 
1
H NMR (500 MHz, CDCl3) δ 2.93 (6H, s, 
N(CH3)2), 6.86 (1H, br s, CH) Hz, 7.02-7.05 (2H, m, H-Ar), 7.26-7.30 (1H, m, H-Ar), 
7.90 (1H, br s, CHN); 
13
C NMR  (125 MHz, CDCl3) δ 45.4 (N(CH3)2), 114.1 (CH), 
114.5 (C-Ar), 125.4 (C-Ar), 125.5 (C-Ar), 129.9 (C-Ar), 153.6 (CHN), 159.2 (d, J = 
245.1 Hz, CF), 188.9 (CO); 
19
F NMR (470 MHz, CDCl3) δ -113.3;  LRMS (ES
+
) m/z 
228.3 [M+H]
+
. 
 
Ethyl 4-(2-chloro-6-fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylate (321) 
 
 
(E)-1-(2-Chloro-6-fluorophenyl)-3-(dimethylamino)prop-2-en-1-one (320) (100 mg, 
0.44 mmol) was dissolved in AcOH (1 mL) before (Z)-Ethyl 2-(hydroxyimino)-3-
oxobutanoate (317) (70 mg, 0.44 mmol) was added followed by NaOAc (108 mg, 1.32 
mmol). Zn dust (247 mg, 3.78 mmol) was added portion-wise with heating to 140 
o
C 
over 6 h. Upon cooling water was added (5 mL) and the product was extracted with 
ethyl acetate (3 x 10 mL). The combined organic layers were dried over Na2SO4 and the 
solvent was removed in vacuo. The crude product was purified by MPLC (0-30% 
EtOAc in petrol) to give the product as a yellow oil (40 mg, 0.13 mmol, 30%); Rf = 0.30 
(5% MeOH in DCM); M.p. 256-257 
oC; λmax (EtOH)/nm 232; νmax/cm
-1
: 3057, 2925, 
2110, 1681 (CO2Me), 1571 (CO); 
1
H NMR (500 MHz, CDCl3) δ 1.33 (3H, t, J = 7.4 
Hz, CH2CH3), 2.37 (3H, s, CH3), 4.28 (2H, q, J = 7.4 Hz, CH2CH3), 7.01 (1H, s, H-5),  
7.21-7.26 (2H, m, H-3’ and H-5’), 7.60 (1H, ddd, J = 6.2, 8.3 and 8.4Hz, H-4’), 9.65 
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(1H, br s, NH); 
13
C NMR  (125 MHz, CDCl3) δ 10.1 (CH3), 15.2 (CH2CH3), 60.1 
(CH2CH3), 113.7 (C-Ar), 118.2 (C-4), 122.1 (C-2), 123.5 (C-Ar), 125.8 (C-5), 128.4 (C-
3), 136.2 (C-Ar), 136.9 (C-Ar), 157.3 (d, J = 256.3 Hz, CF), 186.2 (CO);  
19
F NMR 
(470 MHz, DMSO-d6) δ -113.2; LRMS (ES
+
) m/z 310.2 [M+H]
+
; HRMS m/z calcd for 
C15H14
35
ClFNO3 [M+H]
+ 
310.1023, found 310.1023. 
 
Ethyl 4-(2-chloro-6-fluorobenzoyl)-3-ethyl-1H-pyrrole-2-carboxylate (322)  
 
 
 
(E)-1-(2-Chloro-6-fluorophenyl)-3-(dimethylamino)prop-2-en-1-one (317) (264 mg, 
1.16 mmol) was dissolved in AcOH (1 mL) before (Z)-ethyl 2-(hydroxyimino)-3-
oxopentanoate (318) (100 mg, 0.58 mmol) was added followed by NaOAc (143 mg, 
1.74 mmol). Zn dust (227 mg, 3.48 mmol) was added portion-wise with heating to 140 
o
C over 6 h. Upon cooling water was added (5 mL) and the product was extracted with 
ethyl acetate (3 x 10 mL). The combined organic layers were dried over Na2SO4 and the 
solvent was removed in vacuo. The crude product was purified by MPLC (0-30% 
EtOAc in petrol) to give the product as an orange oil (66 mg, 0.20 mmol, 35%); Rf = 
0.32 (5% MeOH in DCM); M.p. 260-261 
oC; λmax (EtOH)/nm 239; νmax/cm
-1
: 2972, 
2082, 1651 (CO2Me), 1568 (CO); 
1
H NMR (500 MHz, CDCl3) δ 1.17 (3H, t, J = 7.1 
Hz, CH2CH3), 1.31 (3H, t, J = 7.3 Hz, OCH2CH3), 3.15 (2H, q, J = 7.1 Hz, CH2CH3), 
4.30 (2H, q, J = 7.3 Hz, OCH2CH3), 6.93 (1H, s, H-5),  6.97-7.00 (2H, m, H-3’ and H-
5’), 7.27 (1H, ddd, J = 6.0, 8.3 and 8.4 Hz, H-4’), 9.30 (1H, br s, NH); 13C NMR  (125 
MHz, CDCl3) δ 14.1 (CH2CH3), 15.04 (OCH2CH3), 18.7 (CH2CH3), 60.8 (OCH2CH3), 
114.2 (C-Ar), 114.5 (C-Ar), 119.2 (C-4), 121.5 (C-2), 124.1 (C-Ar), 125.2 (C-Ar), 
126.0 (C-5), 129.9 (C-3), 136.2 (C-Ar), 140.1 (C-Ar), 160.2 (d, J = 251.8 Hz, CF), 
188.8 (CO);  
19
F NMR (470 MHz, DMSO-d6) δ -113.3; LRMS (ES
+
) m/z 324.1 
[M+H]
+
; HRMS m/z calcd for C16H16
35
ClFNO3 [M+H]
+ 
324.0804, found 324.0804. 
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4-(2-Chloro-6-fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylic acid (323) 
 
 
 
Ethyl 4-(2-chloro-6-fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylate (321) (150 mg, 
0.48 mmol) was dissolved in THF (4 mL) before LiOH (230 mg, 9.60 mmol) was added 
as a solution in H2O (6 mL). The mixture was heated to 100 
o
C and left to stir for 18 h. 
The reaction was worked up according to general procedure B and the pure product was 
obtained as a yellow solid (105 mg, 0.37 mmol, 78%); Rf = 0.21 (5% MeOH in DCM); 
M.p. 271-272 
oC; λmax (EtOH)/nm 236; νmax/cm
-1
: 3343, 2921, 2087, 1638 (CO2H), 1603 
(CO); 
1
H NMR (500 MHz, CDCl3) δ 2.36 (3H, s, CH3), 6.95 (1H, s, H-5),  7.01-7.25 
(2H, m, H-3’ and H-5’), 7.45 (1H, ddd, J = 6.3, 8.4 and 8.5 Hz, H-4’), 9.32 (1H, br s, 
NH), 9.56 (1H, br s, CO2H); 
13
C NMR  (125 MHz, CDCl3) δ 9.7 (CH3), 115.7 (C-Ar), 
120.1 (C-4), 123.0 (C-2), 124.1 (C-Ar), 126.0 (C-5), 129.3 (C-3), 135.4 (C-Ar), 136.8 
(C-Ar), 160.4 (d, J = 245.3 Hz, CF), 189.0 (CO);  
19
F NMR (470 MHz, DMSO-d6) δ -
111.7; LRMS (ES
+
) m/z 280.1 [M-H]
-
; HRMS m/z calcd for C13H8
35
ClFNO3 [M-H]
- 
280.0182, found 280.0176. 
 
4-(2-Chloro-6-fluorobenzoyl)-3-ethyl-1H-pyrrole-2-carboxylic acid (324) 
 
 
 
Ethyl 4-(2-chloro-6-fluorobenzoyl)-3-ethyl-1H-pyrrole-2-carboxylate (322) (337 mg, 
1.04 mmol) was dissolved in THF (8 mL) before LiOH (499 mg, 20.9 mmol) was added 
as a solution in H2O (14 mL). The mixture was heated to 100 
o
C and left to stir for 18 h. 
The reaction was worked up according to general procedure B and the pure product was 
obtained as a cream solid (230 mg, 0.78 mmol, 75%); Rf = 0.26 (5% MeOH in DCM); 
M.p. 275-276 
oC; λmax (EtOH)/nm 238; νmax/cm
-1
: 3323, 2090, 1704 (CO2H), 1650 
(CO), 1570; 
1
H NMR (500 MHz, CDCl3) δ 1.20 (3H, t, J = 7.4 Hz, CH2CH3), 3.20 (2H, 
q, J = 7.4 Hz, CH2CH3), 7.00 (1H, s, H-5),  7.03-7.05 (2H, m, H-3’ and H-5’), 7.48 (1H, 
ddd, J = 6.1, 8.2 and 8.3 Hz, H-4’), 9.26 (1H, br s, NH), 9.75 (1H, br s, CO2H); 
13
C 
NMR  (125 MHz, CDCl3) δ 14.9 (CH2CH3), 18.2 (CH2CH3), 114.7 (C-Ar), 115.2 (C-
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Ar), 119.9 (C-4), 122.1 (C-2), 124.9 (C-Ar), 126.2 (C-Ar), 127.0 (C-5), 130.2 (C-3), 
137.2 (C-Ar), 140.3 (C-Ar), 157.8 (d, J = 256.7 Hz, CF), 189.1 (CO);  
19
F NMR (470 
MHz, DMSO-d6) δ -112.0; LRMS (ES
+
) m/z 294.3 [M-H]
-
; HRMS m/z calcd for 
C14H10
35
ClFNO3 [M-H]
- 
294.0332, found 294.0331. 
 
4-(2-Chloro-6-fluorobenzoyl)-3-methyl-N-(pyridin-3-yl)-1H-pyrrole-2-
carboxamide (325)  
 
 
Compound 325 was synthesised according to general procedure D using 4-(2-Chloro-6-
fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylic acid (323) (80 mg, 0.28 mmol), 3-
aminopyridine (66 mg, 0.70 mmol), PCl3 (24 µL, 0.28 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM ) to give the title 
compound as a yellow solid (25 mg, 0.07 mmol, 25%); Rf = 0.43 (5% DCM in MeOH); 
M.p. 269-272 
oC; λmax (EtOH)/nm 256; νmax/cm
-1
: 3320, 3077, 2746, 1641, 1520, 1483; 
1
H NMR (500 MHz, DMSO-d6) δ 2.58 (3H, s, CH3), 7.28 (1H, s, H-5), 7.35-7.46 (3H, 
m, H-3’, H-5’ and pyridine-CH), 7.52-7.60 (1H, m, H-4’), 8.10 (1H, d, J = 6.5 Hz, 
pyridine-CH), 8.31 (1H, d, J = 4.9 Hz, pyridine-CH-N), 8.82 (1H, s, pyridine-CH-N), 
9.94 (1H, s, CONH), 12.27 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 11.4 
(CH3), 114.8, 115.0 (C-Ar), 123.6 (C-3), 125.7 (C-2 and C-5), 126.8, (C-Ar), 130.5 (C-
4), 135.5, 141.4, 144.4 (C-pyridine), 158.7 (d, JCF = 251.9 Hz, CF), 159.8 (CONH), 
184.5 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -115.9; LRMS (ES
+
) m/z 358.3 [M+H]
+
; 
HRMS m/z calcd for C18H13ClFN3O2 [M+H]
+ 
358.0759, found 358.0758.  
 
4-(2-Chloro-6-fluorobenzoyl)-3-methyl-N-(pyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (326) 
 
 
Compound 326 was synthesised according to general procedure D using 4-(2-Chloro-6-
fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylic acid (323) (60 mg, 0.21 mmol), 5-
aminopyrimidine (50 mg, 0.53 mmol), PCl3 (18 µL, 0.21 mmol) and MeCN (1 mL). 
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The crude mixture was purified by MPLC (0-8% MeOH in DCM ) to give the title 
compound as an orange solid (15 mg, 0.04 mmol, 20%); Rf = 0.39 (5% MeOH in 
DCM); M.p. 281-282 
oC; λmax (EtOH)/nm 252; νmax/cm
-1
: 3292, 2921, 1643 (CO), 1508 
(CONH); 
1
H NMR (500 MHz, CDCl3) δ 2.83 (3H, s, CH3), 6.98-7.05 (3H, m, H-5, H-3’ 
and H-5’), 7.30 (1H, ddd, J = 6.0, 8.1 and 8.2 Hz, H-4’), 7.70 (1H, br s, CONH), 8.95 
(1H, s, pyrimidine-CH), 9.03 (2H, s, 2 x pyrimidine-CH), 9.75 (1H, br s, NH); 
19
F NMR 
(470 MHz, DMSO-d6) δ -113.2; LRMS (ES
+
) m/z 359.3 [M+H]
+
; HRMS m/z calcd for 
C17H12ClFN4O2 [M+H]
+ 
359.0712, found 359.0712. 
 
4-(2-Chloro-6-fluorobenzoyl)-3-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (327) 
 
 
Compound 327 was synthesised according to general procedure D using 4-(2-Chloro-6-
fluorobenzoyl)-3-methyl-1H-pyrrole-2-carboxylic acid (323) (60 mg, 0.21 mmol), 1-
methyl-4-aminopiperidine (56 µL, 0.53 mmol), PCl3 (18 µL, 0.21 mmol) and MeCN (1 
mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM ) to give the title 
compound as a pale yellow solid (24 mg, 0.06 mmol, 30%); Rf = 0.35 (5% DCM in 
MeOH); M.p. 254-255 
oC; λmax (EtOH)/nm 242; νmax/cm
-1
: 3218 (NMe), 2924, 2791, 
1602 (CO), 1544 (CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.71-1.78 (2H, m, CH2), 
1.97-2.03 (2H, m, CH2), 2.32-2.36 (2H, m, CH2), 2.38 (3H, s, CH3), 2.64 (3H, s, N-
CH3), 2.95 (2H, br s, 2H, m, CH2), 3.94-4.00 (1H, m, CH), 6.43 (1H, br s, CONH), 6.86 
(1H, s, H-5), 6.96-6.99 (1H, m, H-5’), 7.15 (1H, d, J = 8.1 Hz, H-3’), 7.25 (1H, ddd, J = 
6.2, 8.1 and 8.2 Hz, H-4’), 10.49 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) δ 11.7 
(CH3), 31.1 (2 x CH2), 45.3 (N-CH3 and CH), 114.3 (C-Ar), 114.5 (C-4), 123.7 (C-Ar), 
124.7 (C-Ar), 124.8 (C-2), 129.0 (d, JCF = 3.1 Hz, C-Ar), 129.2 (C-5), 130.7 (C-3), 
131.9 (d, JCF = 6.0 Hz, C-Ar), 159.2 (d, JCF = 248.8 Hz, C-F), 161.0 (CONH), 185.5 
(CO); 
19
F NMR (470 MHz, DMSO-d6) δ -113.3; LRMS (ES
+
) m/z 378.4 [M+H]
+
; 
HRMS m/z calcd for C19H21ClFN3O2 [M+H]
+ 
378.1384, found 378.1384. 
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4-(2-Chloro-6-fluorobenzoyl)-3-ethyl-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide 
(328)  
 
 
Compound 328 was synthesised according to general procedure D using 4-(2-Chloro-6-
fluorobenzoyl)-3-ethyl-1H-pyrrole-2-carboxylic acid (324) (100 mg, 0.34 mmol), 3-
aminopyridine (80 mg, 0.85 mmol), PCl3 (30 µL, 0.34 mmol) and MeCN (2 mL). The 
crude mixture was purified by MPLC (0-8% MeOH in DCM ) to give the title 
compound as a cream solid (38 mg, 0.10 mmol, 30%); Rf = 0.45 (5% DCM in MeOH); 
M.p. 269-272 
oC; λmax (EtOH)/nm 256, 289; νmax/cm
-1
: 3142, 3980, 1547 (CO), 1511 
(CONH); 
1
H NMR (500 MHz, CDCl3) δ 1.48 (3H, t, J = 7.6 Hz, CH3), 3.35 (2H, q, J = 
7.6 Hz, CH2), 7.08 (1H, d J = 3.4 Hz, CH-pyridine), 7.09-7.12 (1H, m, H-3’), 7.27 (1H, 
s, H-5), 7.35-7.40 (2H, m, H-4’ and H-5’), 7.79 (1H, br s, CONH), 8.19 (1H, d, J = 7.2 
Hz, CH-pyridine), 8.44 (1H, d, J = 4.9 Hz, CH-N-pyridine), 8.72 (1H, d, J = 2.2 Hz, 
CH-N-pyridine), 9.85 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ; 15.3 (CH2), 19.6 
(CH3), 114.3 (C-Ar), 114.5 (C-4), 123.9 (C-2), 124.6 (C-Ar), 125.6 (C-Ar), 127.7 (d, 
JCF = 3.2 Hz, C-Ar), 130.1 (C-5), 130.8 (d, JCF = 9.2 Hz, C-Ar), 134.3 (C-pyridine), 
141.5 (C-3), 145.7 (C-pyridine), 159.6 (CONH), 185.2 (CO); 
19
F NMR (470 MHz, 
CDCl3) δ -113.3; LRMS (ES
+
) m/z 372.3 [M+H]
+
; HRMS m/z calcd for C19H15ClFN3O2 
[M+H]
+ 
372.0918, found 372.0917. 
 
4-(2-Chloro-6-fluorobenzoyl)-3-ethyl-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (329)  
 
 
Compound 329 was synthesised according to general procedure D using 4-(2-Chloro-6-
fluorobenzoyl)-3-ethyl-1H-pyrrole-2-carboxylic acid (324) (100 mg, 0.34 mmol), 4-
amino-1-methylpiperidine (89 µL, 0.85 mmol), PCl3 (30 µL, 0.34 mmol) and MeCN (2 
mL). The crude mixture was purified by MPLC (0-8% MeOH in DCM ) to give the title 
compound as an orange solid (33 mg, 0.08 mmol, 25%); Rf = 0.36 (5% DCM in 
MeOH); M.p. 262-264 
oC; λmax (EtOH)/nm 242; νmax/cm
-1
: 3385 (NMe), 2925, 1571 
(CO), 1535 (CONH), 1445, 1407; 
1
H NMR (500 MHz, CDCl3) δ 1.25-1.29 (2H, m, 
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CH2), 1.32 (3H, t, J = 7.5 Hz, CH2CH3), 1.86-1.94 (2H, m, CH2),  2.10-2.14 (2H, m, 
CH2N), 2.52 (3H, s, NCH3),  3.10-3.14 (2H, m, CH2N),  3.24 (2H, q, J = 7.5 Hz, 
CH2CH3), 4.10-4.16 (1H, m, CH), 6.81 (1H, br s, CONH), 6.96 (1H, s, H-5), 7.05-7.06 
(1H, m, H-5’), 7.08 (1H, d, J = 8.3 Hz, H-3’), 7.33 (1H, ddd, J = 5.9, 8.3 and 8.4 Hz, H-
4’),  10.76 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) δ; 15.0 (CH2CH3), 18.9 
(CH2CH3), 30.6 (2 x CH2), 44.9 (NCH3), 53.9 (2 x CH2N), 114.2 (C-Ar), 114.4 (C-4), 
124.1 (C-Ar), 124.4 (C-2), 125.5 (d, JCF = 3.4 Hz, C-Ar), 129.3 (C-5), 130.5 (d, J = 9.0 
Hz, C-Ar), 131.9 (d, JCF = 6.2 Hz, C-Ar), 132.0 (C-3), 159.0 (d, JCF = 250.5 Hz, C-F), 
160.8 (CONH), 185.0 (CO); 
19
F NMR (470 MHz, CDCl3) δ -113.2; LRMS (ES
+
) m/z 
372.3 [M+H]
+
; HRMS m/z calcd for C20H23ClFN3O2 [M+H]
+ 
392.1538, found 
392.1538. 
 
Ethyl 3-amino-1H-pyrrole-2-carboxylate (347) 
 
 
Isoxazole (93 µL, 1.5 mmol) was dissolved in ethanol (4 mL) before a 21% by weight 
solution of NaOEt (109 mg, 1.6 mmol) in EtOH (0.5 mL) was added slowly at 0 
o
C. The 
mixture was stirred for 45 min before acetic acid (25 µL, 0.44 mmol) and diethyl 2-
aminomalonate hydrochloride (192 mg, 0.91 mmol) were added and the mixture was 
stirred at RT overnight. The solvent was removed in vacuo and DCM (10 mL) was 
added to dissolve the residue, which was washed with water. The organic layer was 
dried over Na2SO4 and the solvent removed in vacuo. The residue was dissolved in 
EtOH (10 mL) and a 21% by weight solution of NaOEt (59 mg, 0.87 mmol) in EtOH 
(0.28 mL) was added. The reaction was left to stir at RT overnight before acetic acid (54 
µL, 0.94 mmol) was added and the mixture was concentrated in vacuo. Water (10 mL) 
was added to the residue and this was neutralised using a saturated solution of NaHCO3. 
The product was extracted with DCM (3 x 10 mL) and the organic extracts were dried 
over Na2SO4 before the solvent was removed in vacuo. The title compound was 
obtained as a yellow oil (190 mg, 85%); Rf = 0.75 (10% MeOH in EtOAc); λmax 
(EtOH)/nm: 254; νmax/cm
-1
: 3370 (NH2), 2987, 2202, 1732 (CO2Et); 
1
H NMR (500 
MHz, MeOD) δ 1.24 (3H, t, J = 7.2 Hz, CH3), 4.23 (3H, t, J = 7.2 Hz, CH3), 5.49 (2H, 
br s, NH2), 6.94-6.97 (2H, m, H-4 and H-5); 
13
C NMR (125 MHz, MeOD) δ 14.0 (CH3), 
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62.9 (CH2), 119.9 (C-2, C-4, and C-5), 148.4 (C-3), 165.5 (CO); LRMS (ES
+
) m/z 
155.20 [M+H]
+
.  
 
4-Methoxy-3-nitropyridine (351) 
 
Sodium (40 mg, 1.74 mmol) was dissolved in MeOH (1 mL) before 4-chloro-3-
nitropyridine (250 mg, 1.58 mmol) was added as a solution in 3 mL MeOH:dioxane 
(1:1). The reaction mixture was heated to reflux for 2.5 h. After cooling, water was 
added and the product was extracted using EtOAc. The combined organic extracts were 
washed with brine and dried over Na2SO4 to give the pure compound as a pale yellow 
solid (235 mg, 6.50 mmol, 1.52 mmol, 96%); Rf = 0.43 (5% MeOH in DCM) M.p.: 71-
72
o
C (lit.
155
- 72-73 
o
C); λmax (EtOH)/nm 241.5; νmax/cm
-1
 1594 (NO2), 1511; 
1
H NMR 
(500 MHz, DMSO-d6) δ 4.03 (3H, s, OCH3), 7.46 (1H, d, J = 6.1 Hz, CH-pyridine), 
8.70 (1H, d, J = 6.1 Hz, CH-N-pyridine), 8.99 (1H, s, CH-N-pyridine);
 13
C NMR (125 
MHz, CDCl3) δ 56.7 (OCH3), 108.5 (C-5), 147.0 (C-2 and C-3), 154.8 (C-6), 158.9 (C-
4); LRMS (ES
+
) m/z 155.2 [M+H]
+
. 
 
3-Bromo-4-methoxy-5-nitropyridine (352) 
 
 
Sodium (292 mg, 0.23 mmol) was dissolved in MeOH (20 mL), before 3-bromo-4-
chloro-5-nitropyridine (356) (2.74 g, 11.54 mmol) was added as a solution in 40 mL 
MeOH:Dioxane (1:1). The mixture was stirred at RT for 2.5 h before water was added 
and the product was extracted into EtOAc. The combined organic extracts were dried 
over Na2SO4 before the solvent was removed in vacuo to afford the pure product as a 
cream solid (2.30 g, 9.89 mmol, 86%); Rf = 0.35 (5% MeOH in DCM) M.p. 42-43 
o
C 
(lit.
151
- 39-40 
o
C); λmax (EtOH)/nm 259; νmax/cm
-1
 3053, 1640, 1613, 1503 (NO2); 
1
H 
NMR (500 MHz, CDCl3) δ 4.04 (3H, s, OCH3), 8.78 (1H, s, CH-pyridine), 8.83 (1H, s, 
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CH-pyridine); 
13
C NMR (125 MHz, MeOD) δ 59.0 (OCH3), 118.7 (C-3), 138.7 (C-5), 
139.0 (C-6), 144.8 (C-2), 155.5 (C-4); LRMS (ES
+
) m/z 234.1 [M+H]
+
. 
 
6-Bromo-7-methoxy-1H-pyrrolo[3,2-b]pyridine (353) 
 
3-Bromo-4-methoxy-5-nitropyridine (352) (2.20 g, 9.44 mmol) was dissolved in THF 
(35 mL) and cooled to -78 
o
C. Vinylmagnesium bromide (1.0 M solution in THF, 35.0 
mL, 35.0 mmol) was added dropwise and the mixture was left to stir for 5 h. The 
reaction was quenched using a saturated solution of NH4Cl in MeOH (40 mL) before 
being allowed to warm to RT. The product was extracted using EtOAc and the 
combined organic extracts were dried over Na2SO4 before the solvent was removed in 
vacuo. The crude product was purified by MPLC (NH silica; 0-30% MeOH in DCM 
over 24 column volumes) to afford the pure product as an orange oil (857 mg, 3.77 
mmol, 40%); Rf = 0.45 (5% MeOH in DCM); λmax (EtOH)/nm 283; νmax/cm
-1
 2924, 
1597, 1547, 1421; 
1
H NMR (500 MHz, CDCl3) δ 4.10 (3H, s, CH3), 6.67 (1H, dd, J = 
2.1 and 3.3 Hz), 7.31-7.33 (1H, m, H-5), 8.41 (1H, s, CH-pyridine); 
13
C NMR (125 
MHz, CDCl3) δ: 60.7 (CH3), 91.5 (C-3), 104.7 (C-6), 112.4 (C-8), 127.0 (C-8), 127.0 
(C-2), 127.7 (C-9), 147.1 (C-5), 165.6 (C-7); LRMS (ES
+
) m/z 227.1 [M+H]
+
; HRMS 
m/z calcd for C8H8
79
BrN2O [M+H]
+ 
227.1015, found 227.1018. 
 
3-Bromo-5-nitropyridin-4-ol (355) 
 
4-Hydroxy-3-nitropyridine (1.0 mg, 7.20 mmol) was suspended in water (20 mL) before 
Br2 (482 µL, 9.4 mmol) was added. The reaction mixture was heated to 50 
o
C for 2.5 h. 
After cooling, the precipitate was filtered, washed with water followed by Et2O and 
dried under vacuum to give the pure compound as a cream solid (1.42 g, 6.50 mmol, 
90%); Rf = 0.47 (5% MeOH in DCM); M.p.: >300 
o
C (lit.
156
 370 
o
C); λmax (EtOH)/nm: 
332; νmax/cm
-1
: 2886 (OH), 1611, 1531 (NO2); 
1
H NMR (500 MHz, DMSO-d6) δ 8.39 
(1H, s, CH-pyridine), 8.84 (1H, s, CH-pyridine), 12.80 (1H, br s, OH); 
13
C NMR (125 
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MHz, DMSO-d6) 118.7 (C-3), 137.0 (C-5), 138.8 (C-6), 139.0 (C-2), 163.5 (C-4); 
LRMS (ES
+
) m/z 221.1 [M+H]
+
. 
 
3-Bromo-4-chloro-5-nitropyridine (356) 
 
3-Bromo-5-nitropyridin-4-ol (355) (200 mg, 0.92 mmol) and N,N-diethylaniline (140 
µL, 0.92 mmol) were dissolved in POCl3 (2 mL) and the mixture was heated under 
microwave irradiation at 140 
o
C for 15 min. The reaction mixture was added to 
vigourously stirring water (30 mL) at RT and the product was extracted into EtOAc. 
The combined organic layers were dried over Na2SO4 and the solvent removed in vacuo 
to afford the pure product as a clear oil, which crystallised upon cooling (195 mg, 0.82 
mmol, 89%); Rf = 0.60 (5% MeOH in DCM); M.p.: 55-56 
o
C (lit.
151
- 49-50 
o
C); λmax 
(EtOH)/nm 252; νmax/cm
-1
 2871, 1630, 1609, 1515 (NO2); 
1
H NMR (500 MHz, CDCl3) 
δ 8.87 (1H, s, CH-pyridine), 8.88 (1H, s, CH-pyridine); LRMS (ES+) m/z 238.1 
[M+H]
+
. 
 
7-Methoxy-6-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine (357) 
 
6-Bromo-7-methoxy-1H-pyrrolo[3,2-b]pyridine (352) (150 mg, 0.66 mmol) was 
dissolved in dioxane (10 mL) before 4-pyridinyl-boronic acid (54 mg, 0.44 mmol) was 
added followed by Na2CO3 and water (1 mL). The mixture was degassed for 15 min 
before Pd(PPh3)4 (5mg, 0.04 mmol) was added and the mixture degassed for a further 15 
min. The reaction was heated to 110 
o
C for 18 h before being cooled, filtered through 
Celite and the solvent removed in vacuo. The crude product was purified by MPLC 
(silica; 0-20% MeOH in EtOAc ) to give the pure product as a yellow oil (111 mg, 0.49 
mmol, 75%); Rf = 0.42 (5% MeOH in EtOAc); λmax (EtOH)/nm 301, 254; νmax/cm
-1
 
3404, 2925, 1599, 1552, 1517; 
1
H NMR (500 MHz, CDCl3) δ 3.77 (3H, s, CH3), 6.73 
(1H, d, J = 3.2 Hz, H-3), 7.42 (1H, d, J = 3.2 Hz, H-2), 7.48 (2H, d, J = 6.1 Hz, CH-
pyridine), 8.35 (1H, s, H-5), 8.62 (2H, d, J = 6.1 Hz, CH-N-pyridine), 8.74 (1H, br s, 
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NH); 
13
C NMR (125 MHz, CDCl3) δ 60.5 (CH3), 103.7 (C-3), 111.7 (C-8), 118.3 (C-6), 
123.4 (C-pyridine), 128.7 (C-2), 136.9 (C-N-pyridine), 145.8 (C-5 and C-9), 148.2 
(pyridine-C), 150.2 (C-7); LRMS (ES
+
) m/z 226.2 [M+H]
+
; HRMS m/z calcd for 
C13H12N3O [M+H]
+ 
226.0975, found 226.0973. 
 
7-Methoxy-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridine (358) 
 
6-Bromo-7-methoxy-1H-pyrrolo[3,2-b]pyridine (352) (150 mg, 0.66 mmol) was 
dissolved in dioxane (10 mL) before 3-pyridinyl-boronic acid (54 mg, 0.44 mmol) was 
added followed by Na2CO3 and water (1 mL). The mixture was degassed for 15 min 
before Pd(PPh3)4 (5mg, 0.04 mmol) was added and the mixture degassed for a further 15 
min. The reaction was heated to 110 
o
C for 18 h before being cooled, filtered through 
celite and the solvent removed in vacuo. The crude product was purified by MPLC 
(silica; 0-20% MeOH in EtOAc ) to give the pure product as a yellow oil (110 mg, 0.49 
mmol, 75%); Rf = 0.43 (5% MeOH in EtOAc); λmax (EtOH)/nm 302, 254; νmax/cm
-1
 
3404, 1599, 1552, 1515; 
1
H NMR (500 MHz, CDCl3) δ 3.85 (3H, s, CH3), 6.82 (1H, d, 
J = 3.2 Hz, H-3), 7.50 (1H, d, J = 3.2 Hz, H-2), 7.91-7.94 (2H, m, CH-pyridine), 8.41 
(1H, s, H-5), 8.65 (1H, dd, J = 1.6 and 5.0 Hz, CH-N-pyridine), 8.84 (1H, br s, NH), 
8.87 (1H, s, CH-N-pyridine); 
13
C NMR (125 MHz, CDCl3) δ 60.6 (CH3), 103.7 (C-3), 
111.7 (C-8), 118.1 (C-6), 124.4 (C-pyridine), 128.9 (C-2), 138.9 (C-N-pyridine), 145.6 
(C-5 and C-9), 148.2 (pyridine-C), 155.2 (C-7); LRMS (ES
+
) m/z 226.2 [M+H]
+
; 
HRMS m/z calcd for C13H12N3O [M+H]
+ 
226.0975, found 226.0977. 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one (367) 
 
 
Compound 367 was synthesised according to general procedure F using; (part i) 2,6-
difluorobenzoyl chloride (446 µL, 3.55 mmol), 7-methoxy-6-(pyridin-4-yl)-1H-
pyrrolo[3,2-b]pyridine (357) (160 mg, 0.71 mmol), AlCl3 (0.52 g, 3.91 mmol) and DCM 
(6 mL), (part ii) DCM (3 mL), TMSI (170 µL, 1.20 mmol). The crude product was 
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purified by semi-preparative HPLC (C-18 silica; 5-100% CH3CN in water (0.1% formic 
acid)) to give the pure product as a white solid (19 mg, 0.06 mmol, 28%); Rf = 0.35 (5% 
MeOH in EtOAc); M.p. 235-236 
o
C; λmax (EtOH)/nm 252; νmax/cm
-1 
3350, 3042
, 
2858, 
1619 (CO), 1598 (CO-pyridone), 1565; 
1
H NMR (500 MHz, MeOD) δ 7.17-7.20 (1H, 
m, H-Ar), 7.25 (1H, d, J = 8.9 Hz, H-Ar), 7.43-7.48 (1H, m, H-Ar), 7.43-7.48 (2H, m, 
CH-pyridine), 7.50 (1H, s, H-3), 7.61-7.63 (2H, m, CH-pyridine), 7.92 (1H, s, H-5), 
8.06 (1H, d, J = 8.1 Hz, CH-pyridone), 8.41 (1H, br s, NH-pyridone), 8.74 (1H, br s, 
NH); 
19
F NMR (470 MHz, MeOD) δ -115.4; LRMS (ES+) m/z 368.1 [M+H]+. 
 
3-(2,3-Dichlorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one (368) 
 
 
 
Compound 368 was synthesised according to general procedure F using; (part i) 2,3-
dichlorobenzoyl chloride (0.74 g, 3.55 mmol), 7-methoxy-6-(pyridin-4-yl)-1H-
pyrrolo[3,2-b]pyridine (357) (160 mg, 0.71 mmol), AlCl3 (0.52 g, 3.91 mmol) and DCM 
(6 mL), (part ii) DCM (3 mL), TMSI (181 µL, 1.28 mmol). The crude product was 
purified by semi-preparative HPLC (C-18 silica; 5-100% CH3CN in water (0.1% formic 
acid)) to give the pure product as a white solid (20 mg, 0.05 mmol, 24%); Rf = 0.40 (5% 
MeOH in EtOAc); M.p. 140-141 
o
C; λmax (EtOH)/nm 219; νmax/cm
-1 
3300, 2390, 2190, 
1638 (CO), 1637 (CO-pyridone); 
1
H NMR (500 MHz, DMSO-d6) δ 7.06 (2H, dd, J = 
1.3 and 8.0 Hz, H-5’ and H-6’),  7.15-7.17 (2H, m, H-4’ and H-5), 7.78 (2H, d, J = 5.2 
Hz, CH-pyridine), 7.94 (2H, br s, CH-pyridine), 8.14 (1H, s, pyridone CH); LRMS 
(ES
+
) m/z 384.2 [M+H]
+
. 
 
3-(2-Bromo-6-fluorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one 
(370) 
 
 
2-Bromo-6-fluorobenzoic acid (1.36 g, 6.22 mmol) was dissolved in THF (12 mL) 
before SOCl2 (1.36 mL, 18.7 mmol) and DMF (57 µL, 0.62 mmol) were added. The 
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mixture was stirred at RT for 3 h before the solvent was removed in vacuo. The residue 
was re-dissolved in DCM (8 mL) and AlCl3 (0.91 mg, 6.84 mmol) was added followed 
by 7-methoxy-6-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine (357) (280 mg, 1.24 mmol) 
and the reaction was carried out as for general procedure F, (part ii) DCM (8 mL), 
TMSI (338 µL, 2.23 mmol). The crude product was purified by semi-preparative HPLC 
(C-18 silica; 5-100% CH3CN in water (0.1% formic acid)) to give the pure product as a 
white solid (32 mg, 0.08 mmol, 21%); Rf = 0.41 (5% MeOH in EtOAc); M.p. 165-166 
o
C; λmax (EtOH)/nm 253, 320; νmax/cm
-1 
3029, 2903, 2699, 1596 (CO), 1555 (CO-
pyridone)  ; 
1
H NMR (500 MHz, DMSO-d6) δ 7.43-7.46 (1H, m, H-3’), 7.54 (1H, ddd, J 
= 6.2, 8.4 and 8.5 Hz, H-4’), 7.63 (1H, d, J = 8.1 Hz, H-5’), 7.65 (1H, s, H-5), 7.79 (2H, 
d, J = 6.4 Hz, CH-pyridine), 7.96 (1H, s, CH-pyridone), 8.57 (2H, d, J = 6.4 Hz, CH-
pyridine); 
19
F NMR (470 MHz, DMSO-d6) δ -113.4;  LRMS (ES
+
) m/z 414.2 [M+H]
+
. 
 
 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one (371) 
 
Compund 371 was synthesised according to general procedure F using; (part i) 2,6-
difluorobenzoyl chloride (0.28 mL, 2.20 mmol), 7-Methoxy-6-(pyridin-3-yl)-1H-
pyrrolo[3,2-b]pyridine (358) (100 mg, 0.44 mmol), AlCl3 (322 mg, 2.42 mmol) and 
DCM (4 mL), (part ii) DCM (1 mL), TMSI (50 µL, 0.36 mmol). The crude product was 
purified by semi-prepartive HPLC (C-18 silica; 5-100% CH3CN in water (0.1% formic 
acid)) to give the pure product as a white solid (8 mg, 0.02 mmol, 39%); Rf = 0.31 (5% 
MeOH in EtOAc); M.p. 265-266 
o
C; λmax (EtOH)/nm 252; νmax/cm
-1
 3532, 2874, 2160, 
2015, 1618 (CO), 1589 (CO-pyridone); 
1
H NMR (500 MHz, MeOD) δ 7.05-7.10 (3H, 
m, H-2 and H-Ar), 7.34 (1H, d, J = 8.8 Hz, CH-pyridine), 7.47-7.54 (2H, m, H-Ar and 
CH-pyridine), 7.61 (1H, s, H-5), 7.92 (1H, s, CH-N-pyridine), 8.08 (1H, d, J = 6.7 Hz, 
CH-N-pyridine); 
19
F NMR (470 MHz, MeOD) δ -115.0 LRMS (ES+) m/z 352.3 
[M+H]
+
. 
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3-(2,3-Dichlorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one (372) 
 
 
Compound 372 was synthesised according to general procedure F using; (part i) 2,3-
dichlorobenzoyl chloride (461 mg, 2.20 mmol), 7-Methoxy-6-(pyridin-3-yl)-1H-
pyrrolo[3,2-b]pyridine (358) (100 mg, 0.44 mmol), AlCl3 (322 mg, 2.42 mmol) and 
DCM (4 mL), (part ii) DCM (1 mL), TMSI (64 µL, 0.36 mmol). The crude product was 
purified by semi-prepartive HPLC (C-18 silica; 5-100% CH3CN in water (0.1% formic 
acid)) to give the pure product as a white solid (10 mg, 0.03 mmol, 27%); Rf = 0.38 (5% 
MeOH in EtOAc); M.p. 251-252 
o
C; λmax (EtOH)/nm 294; νmax/cm
-1
 3412, 2924, 2853, 
2161, 1590 (CO); 
1
H NMR (500 MHz, MeOD) δ 7.46-7.52 (3H, m, H-Ar),  7.56 (1H, s, 
H-2), 7.73 (1H, dd, J = 2.0 and 7.5 Hz, CH-pyridine), 8.01 (1H, s, H-5), 8.16  (1H, d, J 
= 7.5 Hz, CH-pyridine), 8.50 (1H, d, J = 4.9 Hz CH-N-pyridine), 8.83 (1H, s, CH-N-
pyridine); LRMS (ES
+
) m/z 384.2 [M+H]
+
. 
 
3-(2-Chloro-6-fluorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one 
(373) 
 
Compound 373 was synthesised according to general procedure F using; (part i) 2-
chloro-6-fluorobenzoyl chloride (0.60 mL, 4.45 mmol), 7-methoxy-6-(pyridin-3-yl)-1H-
pyrrolo[3,2-b]pyridine (358) (200 mg, 0.89 mmol), AlCl3 (0.65 g, 4.90 mmol) and DCM 
(8 mL), (part ii) DCM (5 mL), TMSI (189 µL, 1.33 mmol). The crude product was 
purified by semi-preparative HPLC (C-18 silica; 5-100% CH3CN in water (0.1% formic 
acid)) to give the pure product as a white solid (24 mg, 0.07 mmol, 30%); Rf = 0.35 (5% 
MeOH in EtOAc); M.p. 235-236 
o
C; λmax (EtOH)/nm 252; νmax/cm
-1 
3391, 3246, 3067, 
2943, 2682, 1621 (CO); 
1
H NMR (500 MHz, MeOD) δ 7.17-7.20 (1H, m, H-Ar), 7.25 
(1H, d, J = 8.9 Hz, H-Ar), 7.43-7.48 (1H, m, H-Ar), 7.43-7.48 (2H, m, CH-pyridine), 
7.50 (1H, s, H-3), 7.61-7.63 (2H, m, CH-pyridine), 7.92 (1H, s, H-5), 8.06 (1H, d, J = 
8.1 Hz, CH-pyridone), 8.41 (1H, br s, NH-pyridone), 8.74 (1H, br s, NH); 
19
F NMR 
(470 MHz, MeOD) δ -115.4; LRMS (ES+) m/z 368.1 [M+H]+. 
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3-(2-Bromo-6-fluorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-7(4H)-one 
(374) 
 
 
2-Bromo-6-fluorobenzoic acid (1.70 g, 7.76 mmol) was dissolved in THF (12 mL) 
before SOCl2 (1.70 mL, 23.3 mmol) and DMF (70 µL, 0.77 mmol) were added. The 
mixture was stirred at RT for 3 h before the solvent was removed in vacuo. The residue 
was re-dissolved in DCM (8 mL) and AlCl3 (1.14 g, 8.54 mmol) was added followed by 
7-methoxy-6-(pyridin-3-yl)-1H-pyrrolo[3,2-b]pyridine (358) (350 mg, 1.54 mmol) and 
the reaction was carried out as for general procedure F, (part ii) DCM (8 mL), TMSI 
(379 µL, 2.68 mmol). The crude product was purified by semi-preparative HPLC (C-18 
silica; 5-100% CH3CN in water (0.1% formic acid)) to give the pure product as a white 
solid (35 mg, 0.09 mmol, 19%); Rf = 0.41 (5% MeOH in EtOAc); M.p. 165-166 
o
C; 
λmax (EtOH)/nm 253, 320; νmax/cm
-1 
3029, 2903, 2699, 1596 (CO),1555 (CO-pyridone) 
,; 
1
H NMR (500 MHz, DMSO-d6) δ 7.43-7.46 (1H, m, H-3’), 7.54 (1H, ddd, J = 6.2, 8.4 
and 8.5 Hz, H-4’), 7.63 (1H, d, J = 8.1 Hz, H-5’), 7.65 (1H, s, H-5), 7.79 (2H, d, J = 6.4 
Hz, CH-pyridine), 7.96 (1H, s, CH-pyridone), 8.57 (2H, d, J = 6.4 Hz, CH-pyridine); 
19
F NMR (470 MHz, DMSO-d6) δ -113.4;  LRMS (ES
+
) m/z 414.2 [M+H]
+
. 
 
2,5-Dioxopyrrolidin-1-yl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (375) 
 
4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75) (100 mg, 0.40 mmol) was 
dissolved in EtOAc (5 mL) at 0 
o
C in an ice bath. DCC (91 mg, 0.44 mmol) was then 
added followed by N-hydroxysuccinimide (51 mg, 0.44 mmol). The resulting yellow 
mixture was left to stir at 0 
o
C for 2 h before being warmed to RT and left to stir 
overnight. The cream suspension was filtered through a pad of Celite and the filtrate 
concentrated in vacuo to give the title compound as a pale orange gum (137 mg, 99%); 
Rf = 0.25 (50% MeOH in EtOAc); λmax (EtOH)/nm 329, 283; νmax/cm
-1
 3606, 3102, 
2933, 2646, 1724 (CO);
 1
H NMR (500 MHz, DMSO-d6) δ 2.80 (4H, br s, (CH2)2), 7.17-
7.21 (2 H, m, H-3’ and H-5’), 7.29 (1 H, br s, H-3 ), 7.54-7.57 (1 H, m, H-4’), 7.83 ( 
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1H, br s,  H-5), 13.41 (1 H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ 25.5 (2 x 
CH2), 114.6 (C-Ar), 118.1 (C-Ar), 118.8 (C-3), 124.5 (C-2 and C-5), 127.4 (C-4), 133.1 
(C-Ar), 155.5 (d, JCF = 257.3 Hz, CF), 170.4 (2 x CO - succinimide), 172.7 (CO2N), 
186.1 (CO); 
19
F NMR (470 MHz, DMSO-d6) δ -114.2; LRMS (ES
+
) m/z 349.2 [M+H]
+
; 
HRMS m/z calcd for C16H11F2N2O5 [M+H]
+ 
349.0632, found 349.0632. 
  
(2,6-Difluorophenyl)(1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanone (376) 
 
 
1-(Phenylsulfonyl)pyrrole (100 mg, 0.48 mmol) was dissolved in DCM (3 mL) at 0 
o
C. 
AlCl3 (70 mg, 0.53 mmol) was added followed by 2,6-difluorobenzoyl chloride (93 µL, 
0.53 mmol) before the reaction was allowed to warm to RT overnight. The reaction 
mixture was quenched with water followed by a 1.0M aqueous solution of HCl until 
effervescence ceased before being extracted with DCM (3 x 5 mL). The combined 
organic extracts were washed with a saturated aqueous solution of NaHCO3 followed by 
water and a saturated brine solution (2 x 5 mL respectively) before being dried over 
Na2SO4 and the solvent removed in vacuo. The crude product was purified using MPLC 
(silica, 2-100% EtOAc in petrol) to give the title compound as a beige solid (100 mg, , 
60%); Rf = 0.81 (10% MeOH in EtOAc); M.p.: 101-102 
oC; λmax (EtOH)/nm: 246; 
νmax/cm
-1
: 3645, 3303, 3133, 1657 (CO), 1624; 
1
H NMR (500 MHz, CDCl3) δ 6.69 (1H, 
dd, J = 1.6 and 3.4 Hz, H-3), 6.89-6.95 (2H, m, H-3’ and H-5’), 7.09 (1H, dd, J = 2.2 
and 3.4 Hz, H-2), 7.36 (1H, dddd, J = 6.3, 6.4, 8.2 and 8.3 Hz, H-4’), 7.48-7.52 (3H, m, 
H-5 and H-Ar), 7.58-7.62 (1H, m, H-Ar), 7.81-7.83 (2H, m, H-Ar); 
13
C NMR (125 
MHz, MeOD) δ 111.9 (C-3), 112.9 (C-Ar), 117.5 (C-4), 122.0 (C-5 and  C-2), 127.2 (C-
Ar), 128.1 (C-Ar), 129.4 (C-Ar), 131.9 (C-Ar), 134.8 (C-Ar), 137.9 (C-Ar), 160.6 (C-
Ar), 182.3 (CO);
 19
F NMR (470 MHz, CDCl3) δ -112.0; LRMS (ES
+
) m/z 348.20 
[M+H]
+
. 
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